

BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO CHIMERIC ANTIGEN RECEPTOR THERAPY AND USES THEREOF

This application claims priority to U.S. Serial No. 62/061,553 filed October 8, 2014 and
5 U.S. Serial No. 62/144,682 filed April 8, 2015, the contents of which are incorporated herein by
reference in their entireties.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted
electronically in ASCII format and is hereby incorporated by reference in its entirety. Said
10 ASCII copy, created on October 7, 2015, is named N2067-7057WO_SL.txt and is 219,221 bytes
in size.

FIELD OF THE INVENTION

The invention relates to cancer biomarkers and uses thereof.

BACKGROUND OF THE INVENTION

15 Many patients with B cell malignancies are incurable with standard therapy. In addition,
traditional treatment options often have serious side effects. Attempts have been made in cancer
immunotherapy, however, several obstacles render the goal of clinical effectiveness difficult to
achieve. Although hundreds of so-called tumor antigens have been identified, these are generally
derived from self and thus are poorly immunogenic. Furthermore, tumors use several
20 mechanisms to render themselves hostile to the initiation and propagation of immune attack.

Recent developments using chimeric antigen receptor (CAR) modified autologous T cell
(CART) therapy, which relies on redirecting T cells to a suitable cell-surface molecule on cancer
cells such as B cell malignancies, show promising results in harnessing the power of the immune
system to treat B cell malignancies and other cancers (see, e.g., Sadelain et al., CANCER
25 DISCOVERY 3:388-398 (2013)). For example, the clinical results of a CART that binds to CD19
(i.e., "CTL019") have shown promise in establishing complete remissions in patients suffering
with chronic lymphocytic leukemia (CLL), as well as in childhood acute lymphocytic leukemia
(ALL) (see, e.g., Kalos et al., SCI TRANSL MED 3:95ra73 (2011), Porter et al., NEJM 365:725-
733 (2011), Grupp et al., NEJM 368:1509-1518 (2013)).

Besides the ability for the chimeric antigen receptor on the genetically modified T cells to recognize and destroy the targeted cells, a successful therapeutic T cell therapy needs to have the ability to proliferate, to persist over time, and to further monitor for leukemic cell escapees. The variable phenotypic state of T cells, whether it is in a state of anergy, suppression or exhaustion, will have effects on CAR-transformed T cells' efficacy. To be effective, CAR transformed patient T cells need to persist and maintain the ability to proliferate in response to the CAR's antigen.

A need, therefore, exists for a method of using biomarkers for use in connection with the differential diagnosis and treatment of cancer with CAR-expressing cell (e.g., T cell, NK cell) therapy. In particular, there is an unmet need for effective predictors of therapeutic response in subjects having a hematological cancer, such as CLL and ALL, to a CAR-expressing cell therapy, e.g., with CTL019 or other CD19 CAR-expressing cells.

SUMMARY OF THE INVENTION

The present disclosure relates to the identification and use of analytes, analyte profiles, or markers (e.g., gene expression, flow cytometry and/or protein expression profiles) with clinical relevance to cancer (e.g., a hematological cancer such as chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL)). In some embodiments, the disclosure provides the identity of genes, whose expression, at the transcriptional and protein levels, are correlated with CLL and ALL progression, e.g., as a way of predicting a response to a Chimeric Antigen Receptor (CAR)-expressing cell therapy (e.g., a therapy comprising a cell (e.g., an immune effector cell or population of cells) that expresses a CAR that binds to CD19 (also referred to herein as a "CAR19" or "CD19 CAR" -expressing cell). In certain embodiments, one or more of a CD19 CAR-expressing cell gene set signature, a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a

memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature, and combinations thereof) are evaluated. These gene expression profiles may be applied to the diagnosis and/or prognosis of a cancer, e.g., a hematological cancer such as CLL and ALL, and are particularly useful in predicting whether a subject will
5 respond favorably to a CAR therapy (e.g., a CD19 CAR therapy as described here, e.g., a CTL019 therapy) in a subject diagnosed with a cancer, e.g., a hematological cancer such as CLL or ALL. Compared to clinical parameters or biochemical markers used in existing prognosis methods, the expression profiles of the genes disclosed herein constitute a more robust signature of hematological cancer progression (e.g., CLL and ALL progression) and provide a more
10 reliable, non-subjective basis for the selection of appropriate therapeutic regimens.

Amongst other things, the present disclosure provides novel gene signatures, e.g., at the transcriptional and protein levels, and methods of use thereof, that predict subject response to a cell expressing a CAR, e.g., a CD19 CAR (e.g., a CD19 CAR-expressing cell, e.g., T cell, NK cell, described herein such as, e.g., CTL019) therapy in a cancer, e.g., a hematological cancer
15 such as CLL and ALL.

The present disclosure demonstrates, at least in part, that expression profiles and gene signatures, e.g., at the transcriptional and protein levels, are useful to distinguish among a responder, a partial responder, a non-responder, a relapser or a non-relapser to a therapy comprising a CAR-expressing cell (e.g., a CAR-expressing immune effector cell, e.g., a T cell, or an NK cell), (also referred to herein as a “CAR-expressing cell therapy”), in a cancer (e.g., a hematological cancer such as CLL and ALL). In one embodiment, the CAR-expressing cell is a CD19 CAR-expressing cell. In one embodiment, the therapy is a CTL019 therapy. In
20 embodiments, the expression profiles and gene signatures disclosed herein distinguish among a CAR (or CD19 CAR)-expressing cell responder, a CAR (or CD19 CAR)-expressing cell partial responder, or a CAR (or CD19 CAR)-expressing cell non-responder (e.g., a CTL019-responder, a CTL019-partial responder, and a CTL019-non-responder); or a CAR (or CD19 CAR)-
25 expressing cell relapser, or a CAR (or CD19 CAR)-expressing cell non-relapser (e.g., a CTL019-relapser, or a CTL019- relapser), in a cancer (e.g., a hematological cancer such as CLL and ALL). The present disclosure encompasses the identification of novel gene signatures predictive

of subject response to a CAR-expressing cell therapy, e.g., a CD19 CAR-expressing cell therapy such as CTL019.

Thus, disclosed herein are methods, systems, compositions, and kits for the identification, assessment and/or treatment of a subject having cancer. Exemplary cancers include, but are not limited to, B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), B cell promyelocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma (HL), plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, and Waldenstrom macroglobulinemia. In one embodiment, the cancer is ALL. In another embodiment, the cancer is CLL. In an embodiment, the cancer is associated with CD19 expression.

Accordingly, in one aspect, the invention features a method of evaluating a subject having a cancer, e.g., a hematological cancer. The method includes acquiring a value of responder or relapser status (e.g., a value of responder or relapser status as described herein) to a therapy comprising a CAR-expressing cell (e.g., a plurality (e.g., a population) of CAR (e.g., CAR19-)-expressing cells) for the subject, wherein said value is indicative of the subject's responsiveness or relapsing status to the CAR-expressing cell therapy.

In a related aspect, the invention features a method of evaluating or monitoring the effectiveness of a CAR-expressing cell therapy in a subject having a cancer, e.g., a hematological cancer. The method includes acquiring a value of responder or relapser status (e.g., a value of responder or relapser status as described herein) to a therapy comprising a CAR-expressing cell (e.g., a plurality (e.g., a population) of CAR (e.g., CAR19-)-expressing cells) for the subject, wherein said value is indicative of the effectiveness of the CAR-expressing cell therapy, thereby evaluating the effectiveness of the CAR-expressing cell therapy in the subject.

In another aspect, the invention features a method for treating a subject having a cancer, e.g., a hematological cancer. The method includes administering to the subject a therapeutically effective dose of a CAR-expressing cell therapy, if the subject is identified as being responsive (e.g., identified as a complete responder, partial responder or a non-relapser) to a therapy comprising a CAR-expressing cell (e.g., a plurality (e.g., a population) of CAR (e.g., CAR19)-expressing cells), wherein said identifying comprises a value of responder or relapser status (e.g., a value of responder or relapser status as described herein).

In a related aspect, the invention features a method of treating a cancer, e.g., a hematological cancer, in a subject. The method includes acquiring a value of responder or relapser status (e.g., a value of responder or relapser status as described herein) to a therapy comprising a CAR-expressing cell (e.g., a plurality (e.g., a population) of CAR (e.g., CAR19)-expressing cells) for the subject; and responsive to said value, treating the cancer.

In embodiments of any of the methods and compositions for use described herein, the value of responder or relapser status comprises a measure of one, two, three, four, five, six, seven or more (all) of the following:

(i) the level or activity of CD27 and/or CD45RO- (e.g., CD27+ CD45RO-) immune effector cells, e.g., in a CD4+ or a CD8+ T cell population, in a subject, e.g., a sample from the subject (e.g., an apheresis sample or a CAR-expressing cell product sample);

(ii) the level or activity of one, two, three, or more (e.g., all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, in a subject, e.g., a sample from the subject (e.g., an apheresis sample or a CAR-expressing cell product sample);

(iii) the level or activity of one, two, three, or more (e.g., all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in a subject, e.g., a sample from the subject (e.g., an apheresis sample or a manufactured CAR-expressing cell product sample);

(iv) the level or activity of an immune cell exhaustion marker, e.g., one, two or more immune checkpoint inhibitors (e.g., PD-1, TIM-3 and/or LAG-3) in a subject, e.g., a sample

from the subject (e.g., an apheresis sample or a manufactured CAR-expressing cell product sample);

(v) the level or activity of one, two, three, four, five, ten, twenty or more of the biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature;

(vi) a cytokine level or activity (e.g., quality of cytokine repertoire) in a CAR-expressing cell product sample, e.g., CAR19- expressing cell product sample (e.g., CTL019), wherein the cytokine is chosen from one, two, three, four, five or more (or all) of the cytokines listed in Table 16;

(vii) a transduction efficiency of a CAR-expressing cell in a CAR-expressing cell product sample; or

(viii) a quantity of CD27+ PD-1- cells in a subject, e.g., a sample from the subject (e.g., an apheresis sample or a CAR-expressing cell product sample, e.g., CAR19- expressing cell product sample (e.g., CTL019)), e.g., a quantity greater than or equal to 1×10^7 cells.

In an aspect, the invention provides a CAR expressing cell therapy (e.g., CD19 CART cell, e.g., CTL019 cell) for use in the treatment of a subject, wherein the CAR expressing cell has been assayed according to a method herein, e.g., before or after transduction or transfection with a CAR nucleic acid. In a related aspect, the invention provides a CAR expressing cell therapy (e.g., CD19 CART cell, e.g., CTL019 cell), for use in the treatment of a subject that has been identified as being responsive (e.g., identified as a complete responder, partial responder or a non-relapser) to a therapy comprising a CAR-expressing cell population (e.g., a CAR19-expressing cell population). The composition for use can comprise a measure of one, two, three, four, five, six, seven, or more (all) of (i)-(viii) described herein.

Alternatively, or in combination with the methods and compositions for use disclosed herein, responsive to said value, performing one, two, three, four, five, six, seven, or more (e.g., all) of:

identifying the subject as a complete responder, partial responder or non-responder, or a relapser or a non-relapser;

administering e.g., to a responder or a non-relapser, a CAR-expressing cell therapy;

administering an altered dosing of a CAR-expressing cell therapy;

5 altering the schedule or time course of a CAR-expressing cell therapy;

administering, e.g., to a non-responder or a partial responder, an additional agent in combination with a CAR-expressing cell therapy, e.g., a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein;

10 administering to a non-responder or partial responder a therapy that increases the number of younger T cells in the subject prior to treatment with a CAR-expressing cell therapy;

modifying a process, e.g., a manufacturing process, of a CAR-expressing cell therapy, e.g., enriching for younger T cells prior to introducing a nucleic acid encoding a CAR, or increasing the transduction efficiency, e.g., for a subject identified as a non-responder or a partial responder;

15 administering an alternative therapy, e.g., for a non-responder or partial responder or relapser, e.g., a standard of care for a particular cancer type; or

if the subject is, or is identified as, a non-responder or a relapser, decreasing the T_{REG} cell population and/or T_{REG} gene signature, e.g., by one or more of CD25 depletion, or administration of cyclophosphamide, anti-GITR antibody, an mTOR inhibitor, or a combination thereof.

20 In certain embodiments, the subject is pre-treated with an anti-GITR antibody. In certain embodiment, the subject is treated with an anti-GITR antibody prior to infusion or re-infusion. In some embodiments, the subject is a patient with CLL.

25 In another aspect, the invention features a method of, or assay for, identifying a subject having a cancer as having an increased or decreased likelihood to respond to a treatment that comprises a CAR-expressing cell (e.g., a plurality (e.g., a population) of CAR (e.g., CAR19)-expressing cells). The method includes:

(1) providing, e.g., acquiring, a sample from the subject;

30 (2) determining a level or activity of one or more biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6),

Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1 in the sample;

wherein a difference, e.g., a statistically significant difference, between the determined level compared to a reference level is predictive of the subject's responsiveness to the CAR-expressing cell therapy; and

(3) (optionally) identifying the subject as a complete responder, partial responder, non-responder, a relapser or a non-relapser, to the CAR-expressing cell therapy.

In yet another aspect, the invention features a method for treating a subject having a cancer comprising:

determining if the subject has an increased likelihood to respond, or a decreased likelihood to relapse, to a CAR-expressing cell therapy (e.g., a CAR19-expressing therapy, e.g., CTL019) by determining the level or activity of one or more biomarkers in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), FIG. 2B, Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature in a sample from the subject, e.g., relative to a reference level; and

administering to the subject a therapeutically effective dose of a CAR-expressing cell therapy.

In yet another aspect, the invention features a method for treating a subject having cancer comprising:

(1) determining if the subject has an increased likelihood to relapse to a CAR-expressing cell therapy by acquiring a value for the level or activity of one or more markers in a Table herein, e.g., Table 17 in a sample from the subject (e.g., an apheresis sample or a manufactured CAR-expressing product sample), wherein a difference, e.g., a statistically significant difference, in the level or activity of one or more biomarker genes relative to the reference level is indicative of an increased likelihood of relapse to a CAR-expressing cell therapy; and

(2) for a subject with an increased likelihood of relapse, decreasing the T_{REG} cell population and/or decreasing T_{REG} gene signature; and

(3) administering to the subject a therapeutically effective dose of a CAR-expressing cell therapy.

Additional features and embodiments of the present invention include one or more of the following:

In some embodiments of any of the methods and compositions for use disclosed herein, an immune cell has an exhausted phenotype, *e.g.*, co-expresses at least two exhaustion markers, *e.g.*, co-expresses PD-1 and TIM-3. In other embodiments, an immune cell has an exhausted phenotype, *e.g.*, co-expresses at least two exhaustion markers, *e.g.*, co-expresses PD-1 and LAG-3.

In some embodiments of any of the methods, systems, compositions for use, and kits disclosed herein, the CAR-expressing cell therapy comprises a plurality (*e.g.*, a population) of CAR-expressing immune effector cells, *e.g.*, a plurality (*e.g.*, a population) of T cells or NK cells, or a combination thereof. In one embodiment, the CAR-expressing cell therapy is a CAR19 therapy (*e.g.*, CTL019 therapy). In an embodiment, the CAR-expressing cell therapy comprises or consists of CTL019. In an embodiment, the CAR-expressing cell is a CTL019 product. In an embodiment, the CAR-expressing cell is a T cell. In an embodiment, the CAR-expressing cell is a NK cell.

In some embodiments of any of the methods and compositions for use disclosed herein, the measure of one or more of (i)-(viii) is obtained from an apheresis sample acquired from the subject. The apheresis sample can be evaluated prior to infusion or re-infusion.

In some embodiments of any of the methods and compositions for use disclosed herein, the measure of one or more of (i)-(viii) is obtained from a manufactured CAR-expressing cell product sample, *e.g.*, CAR19-expressing cell product sample (*e.g.*, CTL019). The manufactured CAR-expressing cell product can be evaluated prior to infusion or re-infusion.

In some embodiments of any of the methods and compositions for use disclosed herein, the subject is evaluated prior to receiving, during, or after receiving, the CAR-expressing cell therapy.

In some embodiments of any of the methods and compositions for use disclosed herein, the hematological cancer is an ALL or a CLL. The subject can be a human patient.

In some embodiments of any of the methods and compositions for use disclosed herein, the cell, e.g., the population of immune effector cells (e.g., cells expressing a CAR molecule described herein) is administered in combination with an inhibitor of an immune checkpoint molecule chosen from one or more of PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g.,
 5 CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, TGFR (e.g., TGFR beta), or a combination thereof.

In some embodiments of any of the methods and compositions for use disclosed herein,
 10 the subject receives concurrent treatment with an agent, e.g., an mTOR inhibitor, and/or a checkpoint inhibitor. In some embodiments, the subject receives treatment with an agent, e.g., an mTOR inhibitor, and/or a checkpoint inhibitor, post- CAR-expressing cell therapy. In some embodiments, the subject receives a pre-treatment of with an agent, e.g., an mTOR inhibitor, and/or a checkpoint inhibitor, prior to the initiation of a CAR-expressing cell therapy.

15 In some embodiments of any of the methods and compositions for use disclosed herein, T_{REG} cell population and/or T_{REG} gene signature is decreased prior to collection of cells for manufacturing. In some embodiments, the T_{REG} cell population and/or T_{REG} gene signature is decreased prior to CAR-expressing cell (e.g., T cell, NK cell) therapy. In some embodiments, the T_{REG} cell population and/or T_{REG} gene signature is decreased by administration of
 20 cyclophosphamide, anti-GITR antibody, an mTOR inhibitor, or a combination thereof.

In some embodiments of any of the methods and compositions for use disclosed herein the value of responder or relapser status comprises a measure of a combination of a gene signature and a biomarker. In some embodiments, the value of the responder or relapser status comprises a measure of a CD19 CAR-expressing cell gene set signature and a combination of
 25 one or more of: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, or KLRG1.

In some embodiments of any of the methods and compositions for use disclosed herein, the method further comprises identifying the subject as a responder (e.g., a complete or partial
 30 responder), a non-responder, a relapser or a non-relapser, based on a measure of one or more of (i)-(viii).

In some embodiments of any of the methods and compositions for use disclosed herein, the measure of one or more of (i)-(viii) evaluates a profile for one or more of gene expression, flow cytometry or protein expression.

In some embodiments of any of the methods and compositions for use disclosed herein, the expression profile includes one or more gene signatures based on mRNA expression levels of selected genes obtained from the apheresis sample or a manufactured CD19 CAR-expressing cell product (e.g., CTL019). In one embodiment, the expression profile includes one, two, three, four, five, ten, twenty or more of a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature.

In some embodiments of any of the methods and compositions for use disclosed herein, the level or activity of a CD8+ T cell is evaluated using a profile or signature indicative of the percentage of CD8+ T cell in the sample.

In some embodiments of any of the methods and compositions for use disclosed herein, the level or activity of CD27+ CD45RO- immune effector cells is evaluated using a profile or signature indicative of the percentage of CD27+ CD45RO- immune effector cells in the sample.

In some embodiments of any of the methods and compositions for use disclosed herein, the level or activity, e.g., in (i), (ii), or (v), is evaluated using a profile or gene signature according to one, two, three, four, five, ten, twenty, fifty, sixty, seventy, one hundred or more of a biomarker or gene set listed in Tables 1A, 1B, 3, 4, 5, 6, or FIG. 2B.

In some embodiments of any of the methods and compositions for use disclosed herein, the level or activity one, two or more immune checkpoint inhibitors is evaluated, e.g., using flow cytometry, as an indicator of the percentage of PD-1+/LAG-3+ cells in the CAR-expressing cell population (e.g., a CAR19+ cell population).

In some embodiments of any of the methods and compositions for use disclosed herein, the level or activity one, two or more immune checkpoint inhibitors is evaluated, e.g., using flow cytometry, as an indicator of the percentage of PD-1+/TIM-3+ cells in the CAR-expressing cell population (e.g., a CAR19+ cell population).

In some embodiments of any of the methods and compositions for use disclosed herein, the level or activity of one, two, three, four, five, ten, twenty, fifty, sixty, seventy, one hundred or

more of a biomarker or gene set listed in Table 7A, Table 7B, Table 8 and FIG. 2B predicts a subject's response to a CAR19+ cell product (e.g., CTL019).

In some embodiments of any of the methods and compositions for use disclosed herein, the value of responder or relapser status comprises a measure of the level or activity of one, two, three, four, five, ten, twenty or more (e.g., all) of the biomarkers having a given FDR p-value, listed herein, e.g., in a Table herein. In some embodiments, the FDR p-value is below 0.2, 0.1, 0.05, 0.02, 0.01, 0.005, 0.002, or 0.001. In some embodiments, the FDR p-value is below 0.1 or 0.01. In some embodiments, the biomarkers are biomarkers listed in Table 1A, Table 1B, Table 16, Table 17, Table 18, or Table 20, or a combination thereof. In some embodiments, the measure comprises a measure of all of the biomarkers in Table 1A that have a p-value below a threshold of 0.2, 0.1, 0.05, 0.02, 0.01, 0.005, 0.002, or 0.001. In some embodiments, the measure comprises a measure of all of the biomarkers in Table 1B that have a p-value below a threshold of 0.2, 0.1, 0.05, 0.02, 0.01, 0.005, 0.002, or 0.001. In some embodiments, the measure comprises a measure of all of the biomarkers in Table 16 that have a p-value below a threshold of 0.2, 0.1, 0.05, 0.02, 0.01, 0.005, 0.002, or 0.001. In some embodiments, the measure comprises a measure of all of the biomarkers in Table 17 that have a p-value below a threshold of 0.2, 0.1, 0.05, 0.02, 0.01, 0.005, 0.002, or 0.001. In some embodiments, the measure comprises a measure of all of the biomarkers in Table 18 that have a p-value below a threshold of 0.2, 0.1, 0.05, 0.02, 0.01, 0.005, 0.002, or 0.001. In some embodiments, the measure comprises a measure of all of the biomarkers in Table 20 that have a p-value below a threshold of 0.2, 0.1, 0.05, 0.02, 0.01, 0.005, 0.002, or 0.001. In some embodiments, the measure comprises a measure of all of the biomarkers having a p-value below the threshold. In some embodiments, the measure comprises a measure of one, two, three, four, five, ten, twenty, fifty, or one hundred biomarkers having a p-value below the threshold. In some embodiments, the measure comprises a measure of at least one, two, three, four, five, ten, twenty, fifty, or one hundred biomarkers having a p-value below the threshold. In some embodiments, the measure comprises a measure of 1-5, 5-10, 10-20, 20-50, or 50-100 biomarkers having a p-value below the threshold.

In some embodiments, biomarkers of Table 7B that are designated "CR" in the table are upregulated in complete responders compared to non-responders. In some embodiments,

biomarkers of Table 7B that are designated “NR” in the table are upregulated in non-responders compared to complete responders.

In some embodiments of any of the methods and compositions for use disclosed herein, the biomarker is a secreted or a cell surface biomarker listed in Table 8. For example the biomarker can be measured by flow cytometry.

In some embodiments of any of the methods and compositions for use disclosed herein, a responder (e.g., a complete responder) has, or is identified as having, a greater level or activity of one, two, or more (all) of GZMK, PPF1BP2, or naïve T cells as compared to a non-responder.

In some embodiments of any of the methods and compositions for use disclosed herein, a non-responder has, or is identified as having, a greater level or activity of one, two, three, four, five, six, seven, or more (e.g., all) of IL22, IL-2RA, IL-21, IRF8, IL8, CCL17, CCL22, effector T cells, or regulatory T cells, as compared to a responder.

In an embodiment of any of the methods and compositions for use disclosed herein, a relapsing patient is a patient having, or who is identified as having, an increased level of expression of one or more of (e.g., 2, 3, 4, or all of) the following genes, compared to non relapsers: MIR199A1, MIR1203, uc021ovp, ITM2C, and HLA-DQB1 and/or a decreased levels of expression of one or more of (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or all of) the following genes, compared to non relapsers: PPIAL4D, TTTY10, TXLNG2P, MIR4650-1, KDM5D, USP9Y, PRKY, RPS4Y2, RPS4Y1, NCRNA00185, SULT1E1, and EIF1AY.

In some embodiments of any of the methods and compositions for use disclosed herein, a complete responder has, or is identified as having, a greater, e.g., a statistically significant greater, percentage of CD8+ T cells compared to a reference value, e.g., a non-responder percentage of CD8+ T cells.

In some embodiments of any of the methods and compositions for use disclosed herein, a complete responder has, or is identified as having, a greater percentage (e.g., 5%, 6%, 7%, 10%, 15%, 20%, 25%, 27%, 30%, 35%, or 40% or greater number) of CD27+ CD45RO- immune effector cells, e.g., in the CD8+ population, compared to a reference value, e.g., a non-responder number of CD27+ CD45RO- immune effector cells.

In some embodiments of any of the methods and compositions for use disclosed herein, a complete responder or a partial responder has, or is identified as having, a greater, e.g., a

statistically significant greater, percentage of CD4+ T cells compared to a reference value, e.g., a non-responder percentage of CD4+ T cells.

In some embodiments of any of the methods and compositions for use disclosed herein, a complete responder has, or is identified as having, a greater percentage of one, two, three, or
5 more (*e.g.*, all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (*e.g.*, younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, compared to a reference value, e.g., a non-responder number of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (*e.g.*, younger CD4 or CD8 cells), or early memory T cells.

In some embodiments of any of the methods and compositions for use disclosed herein, a
10 non-responder has, or is identified as having, a greater percentage of one, two, three, or more (*e.g.*, all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (*e.g.*, older CD4 or CD8 cells), or late memory T cells, or a combination thereof, compared to a reference value, e.g., a responder number of activated T_{EFF} cells, activated T_{REG} cells, older T cells (*e.g.*, older CD4 or CD8 cells), or late memory T cells.

15 In some embodiments of any of the methods and compositions for use disclosed herein, a non-responder has, or is identified as having, a greater percentage of an immune cell exhaustion marker, *e.g.*, one, two or more immune checkpoint inhibitors (*e.g.*, PD-1, TIM-3 and/or LAG-3). In one embodiment, a non-responder has, or is identified as having, a greater percentage of PD-1 or LAG-3 expressing immune effector cells (*e.g.*, CD4+ T cells and/or CD8+ T cells) (*e.g.*,
20 CAR-expressing CD4+ cells and/or CD8+ T cells) compared to the percentage of PD-1 or LAG-3 expressing immune effector cells from a responder.

In some embodiments of any of the methods and compositions for use disclosed herein, a non-responder has, or is identified as having, a greater percentage of immune cells having an exhausted phenotype, *e.g.*, immune cells that co-express at least two exhaustion markers, *e.g.*,
25 co-expresses PD-1 and TIM-3. In other embodiments, a non-responder has, or is identified as having, a greater percentage of immune cells having an exhausted phenotype, *e.g.*, immune cells that co-express at least two exhaustion markers, *e.g.*, co-expresses PD-1 and LAG-3.

In some embodiments of any of the methods and compositions for use disclosed herein, a non-responder has, or is identified as having, a greater percentage of PD-1+/LAG-3+ cells in the
30 CAR-expressing cell population (*e.g.*, a CAR19+ cell population) compared to a responder (*e.g.*, a complete responder) to the CAR-expressing cell therapy.

In some embodiments of any of the methods and compositions for use disclosed herein, a partial responder has, or is identified as having, a higher percentages of PD-1+/LAG-3+ cells, than a responder, in the CAR-expressing cell population (e.g., a CAR19+ cell population).

5 In some embodiments of any of the methods and compositions for use disclosed herein, a non-responder has, or is identified as having, an exhausted phenotype of PD1+ CAR+ and co-expression of LAG3 in the CAR-expressing cell population (e.g., a CAR19+ cell population).

In some embodiments of any of the methods and compositions for use disclosed herein, a non-responder has, or is identified as having, a greater percentage of PD-1+/TIM-3+ cells in the CAR-expressing cell population (e.g., a CAR19+ cell population) compared to the responder
10 (e.g., a complete responder).

In some embodiments of any of the methods and compositions for use disclosed herein, a partial responders has, or is identified as having, a higher percentage of PD-1+/TIM-3+ cells, than responders, in the CAR-expressing cell population (e.g., a CAR19+ cell population).

15 In some embodiments of any of the methods and compositions for use disclosed herein, the presence of CD8+ CD27+ CD45RO- T cells in an apheresis sample is a positive predictor of the subject response to a CAR-expressing cell therapy (e.g., a CAR19 therapy (e.g., CTL019 therapy)).

In some embodiments of any of the methods and compositions for use disclosed herein, a high percentage of PD1+ CAR+ and LAG3+ or TIM3+ T cells in an apheresis sample is a poor
20 prognostic predictor of the subject response to a CAR-expressing cell therapy (e.g., a CAR19 therapy (e.g., CTL019 therapy)).

In some embodiments of any of the methods and compositions for use disclosed herein, a responder (e.g., a complete responder) to a CAR19 therapy has, or is identified as having, the biomarker profile of Table 9.

25 In some embodiments of any of the methods and compositions for use disclosed herein, a non-responder to a CAR19 therapy has, or is identified as having, the biomarker comprising one or more of PD-1+ immune effector cells, TIM-3+ immune effector cells, LAG-3+ immune effector cells, KLRG1+ immune effector cells, CD27-immune effector cells, activated T_{EFF} cells, activated T_{REG} cells, activated TH1, activated TH2 cells, stimulated memory cells, or late T
30 memory cells, or a combination thereof,

In some embodiments of any of the methods and compositions for use disclosed herein, a non-responder to a CAR19 therapy has, or is identified as having, the biomarker profile of Table 10.

In some embodiments of any of the methods and compositions for use disclosed herein,
5 expression of one, two, three, four or more (all) of KLRG1, CD57, CD27, CD122, or CD62L is predictive of patient response to CTL019 therapy.

In some embodiments of any of the methods and compositions for use disclosed herein, a non-relapser is a patient with B-ALL, and has, or is identified as having, one or more expression profiles (e.g., protein or gene expression profiles) or gene signatures characteristic of resting T_{EFF}
10 cells or resting T_{REG} cells.

In some embodiments of any of the methods and compositions for use disclosed herein, a relapser is a patient with B-ALL, and has, or is identified as having, one or more expression profiles (e.g., protein or gene expression profiles) or gene signatures characteristic of activated T_{EFF} cells or activated T_{REG} cells.

15 In some embodiments of any of the aforesaid methods and compositions for use, a T_{REG} cell (e.g., an activated T_{REG} cell) has upregulated expression of one or more (e.g., at least 10, 20, 30, 40, 50, 60, 70, or all) of the following biomarkers: AIM2, ALAS1, BATF, C5orf32, CCL17, CD40LG, CHAC2, CSF1, CTSL1, EBNA1BP2, EDARADD, EMP1, EPAS1, FABP5, FAM40B, FKBP4, FOSL1, GCLM, GK, GPR56, HMOX1, HSPD1, HSPE1, IKBIP, IL10, IL13,
20 IL15RA, IL1RN, IL2RA, IL3, IL4, IL5, IL9, KCNK5, LTA, MANF, MIR1182, MIR155, MIR155HG, MYOF, NDUFAF1, NLN, NME1, NME1-NME2, PANX2, PDIA6, PGAM4, PPIL1, PPPDE2, PRDX4, PRKAR1B, PSMD1, PSMD11, PUS7, RBBP8, SLC27A2, SLC39A14, SLC43A3, SRXN1, STIP1, STT3A, TBX21, TNFRSF11A, TNFRSF1B, TNFRSF8, TNFRSF9, TXN, UCK2, VDR, VTRNA1-3, WDR12, YWHAG, ZDHHC16, or ZNF282. The
25 upregulated expression may be, e.g., measured 16 hours after stimulation. The upregulated expression may be determined, e.g., by measuring RNA levels for the indicated genes.

In some embodiments of any of the aforesaid methods and compositions for use, a T_{EFF} cell (e.g., an activated T_{EFF} cell) has upregulated expression of one or more (e.g., at least 10, 20, 30, 40, 50, 60, 70, or all) of the following biomarkers: AIM2, ALAS1, B4GALT5, BATF,
30 C3orf26, C4orf43, CCL3, CCL4, CCT3, CCT7, CD40LG, CHAC2, CSF2, CTNNA1, EBNA1BP2, EDARADD, EEF1E1, EIF2B3, EIF2S1, FABP5, FAM40B, FKBP4, FOSL1,

GFOD1, GLRX2, HSPD1, HSPE1, IFNG, IL15RA, IL21, IL2RA, IL3, KCNK5, KIAA0020, LARP4, LRP8, LTA, MANF, MIR1182, MIR155, MIR155HG, MTCH2, MYOF, NDUFAF1, NLN, NME1, NME1-NME2, OTUD7B, PAM, PDIA6, PEA15, PFKM, PGAM1, PGAM4, PPIL1, PRDX4, PRSS23, PSMD1, PSMD11, PSMD14, PTRH2, PUS7, RBBP8, RPF2, RPP25, SFXN1, SLC27A2, SLC39A14, SLC43A3, SORD, SPR, SRXN1, STIP1, STT3A, TBX21, TMCC2, TMEM165, TNFRSF9, TXN, TXNDC5, UCK2, VDR, WDR12, YWHAG, or ZDHHC16. The upregulated expression may be, e.g., measured 16 hours after stimulation. The upregulated expression may be determined, e.g., by measuring RNA levels for the indicated genes.

In some embodiments of any of the methods and compositions for use disclosed herein, a relapser is a patient with B-ALL and has, or is identified as having, one or more protein or gene expression profiles comprising one, two, three, four, five, ten or more genes according to Table 7A, Table 7B or FIG. 2B or a combination thereof.

In some embodiments of any of the methods and compositions for use disclosed herein, a relapser has, or is identified as having, an elevated level of one or more T_{REG} cell biomarkers, or a combination thereof. In some embodiments, the relapser has, or is identified as having, upregulated expression of one or more (e.g., at least 10, 20, 30, 40, 50, 60, 70, or all) of the following genes: AIM2, ALAS1, BATF, C5orf32, CCL17, CD40LG, CHAC2, CSF1, CTSL1, EBNA1BP2, EDARADD, EMP1, EPAS1, FABP5, FAM40B, FKBP4, FOSL1, GCLM, GK, GPR56, HMOX1, HSPD1, HSPE1, IKBIP, IL10, IL13, IL15RA, IL1RN, IL2RA, IL3, IL4, IL5, IL9, KCNK5, LTA, MANF, MIR1182, MIR155, MIR155HG, MYOF, NDUFAF1, NLN, NME1, NME1-NME2, PANX2, PDIA6, PGAM4, PPIL1, PPPDE2, PRDX4, PRKAR1B, PSMD1, PSMD11, PUS7, RBBP8, SLC27A2, SLC39A14, SLC43A3, SRXN1, STIP1, STT3A, TBX21, TNFRSF11A, TNFRSF1B, TNFRSF8, TNFRSF9, TXN, UCK2, VDR, VTRNA1-3, WDR12, YWHAG, ZDHHC16, or ZNF282. In certain embodiment, the relapser has, or is identified as having, upregulated expression of one or more (e.g., at least 10, 20, 25, or all) of the following genes: C5orf32, CCL17, CSF1, CTSL1, EMP1, EPAS1, GCLM, GK, GPR56, HMOX1, IKBIP, IL10, IL13, IL1RN, IL4, IL5, IL9, MIR155, PANX2, PGAM4, PRKAR1B, TNFRSF11A, TNFRSF1B, TNFRSF8, VTRNA1-3, or ZNF282. The upregulated expression may be, e.g., measured 16 hours after stimulation. The upregulated expression may be determined, e.g., by measuring RNA levels for the indicated genes.

In some embodiments of any of the methods and compositions for use disclosed herein, a subject has, or is identified as having, an elevated level of one or more T_{EFF} cell biomarkers, or a combination thereof. In some embodiments, the subject has, or is identified as having, upregulated expression of one or more (e.g., at least 10, 20, 30, 40, 50, 60, 70, or all) of the following genes: AIM2, ALAS1, B4GALT5, BATF, C3orf26, C4orf43, CCL3, CCL4, CCT3, CCT7, CD40LG, CHAC2, CSF2, CTNNA1, EBNA1BP2, EDARADD, EEF1E1, EIF2B3, EIF2S1, FABP5, FAM40B, FKBP4, FOSL1, GFOD1, GLRX2, HSPD1, HSPE1, IFNG, IL15RA, IL21, IL2RA, IL3, KCNK5, KIAA0020, LARP4, LRP8, LTA, MANF, MIR1182, MIR155, MIR155HG, MTCH2, MYOF, NDUFAF1, NLN, NME1, NME1-NME2, OTUD7B, PAM, PDIA6, PEA15, PFKM, PGAM1, PGAM4, PPIL1, PRDX4, PRSS23, PSMD1, PSMD11, PSMD14, PTRH2, PUS7, RBBP8, RPF2, RPP25, SFXN1, SLC27A2, SLC39A14, SLC43A3, SORD, SPR, SRXN1, STIP1, STT3A, TBX21, TMCC2, TMEM165, TNFRSF9, TXN, TXNDC5, UCK2, VDR, WDR12, YWHAG, or ZDHHC16. In certain embodiment, the subject has, or is identified as having, upregulated expression of one or more (e.g., at least 10, 20, 25, or all) of the following genes: B4GALT5, C3orf26, C4orf43, CCL3, CCL4, CCT3, CCT7, CSF2, CTNNA1, EEF1E1, EIF2B3, EIF2S1, GFOD1, GLRX2, IL21, IL2RA, IL3, KIAA0020, LARP4, LRP8, OTUD7B, PAM, PEA15, PFKM, PGAM1, PGAM4, PRSS23, PSMD1, PSMD11, PSMD14, PTRH2, RPF2, SORD, SPR, TMCC2, TMEM165, or TXNDC5. The upregulated expression may be, e.g., measured 16 hours after stimulation. The upregulated expression may be determined, e.g., by measuring RNA levels for the indicated genes.

In some embodiments of any of the methods and compositions for use disclosed herein, the responder (e.g., the complete or partial responder) has one, two, three or more (or all) of the following profile:

- (i) has a greater number of CD27+ immune effector cells compared to a reference value, e.g., a non-responder number of CD27+ immune effector cells;
- (ii) has a greater number of CD8+ T cells compared to a reference value, e.g., a non-responder number of CD8+ T cells;
- (iii) has a lower number of immune cells expressing one or more checkpoint inhibitors, e.g., a checkpoint inhibitor chosen from PD-1, LAG-3, TIM-3, or KLRG-1, or a combination,

compared to a reference value, e.g., a non-responder number of cells expressing one or more checkpoint inhibitors; or

(iv) has a greater number of one, two, three, four or more (all) of resting T_{EFF} cells, resting T_{REG} cells, younger cells, naïve CD4 cells, unstimulated memory cells or early memory T cells, or a combination thereof, compared to a reference value, e.g., a non-responder number of resting T_{EFF} cells, resting T_{REG} cells, naïve CD4 cells, unstimulated memory cells or early memory T cells.

In some embodiments of any of the methods and compositions for use disclosed herein, the cytokine level or activity, e.g., of (vi), is chosen from one, two, three, four, five, six, seven, eight, or more (or all) of cytokine CCL20/MIP3a, IL17A, IL6, GM-CSF, IFN γ , IL10, IL13, IL2, IL21, IL4, IL5, IL9 or TNF α , or a combination thereof. The cytokine can be chosen from one, two, three, four or more (all) of IL-17a, CCL20, IL2, IL6, or TNF α . In one embodiment, an increased level or activity of a cytokine is chosen from one or both of IL-17a and CCL20, is indicative of increased responsiveness or decreased relapse. In some embodiments, the cytokine level is measured after T cell activation.

In some embodiments of any of the methods and compositions for use disclosed herein, a transduction efficiency of 15% or higher, e.g., in (vii), is indicative of increased responsiveness or decreased relapse.

In some embodiments of any of the methods and compositions for use disclosed herein, a transduction efficiency of less than 15%, e.g., in (vii), is indicative of decreased responsiveness or increased relapse.

In another aspect, the invention features a method to identify a likely responder (e.g., a complete responder or a partial responder, a non-relapser) to a therapy comprising a CAR-expressing cell (e.g., a T cell, an NK cell) (e.g., a CD19 CAR-expressing cell therapy, e.g., described herein, e.g., a CTL019 therapy). In an embodiment, a responder status (e.g. a complete responder, a partial responder, a non-responder, a relapser or a non-relapser to a therapy comprising a CAR-expressing cell (e.g., a T cell, an NK cell)) is determined by measuring one or more of a CD19 CAR-expressing cell gene set signature, a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a

CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature, and combinations thereof. In one embodiment, a complete responder (CR) has, e.g., two, three, four or more (e.g., all) of CD27⁺, CD45RO⁻, PD-1⁻, LAG-3⁻, and TIM-3⁻, as described in **Table 9**. In one embodiment, a non-responder (NR) has, e.g., two, three, or more of (e.g., all) of CD27⁻ CD45RO⁺, PD-1⁺, LAG-3⁺, and TIM-3⁺, as described in **Table 10**.

In an embodiment, the responder or relapser status (e.g. complete responder, partial responder, non-responder, relapser or non-relapser to a CAR-expressing cell therapy) is determined by evaluating, e.g., measuring, two, three, four, five, six, seven, eight, nine, ten, fifteen or more of a CD19 CAR-expressing cell gene set signature, a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1.

In an embodiment, any of the methods and compositions for use disclosed herein can be used prior to administration of a CAR-expressing cell therapy. In some embodiments, provided methods can be used before, at the same time, or during course of a CAR-expressing cell therapy.

In an embodiment, any of the methods and compositions for use disclosed herein can be used to identify a subject having cancer, e.g., a hematological cancer such as, e.g., CLL or ALL, as having an increased or a decreased likelihood to respond to a treatment that comprises a CAR-expressing cell (e.g., T cell, NK cell) therapy, e.g., a CD19 CAR-expressing cell therapy. The method comprises: (1) acquiring a sample from the subject (e.g., an apheresis sample obtained from the blood of the subject; and/ or e.g., a manufactured product sample, e.g., genetically engineered T cells); (2) determining a level (e.g., amount or activity) of one or more biomarkers (e.g., 2, 3, 4, 5, 10, 15 or more) listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 in the sample; and (3) (optionally) comparing the determined level of the one or more markers to a reference level;

and (4) identifying the subject as a complete responder, partial responder, non-responder, a relapser or non-relapser to the CAR-expressing cell therapy. In embodiments, a difference, e.g., a statistically significant difference, between the determined level compared to a reference level is predictive of the subjects responsiveness to the CAR-expressing cell therapy.

5 In an aspect, provided methods comprise (1) acquiring a sample (e.g., an apheresis sample obtained from the subject; and/ or e.g., a manufactured product sample, e.g., genetically engineered T cells, e.g., a manufactured CD19 CAR-expressing cell product); (2) acquiring, e.g., determining a gene signature of the sample; and (3) (optionally) comparing the gene signature to a reference gene signature; wherein a difference, e.g., a statistically significant difference, in
 10 expression level of one or more of the biomarkers in the determined gene signature is predictive of the subjects responsiveness to the CAR-expressing cell therapy. In an embodiment, the gene signature comprises one or more markers selected from Table 1A, Table 1B, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27,
 15 CD122, CD62L, KLRG1, and combinations thereof. In one embodiment, the sample is a biological sample selected from a blood, plasma, or a serum sample. In a particular embodiment, a biological sample is a blood sample. In an embodiment, the sample is an apheresis sample, e.g., immune effector cells (e.g., T cells) obtained from the blood of the subject. In an embodiment, the sample is a manufactured product sample, e.g. genetically engineered T cells,
 20 e.g., a manufactured CD19 CAR-expressing cell product.

In an aspect, methods are provided for determining the responsiveness of a subject having cancer, e.g., a hematological cancer such as, e.g., CLL or ALL, to a treatment comprising a CAR-expressing cell (e.g., a T cell, an NK cell) therapy, e.g., a CD19 CAR-expressing cell therapy, e.g., described herein. The method includes: determining a level or activity of one or
 25 more biomarkers (e.g., 2, 3, 4, 5, 10, 15 or more) listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 in a sample obtained prior to treatment; wherein a difference, e.g., a statistically significant difference, in a level (e.g., amount or activity) of one or more markers in the sample relative to a
 30 predetermined value is indicative of increased responsiveness to the CAR-expressing cell. In

one embodiment, the sample is a biological sample selected from a blood, plasma, or a serum sample. In a particular embodiment, a biological sample is a blood sample. In one embodiment, the sample is an apheresis sample, e.g., T cells obtained from the blood of the subject. In an embodiment, the sample is a manufactured product sample, e.g. genetically engineered T cells, e.g., obtained from the blood of the subject, e.g., a manufactured CAR-expressing cell product, e.g., a manufactured CD19 CAR-expressing cell product.

In an embodiment, methods are provided for evaluating a subject having cancer, e.g., a hematological cancer such as, e.g., CLL or ALL, comprising acquiring a value of responder or relapser status for the subject that comprises a measure of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4+ biomarker, a CD8+ biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature, and a CD19 CAR-expressing cell (e.g., T cell, NK cell) gene set signature, thereby evaluating the subject. In an embodiment, methods comprise a measure of one or more of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, and a CD19 CAR-expressing cell gene set signature. In one embodiment, methods comprise a measure of one or more of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, and a CD19 CAR-expressing cell gene set signature, for evaluating a subject having CLL. In another embodiment, methods comprise a measure of one or more of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, and a CD19 CAR-expressing cell gene set signature, for

evaluating a subject having ALL. In one embodiment, the method comprises a measure of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature in a biological sample selected from a blood, plasma, or a serum sample. In a particular embodiment, a biological sample is a blood sample. In an embodiment, the sample is an apheresis sample, e.g., T cells obtained from the blood of the subject. In an embodiment, the sample is a manufactured product sample, e.g. genetically engineered T cells, e.g., obtained from the blood of the subject, e.g., a manufactured CAR-expressing cell product, e.g., a manufactured CD19 CAR-expressing cell product.

In an embodiment, methods are provided for evaluating or monitoring the effectiveness of a CAR-expressing cell (e.g., T cell, NK cell) therapy, e.g., a CD19 CAR-expressing cell therapy, in a subject having cancer comprising acquiring a value of responder or relapser status for the subject that comprises a measure of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature, and a CD19 CAR-expressing cell gene set signature, thereby evaluating or monitoring the effectiveness of the CAR-expressing cell therapy in the subject. In an embodiment, methods comprise a measure of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature. In an embodiment, methods comprise a measure of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17,

Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature, for evaluating or monitoring the effectiveness of a CAR-expressing cell therapy in a subject having CLL. In another embodiment, methods comprise a measure of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) of the following: a biomarker listed in
 5 Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature, for evaluating or monitoring the effectiveness of a CAR-expressing cell therapy in a subject having ALL. In one embodiment, the method comprises a measure of one or more (e.g., 2, 3, 4, 5, 10,
 10 15 or more) of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature in a biological sample selected from a blood, plasma, or a serum sample. In one embodiment, a biological sample is a blood sample. In an
 15 embodiment, the sample is an apheresis sample, e.g., T cells obtained from the blood of the subject. In an embodiment, the sample is a manufactured product sample, e.g. genetically engineered T cells, e.g., obtained from the blood of the subject.

In an embodiment, methods are provided for providing a prediction for success rate of a CAR-expressing cell therapy, e.g., a CD19 CAR-expressing cell therapy, e.g., described herein,
 20 in a subject having cancer, said method comprising steps of providing a biological sample from the subject; determining the levels of expression of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) genes listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), and Table 17 to obtain a gene expression pattern for the sample; and based on the gene expression pattern obtained, providing a prognosis
 25 to the subject. In an embodiment, a biological sample includes, but is not limited to a blood, plasma, or a serum sample. In a particular embodiment, a biological sample is a blood sample. In one embodiment, the sample is an apheresis sample, e.g., T cells obtained from the blood of the subject. In an embodiment, the subject has CLL. In an embodiment, the subject has ALL.

In another aspect, methods for treating a subject having cancer, e.g., a hematological
 30 cancer, are provided. In an embodiment, methods are provided for treating a subject having cancer determining if a subject has a difference, e.g., a statistically significant difference, in

expression level of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) markers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6) and Table 17 relative to a reference level, and if there is a difference, e.g., a statistically significant difference, between the determined level and reference level, administering to the subject a therapeutically effective dose of a CAR-expressing cell (e.g., T cell, NK cell), thereby treating the subject. In an embodiment, wherein there is a difference, e.g., a statistically significant difference, between the determined level and reference level, the method comprises modifying the CAR-expressing cell product prior to infusion into the subject. In an embodiment, wherein there is a difference, e.g., a statistically significant difference, between the determined level and the reference level, the method comprises modifying the manufacture of a CAR-expressing cell product prior to infusion into the subject. In an embodiment, if there is a difference, e.g., a statistically significant difference, between the determined level and reference level, the method comprises adjusting the CAR-expressing cell infusion dose to achieve an anti-cancer effect.

In an embodiment, the methods of treatment described herein comprise determining if a subject has an increased likelihood to respond to a CAR-expressing cell (e.g., T cell, NK cell) therapy, e.g., a CD19 CAR-expressing cell therapy, e.g., a CD19 CAR-expressing cell therapy described herein, by comparing the level of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) markers in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15 and Table 16 (e.g., CCL20, IL-17a and/or IL-6) in a sample from the subject relative to a reference level, wherein a difference, e.g., a statistically significant difference, in expression level of one or more marker genes relative to the reference level is indicative of an increased likelihood of response; and administering to the subject a therapeutically effective dose of a CAR-expressing cell, thereby treating the subject. In one embodiment, the sample is selected from a blood, plasma or a serum sample. In one embodiment, the sample is an apheresis sample, e.g., T cells obtained from the blood of the subject.

In an embodiment, the methods of treatment described herein further comprise obtaining a sample from a subject; determining a level of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) markers in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3,

TIM-3, CD57, CD27, CD122, CD62L, and KLRG1, in the sample; comparing the determined level of one or more markers in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1, to a reference level; and administering a therapeutically effective dose of a CAR-expressing cell (e.g., T cell, NK cell), if the subject is identified as having a difference, e.g., a statistically significant difference, in the determined level of one or more markers in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1, to a reference level in the sample.

In an embodiment, the methods of treatment described herein comprise, or further comprise, acquiring a value of responder or relapser status for the subject that comprises a measure of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature, and a CD19 CAR-expressing cell gene set signature, and responsive to a determination of responder or relapser status, performing one, two, three four or more of: identifying the subject as a complete responder, partial responder or non-responder; administering a CAR-expressing cell therapy; selecting or altering a dosing of a CAR-expressing cell therapy; selecting or altering the schedule or time course of a CAR-expressing cell therapy; administering, e.g., to a non-responder or a partial responder, an additional agent in combination with a CAR-expressing cell therapy, e.g., a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein, or a kinase inhibitor, e.g., a kinase inhibitor described herein; administering to a non-responder or partial responder a therapy that increases the number of naïve T cells in the subject prior to treatment with a CAR-expressing cell therapy; modifying a manufacturing process of a CAR-expressing cell therapy, e.g., enrich for naïve T

cells prior to introducing a nucleic acid encoding a CAR, e.g., for a subject identified as a non-responder or a partial responder; or selecting an alternative therapy, e.g., a standard of care for a particular cancer (e.g., as described herein), e.g., for a non-responder, partial responder or relapser; thereby treating cancer in the subject.

5

Systems

In still another aspect, the present disclosure provides kits for predicting subject response to CAR-expressing cell (e.g., T cell, NK cell) therapy, e.g., a CD19 CAR-expressing cell therapy, e.g., a CD19 CAR-expressing cell therapy described herein. The kits comprise at least
10 one reagent that specifically detects the level or activity of a set of genes (e.g., 2, 3, 4, 5, 10, 15 or more of the genes) selected from Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and/or KLRG1; and instructions for using the kits, e.g., for predicting a subject's response to a CAR-expressing cell therapy. In
15 some embodiments, said instructions for use provide that if one or more of the detected expression levels is different from, e.g., greater than a reference level, the subject is more likely to respond positively to a CAR-expressing cell therapy. In some embodiments, said instructions for use provide that if one or more of the detected expression levels is less than a reference level, the subject is more likely to respond positively to a CAR-expressing cell therapy. In some
20 embodiments, if the level or activity of PD-1, LAG-3, or TIM-3, or any combination thereof, is less than a reference value, the subject is more likely to respond positively to the therapy.

In certain embodiments, at least one reagent that specifically detects expression levels of the set of genes comprises a nucleic acid probe complementary to mRNA expressed from the genes, for example a cDNA or an oligonucleotide. The nucleic acid probe may be immobilized
25 on a substrate surface or may be in solution. The set of reagents may detect the expression of polypeptides, e.g., surface polypeptides, encoded by said set of genes. In one embodiment, the nucleic acid probe comprises a nucleic acid of about 10, 15, 20, 25, 30, 35, 40, 45, 50 or 100 nucleic acid residues complementary the nucleic acid sequence of a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16
30 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and/or KLRG1. The kits may further comprise one or more of:

extraction buffer/reagents and protocol, amplification buffer/reagents and protocol, hybridization buffer/reagents and protocol, and labeling buffer/reagents and protocol.

In certain embodiments, the kits further comprise at least one CD19 CAR-expressing cell (e.g., T cell, NK cell) gene set signature. In one embodiment, the kit further comprises a
5 reference standard.

In an embodiment, the subject has CLL.

In an embodiment, the subject has ALL.

In an embodiment, the subject has B-cell ALL.

In an aspect, the disclosure features a reaction mixture comprising at least one reagent
10 that specifically detects expression levels of a set of genes (e.g., 2, 3, 4, 5, 10, 15 or more of the genes) selected from Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and/or KLRG1; and a biological sample. In one embodiment, the sample is selected from a blood, plasma or a serum sample. In one
15 embodiment, the sample is an apheresis sample, e.g., T cells obtained from the blood of the subject. In one embodiment, the sample comprises CAR-expressing cells, e.g., CART-expressing cells, e.g., CART19 cells.

In certain embodiments, at least one reagent that specifically detects expression levels of the set of genes comprises a nucleic acid probe complementary to mRNA expressed from the
20 genes, for example a cDNA or an oligonucleotide. The nucleic acid probe may be immobilized on a substrate surface or may be in solution. The set of reagents may detect the expression of polypeptides, e.g., surface polypeptides, encoded by said set of genes. In one embodiment, the nucleic acid probe comprises a nucleic acid of about 10, 15, 20, 25, 30, 35, 40, 45, 50 or 100 nucleic acid residues complementary the nucleic acid sequence of a biomarker listed in Table
25 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and/or KLRG1. The reaction mixture may further comprise one or more of: extraction buffer/reagents, amplification buffer/reagents, hybridization buffer/reagents, and labeling buffer/reagents.

In another aspect, the present disclosure features a system for evaluating cancer in a subject. The system comprises at least one processor operatively connected to a memory, the at least one processor when executing is configured to perform any one or more of the steps described herein.

5 In still another aspect, the present disclosure features a system for evaluating cancer in a subject. The system includes at least one processor operatively connected to a memory, the at least one processor when executing is configured to:

acquire a value of responder or relapser status that comprises a measure of one, two, three, four, five, six, seven or more (all) of the following:

10 (i) the level or activity of CD27 and/or CD45RO- (e.g., CD27+ CD45RO-) immune effector cells, e.g., in a CD4+ or a CD8+ T cell population in a sample (e.g., an apheresis sample or a manufactured CAR-expressing cell product sample);

(ii) the level or activity of one, two, three, or more (e.g., all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells, or gamma/delta T cells), early
15 memory T cells, or a combination thereof, in a sample (e.g., an apheresis sample or a manufactured CAR-expressing cell product sample);

(iii) the level or activity of one, two, three, or more (e.g., all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in a sample (e.g., an apheresis sample or a manufactured CAR-expressing
20 cell product sample);

(iv) the level or activity of an immune cell exhaustion marker, e.g., one, two or more immune checkpoint inhibitors (e.g., PD-1, TIM-3 and/or LAG-3) in a sample (e.g., an apheresis sample or a manufactured CAR-expressing cell product sample);

(v) the level or activity of one, two, three, four, five, ten, twenty or more of the
25 biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature;

(vi) a cytokine level or activity (e.g., quality of cytokine repertoire) in a CAR-expressing
30 cell product sample, e.g., CAR19- expressing cell product sample (e.g., CTL019), wherein the

cytokine is chosen from one, two, three, four, five or more (or all) of the cytokines listed in Table 16;

(vii) a transduction efficiency of a CAR-expressing cell in a manufactured CAR-expressing cell product sample; or

5 (viii) a quantity of CD27+ PD-1- cells in a subject, e.g., a sample from the subject (e.g., an apheresis sample or a CAR-expressing cell product sample, e.g., CAR19- expressing cell product sample (e.g., CTL019)), e.g., a quantity greater than or equal to 1×10^7 cells.

responsive to a determination of the value of responder status, perform one, two, three,
10 four, five, six, seven, or more (e.g., all) of:

identify the subject as a complete responder, partial responder, non-responder, relapser or non-relapser;

recommend administering a CAR-expressing cell therapy;

recommend a selection or alteration of a dosing of a CAR-expressing cell therapy;

15 recommend a selection or alteration of a schedule or time course of a CAR-expressing cell therapy;

recommend administering, e.g., to a non-responder or a partial responder, an additional agent in combination with a CAR-expressing cell therapy, e.g., a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein;

20 recommend administering to a non-responder or partial responder a therapy that increases the number of naïve T cells in the subject prior to treatment with a CAR-expressing cell therapy;

recommend modifying a manufacturing process of a CAR-expressing cell therapy, e.g., enrich for naïve T cells prior to introducing a nucleic acid encoding a CAR, e.g., for a subject identified as a non-responder or a partial responder;

25 recommend modifying the CAR-expressing cell product prior to infusion into the patient;

recommend adjusting the CAR-expressing cell infusion dose to achieve clinical efficacy;

recommend administering an alternative therapy, e.g., for a non-responder or partial responder or relapser;

30 recommend a selection of an alternative therapy, e.g., for a non-responder or partial responder, e.g., a standard of care for a particular cancer type, or

if the subject is, or is identified as, a non-responder or a relapser, recommend decreasing the T_{REG} cell population and/or T_{REG} gene signature, e.g., by CD25 depletion, administration of cyclophosphamide, anti-GITR antibody, mTOR inhibitor, or a combination thereof.

5 In one embodiment, the value includes a measure of a CD19 CAR-expressing cell gene set signature and a combination of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) of: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, 10 an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, and a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature; and responsive to a determination of the value of responder status, perform one, two, three, four or more of: 15 identify the subject as a complete responder, partial responder, or non-responder; recommend a CAR-expressing cell therapy; recommend a selection or alteration of a dosing of a CAR-expressing cell therapy; recommend an alternative therapy, recommend a combination therapy, e.g., a combination with a CAR-expressing cell therapy, recommend or alter a manufacturing process of a CAR-expressing cell therapy.

20 In one embodiment, the at least one processor when executing is configured to: acquire a value of responder status that comprises a measure of a CD19 CAR-expressing cell gene set signature and a combination of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) of: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, 25 TIM-3, CD57, CD27, CD122, CD62L, and KLRG1; and responsive to a determination of the value of responder status, perform one, two, three, four or more of: identify the subject as a complete responder, partial responder, or non-responder; recommend a CAR-expressing cell therapy; recommend a selection or alteration of a dosing of a CAR-expressing cell therapy; recommend an alternative therapy, e.g., a standard of care for a particular cancer (e.g., as 30 described herein); recommend a combination therapy, e.g., a combination with a CAR-

expressing cell therapy, recommend or alter a manufacturing process of a CAR-expressing cell therapy, e.g., as described herein.

Manufacturing Methods

- 5 In another aspect, the invention features a method of evaluating the potency of a CAR-expressing cell product, e.g., CAR19-expressing cell product sample (e.g., CTL019). The method includes acquiring a value for one, two, three, four, five, six, seven, eight, or more (e.g., all) of:
- (i) the level or activity of CD27 and/or CD45RO- (e.g., CD27+ CD45RO-) immune effector cells, e.g., in a CD4+ or a CD8+ T cell population, in the CAR-expressing cell product;
 - 10 (ii) the level or activity of one, two, three, or more (e.g., all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, in the CAR-expressing cell product;
 - (iii) the level or activity of one, two, three, or more (e.g., all) of activated T_{EFF} cells, 15 activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in the CAR-expressing cell product;
 - (iv) the level or activity of an immune cell exhaustion marker, e.g., one, two or more immune checkpoint inhibitors (e.g., PD-1, TIM-3 and/or LAG-3) in the CAR-expressing cell product;
 - 20 (v) the level or activity of one, two, three, four, five, ten, twenty or more of the biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature;
 - 25 (vi) a cytokine level or activity in a CAR-expressing cell product sample, e.g., CAR19-expressing cell product sample (e.g., CTL019), wherein the cytokine is chosen from one, two, three, four, five or more (or all) of the cytokines listed in Table 16;
 - (vii) a transduction efficiency of CAR-expressing cells in the product;

(viii) a quantity of CD27+ PD-1- cells in a subject, e.g., a sample from the subject (e.g., an apheresis sample or a CAR-expressing cell product sample, e.g., CAR19- expressing cell product sample (e.g., CTL019)), e.g., a quantity greater than or equal to 1×10^7 cells; or

(ix) the level or activity of a T_{REG} cell or cell population,

5

wherein an increase in (i), (ii), (vi), (vii), (viii), or any combination thereof, is indicative of increased potency of the CAR-expressing cell product, and

wherein an increase in (iii), (iv), (ix), or any combination thereof is indicative of decreased potency of the CAR-expressing cell product.

10

In a related aspect, the invention features a method for optimizing manufacturing of a CAR-expressing cell product, e.g., CAR19- expressing cell product sample (e.g., CTL019). The method includes:

(1) acquiring a sample comprising CAR-expressing cell (e.g., a population of CAR-
15 expressing immune effector cells);

(2) activating the CAR-expressing cell *in vitro*;

(3) evaluating the potency of the activated CAR-expressing cell by determining one, two, three, four, five, six, seven, eight, or more (e.g., all) of:

(i) the level or activity of CD27 and/or CD45RO- (e.g., CD27+ CD45RO-) immune
20 effector cells, e.g., in a CD4+ or a CD8+ T cell population, in the CAR-expressing cell product;

(ii) the level or activity of one, two, three, or more (e.g., all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, in the CAR-expressing cell product;

(iii) the level or activity of one, two, three, or more (e.g., all) of activated T_{EFF} cells,
25 activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in the CAR-expressing cell product;

(iv) the level or activity of an immune cell exhaustion marker, e.g., one, two or more immune checkpoint inhibitors (e.g., PD-1, TIM-3 and/or LAG-3) in the CAR-expressing cell product;

(v) the level or activity of one, two, three, four, five, ten, twenty or more of the
30 biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table

14 (e.g., CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature;

(vi) a cytokine level or activity in a CAR-expressing cell product sample, e.g., CAR19-
5 expressing cell product sample (e.g., CTL019), wherein the cytokine is chosen from one, two, three, four, five or more (or all) of the cytokines listed in Table 16;

(vii) a transduction efficiency of CAR-expressing cells in the product;

(viii) a quantity of CD27+ PD-1- cells in a subject, e.g., a sample from the subject (e.g., an apheresis sample or a CAR-expressing cell product sample, e.g., CAR19- expressing cell
10 product sample (e.g., CTL019)), e.g., a quantity greater than or equal to 1×10^7 cells; or

(ix) the level or activity of a T_{REG} cell or cell population,

wherein an increase in (i), (ii), (vi), (vii), (viii), or any combination thereof is indicative of increased potency of the CAR-expressing cell product, and

wherein an increase in (iii), (iv), (ix), or any combination thereof, is indicative of
15 decreased potency of the CAR-expressing cell product.

In a related aspect, disclosed herein is a manufacturing process of a CAR-expressing cell (e.g., T cell, NK cell) product (e.g., a CD19 CAR-expressing cell, e.g., a CD19 CAR-expressing cell described herein, e.g., CTL019) to determine the potency or efficacy of the product. In an
20 embodiment, provided methods comprise steps of providing a biological sample from a subject, e.g., a blood, serum or plasma sample; determining the levels of expression of one or more (e.g., 2, 3, 4, 5, 10, 15 or more) genes listed in Table 1A, 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1, to obtain a gene
25 expression pattern for the sample; (optionally) comparing the obtained gene expression pattern to a predetermined value; and determining a difference between the obtained and the predetermined value. In an embodiment, the determined difference is recorded in a quality control record.

In some embodiments, any of the methods disclosed herein further comprise a step of
30 enriching for, e.g., isolating, cells having an increase in any of (i), (ii), (vi), (vii), (viii), or any combination thereof, or a decrease in any of (iii), (iv), (ix), or any combination thereof.

In another aspect, the invention features a method for manufacturing of a product sample, e.g., genetically engineered T cells, e.g., obtained from the blood of a subject, e.g., a manufactured CAR-expressing cell (e.g., T cell, NK cell) product, e.g., a CD 19 CAR-expressing cell product, e.g., a CD19 CAR-expressing cell product described herein, e.g., CTL019). In an embodiment, the method comprises:

providing a manufactured product sample, e.g., genetically engineered T cells, e.g., obtained from the blood of a subject, e.g., a manufactured CAR-expressing cell product, e.g., a CD 19 CAR-expressing cell product, e.g., a CD19 CAR-expressing cell product described herein, e.g., CTL019);

(i) acquiring a cytokine expression profile (e.g., of Table 14, Table 15 or Table 16 (e.g., CCL20, IL-6 and/or IL-17a) secreted from the CAR-expressing cell product; and/or

(ii) acquiring measure of a transduction efficiency of CAR-expressing cells in the product;

identifying the CAR-expressing cell product as suitable for administration based on the determined cytokine level or transduction efficiency (or both); and

optionally, selecting the CAR-expressing cell product for administration to a subject, thereby manufacturing a CAR-expressing cell product.

In certain embodiments of the aforesaid manufacturing methods, the cytokine is chosen from one, two, three, four, five, six, seven, eight, or more (or all) of CCL20/MIP3a, IL17A, IL6, GM-CSF, IFN γ , IL10, IL13, IL2, IL21, IL4, IL5, IL9 or TNF α , or a combination thereof. In one embodiment, the cytokine is chosen from one, two, three, four or more (all) of IL-17a, CCL20, IL2, IL6, or TNF α . For example, the cytokine can be chosen from: one or both of IL-17a and CCL20; one or both of CCL20/MIP3a and IL17A; or one, two, or all of CCL20/MIP3a, IL17A and IL6. In one embodiment, the cytokine is CCL20/MIP3a. In another embodiment, the cytokine is IL17A. In yet another embodiment, the cytokine is IL6.

In certain embodiments of the aforesaid manufacturing methods, a transduction efficiency of 15% or higher is indicative of increased potency. In other embodiments, a transduction efficiency of less than 15% is indicative of decreased potency.

In certain embodiments, any of the aforesaid manufacturing methods further comprise reducing the number (e.g., depleting) T_{REG} cells, e.g., via CD25-depletion, GITR depletion, or mTOR inhibition. Alternatively, or in combination, the manufacturing methods further comprise contacting the sample, e.g., the apheresis sample, with an anti-GITR antibody.

5 In certain embodiments, any of the aforesaid manufacturing methods each of (i), (ii) or (iii), (iv), (v), (vi), (vii), (viii), (ix), or any combination thereof (e.g., all) are evaluated following activation *in vitro*.

In an embodiment, the cytokine profile includes one or more (e.g., one, two, three, four, five, six or more) of CCL20 (also referred to as MIP3a), IL-17a, IL-6, GM-CSF, IFN γ , IL-10,
10 IL-13, IL-2, IL-21, IL-4, IL-5, IL-9 and TNF α . In an embodiment, the cytokine profile includes CCL20. In an embodiment, the cytokine profile includes IL-17a. In an embodiment, the cytokine profile includes IL-6. In one embodiment, the cytokine profile includes two or more (e.g., all three) of CCL20, IL-17a and IL-6.

In one embodiment, the method further includes determining an expression level of one
15 or more cytokines of Table 14, Table 15 or Table 16 (e.g., CCL20, IL-17a and/or IL-6) secreted by the CAR-expressing cell (e.g., T cell, NK cell) product. In an embodiment, secretion of one or more cytokines of Table 14, Table 15 or Table 16 (e.g., CCL20, IL-17a and/or IL-6) is in response to CAR-expressing cell product stimulation with one or more target tumor antigen(s).

In an embodiment, the cytokine signature or level described herein is indicative of the
20 potency of a CAR-expressing cell product. In an embodiment, cytokine signatures described herein are markers of response to a CAR-expressing cell product in a hematological cancer (e.g., CLL and ALL).

In an embodiment, the cytokine signature or level described herein predict subject response to a CAR-expressing cell product.

25 In an embodiment, the cytokine signature or level described in **Table 16** predict subject response to a CAR-expressing cell product.

In an embodiment, the IL-17a and CCL-20 expression level predict subject response to a CAR-expressing cell product.

In an embodiment, the method further includes one or more of (e.g., one, two, three or all of): obtaining a blood sample, e.g., a population of T cells obtained from the blood of a subject; activating the population of T cells, e.g., by a method described herein; genetically engineering a cell from the population of T cells, e.g., transducing a cell from the population of T cells, with a vector comprising a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, e.g., CTL019; expanding a population of T cells that comprises a genetically engineered T cell, e.g., a cell transduced with a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, e.g., by a method described herein.

In an embodiment, the CAR transduction efficiency described herein is indicative of subject's response to a CAR-expressing cell therapy in a hematological cancer (e.g., CLL and ALL).

In an embodiment, a CAR transduction efficiency described herein is predictive of subject response to CAR-expressing cell therapy in a hematological disease (e.g., CLL and ALL).

In an embodiment, a cytokine signature or level described herein is used to improve and/or modify CAR-expressing cell product (e.g., a CD19 CAR-expressing cell product such as, e.g., CTL019) prior to infusion in patients.

In an embodiment, a cytokine signature or level described herein is used to assess manufactured CAR-expressing cell (e.g., T cell, NK cell) products. In an embodiment, the cytokine signature or level described herein provide an end point in manufacturing process optimization.

In an embodiment, any of the aforesaid manufacturing methods comprise a step of recording the result of the comparison in a quality control record for the CAR-expressing cell (e.g., T cell, NK cell) preparation (e.g., a CD19 CAR-expressing cell preparation as described herein such as, e.g., CTL019). In an embodiment, the method further comprises obtaining a preparation of T cells from a subject identified as a partial responder or non-responder and increasing the number of naïve T cells in the preparation. In one embodiment, the method further comprises introducing a nucleic acid encoding a CAR into the T cell preparation.

In an embodiment, the method further comprises obtaining a preparation of immune effector cells (e.g., T cells) from a subject identified as a partial responder or non-responder and who has been subsequently treated with an agent that increases the number of naïve T cells in the subject, e.g., the subject has been treated with a kinase inhibitor, e.g., an mTOR inhibitor, e.g., as described herein, and/or a checkpoint inhibitor, e.g., as described herein. In one embodiment, the method further comprises introducing a nucleic acid encoding a CAR into a plurality of the immune effector cells (e.g., T cells) of the preparation.

In an embodiment, the CAR-expressing cell (e.g., T cell, NK cell) product is a CD19 CAR-expressing cell, e.g., a CD19 CAR-expressing cell described herein, e.g., CTL019.

In still another aspect, the present disclosure provides one or more gene signatures or expression profiles that discriminate relapsers to CAR-expressing cell (e.g., T cell, NK cell) therapy from non-relapsers to CAR-expressing cell therapy in a cancer, e.g., a hematological cancer (e.g., ALL and CLL).

In an embodiment, the one or more gene signatures or expression profiles described herein enable manufactured product improvements, thereby reducing the likelihood of patient relapse. In an embodiment, gene signatures described herein are used to modify therapeutic application of manufactured product, thereby reducing the likelihood of patient relapse.

In an embodiment, the one or more gene signatures or expression profiles described herein are identified in a subject prior to CAR-expressing cell treatment (e.g., a CD19 CAR-expressing cell treatment, e.g., CTL019 therapy) that predict relapse to CAR-expressing cell treatment. In an embodiment, the one or more gene signatures or expression profiles described herein are identified in an apheresis sample. In an embodiment, the one or more gene signatures or expression profiles described herein are identified in a bone marrow sample. In an embodiment, the one or more gene signatures or expression profiles described herein are identified in a manufactured CAR-expressing cell product (e.g., a CD19 CAR-expressing cell product, e.g., CTL019) prior to infusion.

In an embodiment, decreasing the T_{REG} level or gene signature in a subject prior to apheresis or during manufacturing of a CAR-expressing cell product significantly reduces the risk of subject relapse.

In an embodiment, a subject is pre-treated with one or more therapies that reduce T_{REG} cells prior to collection of cells for CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to CAR-expressing cell treatment (e.g., CTL019 treatment).

In an embodiment, methods of decreasing T_{REG} cells include, but are not limited to,

5 administration to the subject of one or more of cyclophosphamide, anti-GITR antibody, CD25-depletion, mTOR inhibitor, or a combination thereof. Administration of one or more of cyclophosphamide, anti-GITR antibody, CD25-depletion, mTOR inhibitor, or a combination thereof, can occur before, during or after an infusion of the CAR-expressing cell product.

10 In an embodiment, a subject is pre-treated with cyclophosphamide prior to collection of cells for CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to CAR-expressing cell treatment (e.g., CTL019 treatment).

In an embodiment, a subject is pre-treated with an anti-GITR antibody prior to collection of cells for CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to CAR-expressing cell treatment (e.g., CTL019 treatment).

15 In an embodiment, a CAR-expressing cell manufacturing process is modified to deplete T_{REG} cells prior to manufacturing of the CAR-expressing cell product (e.g., a CTL019 product). In an embodiment, CD25-depletion is used to deplete T_{REG} cells prior to manufacturing of the CAR-expressing cell product (e.g., a CTL019 product). Accordingly, in some embodiments, the method further comprises:

- 20 a. providing a population of immune effector cells (e.g., T cells or NK cells); and
- b. removing T regulatory cells from the population, thereby providing a population of T regulatory-depleted cells;

wherein steps a) and b) are performed prior to introducing the nucleic acid encoding the CAR to the population.

25 In embodiments of the methods, the T regulatory cells comprise CD25+ T cells, and are removed from the cell population using an anti-CD25 antibody, or fragment thereof. The anti-CD25 antibody, or fragment thereof, can be conjugated to a substrate, e.g., a bead.

In other embodiments, the population of T regulatory-depleted cells provided from step (b) contains less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells.

In yet other embodiments, the method further comprises removing cells from the population which express a tumor antigen that does not comprise CD25 to provide a population
5 of T regulatory-depleted and tumor antigen depleted cells prior to introducing the nucleic acid encoding a CAR to the population. The tumor antigen can be selected from CD19, CD30, CD38, CD123, CD20, CD14 or CD11b, or a combination thereof.

In other embodiments, the method further comprises removing cells from the population which express a checkpoint inhibitor, to provide a population of T regulatory-depleted and
10 inhibitory molecule depleted cells prior to introducing the nucleic acid encoding a CAR to the population. An inhibitory molecule, e.g., a checkpoint inhibitor, can be chosen from PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFRbeta), e.g., as described herein.
15

Further embodiments disclosed herein encompass providing a population of immune effector cells. The population of immune effector cells provided can be selected based upon the expression of one or more of CD3, CD28, CD4, CD8, CD45RA, and/or CD45RO. In certain embodiments, the population of immune effector cells provided are CD3+ and/or CD28+.

20 In certain embodiments of the method, the method further comprises expanding the population of cells after the nucleic acid molecule encoding a CAR has been introduced.

In embodiments, the population of cells is expanded for a period of 8 days or less.

In certain embodiments, the population of cells is expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same
25 culture conditions.

In other embodiments, the population of cells is expanded in culture for 5 days, and shows at least a one, two, three or four fold increase in cell doublings upon antigen stimulation as compared to the same cells expanded in culture for 9 days under the same culture conditions.

In yet other embodiments, the population of cells is expanded in culture for 5 days, and the resulting cells exhibit higher proinflammatory IFN- γ and/or GM-CSF levels, as compared to the same cells expanded in culture for 9 days under the same culture conditions.

5 In other embodiments, the population of cells is expanded by culturing the cells in the presence of an agent that stimulates a CD3/TCR complex associated signal and/or a ligand that stimulates a costimulatory molecule on the surface of the cells. The agent can be a bead conjugated with anti-CD3 antibody, or a fragment thereof, and/or anti-CD28 antibody, or a fragment thereof.

10 In other embodiments, the population of cells is expanded in an appropriate media that includes one or more interleukin that result in at least a 200-fold, 250-fold, 300-fold, or 350-fold increase in cells over a 14 day expansion period, as measured by flow cytometry.

In other embodiments, the population of cells is expanded in the presence IL-15 and/or IL-7.

15 In certain embodiments, the method further includes cryopreserving the population of the cells after the appropriate expansion period.

In yet other embodiments, the method of making disclosed herein further comprises contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT. The nucleic acid encoding the telomerase subunit can be DNA.

20 In yet other embodiments, the method of making disclosed herein further comprises culturing the population of immune effector cells in serum comprising 2% hAB serum.

In any of the methods, systems and kits described herein, the CD19 CAR can comprise an anti-CD19 binding domain described in **Table 12**, or CDRs, e.g., one or more (e.g., all) of HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 of an anti-CD19 binding domain described in **Table 12**. In an embodiment, the CAR can comprise one of more of: a
25 leader sequence, e.g., a leader sequence described herein, e.g., in **Table 11**; an anti-CD19 binding domain, e.g., an anti-CD19 binding domain described herein, e.g., in **Table 12**; a hinge region, e.g., a hinge region described herein, e.g., a hinge region described in **Table 11**; a transmembrane domain, e.g., a transmembrane domain described herein, e.g., in **Table 11**; and an intracellular signaling domain (e.g., a costimulatory domain and/or a primary signaling

domain, e.g., a costimulatory domain described herein, e.g., in **Table 11** and/or a primary signaling domain described herein, e.g., in **Table 11**). In an embodiment, the CD19 CAR-expressing cell (e.g., T cell, NK cell) is CTL019 or a CD19 CAR described in **Table 13**.

Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references (e.g., sequence database reference numbers) mentioned herein are incorporated by reference in their entirety. For example, all GenBank, Unigene, and Entrez sequences referred to herein, e.g., in any Table herein, e.g., in any of Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 14, Table 17, Table 18, and Table 20, are incorporated by reference. Unless otherwise specified, the sequence accession numbers specified herein, including in any Table herein, e.g., in any of Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 14, Table 17, Table 18, and Table 20, refer to the database entries current as of October 8, 2014. When one gene or protein references a plurality of sequence accession numbers, all of the sequence variants are encompassed.

In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Headings, sub-headings or numbered or lettered elements, e.g., (a), (b), (i) etc., are presented merely for ease of reading. The use of headings or numbered or lettered elements in this document does not require the steps or elements be performed in alphabetical order or that the steps or elements are necessarily discrete from one another. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts an exemplary model illustrating findings from a whole genome CTL019 RNAseq analysis performed on T cells at apheresis and after CTL019 manufacturing for 21 CLL and 7 ALL samples. This model demonstrates that expression patterns of complete responders (CRs) have a younger T cell phenotype than non-responders (NRs). Memory T cell subsets are differentially enriched between CRs versus NRs with CRs showing similarity to T memory stem cells.

FIG. 2A depicts an exemplary histogram of the number of samples analyzed in the whole genome CTL019 RNAseq analysis described herein. p= product; a=apheresis. **FIG. 2B** is an exemplary schematic illustrating an overview of the analysis. Briefly, for each gene set, a 3-group statistical model was applied to determine whether the meta-gene was statistically different between the CLL product CRs, PRs, and NRs. CRs are more like resting T_{EFF} cells, whereas NR are more like activated T_{EFF} cells. CTL019 NR samples are in a more activated state than CR samples.

FIG. 3 depicts an exemplary schematic of memory T cell precursors and subsets. Without wishing to be bound by a particular theory, the state of memory T cells in CTL019 samples is likely a major component of response.

FIG. 4 depicts an exemplary result illustrating meta-gene scores for the T_{SCM} vs T_{CM} upregulated gene set. The x-axis is samples by response group where a=apheresis and p=product. The y-axis is normalized meta-gene expression scores. Gene sets enriched in CLL CRs (e.g., CTL019 CRs) are also enriched in acute lymphoblastic leukemias (ALLs). ALL and CLL CRs are enriched in T stem cell (T_{SCM}) subset specific genes, whereas CLL PRs and NRs are enriched in T central memory (T_{CM}) subset genes. The same pattern is seen in apheresis as in product samples. ALL expression patterns are most similar to CLL CRs and are even more extreme in the direction of resting/unstimulated/early memory T cells.

FIG. 5A depicts an exemplary result from a Principle Component Analysis (PCA) of CTL019 samples. This exemplary PCA result illustrates that CRs, ALL and Normal samples cluster separately from PRs and NRs. **FIG. 5B** depicts an exemplary result from a PCA of CTL019 and apheresis samples. This exemplary PCA result illustrates that CRs, ALL and Normal samples cluster separately from PRs and NRs and from the apheresis cluster.

FIG. 6 depicts an exemplary schematic depicting immunophenotyping of apheresis and product samples.

FIG. 7A and **FIG. 7B** depict exemplary multi-color flow cytometry analysis results identifying correlates of response in product samples. 36 manufactured CTL019 samples from CLL patients were analyzed. Samples included 5 CR, 8 PR, 19NR and 3 pending. **FIG. 7A**

depicts an exemplary result illustrating percent CD4+ cells and patient response. **FIG. 7B** depicts an exemplary result illustrating percent CD8+ cells and patient response.

FIG. 8A, FIG. 8B, FIG. 8C and FIG. 8D depicts an exemplary flow cytometry analysis of PD1 and CAR19 expression on T cells. **FIG. 8A** and **FIG. 8B** are representative flow
5 cytometry profiles demonstrating the distribution of PD-1 and CAR19 expression on CD4+ T cells from subjects that are complete responders (CR) or non-responders (NR) to CAR-expressing cell therapy. **FIG. 8C** is a graph showing the percent of PD1 cells in the CD4+ T cell population from groups of subjects with different responses to CAR-expressing cell therapy. **FIG. 8D** is a graph showing the percent of PD1 cells in the CD8+ T cell population from groups
10 of subjects with different responses to CAR-expressing cell therapy.

FIG. 9A and **FIG. 9B** depict an exemplary flow cytometry analysis of PD1, CAR 19, and LAG-3 expression on T cells from subjects that are complete responders (CR) or non-responders (NR) to CAR-expressing cell therapy. **FIG. 9C** depicts exemplary results that show the
15 distribution of PD1 and LAG-3 expression from groups of subjects with different responses to CAR-expressing cell therapy. Non-responder (NR) products have higher percentages of PD1+ CAR19+ LAG3+ T cells than CRs. These data demonstrate that NR products exhibit an exhausted phenotype of PD1+ CAR+ and co-expression of LAG3.

FIG. 10A and **FIG. 10B** depict an exemplary flow cytometry analysis of PD1, CAR 19, and TIM-3 expression on T cells from subjects that are complete responders (CR) or non-
20 responders (NR) to CAR-expressing cell therapy. **FIG. 10C** depicts exemplary results that show the distribution of PD1 and TIM-3 expression from groups of subjects with different responses to CAR-expressing cell therapy. Non-responder (NR) products have higher percentages of CAR19+ PD1+ TIM3+ cells than CRs. These data demonstrate that NR products exhibit an exhausted phenotype of PD1+ CAR+ and co-expression of TIM3.

FIG. 11 depicts an exemplary result illustrating that CD27 levels in the CAR product correlate with patient response. CRs CD8+ cells displayed a higher percentage of CD27+ cells
25 as compared to PRs and NRs.

FIG. 12 depicts an exemplary multi-color flow cytometry analysis result identifying correlates of response in apheresis samples. 26 apheresed samples from CLL patients were analyzed. Samples included 4 CR, 6 PR, 14NR and 1 patient was not infused.

FIG. 13 depicts an exemplary multi-color flow cytometry analysis result illustrating a correlation between a younger T cell phenotype and response to CTL019 therapy. These data demonstrate that the percentage of CD27+ CD45RO- in CD8+ T cells is predictive of which CLL patients will undergo a complete response to CTL019.

FIG. 14 depicts an exemplary analysis of apheresis in a human patient prior to CTL019 therapy. Exemplary results illustrate that while patient 1000-00045 presented with very few T cells, 27% of the T cells were CD8+ CD27+ CD45RO-.

FIG. 15 depicts an exemplary result of a patient response (patient 1000-00045) to CTL019 therapy. CD8+ CD27+ CD45RO- T cells were a positive predictor of the patient response to CTL019 therapy. These exemplary results illustrate that a good prognostic phenotype in apheresis is a high percentage of CD8+ CD27+ CD45RO- T cells (naïve or T_{SCM} phenotype). A poor prognostic phenotype in CTL019 product is a high percentage of PD1+ CAR+ and LAG3+ or TIM3+ T cells (exhausted phenotype).

FIG. 16 depicts an exemplary block diagram of a computer system on which various aspects and embodiments may be practiced.

FIG. 17 depicts an exemplary heatmap showing bi-clustering of cytokine expression in stimulated CTL019 products and CLL patients. Two clusters (Cluster 1 and Cluster 3) were almost exclusively comprised of CRs and PRs, whereas the other two clusters (Cluster 2 and Cluster 4) contained predominantly NRs. On average, cytokine expression levels were higher in CRs/PRs versus NRs. The top panel shows the red channel of the heatmap image, the center panel shows the blue channel, and the bottom panel shows the green channel.

FIG. 18 depicts exemplary results of log-normalized expressions of statistically significant cytokines (e.g., CCL20/MIP3a, IL2, TNF α , IL17a and IL6) to distinguish CRs, PRs and NRs in CLL patients.

FIG. 19A depicts an exemplary scatter plot showing log-normalized correlation of IL17A (y-axis) and CCL20 (x-axis) expression. Dashed lines represent the classification boundary for

separating NRs from CRs/PRs. Each dot represents a CLL patient, and the cross-hatch (NR), black (PR) and white (CR) represent the clinical response. The correlation coefficient is represented by “r” (e.g., a correlation coefficient of 0.928) and corresponding p-value for correlation using “p.value” (e.g., corresponding p-value of 1.36e-09). **FIG. 19B** depicts an

5 exemplary scatter plot showing correlation of CCL20 with percentage of CAR+ cells with a correlation coefficient of 0.395 and corresponding p-value of 0.0761. Each dot represents a CLL patient, and the cross-hatch (NR), black (PR) and white (CR) represent the clinical response. The correlation coefficient is represented by “r” and corresponding p-value for correlation using “p.value”. **FIG. 19C** depicts an exemplary scatter plot showing correlation of IL17a with

10 percentage of CAR+ cells with a correlation coefficient of 0.278 and corresponding p-value of 0.222. Each dot represents a CLL patient, and the cross-hatch (NR), black (PR) and white (CR) represent the clinical response. The correlation coefficient is represented by “r” and corresponding p-value for correlation using “p.value”.

FIG. 20 depicts exemplary results ($p=0.000215$) illustrating that T_{REG} genes have high

15 expression levels in relapsers (R) compared to non-relapser, complete responders (CR). The x-axis is samples by response group where CR=complete responder and R=relapser. The y-axis is normalized meta-gene expression scores.

FIG. 21 depicts an exemplary scatter plot showing percent of CAR+ cells (i.e., transduction rate) at pre-harvest for complete responders (CR) in white, partial responders (PR) in black and non-responders (NR) in hatching. Transduction efficiencies were measured pre-

20 harvest and correlated with subject response (e.g., CR, PR, or NR). The solid line represents a 15% transduction efficiency that separates the majority of non-responders from responders. Without wishing to be bound to a particular theory, these data indicate that pre-harvest CAR transduction rate is a marker of response to CAR-expressing cell (e.g., T cell, NK cell) therapy in

25 CLL.

FIG. 22 is a bar graph depicting the relationship between number of CD27+ PD1- CART cells infused and response to therapy.

FIG. 23 is a scatter plot depicting the relationship between number of CD27+ PD1- CART cells infused and response to therapy.

DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention
5 pertains.

The term “a” and “an” refers to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

The term “about” when referring to a measurable value such as an amount, a temporal
10 duration, and the like, is meant to encompass variations of $\pm 20\%$ or in some instances $\pm 10\%$, or in some instances $\pm 5\%$, or in some instances $\pm 1\%$, or in some instances $\pm 0.1\%$ from the specified value, as such variations are appropriate to perform the disclosed methods.

“Acquire” or “acquiring” as the terms are used herein, refer to obtaining possession of a physical entity (*e.g.*, a sample, a polypeptide, a nucleic acid, or a sequence), or a value, *e.g.*, a
15 numerical value, by “directly acquiring” or “indirectly acquiring” the physical entity or value. “Directly acquiring” means performing a process (*e.g.*, performing a synthetic or analytical method) to obtain the physical entity or value. “Indirectly acquiring” refers to receiving the physical entity or value from another party or source (*e.g.*, a third party laboratory that directly acquired the physical entity or value). Directly acquiring a physical entity includes performing a
20 process that includes a physical change in a physical substance, *e.g.*, a starting material. Exemplary changes include making a physical entity from two or more starting materials, shearing or fragmenting a substance, separating or purifying a substance, combining two or more separate entities into a mixture, performing a chemical reaction that includes breaking or forming a covalent or non-covalent bond. Directly acquiring a value includes performing a process that
25 includes a physical change in a sample or another substance, *e.g.*, performing an analytical process which includes a physical change in a substance, *e.g.*, a sample, analyte, or reagent (sometimes referred to herein as “physical analysis”), performing an analytical method, *e.g.*, a method which includes one or more of the following: separating or purifying a substance, *e.g.*, an analyte, or a fragment or other derivative thereof, from another substance; combining an analyte,

or fragment or other derivative thereof, with another substance, *e.g.*, a buffer, solvent, or reactant; or changing the structure of an analyte, or a fragment or other derivative thereof, *e.g.*, by breaking or forming a covalent or non-covalent bond, between a first and a second atom of the analyte; or by changing the structure of a reagent, or a fragment or other derivative thereof,
5 *e.g.*, by breaking or forming a covalent or non-covalent bond, between a first and a second atom of the reagent.

The term “antibody,” as used herein, refers to a protein, or polypeptide sequence derived from an immunoglobulin molecule which specifically binds with an antigen. Antibodies can be polyclonal or monoclonal, multiple or single chain, or intact immunoglobulins, and may be
10 derived from natural sources or from recombinant sources. Antibodies can be tetramers of immunoglobulin molecules.

The term “altered level of expression” of a biomarker as described herein (*e.g.*, a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122,
15 CD62L, KLRG1, and a CD19 CAR-expressing cell (*e.g.*, T cell, NK cell) gene signature) refers to an increase (or decrease) in the expression level of a marker in a test sample, such as a sample derived from a patient suffering from cancer (*e.g.*, a hematological cancer such as ALL and CLL) that is greater or less than the standard error of the assay employed to assess expression. In embodiments, the alteration can be at least twice, at least twice three, at least twice four, at
20 least twice five, or at least twice ten or more times greater than or less than the expression level of the biomarkers in a control sample (*e.g.*, a sample from a healthy subject not having the associated disease), or the average expression level in several control samples. An “altered level of expression” can be determined at the protein or nucleic acid (*e.g.*, mRNA) level.

The term “antibody fragment” refers to at least one portion of an antibody, that retains the
25 ability to specifically interact with (*e.g.*, by binding, steric hindrance, stabilizing/destabilizing, spatial distribution) an epitope of an antigen. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')₂, Fv fragments, scFv antibody fragments, disulfide-linked Fvs (sdFv), a Fd fragment consisting of the VH and CH1 domains, linear antibodies, single domain antibodies such as sdAb (either VL or VH), camelid VHH domains, multi-specific antibodies
30 formed from antibody fragments such as a bivalent fragment comprising two Fab fragments

linked by a disulfide bridge at the hinge region, and an isolated CDR or other epitope binding fragments of an antibody. An antigen binding fragment can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv (see, e.g., Hollinger and Hudson, Nature Biotechnology 5 23:1126-1136, 2005). Antigen binding fragments can also be grafted into scaffolds based on polypeptides such as a fibronectin type III (Fn3)(see U.S. Patent No.: 6,703,199, which describes fibronectin polypeptide minibodies). The term “scFv” refers to a fusion protein comprising at least one antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy 10 chain variable regions are contiguously linked via a short flexible polypeptide linker, and capable of being expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless specified, as used herein an scFv may have the VL and VH variable regions in either order, e.g., with respect to the N-terminal and C-terminal ends of the polypeptide, the scFv may comprise VL-linker-VH or may comprise VH- 15 linker-VL.

The term “antibody heavy chain,” refers to the larger of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations, and which normally determines the class to which the antibody belongs.

The term “antibody light chain,” refers to the smaller of the two types of polypeptide 20 chains present in antibody molecules in their naturally occurring conformations. Kappa (κ) and lambda (λ) light chains refer to the two major antibody light chain isotypes.

The term “complementarity determining region” or “CDR,” as used herein, refers to the sequences of amino acids within antibody variable regions which confer antigen specificity and binding affinity. For example, in general, there are three CDRs in each heavy chain variable 25 region (e.g., HCDR1, HCDR2, and HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, and LCDR3). The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme), or a combination thereof. 30

Under the Kabat numbering scheme, in some embodiments, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under the Chothia numbering
5 scheme, in some embodiments, the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). In a combined Kabat and Chothia numbering scheme, in some embodiments, the CDRs correspond to the amino acid residues that are part of a Kabat CDR, a Chothia CDR, or both. For instance, in some
10 embodiments, the CDRs correspond to amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) in a VH, e.g., a mammalian VH, e.g., a human VH; and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) in a VL, e.g., a mammalian VL, e.g., a human VL.

The term “anti-cancer effect” refers to a biological effect which can be manifested by
15 various means, including but not limited to, e.g., a decrease in tumor volume, a decrease in the number of cancer cells, a decrease in the number of metastases, an increase in life expectancy, decrease in cancer cell proliferation, decrease in cancer cell survival, or amelioration of various physiological symptoms associated with the cancerous condition. An “anti-cancer effect” can also be manifested by the ability of the peptides, polynucleotides, cells and antibodies in
20 prevention of the occurrence of cancer in the first place. The term “anti-tumor effect” refers to a biological effect which can be manifested by various means, including but not limited to, e.g., a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in tumor cell proliferation, or a decrease in tumor cell survival.

The term “allogeneic” refers to any material derived from a different animal of the same
25 species as the individual to whom the material is introduced. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical. In some aspects, allogeneic material from individuals of the same species may be sufficiently unlike genetically to interact antigenically.

The term “apheresis” as used herein refers to an extracorporeal process by which the
30 blood of a donor or patient is removed from the donor or patient and passed through an apparatus

that separates out selected particular constituent(s) and returns the remainder to the circulation of the donor or patient, e.g., by retransfusion. Thus, in the context of “an apheresis sample” refers to a sample obtained using apheresis.

The term “autologous” refers to any material derived from the same individual to whom it is later to be re-introduced into the individual.

A “biomarker” or “marker” is a gene, mRNA, or protein that undergoes alterations in expression that are associated with progression of cancer (e.g., a hematological cancer such as ALL and CLL) or responsiveness to treatment. The alteration can be in amount and/or activity in a biological sample (e.g., a blood, plasma, or a serum sample) obtained from a subject having cancer, as compared to its amount and/or activity, in a sample obtained from a baseline or prior value for the subject, the subject at a different time interval, an average or median value for a cancer patient population, a healthy control, or a healthy subject population (e.g., a control); such alterations in expression and/or activity are associated with of the responsiveness of a subject having a cancer disease state (e.g., a hematological cancer such as ALL and CLL) to a CAR-expressing cell (e.g., a CAR-expressing immune effector cell (e.g., a CAR-expressing T cell, NK cell) therapy, e.g., a CD19 CAR-expressing cell therapy. For example, a marker of the invention which is predictive of responsiveness to therapeutics can have an altered expression level, protein level, or protein activity, in a biological sample obtained from a subject having, or suspected of having, cancer as compared to a biological sample obtained from a control subject.

The term “cancer” refers to a disease characterized by the uncontrolled growth of aberrant cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Examples of various cancers are described herein and include but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer and the like. Cancers include, but are not limited to, B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), B cell promyelocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT

lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, and Waldenstrom macroglobulinemia. In an embodiment, the cancer is associated with CD19 expression. The terms “tumor” and “cancer” are used interchangeably herein, e.g., both terms encompass solid and liquid tumors. As used herein, the term “cancer” or “tumor” includes premalignant, as well as malignant cancers and tumors.

The terms “cancer associated antigen” or “tumor antigen” interchangeably refers to a molecule (typically protein, carbohydrate or lipid) that is preferentially expressed on the surface of a cancer cell, either entirely or as a fragment (e.g., MHC/peptide), in comparison to a normal cell, and which is useful for the preferential targeting of a pharmacological agent to the cancer cell. In some embodiments, a tumor antigen is a marker expressed by both normal cells and cancer cells, e.g., a lineage marker, e.g., CD19 on B cells. In some embodiments, a cancer-associated antigen is a cell surface molecule that is overexpressed in a cancer cell in comparison to a normal cell, for instance, 1-fold over expression, 2-fold overexpression, 3-fold overexpression or more in comparison to a normal cell. In some embodiments, a cancer-associated antigen is a cell surface molecule that is inappropriately synthesized in the cancer cell, for instance, a molecule that contains deletions, additions or mutations in comparison to the molecule expressed on a normal cell. In some embodiments, a tumor antigen will be expressed exclusively on the cell surface of a cancer cell, entirely or as a fragment (e.g., MHC/peptide), and not synthesized or expressed on the surface of a normal cell. In some embodiments, the CARs of the present invention includes CARs comprising an antigen binding domain (e.g., antibody or antibody fragment) that binds to a MHC presented peptide. Normally, peptides derived from endogenous proteins fill the pockets of Major histocompatibility complex (MHC) class I molecules, and are recognized by T cell receptors (TCRs) on CD8 + T lymphocytes. The MHC class I complexes are constitutively expressed by all nucleated cells. In cancer, virus-specific and/or tumor-specific peptide/MHC complexes represent a unique class of cell surface targets for immunotherapy. TCR-like antibodies targeting peptides derived from viral or tumor antigens in the context of human leukocyte antigen (HLA)-A1 or HLA-A2 have been described (see, e.g., Sastry et al., J Virol. 2011 85(5):1935-1942; Sergeeva et al., Blood, 2011

117(16):4262-4272; Verma et al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther 2001 8(21) :1601-1608 ; Dao et al., Sci Transl Med 2013 5(176) :176ra33 ; Tassev et al., Cancer Gene Ther 2012 19(2):84-100). For example, TCR-like antibody can be identified from screening a library, such as a human scFv phage displayed library.

5 As used herein, the term “CD19” refers to the Cluster of Differentiation 19 protein, which is an antigenic determinant detectable on leukemia precursor cells. The human and murine amino acid and nucleic acid sequences can be found in a public database, such as GenBank, UniProt and Swiss-Prot. For example, the amino acid sequence of human CD19 can be found as UniProt/Swiss-Prot Accession No. P15391 and the nucleotide sequence encoding of the human
10 CD19 can be found at Accession No. NM_001178098. As used herein, “CD19” includes proteins comprising mutations, e.g., point mutations, fragments, insertions, deletions and splice variants of full length wild-type CD19. CD19 is expressed on most B lineage cancers, including, e.g., acute lymphoblastic leukemia, chronic lymphocyte leukemia and non-Hodgkin lymphoma. Other cells which express CD19 are provided below in the definition of “disease associated with
15 expression of CD19.” It is also an early marker of B cell progenitors. See, e.g., Nicholson et al., MOL. IMMUN. 34 (16-17): 1157-1165 (1997). In one aspect the antigen-binding portion of the CAR-expressing cell (e.g., T cell, NK cell) recognizes and binds an antigen within the extracellular domain of the CD19 protein. In one aspect, the CD19 protein is expressed on a cancer cell. In one embodiment, the CD19 has a wild-type sequence, e.g., a wild-type human
20 sequence. In another embodiment, the CD19 has a mutant sequence, e.g., a mutant human sequence.

The term “Chimeric Antigen Receptor” or alternatively a “CAR” refers to a set of polypeptides, typically two in the simplest embodiments, which when in an immune effector cell, provides the cell with specificity for a target cell, typically a cancer cell, and with intracellular
25 signal generation. In some embodiments, a CAR comprises at least an extracellular antigen binding domain, a transmembrane domain and a cytoplasmic signaling domain (also referred to herein as “an intracellular signaling domain”) comprising a functional signaling domain derived from a stimulatory molecule and/or costimulatory molecule as defined below. In some embodiments, the set of polypeptides are in the same polypeptide chain (e.g., comprise a
30 chimeric fusion protein). In some embodiments, the set of polypeptides are not contiguous with

each other, e.g., are in different polypeptide chains. In some aspects, the set of polypeptides include a dimerization switch that, upon the presence of a dimerization molecule, can couple the polypeptides to one another, e.g., can couple an antigen binding domain to an intracellular signaling domain. In one aspect, the stimulatory molecule of the CAR is the zeta chain
5 associated with the T cell receptor complex. In one aspect, the cytoplasmic signaling domain comprises a primary signaling domain (e.g., a primary signaling domain of CD3-zeta). In one aspect, the cytoplasmic signaling domain further comprises one or more functional signaling domains derived from at least one costimulatory molecule as defined below. In one aspect, the costimulatory molecule is chosen from 4-1BB (i.e., CD137), CD27, ICOS, and/or CD28. In one
10 aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular signaling domain comprising a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular signaling domain comprising a functional signaling
15 domain derived from a co-stimulatory molecule and a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular signaling domain comprising two functional signaling domains derived from one or more co-stimulatory molecule(s) and a functional signaling domain derived from a stimulatory molecule.
20 In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular signaling domain comprising at least two functional signaling domains derived from one or more co-stimulatory molecule(s) and a functional signaling domain derived from a stimulatory molecule. In one aspect the CAR comprises an optional leader sequence at the amino-terminus (N-ter) of the CAR fusion protein.
25 In one aspect, the CAR further comprises a leader sequence at the N-terminus of the extracellular antigen recognition domain, wherein the leader sequence is optionally cleaved from the antigen recognition domain (e.g., a scFv) during cellular processing and localization of the CAR to the cellular membrane. In an embodiment, the CAR is CTL019.

The portion of the CAR composition comprising an antibody or antibody fragment
30 thereof may exist in a variety of forms where the antigen binding domain is expressed as part of

a contiguous polypeptide chain including, for example, a single domain antibody fragment (sdAb), a single chain antibody (scFv) and a humanized antibody (Harlow et al., 1999, In: USING ANTIBODIES: A LABORATORY MANUAL, COLD SPRING HARBOR LABORATORY PRESS, NY; Harlow et al., 1989, In: ANTIBODIES: A LABORATORY MANUAL, Cold Spring Harbor, New York; Houston et al., 1988, PROC. NATL. ACAD. SCI. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen binding domain of a CAR composition of the invention comprises an antibody fragment. In a further aspect, the CAR comprises an antibody fragment that comprises a scFv.

As used herein, the term “binding domain” or “antibody molecule” refers to a protein, e.g., an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain sequence. The term “binding domain” or “antibody molecule” encompasses antibodies and antibody fragments. In an embodiment, an antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In an embodiment, a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope.

The portion of the CAR of the invention comprising an antibody or antibody fragment thereof may exist in a variety of forms where the antigen binding domain is expressed as part of a contiguous polypeptide chain including, for example, a single domain antibody fragment (sdAb), a single chain antibody (scFv), a humanized antibody, or bispecific antibody (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen binding domain of a CAR composition of the invention comprises an antibody fragment. In a further aspect, the CAR comprises an antibody fragment that comprises a scFv.

The phrase “disease associated with expression of CD19” includes, but is not limited to, a disease associated with expression of CD19 (e.g., wild type or mutant CD19) or condition associated with cells which express, or at any time expressed, CD19 including, e.g., proliferative diseases such as a cancer or malignancy or a precancerous condition such as a myelodysplasia, a myelodysplastic syndrome or a preleukemia; or a noncancer related indication associated with cells which express CD19. For the avoidance of doubt, a disease associated with expression of CD19 may include a condition associated with cells which do not presently express CD19, e.g., because CD19 expression has been downregulated, e.g., due to treatment with a molecule targeting CD19, e.g., a CD19 CAR, but which at one time expressed CD19. In one aspect, a cancer associated with expression of CD19 is a hematological cancer. In one aspect, the hematological cancer is a leukemia or a lymphoma. In one aspect, a cancer associated with expression of CD19 includes cancers and malignancies including, but not limited to, e.g., one or more acute leukemias including but not limited to, e.g., acute myeloid leukemia (AML), B-cell acute lymphocytic leukemia (“B-ALL”), T-cell acute lymphocytic leukemia (“T-ALL”), acute lymphocytic leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL). Additional cancers or hematologic conditions associated with expression of CD19 comprise, but are not limited to, e.g., B cell promyelocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, myeloproliferative neoplasm; a histiocytic disorder (e.g., a mast cell disorder or a blastic plasmacytoid dendritic cell neoplasm); a mast cell disorder, e.g., systemic mastocytosis or mast cell leukemia; B-cell prolymphocytic leukemia, plasma cell myeloma, and “preleukemia” which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. Further diseases associated with expression of CD19 expression include, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases associated with expression of CD19. Non-cancer related indications associated with expression of CD19

include, but are not limited to, e.g., autoimmune disease, (e.g., lupus), inflammatory disorders (allergy and asthma) and transplantation. In some embodiments, the tumor antigen-expressing cells express, or at any time expressed, mRNA encoding the tumor antigen. In an embodiment, the tumor antigen -expressing cells produce the tumor antigen protein (e.g., wild-type or mutant),
 5 and the tumor antigen protein may be present at normal levels or reduced levels. In an embodiment, the tumor antigen -expressing cells produced detectable levels of a tumor antigen protein at one point, and subsequently produced substantially no detectable tumor antigen protein. In other embodiments, the disease is a CD19-negative cancer, e.g., a CD19-negative relapsed cancer. In some embodiments, the tumor antigen (e.g., CD19)-expressing cell
 10 expresses, or at any time expressed, mRNA encoding the tumor antigen. In an embodiment, the tumor antigen (e.g., CD19)-expressing cell produces the tumor antigen protein (e.g., wild-type or mutant), and the tumor antigen protein may be present at normal levels or reduced levels. In an embodiment, the tumor antigen (e.g., CD19)-expressing cell produced detectable levels of a tumor antigen protein at one point, and subsequently produced substantially no detectable tumor
 15 antigen protein.

The term “costimulatory molecule” refers to the cognate binding partner on a T cell that specifically binds with a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for an efficient immune
 20 response. Costimulatory molecules include, but are not limited to MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signalling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR,
 25 LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244,
 30 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1,

CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.

A costimulatory intracellular signaling domain refers to an intracellular portion of a costimulatory molecule. The intracellular signaling domain can comprise the entire intracellular portion, or the entire native intracellular signaling domain, of the molecule from which it is derived, or a functional fragment thereof.

As used herein, a “value of responder or relapser status” includes a measure (e.g., level) predictive of responsiveness or relapse of a subject to a treatment (e.g., a treatment that comprises, or consists of, a CAR-expressing cell therapy as described herein). In some embodiments, the measure is qualitative or quantitative. In some embodiments, the value of responder or relapser status is complete responder, partial responder, non-responder, relapser or non-relapser. In some embodiments, the value of responder or relapser status is a probability of being a complete responder, a partial responder, a non-responder, a relapser or a non-relapser. In some embodiments, the value of responder or relapser status can be determined based on the measure of any of (i)-(viii) as described herein.

With respect to responsiveness, a subject responds to treatment if a parameter of a cancer (e.g., a hematological cancer, e.g., cancer cell growth, proliferation and/or survival) in the subject is retarded or reduced by a detectable amount, e.g., about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more as determined by any appropriate measure, e.g., by mass, cell count or volume. In one example, a subject responds to treatment if the subject experiences a life expectancy extended by about 5%, 10%, 20%, 30%, 40%, 50% or more beyond the life expectancy predicted if no treatment is administered. In another example, a subject responds to treatment, if the subject has an increased disease-free survival, overall survival or increased time to progression.

Several methods can be used to determine if a patient responds to a treatment including, for example, criteria provided by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]). For example, in the context of B-ALL, a complete response or complete responder, may involve one or more of: < 5% BM blast, >1000 neutrophil/ANC (/μL). >100,000

platelets (/μL) with no circulating blasts or extramedullary disease (No lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement), Trilineage hematopoiesis, and no recurrence for 4 weeks. A partial responder may involve one or more of ≥50% reduction in BM blast, >1000 neutrophil/ANC (/μL). >100,000 platelets (/μL). A non-responder can show disease progression, e.g., > 25% in BM blasts.

A “complete responder” as used herein refers to a subject having a disease, e.g., a cancer, who exhibits a complete response, e.g., a complete remission, to a treatment. A complete response may be identified, e.g., using the NCCN Guidelines[®], or Cheson et al, J Clin Oncol 17:1244 (1999) and Cheson et al., “Revised Response Criteria for Malignant Lymphoma”, J Clin Oncol 25:579-586 (2007) (both of which are incorporated by reference herein in their entireties), as described herein.

A “partial responder” as used herein refers to a subject having a disease, e.g., a cancer, who exhibits a partial response, e.g., a partial remission, to a treatment. A partial response may be identified, e.g., using the NCCN Guidelines[®], or Cheson criteria as described herein.

A “non-responder” as used herein refers to a subject having a disease, e.g., a cancer, who does not exhibit a response to a treatment, e.g., the patient has stable disease or progressive disease. A non-responder may be identified, e.g., using the NCCN Guidelines[®], or Cheson criteria as described herein.

The term “relapse” as used herein refers to reappearance of a disease (e.g., cancer) after an initial period of responsiveness, e.g., after prior treatment with a therapy, e.g., cancer therapy (e.g., complete response or partial response). The initial period of responsiveness may involve the level of cancer cells falling below a certain threshold, e.g., below 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1%. The reappearance may involve the level of cancer cells rising above a certain threshold, e.g., above 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1%. For example, e.g., in the context of B-ALL, the reappearance may involve, e.g., a reappearance of blasts in the blood, bone marrow (> 5%), or any extramedullary site, after a complete response. A complete response, in this context, may involve < 5% BM blast. More generally, in an embodiment, a response (e.g., complete response or partial response) can involve the absence of detectable MRD (minimal residual disease). In an embodiment, the initial period of responsiveness lasts at

least 1, 2, 3, 4, 5, or 6 days; at least 1, 2, 3, or 4 weeks; at least 1, 2, 3, 4, 6, 8, 10, or 12 months; or at least 1, 2, 3, 4, or 5 years.

In some embodiments, a therapy that includes a CD19 inhibitor, e.g., a CD19 CAR therapy, may relapse or be refractory to treatment. The relapse or resistance can be caused by
5 CD19 loss (e.g., an antigen loss mutation) or other CD19 alteration that reduces the level of CD19 (e.g., caused by clonal selection of CD19-negative clones). A cancer that harbors such CD19 loss or alteration is referred to herein as a “CD19-negative cancer” or a “CD19-negative relapsed cancer”). It shall be understood that a CD19-negative cancer need not have 100% loss of CD19, but a sufficient reduction to reduce the effectiveness of a CD19 therapy such that the
10 cancer relapses or becomes refractory. In some embodiments, a CD19-negative cancer results from a CD19 CAR therapy. In some embodiments, a CD19-negative multiple myeloma can be treated with a CD19 CAR-expressing therapy, e.g., as described in PCT/US2015/024671, filed April 7, 2015 (e.g., paragraphs 9 and 90, and Example 6 therein), which is incorporated by reference in its entirety. In some embodiments, a CD19-negative cancer can be treated with a
15 CAR-expressing therapy, e.g., a CD123 CAR-expressing therapy, e.g., as described in PCT/US2015/045898 filed August 19, 2015 (e.g., p. 26, p. 30, and Example 7 therein) which is incorporated by reference in its entirety.

The term “endogenous” refers to any material from or produced inside an organism, cell, tissue or system.

20 The term “effective amount” or “therapeutically effective amount” are used interchangeably herein, and refer to an amount of a compound, formulation, material, or composition, as described herein effective to achieve a particular biological result.

The term “exogenous” refers to any material introduced from or produced outside an organism, cell, tissue or system.

25 The term “expression” refers to the transcription and/or translation of a particular nucleotide sequence driven by a promoter.

The term “flexible polypeptide linker” or “linker” as used in the context of a scFv refers to a peptide linker that consists of amino acids such as glycine and/or serine residues used alone or in combination, to link variable heavy and variable light chain regions together. In one

embodiment, the flexible polypeptide linker is a Gly/Ser linker and comprises the amino acid sequence (Gly-Gly-Gly-Ser)_n, where n is a positive integer equal to or greater than 1. For example, n=1, n=2, n=3, n=4, n=5, n=6, n=7, n=8, n=9 and n=10 (SEQ ID NO:28). In one embodiment, the flexible polypeptide linkers include, but are not limited to, (Gly₄Ser)₄ (SEQ ID NO:29) or (Gly₄Ser)₃ (SEQ ID NO:30). In another embodiment, the linkers include multiple repeats of (Gly₂Ser), (GlySer) or (Gly₃Ser) (SEQ ID NO:31). Also included within the scope of the invention are linkers described in WO2012/138475, incorporated herein by reference.

The terms "homology" or "identity," as used interchangeably herein, refer to sequence similarity between two polynucleotide sequences or between two polypeptide sequences, with identity being a more strict comparison. The phrases "percent identity or homology" and "% identity or homology" refer to the percentage of sequence similarity found in a comparison of two or more polynucleotide sequences or two or more polypeptide sequences. "Sequence similarity" refers to the percent similarity in base pair sequence (as determined by any suitable method) between two or more polynucleotide sequences. Two or more sequences can be anywhere from 0-100% similar, or any integer value there between. Identity or similarity can be determined by comparing a position in each sequence that can be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same nucleotide base or amino acid, then the molecules are identical at that position. A degree of similarity or identity between polynucleotide sequences is a function of the number of identical or matching nucleotides at positions shared by the polynucleotide sequences. A degree of identity of polypeptide sequences is a function of the number of identical amino acids at positions shared by the polypeptide sequences. A degree of homology or similarity of polypeptide sequences is a function of the number of amino acids at positions shared by the polypeptide sequences. The term "substantial homology," as used herein, refers to homology of at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more.

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies and antibody fragments

thereof are human immunoglobulins (recipient antibody or antibody fragment) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, a humanized antibody/antibody fragment can comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications can further refine and optimize antibody or antibody fragment performance. In general, the humanized antibody or antibody fragment thereof will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or a significant portion of the FR regions are those of a human immunoglobulin sequence. The humanized antibody or antibody fragment can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., NATURE, 321: 522-525, 1986; Reichmann et al., NATURE, 332: 323-329, 1988; Presta, CURR. OP. STRUCT. BIOL., 2: 593-596, 1992.

“Immune effector cell,” as that term is used herein, refers to a cell that is involved in an immune response, *e.g.*, in the promotion of an immune effector response. Examples of immune effector cells include T cells, *e.g.*, alpha/beta T cells and gamma/delta T cells, B cells, natural killer (NK) cells, natural killer T (NK-T) cells, mast cells, and myeloid-derived phagocytes.

“Immune effector function or immune effector response,” as that term is used herein, refers to function or response, *e.g.*, of an immune effector cell, that enhances or promotes an immune attack of a target cell. *E.g.*, an immune effector function or response refers a property of a T or NK cell that promotes killing or the inhibition of growth or proliferation, of a target cell. In the case of a T cell, primary stimulation and co-stimulation are examples of immune effector function or response.

The term “effector function” refers to a specialized function of a cell. Effector function of a T cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines.

The term “4-1BB” refers to a member of the TNFR superfamily with an amino acid sequence provided as GenBank Acc. No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like; and a “4-1BB costimulatory domain” is defined as amino acid residues 214-255 of GenBank Acc No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like. In one aspect, the “4-1BB costimulatory domain” is the sequence provided as SEQ ID NO:14 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like.

An “intracellular signaling domain,” as the term is used herein, refers to an intracellular portion of a molecule. The intracellular signaling domain can generate a signal that promotes an immune effector function of the CAR containing cell, e.g., a CAR-expressing cell, e.g., a T cell or an NK cell. Examples of immune effector function, e.g., in a CAR-expressing cell include, cytolytic activity and helper activity, including the secretion of cytokines. In embodiments, the intracellular signal domain transduces the effector function signal and directs the cell to perform a specialized function. While the entire intracellular signaling domain can be employed, in many cases it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such truncated portion may be used in place of the intact chain as long as it transduces the effector function signal. The term intracellular signaling domain is thus meant to include any truncated portion of the intracellular signaling domain sufficient to transduce the effector function signal.

In an embodiment, the intracellular signaling domain can comprise a primary intracellular signaling domain. Exemplary primary intracellular signaling domains include those derived from the molecules responsible for primary stimulation, or antigen dependent stimulation. In an embodiment, the intracellular signaling domain can comprise a costimulatory intracellular domain. Exemplary costimulatory intracellular signaling domains include those derived from molecules responsible for costimulatory signals, or antigen independent stimulation. For example, in the case of a CAR-expressing cell (e.g., a T cell, an NK cell), a primary intracellular signaling domain can comprise a cytoplasmic sequence of a T cell receptor, and a costimulatory intracellular signaling domain can comprise cytoplasmic sequence from co-receptor or costimulatory molecule.

A primary intracellular signaling domain can comprise a signaling motif which is known as an immunoreceptor tyrosine-based activation motif or ITAM. Examples of ITAM containing primary cytoplasmic signaling sequences include, but are not limited to, those derived from CD3 zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 ("ICOS"), FcεRI, CD66d, CD32, DAP10, and DAP12.

As used herein, "in vitro transcribed RNA" refers to RNA, preferably mRNA, that has been synthesized in vitro. Generally, the in vitro transcribed RNA is generated from an in vitro transcription vector. The in vitro transcription vector comprises a template that is used to generate the in vitro transcribed RNA.

The term "isolated" means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.

The term "lentivirus" refers to a genus of the Retroviridae family. Lentiviruses are unique among the retroviruses in being able to infect non-dividing cells; they can deliver a significant amount of genetic information into the DNA of the host cell, so they are one of the most efficient methods of a gene delivery vector. HIV, SIV, and FIV are all examples of lentiviruses.

The term "lentiviral vector" refers to a vector derived from at least a portion of a lentivirus genome, including especially a self-inactivating lentiviral vector as provided in Milone et al., MOL. THER. 17(8): 1453–1464 (2009). Other examples of lentivirus vectors that may be used in the clinic, include but are not limited to, e.g., the LENTIVECTOR® gene delivery technology from Oxford BioMedica, the LENTIMAX™ vector system from Lentigen and the like. Nonclinical types of lentiviral vectors are also available and would be known to one skilled in the art.

The term "low, immune enhancing, dose" when used in conjunction with an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., RAD001 or rapamycin, or a catalytic mTOR inhibitor, refers to a dose of mTOR inhibitor that partially, but not fully, inhibits mTOR activity, e.g., as measured by the inhibition of P70 S6 kinase activity. Methods for evaluating mTOR

activity, e.g., by inhibition of P70 S6 kinase, are discussed herein. The dose is insufficient to result in complete immune suppression but is sufficient to enhance the immune response. In an embodiment, the low, immune enhancing, dose of mTOR inhibitor results in a decrease in the number of PD-1 positive immune effector cells, e.g., T cells or NK cells and/or an increase in the number of PD-1 negative immune effector cells, e.g., T cells or NK cells, or an increase in the ratio of PD-1 negative immune effector cells, e.g., T cells or NK cells/PD-1 positive immune effector cells, e.g., T cells or NK cells.

In general, the term “naïve T cell” refers to immune cells that comprise antigen-inexperienced cells, e.g., immune cells that are precursors of memory cells. In some embodiments, naïve T cells may be differentiated, but have not yet encountered their cognate antigen, and therefore are activated T cells or memory T cells. In some embodiments, naïve T cells may be characterized by expression of CD62L, CD27, CCR7, CD45RA, CD28, and CD127, and the absence of CD95, or CD45RO isoform. In certain embodiments, a naïve T cells is a type of younger T cell as described herein.

The term “less exhausted” or “less exhausted phenotype” refers to immune effector cells that have reduced (e.g., lack) expression of immune cell exhaustion markers, e.g. PD1, TIM3, and LAG3. In some embodiments, a less exhausted cell may be a younger T cell as described herein.

The term “nucleic acid” or “polynucleotide” refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), or a combination of a DNA or RNA thereof, and polymers thereof in either single- or double-stranded form. The term “nucleic acid” includes a gene, cDNA or an mRNA. In one embodiment, the nucleic acid molecule is synthetic (e.g., chemically synthesized) or recombinant. Unless specifically limited, the term encompasses nucleic acids containing analogues or derivatives of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., NUCLEIC ACID RES. 19:5081 (1991);

Ohtsuka et al., J. BIOL. CHEM. 260:2605-2608 (1985); and Rossolini et al., MOL. CELL. Probes 8:91-98 (1994)). In the context of the present invention, the following abbreviations for the commonly occurring nucleic acid bases are used. "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.

5 A "nucleic acid" "marker" or "biomarker" is a nucleic acid (*e.g.*, DNA, mRNA, cDNA) encoded by or corresponding to a marker as described herein. For example, such marker nucleic acid molecules include DNA (*e.g.*, genomic DNA and cDNA) comprising the entire or a partial sequence of any of the nucleic acid sequences set forth, or the complement or hybridizing fragment of such a sequence. The marker nucleic acid molecules also include RNA comprising
10 the entire or a partial sequence of any of the nucleic acid sequences set forth herein, or the complement of such a sequence, wherein all thymidine residues are replaced with uridine residues. A "marker protein" is a protein encoded by or corresponding to a marker of the invention. A marker protein comprises the entire or a partial sequence of a protein encoded by any of the sequences set forth herein, or a fragment thereof. The terms "protein" and
15 "polypeptide" are used interchangeably herein.

 An "overexpression" or "significantly higher level of expression" of the gene products refers to an expression level or copy number in a test sample that is greater than the standard error of the assay employed to assess the level of expression. In embodiments, the overexpression can be at least two, at least three, at least four, at least five, or at least ten or more
20 times the expression level of the gene in a control sample or the average expression level of gene products in several control samples.

 The terms "peptide," "polypeptide," and "protein" are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum
25 number of amino acids that can comprise a protein's or peptide's sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. "Polypeptides"
30 include, for example, biologically active fragments, substantially homologous polypeptides,

oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. A polypeptide includes a natural peptide, a recombinant peptide, or a combination thereof.

As used herein, a “poly(A)” is a series of adenosines attached by polyadenylation to the mRNA. In some embodiments of a construct for transient expression, the polyA is between 50 and 5000 (SEQ ID NO: 34) (e.g., 2000; SEQ ID NO: 32), e.g., 64 (SEQ ID NO: 37), e.g., greater than 100 (e.g., 150, SEQ ID NO: 33), e.g., greater than 400 (SEQ ID NO: 38). poly(A) sequences can be modified chemically or enzymatically to modulate mRNA functionality such as localization, stability or efficiency of translation.

The term “probe” refers to any molecule which is capable of selectively binding to a specifically intended target molecule, for example a marker of the invention. Probes can be either synthesized by one skilled in the art, or derived from appropriate biological preparations. For purposes of detection of the target molecule, probes can be specifically designed to be labeled, as described herein. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic monomers.

The term “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence.

The term “promoter/regulatory sequence” refers to a nucleic acid sequence which is required for expression of a gene product operably linked to the promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product. The promoter/regulatory sequence may, for example, be one which expresses the gene product in a tissue specific manner.

The term “prophylaxis” as used herein means the prevention of or protective treatment for a disease or disease state.

Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of

the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity, includes something with 95%, 96%, 97%, 98% or 99% identity, and includes subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98% and 98-99% identity. This applies regardless of the breadth of the range.

The term “recombinant antibody” refers to an antibody which is generated using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage or yeast expression system. The term should also be construed to mean an antibody which has been generated by the synthesis of a DNA molecule encoding the antibody and which DNA molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence has been obtained using recombinant DNA or amino acid sequence technology which is available and well known in the art.

“Refractory” as used herein refers to a disease, e.g., cancer, that does not respond to a treatment. In embodiments, a refractory cancer can be resistant to a treatment before or at the beginning of the treatment. In other embodiments, the refractory cancer can become resistant during a treatment. A refractory cancer is also called a resistant cancer.

In embodiments, a reference or control level or activity is the level and/or activity in a subject, e.g., a sample obtained from one or more of: a baseline or prior value for the subject (e.g., prior to treatment with a CAR-expressing cell); the subject at a different time interval; an average or median value for a cancer patient population; a healthy control; or a healthy subject population (e.g., a control).

“Sample,” “tissue sample,” “patient sample,” “patient cell or tissue sample” or “specimen” each refers to a biological sample obtained from a tissue or bodily fluid of a subject or patient. The source of the tissue sample can be solid tissue as from a fresh, frozen and/or preserved organ, tissue sample, biopsy, or aspirate; blood or any blood constituents (e.g., serum, plasma); bodily fluids such as urine, cerebral spinal fluid, whole blood, plasma and serum. The sample

can include a non-cellular fraction (*e.g.*, urine, plasma, serum, or other non-cellular body fluid).

In one embodiment, the sample is a urine sample. In other embodiments, the body fluid from which the sample is obtained from an individual comprises blood (*e.g.*, whole blood). In an

embodiment, the sample is a whole blood sample obtained from the subject. In certain

5 embodiments, the blood can be further processed to obtain plasma or serum. In an embodiment,

the sample is an apheresis sample obtained from the blood of the subject. In an embodiment, the

sample is a manufactured product sample, *e.g.*, genetically engineered T cells obtained from the

blood of the subject, *e.g.*, a manufactured CAR-expressing cell (*e.g.*, T cell, NK cell) product,

e.g., a manufactured CD19 CAR-expressing cell product. In another embodiment, the sample

10 contains a tissue, cells (*e.g.*, peripheral blood mononuclear cells (PBMC)). For example, the

sample can be a fine needle biopsy sample, an archival sample (*e.g.*, an archived sample with a

known diagnosis and/or treatment history), a histological section (*e.g.*, a frozen or formalin-fixed

section, *e.g.*, after long term storage), among others. The term sample includes any material

obtained and/or derived from a biological sample, including a polypeptide, and nucleic acid (*e.g.*,

15 genomic DNA, cDNA, RNA) purified or processed from the sample. Purification and/or

processing of the sample can involve one or more of extraction, concentration, antibody

isolation, sorting, concentration, fixation, addition of reagents and the like. The sample can

contain compounds that are not naturally intermixed with the tissue in nature such as

preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics or the like.

20 The term “product” or “manufactured product” as used herein, refers to a manufactured

composition comprising a genetically engineered cell (*e.g.*, an immune effector cell), *e.g.*, a

population of cells in which a plurality of cells are engineered to express a CAR, *e.g.*, a CAR

described herein. A manufactured product can be any genetically engineered immune effector

cell (*e.g.*, T cell, NK cell), *e.g.*, genetically engineered immune effector cells obtained from the

25 blood of the subject, *e.g.*, a manufactured CAR-expressing cell product, *e.g.*, a manufactured

CD19 CAR-expressing cell product. In an embodiment, a cell (*e.g.*, an immune effector cell)

engineered to express a CAR may be obtained from an activated cryopreserved expanded cell

population (*e.g.*, an expanded immune effector cell population).

The term “signaling domain” refers to the functional portion of a protein which acts by

30 transmitting information within the cell to regulate cellular activity via defined signaling

pathways by generating second messengers or functioning as effectors by responding to such messengers.

The amount of a biomarker, *e.g.*, expression of gene products (*e.g.*, one or more the biomarkers described herein), in a subject is "significantly" higher or lower than the normal amount of a marker, if the amount of the marker is greater or less, respectively, than the normal level by an amount greater than the standard error of the assay employed to assess amount, or at least two, three, four, five, ten or more times that amount. Alternatively, the amount of the marker in the subject can be considered "significantly" higher or lower than the normal amount if the amount is at least about 1.5, two, at least about three, at least about four, or at least about five times, higher or lower, respectively, than the normal amount of the marker.

The term "specifically binds," refers to an antibody, or a ligand, which recognizes and binds with a cognate binding partner protein present in a sample, but which antibody or ligand does not substantially recognize or bind other molecules in the sample.

The term "stimulation," refers to a primary response induced by binding of a stimulatory molecule (*e.g.*, a TCR/CD3 complex) with its cognate ligand thereby mediating a signal transduction event, such as, but not limited to, signal transduction via the TCR/CD3 complex. Stimulation can mediate altered expression of certain molecules, such as down regulation of TGF- β , and/or reorganization of cytoskeletal structures, and the like.

The term "stimulatory molecule," refers to a molecule expressed by a T cell that provides the primary cytoplasmic signaling sequence(s) that regulate primary activation of the TCR complex in a stimulatory way for at least some aspect of the T cell signaling pathway. In one aspect, the primary signal is initiated by, for instance, binding of a TCR/CD3 complex with an MHC molecule loaded with peptide, and which leads to mediation of a T cell response, including, but not limited to, proliferation, activation, differentiation, and the like. A primary cytoplasmic signaling sequence (also referred to as a "primary signaling domain") that acts in a stimulatory manner may contain a signaling motif which is known as immunoreceptor tyrosine-based activation motif or ITAM. Examples of an ITAM containing cytoplasmic signaling sequence that is of particular use in the invention includes, but is not limited to, those derived from CD3 zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc Epsilon R1b),

CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12. In a specific CAR of the invention, the intracellular signaling domain in any one or more CARS of the invention comprises an intracellular signaling sequence, e.g., a primary signaling sequence of CD3-zeta. In a specific CAR of the invention, the primary signaling sequence of CD3-zeta is the sequence
5 provided as SEQ ID NO:18 (mutant CD3 zeta), or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like. In a specific CAR of the invention, the primary signaling sequence of CD3-zeta is the sequence as provided in SEQ ID NO:20 (wild-type human CD3 zeta), or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like.

10 The term “subject” is intended to include living organisms in which an immune response can be elicited (e.g., mammals, human). In an embodiment, a subject is a mammal. In an embodiment, a subject is a human. In an embodiment, a subject is a patient.

The term “therapeutic” as used herein means a treatment. A therapeutic effect is obtained by reduction, suppression, remission, or eradication of a disease state.

15 The term “transfected” or “transformed” or “transduced” refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A “transfected” or “transformed” or “transduced” cell is one which has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.

20 As used herein, “transient” refers to expression of a non-integrated transgene for a period of hours, days or weeks, wherein the period of time of expression is less than the period of time for expression of the gene if integrated into the genome or contained within a stable plasmid replicon in the host cell.

25 The term “transmembrane domain,” refers to a polypeptide that spans the plasma membrane. In an embodiment, it links an extracellular sequence, e.g., a switch domain, an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain, to an intracellular sequence, e.g., to a switch domain or an intracellular signaling domain. A transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acid associated with the extracellular region of the protein from which the transmembrane was

derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the extracellular region) and/or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the intracellular region). Examples of transmembrane domains are disclosed herein.

5 The terms “treat”, “treatment” and “treating” refer to the reduction or amelioration of the progression, severity and/or duration of a proliferative disorder, or the amelioration of one or more symptoms (e.g., one or more discernible symptoms) of a proliferative disorder resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as a CAR of the invention). In specific embodiments, the terms “treat”, “treatment” and “treating”
 10 refer to the amelioration of at least one measurable physical parameter of a proliferative disorder, such as growth of a tumor, not necessarily discernible by the patient. In other embodiments the terms “treat”, “treatment” and “treating” -refer to the inhibition of the progression of a proliferative disorder, either physically by, e.g., stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both. In other embodiments the
 15 terms “treat”, “treatment” and “treating” refer to the reduction or stabilization of tumor size or cancerous cell count.

 An “underexpression” or “significantly lower level of expression” of products (e.g., the markers set forth herein) refers to an expression level in a test sample that is greater than the standard error of the assay employed to assess expression, for example, at least 1.5, twice, at
 20 least three, at least four, at least five, or at least ten or more times less than the expression level of the gene in a control sample, or the average expression level of gene products in several control samples.

 The term “xenogeneic” refers to a graft derived from an animal of a different species.

 As used herein, the term “young T cell” or “younger T cell”, refers to an immune effector
 25 cell that comprises a less differentiated phenotype, e.g., a younger cell, e.g., a young T cell. In some embodiments, a younger T cell may be a naïve T cell (T_N). In some embodiments, a young T cell may be characterized by expression of CD62L, and the absence of CD25, CD44, or CD45RO isoform. In some embodiments, a younger T cell may be a memory stem cell (T_{SCM}). In some embodiments, a younger T cells may be a central memory T cell (T_{CM}). Phenotypic

markers associated with T_N, T_{SCM} and T_{CM} are disclosed in, *e.g.*, Maus, M. *et al.* (2014) *Annu. Rev. Immunol.* 32:189-225 (see for example, Figure 3), incorporated by reference herein.

Exemplary phenotypes of T_N include one or more (or all) of the following: CD45RA+, CD45RO-, CD62L^{high}, CCR7^{high}, CD95-, CD122-, CD27^{high}, CD28+, CD57-, KLRG-1-, or long telomere length (or any combination of two, three, four, five, six, seven, eight, nine, or all of the aforesaid T_N markers). Exemplary phenotypes of T_{SCM} include one or more (or all) of the following: CD45RA+, CD45RO-, CD62L^{high}, CCR7^{high}, CD95+, CD122+, CD27^{high}, CD28^{high}, CD57-, KLRG-1-, or long telomere length (or any combination of two, three, four, five, six, seven, eight, nine, or all of the aforesaid T_{SCM} markers). Exemplary phenotypes of T_{CM} include one or more (or all) of the following: CD45RA-, CD45RO^{high}, CD62L^{high}, CCR7+, CD95+, CD122^{high}, CD27+, CD28^{high}, CD57-, KLRG-1-/+, or long/intermediate telomere length (or any combination of two, three, four, five, six, seven, eight, nine, or all of the aforesaid T_{CM} markers).

As used herein, the term “older T cell” refers to an immune effector cell that comprises a more exhausted phenotype. In some embodiments, an older T cell may be an effector memory T cell (T_{EM}). In other embodiments, an older T cell may be an effector T cell (T_{EFF}). In other embodiments, an older T cell has an exhausted phenotype. Phenotypic markers associated with T_{EM}, T_{EFF} and exhausted T cells are disclosed in, *e.g.*, Maus, M. *et al.* (2014) *Annu. Rev. Immunol.* 32:189-225 (see for example, Figure 3), incorporated by reference herein.

Exemplary phenotypes of T_{EM} include one or more (or all) of the following: CD45RA-/+, CD45RO^{high}, CD62L-, CCR7-, CD95-, CD122^{high}, CD27-/+, CD28-/+, CD57^{low}, KLRG-1+, or intermediate telomere length (or any combination of two, three, four, five, six, seven, eight, nine, or all of the aforesaid T_{EM} markers). Exemplary phenotypes of T_{EFF} include one or more (or all) of the following: CD45RA-/+, CD45RO+, CD62L-, CCR7-, CD95^{high}, CD122-/+, CD27-, CD28-, CD57+, KLRG-1^{high}, or short/intermediate telomere length (or any combination of two, three, four, five, six, seven, eight, nine, or all of the aforesaid T_{EFF} markers). Exemplary phenotypes of an exhausted T cell phenotype include one or more (or all) of the following: CD45RA-/+, CD45RO+, CD62L-, CCR7-, CD95^{high}, CD122^{low}, CD27-, CD28-, CD57^{high}, KLRG-1^{high}, or short telomere length (or any combination of two, three, four, five, six, seven, eight, nine, or all of the aforesaid markers).

The term “zeta” or alternatively “zeta chain”, “CD3-zeta” or “TCR-zeta” is defined as the protein provided as GenBank Acc. No. BAG36664.1, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like, and a “zeta stimulatory domain” or alternatively a “CD3-zeta stimulatory domain” or a “TCR-zeta stimulatory domain” is defined as the amino acid residues from the cytoplasmic domain of the zeta chain that are sufficient to functionally transmit an initial signal necessary for T cell activation. In one aspect the cytoplasmic domain of zeta comprises residues 52 through 164 of GenBank Acc. No. BAG36664.1 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like, that are functional orthologs thereof. In one aspect, the “zeta stimulatory domain” or a “CD3-zeta stimulatory domain” is the sequence provided as SEQ ID NO:18. In one aspect, the “zeta stimulatory domain” or a “CD3-zeta stimulatory domain” is the sequence provided as SEQ ID NO:20.

Various aspects of the invention are described in further detail below. Additional definitions are set out throughout the specification.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

Biomarkers predicting response to a therapy in subjects having cancer (e.g., a hematological cancer such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL)) are provided herein.

In one aspect, biomarkers predicting response to a cell expressing a CAR, e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) (e.g., a CD19 CAR-expressing cell described herein such as, e.g., CTL019) in subjects having CLL and ALL are provided herein.

Methods are provided for the diagnosis and monitoring of treatment of cancer (e.g., a hematological cancer such as ALL and CLL) based on detection of certain biomarkers in samples from patients who have, or are suspected of having, cancer. Further, expression of one or more such biomarkers can be used to distinguish subjects that respond favorably to a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., “complete responders” or “CR”) from subjects that don’t respond to a CAR-expressing cell therapy (e.g., “non-responders” or “NR”)

and from subjects that have a partial response to a CAR-expressing cell therapy (e.g., “partial responders” or “PR”).

Use of Biomarkers to Evaluate Disease Progression and Predict Subject Response to CAR-Expressing Cell Therapy

5 In an embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more genes in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1 and/or a CD19 CAR-expressing cell (e.g., T cell, NK cell) gene signature can be used with methods of the present disclosure to acquire a disease progression value. The

10 disease progression value can be used for, e.g., in evaluating the effectiveness of therapies in treating cancer (e.g., a hematological cancer such as ALL and CLL). In an embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more genes in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and/or KLRG1 and/or

15 a CD19 CAR-expressing cell gene signature are used to classify a subject as a complete responder, partial responder, or non-responder to CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019). In an embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more genes in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and/or KLRG1, and/or

20 a CD19 CAR-expressing cell gene signature are used to predict a subject’s responsiveness to a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019).

25 Subjects

For any of the methods and kits disclosed herein, the subject treated, or the subject from which the value is obtained, is a subject having, or at risk of having, cancer at any stage of treatment. Exemplary cancers include, but are not limited to, B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), acute lymphocytic leukemia (ALL),

chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), B cell promyelocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, and Waldenstrom macroglobulinemia. In an embodiment, the cancer is a hematological cancer. In an embodiment, the cancer is ALL. In another embodiment, the cancer is CLL. In an embodiment, the cancer is associated with CD19 expression.

In an embodiment, the subject has received a pretreatment of an additional therapy, e.g., a subject that has been identified as a partial responder or non-responder and subsequently has been pretreated with an additional therapy. In an embodiment, the subject receives pretreatment with an mTOR inhibitor. In an embodiment, the mTOR inhibitor is administered at a dose or dosing schedule described herein. In one embodiment, a low, immune enhancing dose of an mTOR inhibitor is given to the subject prior to treatment with a CAR-expressing cell (e.g., a T cell, an NK cell). In an embodiment, administration of a low, immune enhancing, dose of an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, or a catalytic inhibitor, is initiated prior to administration of a CAR expressing cell described herein, e.g., T cells. In an embodiment, the CAR cells are administered after a sufficient time, or sufficient dosing, of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells, or the ratio of PD1 negative immune effector cells, e.g., T cells/ PD1 positive immune effector cells, e.g., T cells, has been, at least transiently, increased. In an embodiment, the cell, e.g., T cell, to be engineered to express a CAR, is harvested after a sufficient time, or after sufficient dosing of the low, immune enhancing, dose of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells, or the ratio of PD1 negative immune effector cells, e.g., T cells/ PD1 positive immune effector cells, e.g., T cells, in the subject or harvested from the subject has been, at least transiently, increased.

In one embodiment, the subject has received a pretreatment with a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein. Examples of inhibitory molecules, e.g., checkpoint

molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFRbeta). In embodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA; or e.g., an inhibitory protein or system, e.g., a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription-activator like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN), e.g., as described herein, can be used to inhibit expression of a molecule that modulates or regulates, e.g., inhibits, T-cell function in the CAR-expressing cell. In an embodiment the agent is an shRNA, e.g., an shRNA described herein. In one embodiment, the inhibitor of checkpoint molecule can be, e.g., an antibody or antibody fragment that binds to a checkpoint molecule. For example, the agent can be an antibody or antibody fragment that binds to PD1, PD-L1, PD-L2 (e.g., as described herein) or CTLA4 (e.g., ipilimumab (also referred to as MDX-010 and MDX-101, and marketed as Yervoy®; Bristol-Myers Squibb; Tremelimumab (IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206)). In an embodiment, the agent is an antibody or antibody fragment that binds to TIM3, e.g., as described herein. In an embodiment, the agent is an antibody or antibody fragment that binds to LAG3, e.g., as described herein. In an embodiment, the agent is an antibody or antibody fragment that binds to CEACAM, e.g., as described herein.

In an embodiment, the subject receives an additional therapy in combination with CAR-expressing cell (e.g., a T cell, an NK cell) therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019). In an embodiment, the subject receives an mTOR inhibitor, e.g., an mTOR inhibitor described herein, in combination with CAR-expressing cell therapy. In one embodiment, the mTOR inhibitor is administered at a dose and/or dosing schedule described herein. In one embodiment, the subject receives a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein, in combination with CAR-expressing cell therapy. In one embodiment, the checkpoint inhibitor is administered at a dose and/or dosing schedule described herein. In an embodiment, the subject receives a kinase inhibitor, e.g., a kinase inhibitor described herein. In one embodiment, the kinase inhibitor is administered at a dose and/or dosing schedule described herein.

In an embodiment, the subject has been identified as a non-responder and the subject receives a therapy other than a CAR-expressing cell therapy, e.g., a standard of care therapy for the particular cancer type. In one embodiment, the subject receives one or more of an anti-CD20 antibody, or functional fragment thereof (e.g., ofatumumab, rituximab, obinutuzumab), an anti-
 5 CD52 antibody or functional fragment thereof (e.g., alemtuzumab), an alkylating agent (e.g., a nitrogen mustard alkylating agent such as, e.g., bendamustine HCl, chlorambucel, cyclophosphamide), a kinase inhibitor (e.g., a kinase inhibitor described herein such as, e.g., a BTK inhibitor described herein or a phosphoinositide-3 kinase inhibitor described herein). In one embodiment, the subject receives a stem cell transplant.

10

Biomarkers Assessment

Analysis of CTL019 Biomarkers

Analysis of levels of expression and/or activity of gene products correlated with a subject's response to CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-
 15 expressing cell therapy described herein such as, e.g., CTL019) and cancer disease progression (e.g., a hematological cancer such as CLL and ALL) has led to the identification of novel CD19 CAR-expressing cell gene signatures. For example, the present invention provides methods for evaluation of expression level of one, two, three, four, five, six, seven, eight, nine, ten, fifteen, twenty, twenty-five, thirty, thirty-five, forty, forty-five, fifty, one hundred, or more genes from
 20 Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 that comprise a CD19 CAR-expressing cell gene signature.

Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15,
 25 Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and/or KLRG1 lists genes (e.g., protein biomarkers) that are differentially expressed by complete responders compared to partial responders and non-responders.

In some embodiments, methods of the present disclosure can be used to determine the responsiveness of a subject to treatment with a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy described herein such as, e.g., CTL019), wherein a statistically significant difference in the amount, e.g., expression, and/or activity of a marker disclosed herein relative to a reference, e.g., a median value for a cancer patient population (e.g., a hematological cancer such as CLL and ALL), a median value for a population of healthy, cancer-free subjects, a median value for a population of non-responders or partial responders, in a subjects sample, then the more likely the disease is to respond to CAR-expressing cell therapy.

In an embodiment, the disclosure provides a method of, or assay for, identifying a subject having cancer (e.g., a hematological cancer such as CLL and ALL) as having an increased or decreased likelihood to respond to a treatment that comprises a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019), the method comprising:

- (1) acquiring a sample from the subject;
- (2) determining a level of one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or more) markers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 in the sample; and

- (3) comparing the determined level of one or more markers to a reference level; wherein a difference, e.g., statistically significant difference in the determined level to the reference level is predictive of the subjects responsiveness to the CAR-expressing cell therapy; and

- (4) identifying the subject as a complete responder, partial responder or non-responder to the CAR-expressing cell therapy.

In one embodiment, the sample is a blood, plasma or a serum sample. In one embodiment, the sample is an apheresis sample, e.g., T cells obtained from the blood of the subject. In an embodiment, the sample is a manufactured product sample, e.g., genetically engineered T cells obtained from the blood of the subject, e.g., a manufactured CAR-expressing cell product, e.g., a manufactured CD19 CAR-expressing cell product.

In an embodiment, the disclosure provides a method of, or assay for, identifying a subject having a cancer including, but not limited to, B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), B cell promyelocytic leukemia, blastic
5 plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic
10 cell neoplasm, and Waldenstrom macroglobulinemia. In an embodiment, the cancer is a hematological cancer. In an embodiment, the cancer is ALL. In another embodiment, the cancer is CLL. In an embodiment, the cancer is associated with CD19 expression.

In an embodiment, a CAR-expressing cell therapy comprises a CAR-expressing cell therapy described herein, e.g., CTL019.

15 In an embodiment, a CAR-expressing cell therapy consists of a CAR-expressing cell therapy described herein, e.g., CTL019.

In an embodiment, the disclosure provides a method of, or assay for, identifying a subject having cancer (e.g., a hematological cancer such as CLL and ALL) as having an increased or decreased likelihood to respond to a treatment that comprises a CAR-expressing cell therapy
20 (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019), the method comprising:

- (1) acquiring a sample from the subject;
- (2) determining a gene signature of the sample; and
- (3) comparing the determined gene signature to a reference gene signature;

25 wherein a difference, e.g., statistically significant difference in expression level of one or more of the markers in the determined gene signature, e.g., as compared to a predetermined value, is predictive of the subjects responsiveness to the CAR-expressing cell therapy.

In an embodiment, the disclosure provides a method of, or assay for, determining the responsiveness of a subject having cancer (e.g., a hematological cancer such as CLL and ALL) to

a treatment comprising a cell expressing a CAR (e.g., a cell expressing a CD19 CAR, e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) described herein such as, e.g., CTL019), the method comprising:

determining a level of one or more markers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 in a sample obtained prior to treatment;

wherein a statistically significant difference in expression level of one or more markers in the sample relative to a predetermined value is indicative of increased responsiveness to the CAR-expressing cell.

The methods provided herein are particularly useful for identifying subjects that are likely to respond to CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019) prior to initiation of such treatment (e.g., pre-therapy) or early in the therapeutic regimen. In some embodiments, expression or activity of biomarkers is measured in a subject at least 2 weeks, at least 1 month, at least 3 months, at least 6 months, or at least 1 year prior to initiation of therapy. In some embodiments, expression or activity of biomarkers is measured less than 6 months prior to the initiation of therapy. Thus, in some embodiments, expression or activity of biomarkers is measured within 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day prior to the initiation of therapy. In other embodiments, the expression or activity of biomarkers is determined after initiation of therapy (e.g., 1 month, 2 months, 3 months, 3.5 months, 4 months, 4.5 months, 5 months, 5.5 months, 6 months).

In an embodiment, the invention provides a method of evaluating a subject having cancer (e.g., a hematological cancer such as CLL and ALL) comprising:

acquiring a value of responder status for the subject that comprises a measure of one or more of the following:

one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more) biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27

biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature, and a CD19 CAR-expressing cell gene set signature,

thereby evaluating the subject.

In an embodiment, the disclosure provides a method of evaluating a subject having cancer (e.g., a hematological cancer such as CLL and ALL) comprising acquiring a value of responder status for the subject that comprises a measure of one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more) of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, and a CD19 CAR-expressing cell gene set signature, thereby

evaluating the subject.

In an embodiment, the disclosure provides a method of evaluating or monitoring the effectiveness of a CAR-expressing cell therapy in a subject having cancer comprising:

acquiring a value of responder status for the subject that comprises a measure of one or more of the following:

a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature, and a CD19 CAR-expressing cell gene set signature,

thereby evaluating or monitoring the effectiveness of the CAR therapy in the subject.

In an embodiment, the disclosure provides a method of evaluating or monitoring the effectiveness of a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019) in a subject having cancer (e.g., a hematological cancer such as CLL and ALL) comprising: acquiring a value of responder status
 5 for the subject that comprises a measure of one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more) of the following: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, and a CD19 CAR-expressing cell (e.g., T cell, NK cell) gene set signature, thereby
 10 evaluating or monitoring the effectiveness of the CAR-expressing cell (e.g., T cell, NK cell) therapy in the subject.

In an embodiment, the value of responder status comprises a measure of a combination of a gene signature and a biomarker.

In an embodiment, the value of the responder status comprises a measure of a CD19
 15 CAR-expressing cell gene set signature and a combination of one or more of: a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene
 20 set signature, a TH2+ helper T cell gene set signature, and a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature.

In an embodiment, the value of the responder status comprises a measure of a CD19 CAR-expressing cell gene set signature and a combination of one or more of: a biomarker listed
 25 in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1.

In an embodiment, the value of the responder status comprises a measure of one or more biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B and a combination of one or more
 30 of: a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3

biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature, and a
5 CD19 CAR-expressing cell gene set signature.

In an embodiment, the value of the responder status comprises a measure of one or more biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B and a combination of one or more of: CD57, CD27, CD122, CD62L, and KLRG1.

10 In an embodiment, the CD19 CAR-expressing cell gene signature comprises a value for expression of at least 5, 6, 7, 8, 9 or 10 genes comprising a CD19 CAR-expressing cell gene signature.

In an embodiment, the value for expression of the gene comprises a value for a transcriptional parameter, e.g., the level of an mRNA encoded by the gene.

15 In an embodiment, the value for expression of the protein comprises a value for a translational parameter, e.g., the level of a protein.

In an embodiment, provided methods further comprise obtaining a sample from the subject, wherein the sample comprises a cellular or tissue fraction. In an embodiment, the cellular fraction comprises blood.

20 In an embodiment, the measure of biomarker and/or gene signature is acquired before, at the same time, or during course of a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019).

25 In an embodiment, the measure of biomarker and/or gene signature is acquired less than 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days, 2 days prior to the initiation of a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019).

The methods described herein can also be used to monitor a positive response of a subject to CAR-expressing cell (e.g., T cell, NK cell) treatment (e.g., a CD19 CAR-expressing cell treatment described herein such as, e.g., CTL019). Such methods are useful for early detection of tolerance to therapy or to predict whether disease in a subject will progress. In such

embodiments, the expression or activity of biomarkers is determined e.g., at least every week, at least every 2 weeks, at least every month, at least every 2 months, at least every 3 months, at least every 4 months, at least every 5 months, at least every 6 months, at least every 7 months, at least every 8 months, at least every 9 months, at least every 10 months, at least every 11 months, at least every year, at least every 18 months, at least every 2 years, at least every 3 years, at least every 5 years or more. It is also contemplated that expression or activity of the biomarkers is at irregular intervals e.g., biomarkers can be detected in a subject at 3 months of treatment, at 6 months of treatment, and at 7 months of treatment. Thus, in some embodiments, the expression or activity of the biomarkers is determined when deemed necessary by the skilled physician monitoring treatment of the subject.

The methods described herein can be used in treating any subject having cancer (e.g., a hematological cancer such as CLL and ALL). In one aspect, the invention pertains to methods of treating cancer (e.g., a hematological cancer such as CLL and ALL) in a subject.

In an embodiment, the disclosure provides methods for treating cancer including, but not limited to, B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), B cell promyelocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, and Waldenstrom macroglobulinemia. In an embodiment, the invention provides methods for treating ALL. In another embodiment, the invention provides methods for treating CLL. In an embodiment, the invention provides methods for treating cancer that is associated with CD19 expression.

In an embodiment, provided methods comprise administering to the subject a cell expressing a CAR, e.g. a CAR T cell, e.g. a CD19 CAR T cell, e.g., a CTL019 product, if the subject is identified as having a difference, e.g., statistically significant difference in expression level of one or more markers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9,

Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 relative to a reference level, such that the cancer (e.g., a hematological cancer such as ALL and CLL) is treated in the subject.

5 As discussed above, an example of a cancer that is treatable by disclosed methods is a cancer associated with expression of CD19. In one aspect, the cancer associated with expression of CD19 is a hematological cancer. In one aspect, the hematological cancer is a leukemia or a lymphoma. In one aspect, a cancer associated with expression of CD19 includes cancers and malignancies including, but not limited to, e.g., one or more acute leukemias including but not
10 limited to, e.g., B-cell acute lymphoid leukemia (“B-ALL”), T-cell acute lymphoid leukemia (“T-ALL”), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL). Additional cancers or hematologic conditions associated with expression of CD19 include, but are not limited to, e.g., B cell promyelocytic leukemia, blastic plasmacytoid dendritic cell
15 neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm,
20 Waldenstrom macroglobulinemia, and “preleukemia” which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. Further, a disease associated with CD19 expression include, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases associated with expression of CD19.

25 In an embodiment, the disclosure provides a method for treating a subject having cancer (e.g., a hematological cancer such as ALL and CLL) comprising:

determining if the subject has an increased likelihood to respond to a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019) by comparing the level of one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15,
30 20, 25, 30, 35, 40, 45, 50 or more) markers in Table 1A, Table 1B, Table 7A, Table 7B, Table 8,

Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 in a sample from the subject relative to a reference level, wherein a statistically significant difference in expression level of one or more marker genes relative to the reference level is indicative of an increased likelihood of response; and

administering to the subject a therapeutically effective dose of a CAR-expressing cell therapy.

In an embodiment, the disclosure provides a method for treating a subject having cancer (e.g., a hematological cancer such as ALL and CLL), comprising:

obtaining a sample from the subject;
determining a level of one or more markers in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 in the sample;

comparing the determined level of one or more markers in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 to a reference level; and

administering a therapeutically effective dose of a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019), if the subject is identified as having a statistically significant difference in the determined level of one or more markers in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 to a reference level, in the sample.

In an embodiment, the disclosure provides a method of treating cancer (e.g., a hematological cancer such as ALL and CLL) in a subject, comprising:

acquiring a value of responder status for the subject that comprises a measure of one or more of the following:

a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a
 5 TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature, and a CD19 CAR-expressing cell gene set signature, and

responsive to a determination of responder status, performing one, two, three, four or
 10 more of:

identifying the subject as a complete responder, partial responder or non-responder;
 administering a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019);

selecting or altering a dosing of a CAR-expressing cell therapy;

15 selecting or altering the schedule or time course of a CAR-expressing cell therapy;
 administering, e.g., to a non-responder or a partial responder, an additional agent in combination with a CAR-expressing cell therapy, e.g., a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein;

administering to a non-responder or partial responder a therapy that increases the number
 20 of naïve T cells in the subject prior to treatment with a CAR-expressing cell therapy;

modifying a manufacturing process of a CAR-expressing cell therapy, e.g., enrich for naïve T cells prior to introducing a nucleic acid encoding a CAR, e.g., for a subject identified as a non-responder or a partial responder; or selecting an alternative therapy, e.g., for a non-responder or partial responder; or

25 selecting an alternative therapy, e.g., an alternative therapy described herein, e.g., a standard of care therapy for the cancer; thereby treating cancer in a subject.

In an embodiment, the disclosure provides a method of treating cancer (e.g., a hematological cancer such as ALL and CLL) in a subject, comprising: acquiring a value of responder status for the subject that comprises a measure of one or more of the following: a
 30 biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table

14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, and a CD19 CAR-expressing cell gene set signature, and responsive to a determination of responder status, performing one, two, three four or more of: identifying the subject as a complete responder, partial responder or non-
5 responder; administering a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019); selecting or altering a dosing of a CAR-expressing cell therapy; selecting or altering the schedule or time course of a CAR-expressing cell therapy; administering, e.g., to a non-responder or a partial responder, an additional agent in combination with a CAR-expressing cell therapy, e.g., a checkpoint inhibitor, e.g., a checkpoint
10 inhibitor described herein; administering to a non-responder or partial responder a therapy that increases the number of naïve T cells in the subject prior to treatment with a CAR-expressing cell therapy; modifying a manufacturing process of a CAR-expressing cell therapy, e.g., enrich for naïve T cells prior to introducing a nucleic acid encoding a CAR into the T cells, e.g., for a subject identified as a non-responder or a partial responder; selecting an alternative therapy, e.g.,
15 a standard of care for the cancer, e.g., for a non-responder or partial responder; or selecting an alternative CAR-expressing cell therapy; thereby treating cancer in a subject.

In some embodiments, the amount of the biomarker determined in a sample from a subject is quantified as an absolute measurement (e.g., ng/mL). Absolute measurements can easily be compared to a reference value or cut-off value. For example, a cut-off value can be
20 determined that represents a disease progressing status; any absolute values falling either above (i.e., for biomarkers that increase expression with progression of a cancer, e.g., a hematological cancer such as ALL and CLL) or falling below (i.e., for biomarkers with decreased expression with progression of a cancer, e.g., a hematological cancer such as ALL and CLL) the cut-off value are likely to be disease progressing.

25 Alternatively, the relative amount of a biomarker is determined. In one embodiment, the relative amount is determined by comparing the expression and/or activity of one or more biomarkers in a subject with cancer to the expression of the biomarkers in a reference parameter. In some embodiments, a reference parameter is obtained from one or more of: a baseline or prior value for the subject, the subject at a different time interval, an average or median value for a
30 cancer subject (e.g., patient) population, a healthy control, or a healthy subject population.

The present disclosure also pertains to the field of predictive medicine in which diagnostic assays, pharmacogenomics, and monitoring clinical trials are used for predictive purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present disclosure relates to assays for determining the amount, structure, and/or activity of polypeptides or nucleic acids corresponding to one or more markers described herein, in order to determine whether an individual having cancer (e.g., a hematological cancer such as CLL and ALL) or at risk of developing cancer (e.g., a hematological cancer such as CLL and ALL) will be more likely to respond to CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019).

Accordingly, in one aspect, the disclosure provides a method for determining whether a subject with cancer (e.g., a hematological cancer such as CLL and ALL) is likely to respond to a cell expressing a CAR, e.g., a CD19 CAR-expressing cell described herein, such as CTL019. In another aspect, the disclosure is drawn to a method for predicting a time course of disease. In still another aspect, the method is drawn to a method for predicting a probability of a significant event in the time course of the disease (e.g., reoccurrence or remission). In certain embodiments, the method comprises detecting a combination of biomarkers associated with responsiveness to treatment as described herein and determining whether the subject is likely to respond to treatment.

In an aspect, the disclosure provides a method for providing a prognosis for success rate of a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019) in a subject having cancer (e.g., a hematological cancer such as ALL and CLL), said method comprising steps of:

providing a biological sample from the subject;

determining the levels of expression of one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more) genes listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 to obtain a gene expression pattern for the sample; and

based on the gene expression pattern obtained, providing a prognosis to the subject.

In an embodiment, the step of determining the levels of expression of the set of genes further comprises detecting the expression of mRNA expressed from said genes. In an embodiment, provided methods further comprise a step wherein determining the expression of mRNA comprises exposing said mRNA to a nucleic acid probe complementary to said mRNA.

5 In an embodiment, the step of determining the levels of expression of the set of genes further comprises detecting the expression of a polypeptide encoded by said genes.

In an embodiment, provided methods comprise selecting a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell therapy described herein such as, e.g., CTL019) for the subject, based on the prognosis provided.

10 In some embodiments, the methods involve evaluation of a biological sample, e.g., a sample from a subject, e.g., a patient who has been diagnosed with or is suspected of having cancer (e.g., a hematological cancer such as CLL or ALL, e.g., presents with symptoms of CLL or ALL) to detect changes in expression and/or activity of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or more genes in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table
15 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 and a CD19 CAR-expressing cell (e.g., T cell, NK cell) gene signature.

The results of the screening method and the interpretation thereof are predictive of the patient's disease progression (e.g., progression of a cancer, e.g., a hematological cancer such as
20 ALL or CLL). According to the present invention, alterations in expression or activity of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or more genes in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 and a CD19 CAR-expressing cell (e.g., T cell, NK cell) gene signature is indicative of cancer progression (e.g., a
25 hematological cancer such as ALL and CLL) relative to an average or median value for a cancer patient population or to an average median for a population of healthy, cancer free subjects.

In yet another embodiment, the one or more alterations, e.g., alterations in biomarker expression are assessed at pre-determined intervals, e.g., a first point in time and at least at a subsequent point in time. In one embodiment, a time course is measured by determining the time

between significant events in the course of a subject's disease, wherein the measurement is predictive of whether a subject has a long time course. In another embodiment, the significant event is the progression from diagnosis to death. In another embodiment, the significant event is the progression from diagnosis to worsening disease.

5

Methods for Detection of Gene Expression

Biomarker expression level can also be assayed. Expression of a marker described herein can be assessed by any of a wide variety of known methods for detecting expression of a transcribed molecule or protein. Non-limiting examples of such methods include immunological
10 methods for detection of secreted, cell-surface, cytoplasmic, or nuclear proteins, protein purification methods, protein function or activity assays, nucleic acid hybridization methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods.

In certain embodiments, activity of a particular gene is characterized by a measure of gene transcript (*e.g.*, mRNA), by a measure of the quantity of translated protein, or by a measure
15 of gene product activity. Marker expression can be monitored in a variety of ways, including by detecting mRNA levels, protein levels, or protein activity, any of which can be measured using standard techniques. Detection can involve quantification of the level of gene expression (*e.g.*, genomic DNA, cDNA, mRNA, protein, or enzyme activity), or, alternatively, can be a qualitative assessment of the level of gene expression, in particular in comparison with a control
20 level. The type of level being detected will be clear from the context.

Methods of detecting and/or quantifying the gene transcript (mRNA or cDNA made therefrom) using nucleic acid hybridization techniques are known to those of skill in the art (see *e.g.*, Sambrook *et al. supra*). For example, one method for evaluating the presence, absence, or quantity of cDNA involves a Southern transfer as described above. Briefly, the mRNA is
25 isolated (*e.g.*, using an acid guanidinium-phenol-chloroform extraction method, Sambrook *et al. supra*.) and reverse transcribed to produce cDNA. The cDNA is then optionally digested and run on a gel in buffer and transferred to membranes. Hybridization is then carried out using the nucleic acid probes specific for the target cDNA.

A general principle of such diagnostic and prognostic assays involves preparing a sample or reaction mixture that can contain a marker, and a probe, under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways.

For example, one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, a sample from a subject, which is to be assayed for presence and/or concentration of marker, can be anchored onto a carrier or solid phase support. In another embodiment, the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay.

In order to conduct assays with the above-mentioned approaches, the non-immobilized component is added to the solid phase upon which the second component is anchored. After the reaction is complete, uncomplexed components can be removed (*e.g.*, by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase. The detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein.

In another embodiment, the probe, when it is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art.

It is also possible to directly detect marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (see, for example, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos, *et al.*, U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent energy will be absorbed by a fluorescent label on a second 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately,

the ‘donor’ protein molecule can simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the ‘acceptor’ molecule label can be differentiated from that of the ‘donor’. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial
5 relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the ‘acceptor’ molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (*e.g.*, using a fluorimeter).

In another embodiment, determination of the ability of a probe to recognize a marker can
10 be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, *e.g.*, Sjolander, S. and Urbaniczky, C., 1991, ANAL. CHEM. 63:2338-2345 and Szabo et al., 1995, CURR. OPIN. STRUCT. BIOL. 5:699-705). As used herein, “BIA” or “surface plasmon resonance” is a technology for studying biospecific interactions in real time, without labeling any of the
15 interactants (*e.g.*, BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

Alternatively, in another embodiment, analogous diagnostic and prognostic assays can be
20 conducted with marker and probe as solutes in a liquid phase. In such an assay, the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In differential centrifugation, marker/probe complexes can be separated from uncomplexed assay components through a series of centrifugal steps, due
25 to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P., 1993, *Trends Biochem Sci.* 18(8):284-7). Standard chromatographic techniques can also be utilized to separate complexed molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for
30 example, the relatively larger complex can be separated from the relatively smaller uncomplexed

components. Similarly, the relatively different charge properties of the marker/probe complex as compared to the uncomplexed components can be exploited to differentiate the complex from uncomplexed components, for example, through the utilization of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, 5 *e.g.*, Heegaard, N.H., 1998, J. MOL. RECOGNIT. Winter 11(1-6):141-8; Hage, D.S., and Tweed, S.A. J CHROMATOGR B BIOMED SCI APPL 1997 Oct 10;699(1-2):499-525). Gel electrophoresis can also be employed to separate complexed assay components from unbound components (see, *e.g.*, Ausubel *et al.*, ed., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987-1999). In this technique, protein or nucleic acid complexes are separated based 10 on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process, non-denaturing gel matrix materials and conditions in the absence of reducing agent are typical. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art.

In a particular embodiment, the level of mRNA corresponding to the marker can be 15 determined both by *in situ* and by *in vitro* formats in a biological sample using methods known in the art. The term "biological sample" is intended to include tissues, cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject. Many expression detection methods use isolated RNA. For *in vitro* methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the 20 purification of RNA from cells (see, *e.g.*, Ausubel *et al.*, ed., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York 1987-1999). Additionally, large numbers of tissue samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Patent No. 4,843,155).

25 The isolated nucleic acid can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays. One diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe can be, for example, a full- 30 length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250

or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present invention. Other suitable probes for use in the diagnostic assays are described herein. Hybridization of an mRNA with the probe indicates that the marker in question is being expressed.

5 In one format, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods
10 for use in detecting the level of mRNA encoded by the markers described herein.

The probes can be full length or less than the full length of the nucleic acid sequence encoding the protein. Shorter probes are empirically tested for specificity. Exemplary nucleic acid probes are 20 bases or longer in length (See, *e.g.*, Sambrook *et al.* for methods of selecting nucleic acid probe sequences for use in nucleic acid hybridization). Visualization of the
15 hybridized portions allows the qualitative determination of the presence or absence of cDNA.

An alternative method for determining the level of a transcript corresponding to a marker of the present invention in a sample involves the process of nucleic acid amplification, *e.g.*, by rtPCR (the experimental embodiment set forth in Mullis, 1987, U.S. Patent No. 4,683,202), ligase chain reaction (Barany, 1991, *Proc. Natl. Acad. Sci. USA*, 88:189-193), self-sustained
20 sequence replication (Guatelli *et al.*, 1990, *PROC. NATL. ACAD. SCI. USA* 87:1874-1878), transcriptional amplification system (Kwoh *et al.*, 1989, *PROC. NATL. ACAD. SCI. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.*, 1988, *BIO/TECHNOLOGY* 6:1197), rolling circle replication (Lizardi *et al.*, U.S. Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to
25 those of skill in the art. Fluorogenic rtPCR can also be used in the methods of the invention. In fluorogenic rtPCR, quantitation is based on amount of fluorescence signals, *e.g.*, TaqMan and sybr green. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions
30 of a gene (plus and minus strands, respectively, or *vice-versa*) and contain a short region in

between. In general, amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

5 For *in situ* methods, mRNA does not need to be isolated from the cells prior to detection. In such methods, a cell or tissue sample is prepared/processed using known histological methods. The sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the marker.

As an alternative to making determinations based on the absolute expression level of the
10 marker, determinations can be based on the normalized expression level of the marker. Expression levels are normalized by correcting the absolute expression level of a marker by comparing its expression to the expression of a gene that is not a marker, *e.g.*, a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene, or epithelial cell-specific genes. This normalization allows the
15 comparison of the expression level in one sample, *e.g.*, a subject sample, to another sample, *e.g.*, a healthy subject, or between samples from different sources.

Alternatively, the expression level can be provided as a relative expression level. To determine a relative expression level of a marker, the level of expression of the marker can be determined for 10 or more samples of normal versus cancer isolates, or even 50 or more samples,
20 prior to the determination of the expression level for the sample in question. The mean expression level of each of the genes assayed in the larger number of samples can be determined and this can be used as a baseline expression level for the marker. The expression level of the marker determined for the test sample (absolute level of expression) then can be divided by the mean expression value obtained for that marker. This provides a relative expression level.

25 In certain embodiments, the samples used in the baseline determination will be from samples derived from a subject having cancer (*e.g.*, a hematological cancer such as ALL and CLL) versus samples from a healthy subject of the same tissue type. The choice of the cell source is dependent on the use of the relative expression level. Using expression found in normal tissues as a mean expression score aids in validating whether the marker assayed is

specific to the tissue from which the cell was derived (*versus* normal cells). In addition, as more data is accumulated, the mean expression value can be revised, providing improved relative expression values based on accumulated data. Expression data from normal cells provides a means for grading the severity of the cancer disease state.

5 In another embodiment, expression of a marker is assessed by preparing genomic DNA or mRNA/cDNA (*i.e.*, a transcribed polynucleotide) from cells in a subject sample, and by hybridizing the genomic DNA or mRNA/cDNA with a reference polynucleotide which is a complement of a polynucleotide comprising the marker, and fragments thereof. cDNA can, optionally, be amplified using any of a variety of polymerase chain reaction methods prior to
10 hybridization with the reference polynucleotide. Expression of one or more markers can likewise be detected using quantitative PCR (QPCR) to assess the level of expression of the marker(s). Alternatively, any of the many known methods of detecting mutations or variants (*e.g.*, single nucleotide polymorphisms, deletions, *etc.*) of a marker of the invention can be used to detect occurrence of a mutated marker in a subject.

15 In a related embodiment, a mixture of transcribed polynucleotides obtained from the sample is contacted with a substrate having fixed thereto a polynucleotide complementary to or homologous with at least a portion (*e.g.*, at least 7, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 500, or more nucleotide residues) of a marker described herein. If polynucleotides complementary to, or homologous with, a marker
20 described herein are differentially detectable on the substrate (*e.g.*, detectable using different chromophores or fluorophores, or fixed to different selected positions), then the levels of expression of a plurality of markers can be assessed simultaneously using a single substrate (*e.g.*, a "gene chip" microarray of polynucleotides fixed at selected positions). When a method of assessing marker expression is used which involves hybridization of one nucleic acid with
25 another, the hybridization can be performed under stringent hybridization conditions.

In another embodiment, a combination of methods to assess the expression of a marker is utilized.

Because the compositions, kits, and methods rely on detection of a difference in expression levels of one or more markers described herein, in certain embodiments the level of

expression of the marker is significantly greater than the minimum detection limit of the method used to assess expression in at least one of a biological sample from a subject with cancer (e.g., a hematological cancer such as ALL and CLL) or a reference (e.g., a biological sample from a healthy subject, e.g., a subject without cancer).

5

Nucleic Acid Molecules and Probes

One aspect of the disclosure pertains to isolated nucleic acid molecules that correspond to one or markers described herein, including nucleic acids which encode a polypeptide corresponding to one or more markers described herein or a portion of such a polypeptide. The nucleic acid molecules include those nucleic acid molecules which reside in genomic regions identified herein. Isolated nucleic acid molecules also include nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules that correspond to a marker described herein, including nucleic acid molecules which encode a polypeptide corresponding to a marker described herein, and fragments of such nucleic acid molecules, e.g., those suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules. Nucleic acid molecules can be DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded; in certain embodiments the nucleic acid molecule is double-stranded DNA.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. In certain embodiments, an "isolated" nucleic acid molecule is free of sequences (such as protein-encoding sequences) which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.

The language "substantially free of other cellular material or culture medium" includes preparations of nucleic acid molecule in which the molecule is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, nucleic acid molecule that is substantially free of cellular material includes preparations of nucleic acid

molecule having less than about 30%, less than about 20%, less than about 10%, or less than about 5% (by dry weight) of other cellular material or culture medium.

If so desired, a nucleic acid molecule, e.g., the marker gene products identified herein, can be isolated using standard molecular biology techniques and the sequence information in the database records described herein. Using all or a portion of such nucleic acid sequences, nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., ed., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

A nucleic acid molecule can be amplified using cDNA, mRNA, or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid molecules so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts (e.g., mRNA) or genomic sequences corresponding to one or more markers described herein. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which mis-express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

Polypeptide Detection

Methods to measure biomarkers described herein, include, but are not limited to: Western blot, immunoblot, enzyme-linked immunosorbant assay (ELISA), radioimmunoassay (RIA), immunoprecipitation, surface plasmon resonance, chemiluminescence, fluorescent polarization, phosphorescence, immunohistochemical analysis, liquid chromatography mass spectrometry (LC-MS), matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass

spectrometry, microcytometry, microarray, microscopy, fluorescence activated cell sorting (FACS), magnetic activated cell sorting (MACS), flow cytometry, laser scanning cytometry, hematology analyzer and assays based on a property of the protein including but not limited to DNA binding, ligand binding, or interaction with other protein partners.

5 The activity or level of a marker protein can also be detected and/or quantified by detecting or quantifying the expressed polypeptide. The polypeptide can be detected and quantified by any of a number of means well known to those of skill in the art. These can include analytic biochemical methods such as electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion
10 chromatography, and the like, or various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, Western blotting, immunohistochemistry and the like. A skilled artisan can readily adapt known protein/antibody detection methods for use in determining the expression level of one or more
15 biomarkers in a serum sample.

 Another agent for detecting a polypeptide is an antibody capable of binding to a polypeptide corresponding to a marker described herein, e.g., an antibody with a detectable label. Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to
20 encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled
25 streptavidin.

 In another embodiment, the antibody is labeled, *e.g.*, a radio-labeled, chromophore-labeled, fluorophore-labeled, or enzyme-labeled antibody. In another embodiment, an antibody derivative (*e.g.*, an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair (*e.g.*, biotin-streptavidin)), or an antibody fragment (*e.g.*, a single-chain
30 antibody, an isolated antibody hypervariable domain, *etc.*) which binds specifically with a

protein corresponding to the marker, such as the protein encoded by the open reading frame corresponding to the marker or such a protein which has undergone all or a portion of its normal post-translational modification, is used.

Proteins from cells can be isolated using techniques that are well known to those of skill
5 in the art. The protein isolation methods employed can, for example, be such as those described in Harlow and Lane (Harlow and Lane, 1988, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

In one format, antibodies, or antibody fragments, can be used in methods such as Western blots or immunofluorescence techniques to detect the expressed proteins. In such uses, one can
10 immobilize either the antibody or proteins on a solid support. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

In another embodiment, the polypeptide is detected using an immunoassay. As used
15 herein, an immunoassay is an assay that utilizes an antibody to specifically bind to the analyte. The immunoassay is thus characterized by detection of specific binding of a polypeptide to an anti-antibody as opposed to the use of other physical or chemical properties to isolate, target, and quantify the analyte.

The polypeptide is detected and/or quantified using any of a number of well recognized
20 immunological binding assays (see, e.g., U.S. Patent Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also Asai (1993) *Methods in Cell Biology* Volume 37: *Antibodies in Cell Biology*, Academic Press, Inc. New York; Stites & Terr (1991) *Basic and Clinical Immunology* 7th Edition.

In another embodiment, the polypeptide is detected and/or quantified using Luminex®
25 assay technology. The Luminex® assay separates tiny color-coded beads into e.g., distinct sets that are each coated with a reagent for a particular bioassay, allowing the capture and detection of specific analytes from a sample in a multiplex manner. The Luminex® assay technology can be compared to a multiplex ELISA assay using bead-based fluorescence cytometry to detect analytes such as biomarkers.

The disclosure also encompasses kits for detecting the presence of a polypeptide or nucleic acid corresponding to a marker described herein in a biological sample, *e.g.*, a sample containing tissue, whole blood, serum, plasma, buccal scrape, saliva, cerebrospinal fluid, urine, stool, and bone marrow. Such kits can be used to determine if a subject is suffering from or is at
5 increased risk of developing cancer (*e.g.*, a hematological cancer such as CLL and ALL). For example, the kit can comprise a labeled compound or agent capable of detecting a polypeptide or an mRNA encoding a polypeptide corresponding to a marker described herein in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (*e.g.*, an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or
10 mRNA encoding the polypeptide). Kits can also include instructions for interpreting the results obtained using the kit.

The disclosure thus includes a kit for assessing the disease progression of a subject having cancer (*e.g.*, a hematological cancer such as CLL and ALL).

In an embodiment, a kit can be used to assess the disease progression of a cancer
15 including, but not limited to, B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), B cell promyelocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma,
20 malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, and Waldenstrom macroglobulinemia. In an embodiment, the disclosure provides a kit for assessing the disease progression of a subject having a hematological cancer. In an
25 embodiment, the disclosure provides a kit for assessing the disease progression of a subject having ALL. In another embodiment, the disclosure provides a kit for assessing the disease progression of a subject having CLL. In an embodiment, the disclosure provides a kit for assessing the disease progression of a subject having cancer that is associated with CD19 expression.

In an embodiment, the disclosure provides a kit for assessing and characterizing responder status (e.g., compete responder, partial responder or non-responder) of a subject having a hematological cancer to a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell therapy as described herein, such as e.g., CTL019). In an
5 embodiment, the disclosure provides a kit for assessing and characterizing responder status (e.g., compete responder, partial responder or non-responder) of a subject having ALL to a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy as described herein, such as e.g., CTL019). In an embodiment, the disclosure provides a kit for assessing and characterizing responder status (e.g., compete responder, partial responder or non-responder) of a subject
10 having CLL to a CAR-expressing cell therapy (e.g., a CD19 CAR-expressing cell therapy as described herein, such as e.g., CTL019).

Suitable reagents for binding with a polypeptide corresponding to a marker described herein include antibodies, antibody derivatives, antibody fragments, and the like. Suitable reagents for binding with a nucleic acid (e.g., a genomic DNA, an mRNA, a spliced mRNA, a
15 cDNA, or the like) include complementary nucleic acids. For example, the nucleic acid reagents can include oligonucleotides (labeled or non-labeled) fixed to a substrate, labeled oligonucleotides not bound with a substrate, pairs of PCR primers, molecular beacon probes, and the like.

The kit can optionally comprise additional components useful for performing the
20 methods described herein. By way of example, the kit can comprise fluids (e.g., SSC buffer) suitable for annealing complementary nucleic acids or for binding an antibody with a protein with which it specifically binds, one or more sample compartments, an instructional material which describes performance of a method of the invention, a reference sample for comparison of expression levels of the biomarkers described herein, and the like.

25 A kit of the invention can comprise a reagent useful for determining protein level or protein activity of a marker.

In an embodiment, a kit is provided for providing a prognosis for success rate of a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell therapy as

described herein, such as e.g., CTL019) in a subject having cancer (e.g., a hematological cancer such as CLL and ALL), said kit comprising:

a set of reagents that specifically detects expression levels of one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 50 or more) genes listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 and a CD19 CAR-expressing cell gene set signature; and

instructions for using said kit;

wherein said instructions for use provide that if one or more of the detected expression levels is greater than a reference level, the subject is more likely to respond positively to a CAR-expressing cell therapy.

In an embodiment, the set of reagents detects the expression of mRNA expressed from said set of genes.

In an embodiment, the set of reagents comprises nucleic acid probes complementary to mRNA expressed from said set of genes.

In an embodiment, the nucleic acid probes complementary to mRNA are cDNA or oligonucleotides.

In an embodiment, the nucleic acid probes complementary to mRNA are immobilized on a substrate surface.

In an embodiment, the set of reagents detects the expression of polypeptides encoded by said set of genes.

Therapeutic Agents, Compositions and Administration

The methods described herein can be used to assess a responder status to a cell expressing a CAR. In one embodiment, the cell expresses a CAR molecule comprising an antigen binding domain (e.g., an antibody or antibody fragment that specifically binds to a tumor antigen), a transmembrane domain, and an intracellular signaling domain (e.g., an intracellular signaling domain comprising a costimulatory domain and/or a primary signaling domain). In an

embodiment, the antigen binding domain comprises any antibody, or a fragment thereof, e.g., an scFv, known in the art that targets or specifically binds to any of the tumor antigens described herein. For example, the tumor antigen is BCMA (also known as TNFRSF17, Tumor Necrosis Factor Receptor Superfamily, Member 17, or B Cell Maturation Antigen), CD33, CLL-1 (also
5 known as C-type Lectin-Like domain family 1, or CLECL1) or claudin-6 (CLDN6). The antibody, or fragment thereof, can be a murine, humanized, or fully human antibody or fragment thereof, e.g., an scFv.

In one embodiment, the CAR comprises an antibody or antibody fragment which includes an anti-CD19 binding domain described herein (e.g., a murine or humanized antibody or
10 antibody fragment that specifically binds to CD19 as described herein), a transmembrane domain described herein, and an intracellular signaling domain described herein (e.g., an intracellular signaling domain comprising a costimulatory domain and/or a primary signaling domain described herein).

Antigen Binding Domain

In one aspect, the CAR of the invention comprises a target-specific binding element otherwise referred to as an antigen binding domain. The choice of moiety depends upon the type and number of ligands that define the surface of a target cell. For example, the antigen binding domain may be chosen to recognize a ligand that acts as a cell surface marker on target cells associated with a particular disease state. Thus, examples of cell surface markers that may act as
20 ligands for the antigen binding domain in a CAR of the invention include those associated with viral, bacterial and parasitic infections, autoimmune disease and cancer cells.

In one aspect, the CAR-mediated T-cell response can be directed to an antigen of interest by way of engineering an antigen binding domain that specifically binds a desired antigen into the CAR.

25 In one aspect, the portion of the CAR comprising the antigen binding domain comprises an antigen binding domain that targets a tumor antigen, e.g., a tumor antigen described herein.

The antigen binding domain can be any domain that binds to the antigen including but not limited to a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, and a functional fragment thereof, including but not limited to a

single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL) and a variable domain (VHH) of camelid derived nanobody, and to an alternative scaffold known in the art to function as antigen binding domain, such as a recombinant fibronectin domain, a T cell receptor (TCR), or a fragment thereof, e.g., single chain TCR, and the like. In some instances, it is beneficial for the antigen binding domain to be derived from the same species in which the CAR will ultimately be used in. For example, for use in humans, it may be beneficial for the antigen binding domain of the CAR to comprise human or humanized residues for the antigen binding domain of an antibody or antibody fragment.

Any known CD19 CAR, e.g., the CD19 antigen binding domain of any known CD19 CAR, in the art can be used in accordance with the instant invention. For example, LG-740; CD19 CAR described in the US Pat. No. 8,399,645; US Pat. No. 7,446,190; Xu et al., *Leuk Lymphoma*. 2013 54(2):255-260(2012); Cruz et al., *Blood* 122(17):2965-2973 (2013); Brentjens et al., *Blood*, 118(18):4817-4828 (2011); Kochenderfer et al., *Blood* 116(20):4099-102 (2010); Kochenderfer et al., *Blood* 122 (25):4129-39(2013); and 16th Annu Meet Am Soc Gen Cell Ther (ASGCT) (May 15-18, Salt Lake City) 2013, Abst 10.

Exemplary target antigens that can be targeted using the CAR-expressing cells, include, but are not limited to, CD19, CD123, EGFRvIII, mesothelin, among others, as described in, for example, WO 2014/130635, WO 2014/130657, and WO 2015/090230, each of which is herein incorporated by reference in its entirety.

In one embodiment, the CAR T cell that specifically binds to CD19 has the USAN designation TISAGENLEUCCEL-T. CTL019 is made by a gene modification of T cells is mediated by stable insertion via transduction with a self-inactivating, replication deficient Lentiviral (LV) vector containing the CTL019 transgene under the control of the EF-1 alpha promoter. CTL019 can be a mixture of transgene positive and negative T cells that are delivered to the subject on the basis of percent transgene positive T cells.

In other embodiments, the CAR-expressing cells can specifically bind to human CD19, e.g., can include a CAR molecule, or an antigen binding domain (e.g., a humanized antigen binding domain) according to Table 3 of WO2014/153270, incorporated herein by reference.

In other embodiments, the CAR-expressing cells can specifically bind to CD123, *e.g.*, can include a CAR molecule (*e.g.*, any of the CAR1-CAR8), or an antigen binding domain according to Tables 1-2 of WO 2014/130635, incorporated herein by reference.

5 In other embodiments, the CAR-expressing cells can specifically bind to EGFRvIII, *e.g.*, can include a CAR molecule, or an antigen binding domain according to Table 2 or SEQ ID NO:11 of WO 2014/130657, incorporated herein by reference.

In other embodiments, the CAR-expressing cells can specifically bind to mesothelin, *e.g.*, can include a CAR molecule, or an antigen binding domain according to Tables 2-3 of WO 2015/090230, incorporated herein by reference.

10 In one embodiment, the antigen binding domain comprises one, two three (*e.g.*, all three) heavy chain CDRs, HC CDR1, HC CDR2 and HC CDR3, from an antibody listed above, and/or one, two, three (*e.g.*, all three) light chain CDRs, LC CDR1, LC CDR2 and LC CDR3, from an antibody listed above. In one embodiment, the antigen binding domain comprises a heavy chain variable region and/or a variable light chain region of an antibody listed or described above.

15 In some embodiments, the tumor antigen is a tumor antigen described in International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety. In some embodiments, the tumor antigen is chosen from one or more of: CD19; CD123; CD22; CD30; CD171; CS-1 (also referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3
20 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDGlc(1-1)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAc α -Ser/Thr)); prostate-specific membrane antigen (PSMA); Receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-Like Tyrosine Kinase 3 (FLT3); Tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6;
25 Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); Interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); Mesothelin; Interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); Protease Serine 21 (Testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet-derived growth factor receptor beta (PDGFR-beta); Stage-specific
30 embryonic antigen-4 (SSEA-4); CD20; Folate receptor alpha; Receptor tyrosine-protein kinase

ERBB2 (Her2/neu); Mucin 1, cell surface associated (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); Prostate; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); Ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX);

5 Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); glycoprotein 100 (gp100); oncogene fusion protein consisting of breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl) (bcr-abl); tyrosinase; ephrin type-A receptor 2 (EphA2); Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDGlc(1-1)Cer); transglutaminase 5 (TGS5); high molecular weight-melanoma-

10 associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Polysialic acid; placenta-specific 1

15 (PLAC1); hexasaccharide portion of globoH glycosphingolipid (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51E2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein

20 (WT1); Cancer/testis antigen 1 (NY-ESO-1); Cancer/testis antigen 2 (LAGE-1a); Melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53

25 (p53); p53 mutant; prostein; surviving; telomerase; prostate carcinoma tumor antigen-1 (PCTA-1 or Galectin 8), melanoma antigen recognized by T cells 1 (MelanA or MART1); Rat sarcoma (Ras) mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-Acetyl glucosaminyl-transferase V (NA17); paired box

30 protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC);

Tyrosinase-related protein 2 (TRP-2); Cytochrome P450 1B1 (CYP1B1); CCCTC-Binding Factor (Zinc Finger Protein)-Like (BORIS or Brother of the Regulator of Imprinted Sites), Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); Receptor for Advanced Glycation Endproducts (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papilloma virus E6 (HPV E6); human papilloma virus E7 (HPV E7); intestinal carboxyl esterase; heat shock protein 70-2 mutated (mut hsp70-2); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR or CD89); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1).

CD19 CAR Constructs

Murine CD19 CAR constructs are described in PCT publication WO 2012/079000, incorporated herein by reference, and the amino acid sequence of the murine CD19 CAR and scFv constructs are shown in Table 2 below.

Table 2: Murine CD19 CAR Constructs

CTL019 Full - aa	SEQ ID NO: 81	MALPVTALLLPLALLLHAARPdiqmtqttsslsaslgdrvtiscrasqdiskylnw yqqkpdgtvkllyhtsrhlhsgvpsrfsfgsgsgtdysltisnleqediatyfcqqg ntlpytfgggtkleitggggsgggsggggsevkqlqesgpglvapsqslsvtctvs gvsldpygvswirqprrkglewlgviwgsettyynsalksrlytiikdnksqvflk mnsiqtdtdaiyycahyyyggsyamydwgqgtsvtvssttppaprpptpaptias qplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvllslvitlyckrgr klllyifkqpfmrpvqttqeedgcscrfeeeeeggcclrvkfsrsadapaykqqn qllynelnlgrreeydvldkrrgrdpemggkprknpqeglynelqkdkmaeysei gmkgerrrrgkghdglyqglstatkdydalhmqalppr
CTL019 scFv domain	SEQ ID NO: 52	Diqmtqttsslsaslgdrvtiscrasqdiskylnw yqqkpdgtvkllyhtsrhlhsgvpsrfsfgsgsgtdysltisnleqediatyfcqqgntlpytfgggtkleitggggsgggsggggsevkqlqesgpglvapsqslsvtctvsgvsldpygvswirqprrkgle

		wlgviwgsettyynsalksrltiikdnksqvfllkmnslqtdddtaiyycahyyyg gsyamdywgqgtsvtvss
mCAR1 scFv	SEQ ID NO: 84	QVQLLES GAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPQG GLEWIGQIYPGDG DTNYNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISVVDFYFDYW GQGTTVTGGGSGGGSGGGSGGGSELVLTQSPKFMSTSVGDRVSVTCKASQNVGTNV AWYQQKPGQSPKPLIYSATYRNSGVPDRFTGSGSGTDFTLTITNVQSKDLADYFCQ YNRYPYTSFFFTKLEIKRRS
mCAR1 Full - aa	SEQ ID NO: 85	QVQLLES GAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPQG GLEWIGQIYPGDG DTNYNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISVVDFYFDYW GQGTTVTGGGSGGGSGGGSGGGSELVLTQSPKFMSTSVGDRVSVTCKASQNVGTNV AWYQQKPGQSPKPLIYSATYRNSGVPDRFTGSGSGTDFTLTITNVQSKDLADYFCQ YNRYPYTSFFFTKLEIKRRSKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLPG PSKPFVWL VVVGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRK HYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRG RDPGEMGGKPRRKNPQEGLYNELQDKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTA TKD TYDALHMQALPPR
mCAR2 scFv	SEQ ID NO: 86	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHS GVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSG SGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRK GLEWLGVIWGSETTYNSALKSRLTIIKDNSKSQVFLKMNSLQTD DTAIYYCAKHY YGGSYAMDYWGQGTSTVTSSE
mCAR2 CAR - aa	SEQ ID NO: 87	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHS GVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSG SGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRK GLEWLGVIWGSETTYNSALKSRLTIIKDNSKSQVFLKMNSLQTD DTAIY YCAKHYYYGGSYAMDYWGQGTSTVTSSES KYGPPCPPCPMFVWL VVVGVLACYSL LVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFE EEEGGCEL RVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYN ELQDKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKD TYDALHMQALPPRL
mCAR2 Full - aa	SEQ ID NO: 88	DIQMTQTT SLSASLGDR VTISCRASQD ISKYLNWYQQ KPDGTVKLLI YHTSRLHSGV PSRFSGSGSG TDYSLTISNL EQEDIATYFC QQGNTLPYTF GGGTKLEITG STSGSGKPGS GEGSTKGEVK LQESGPGLV A PSQSLSVTCT VSGVSLPDYG VSWIRQPPRK GLEWLGVIWG SETTYNSAL KSRLTIIKDN SKSQVFLKMN SLQTD DTAIY YCAKHYYYGG SYAMDYWGQG TSVTSSES K YGPPCPPCPM FVWL VVVGVLACYSLLVT AFIIFWVKRG RKKLLYIFKQ PFMRPVQTTQ EEDGCSCRFE EEEGGCEL RV KFSRSADAPA YQQGQNQLYN ELNLGRREEY DVLDKRRGRD PEMGGKPRRK NPQEGLYNEL QDKMAEAYS EIGMKGERRR GKGGHDGLYQG LSTATKD TYD ALHMQALPPR LEGGGEGRGS LLTCGDVEEN PGPRMLLLVT SLLCELPH AFLIPRVC NGIGIGEFKD SLSINATNIK HFKNCTSIG DLHILPVAFR GDSFTHTPPL DPQELDILKT VKEITGFLLI QAWPENRTDL HAFENLEIR GRKQHGQFS LAVVSLNITS LGLRSLKEIS DGDV IISGNK NLCYANTINW KKLFGTSGQK TKIISNRGEN SCKATGQVCH ALCSPGECWG PEPRDCVSCR NVSRGRECVD KCNLLGEPR EFVENSECIQ CHPECLPQAM NITCTGRGPD

		NCIQCAHYID GPHCVKTCPA GVMGENNTLV WKYADAGHVC HLCHPNCTYG CTGPGLEGCP TNGPKIPSIA TGMVGALLLL LVVALGIGLF M
mCAR3 scFv	SEQ ID NO: 89	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHS GVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSG SGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRK GLEWLGVIWGSETTYNSALKSRLTI IKDNSKSQVFLKMNSLQTD DTAIYYCAKHY YYGGSYAMDYWGQGTSTVTVSS
mCAR3 Full - aa	SEQ ID NO: 90	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHS GVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSG SGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRK GLEWLGVIWGSETTYNSALKSRLTI IKDNSKSQVFLKMNSLQTD DTAIYYCAKHY YYGGSYAMDYWGQGTSTVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSP LFPGPSKPFVVLVVGGVLACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGP TRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLRREEYDVLDK RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGDGLYQGL STATKDTYDALHMQALPPR

CD19 CAR constructs containing humanized anti-CD19 scFv domains are described in PCT publication WO 2014/153270, incorporated herein by reference.

In an embodiment, the antigen binding domain comprises an anti-CD19 antibody, or fragment thereof, e.g., an scFv. For example, the antigen binding domain comprises a variable heavy chain and a variable light chain listed in **Table 12**. The linker sequence joining the variable heavy and variable light chains can be, e.g., any of the linker sequences described herein, or alternatively, can be GSTSGSGKPGSGEGSTKG (SEQ ID NO:45).

Table 12: Anti-CD 19 antibody binding domains

CD19	huscFv1	EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLPEDFAVYFCQQGNTLPYTFGGGKLEIKG GGGSGGGSGGGGSQVQLQESGPGLVKPSSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTSLVTVSS (SEQ ID NO: 24)
CD19	huscFv2	Eivmtqspatls slspgeratlscrasqdiskylnw yqqkpgqaprlliyhtsrlhsgip arfsgsgsgtdytl t isslqpedfavyfcqqgntlp ytfgggk leik <u>ggggsgggsgg</u> <u>gggsqvqlqesgpglvkpsetls l tctvsgvslpdygvswirpppgkglewigviwgse</u> t tyyqsslskrvtiskdnsk nqvslklssvtaadtavyyca khyyyggsyamydgqgt lvtvss (SEQ ID NO: 25)
CD19	huscFv3	Qvqlqesgpglvkpsetls l tctvsgvslpdygvswirpppgkglewigviwgsetty ssslksrvtiskdnsk nqvslklssvtaadtavyyca khyyyggsyamydgqgtlvtv ssggggsgggsggggseivmtqspatls slspgeratlscrasqdiskylnw yqqkpgq aprlliyhtsrlhsgiparfsgsgsgtdytl t isslqpedfavyfcqqgntlp ytfggg tkleik (SEQ ID NO: 26)

CD19	huscFv4	Qvqlqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigviwgsettyy qsslksrvtiskdnskqvslklssvtaadtavyycahyyyggsyamdywgqgtltvtv ssggggsgggsgggsgggseivmtqspatlsispgeratlscrasqdiskynlwyqqkpgq aprlliyhtsrhsgiparfsgsgsgtdytlitisslqpedfavyfcqqgntlpytfgqg tkleik (SEQ ID NO: 27)
CD19	huscFv5	Eivmtqspatlsispgeratlscrasqdiskynlwyqqkpgqaprlliyhtsrhsgip arfsgsgsgtdytlitisslqpedfavyfcqqgntlpytfgqgtkleik <u>ggggsgggsgg</u> <u>ggsgggsggsvqlqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigv</u> <u>iwgsettyyssslksrvtiskdnskqvslklssvtaadtavyycahyyyggsyamdy</u> <u>wgqgtltvtvss</u> (SEQ ID NO: 39)
CD19	huscFv6	Eivmtqspatlsispgeratlscrasqdiskynlwyqqkpgqaprlliyhtsrhsgip arfsgsgsgtdytlitisslqpedfavyfcqqgntlpytfgqgtkleik <u>ggggsgggsgg</u> <u>ggsgggsggsvqlqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigv</u> <u>iwgsettyyqsslksrvtiskdnskqvslklssvtaadtavyycahyyyggsyamdy</u> <u>wgqgtltvtvss</u> (SEQ ID NO: 43)
CD19	huscFv7	Qvqlqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigviwgsettyy qsslksrvtiskdnskqvslklssvtaadtavyycahyyyggsyamdywgqgtltvtv ssggggsgggsgggsgggsgggseivmtqspatlsispgeratlscrasqdiskynlwyq qkpgqaprlliyhtsrhsgiparfsgsgsgtdytlitisslqpedfavyfcqqgntlpy tfgqgtkleik (SEQ ID NO: 46)
CD19	huscFv8	Qvqlqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigviwgsettyy qsslksrvtiskdnskqvslklssvtaadtavyycahyyyggsyamdywgqgtltvtv ssggggsgggsgggsgggsgggseivmtqspatlsispgeratlscrasqdiskynlwyq qkpgqaprlliyhtsrhsgiparfsgsgsgtdytlitisslqpedfavyfcqqgntlpy tfgqgtkleik (SEQ ID NO: 47)
CD19	huscFv9	Eivmtqspatlsispgeratlscrasqdiskynlwyqqkpgqaprlliyhtsrhsgip arfsgsgsgtdytlitisslqpedfavyfcqqgntlpytfgqgtkleik <u>ggggsgggsgg</u> <u>ggsgggsggsvqlqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigv</u> <u>iwgsettyynssslksrvtiskdnskqvslklssvtaadtavyycahyyyggsyamdy</u> <u>wgqgtltvtvss</u> (SEQ ID NO: 48)
CD19	Hu scFv10	Qvqlqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigviwgsettyy nssslksrvtiskdnskqvslklssvtaadtavyycahyyyggsyamdywgqgtltvtv ssggggsgggsgggsgggsgggseivmtqspatlsispgeratlscrasqdiskynlwyq qkpgqaprlliyhtsrhsgiparfsgsgsgtdytlitisslqpedfavyfcqqgntlpy tfgqgtkleik (SEQ ID NO: 49)
CD19	Hu scFv11	Eivmtqspatlsispgeratlscrasqdiskynlwyqqkpgqaprlliyhtsrhsgip arfsgsgsgtdytlitisslqpedfavyfcqqgntlpytfgqgtkleik <u>ggggsgggsgg</u> <u>ggsgsvqlqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigv</u> <u>iwgsettyynssslksrvtiskdnskqvslklssvtaadtavyycahyyyggsyamdywgqgt</u> <u>ltvtvss</u> (SEQ ID NO: 50)
CD19	Hu scFv12	Qvqlqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigviwgsettyy nssslksrvtiskdnskqvslklssvtaadtavyycahyyyggsyamdywgqgtltvtv ssggggsgggsgggsgggseivmtqspatlsispgeratlscrasqdiskynlwyqqkpgq aprlliyhtsrhsgiparfsgsgsgtdytlitisslqpedfavyfcqqgntlpytfgqg tkleik (SEQ ID NO: 51)
CD19	muCTL0 19	Diqmtqtsslsaslgdrvtiscrasqdiskynlwyqqkpdgtvkllyhtsrhsgvp srfsgsgsgtdytlitisslqpedfavyfcqqgntlpytfgqgtkleit <u>ggggsgggsgg</u> <u>gggsevlqesgpglvapsqslsvtctvsgvslpdygvswirqpprkglewigv</u> <u>iwgsettyynsalksrliikdnskqvflkmnslqtddtaiyycahyyyggsyamdywgqgt</u> <u>svtvss</u> (SEQ ID NO: 52)
CD19	SSJ25- C1 VH sequence	QVQLLESGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIYPGDGDTN YNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISSVVDFYFDYWGGQTTV T (SEQ ID NO: 53)
CD19	SSJ25- C1 VL	ELVLTQSPKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKPLIYSATYRNSGVP DRFTGSGSGTDFTLTITINVSQSKDLADYFYFCQYNRYPYTSGGGTKLEIKRRS (SEQ

	sequence	ID NO: 54)
--	----------	------------

Any known CD19 CAR, e.g., the CD19 antigen binding domain of any known CD19 CAR, in the art can be used in accordance with the present disclosure. For example, LG-740; CD19 CAR described in the US Pat. No. 8,399,645; US Pat. No. 7,446,190; Xu et al., LEUK Lymphoma. 2013 54(2):255-260(2012); Cruz et al., BLOOD 122(17):2965-2973 (2013); Brentjens et al., BLOOD, 118(18):4817-4828 (2011); Kochenderfer et al., BLOOD 116(20):4099-102 (2010); Kochenderfer et al., BLOOD 122 (25):4129-39(2013); and 16th Annu Meet Am Soc Gen Cell Ther (ASGCT) (May 15-18, Salt Lake City) 2013, Abst 10.

In one embodiment, the antigen binding domain comprises one, two three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2 and HC CDR3, from an antibody listed above, and/or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2 and LC CDR3, from an antibody listed above. In one embodiment, the antigen binding domain comprises a heavy chain variable region and/or a variable light chain region of an antibody listed or described above.

In an embodiment, an antigen binding domain against CD22 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Haso et al., BLOOD, 121(7): 1165-1174 (2013); Wayne et al., CLIN CANCER RES 16(6): 1894-1903 (2010); Kato et al., LEUK RES 37(1):83-88 (2013); Creative BioMart (creativebiomart.net): MOM-18047-S(P).

In an embodiment, an antigen binding domain against CD20 is an antigen binding portion, e.g., CDRs, of the antibody Rituximab, Ofatumumab, Ocrelizumab, Veltuzumab, or GA101.

In an embodiment, an antigen binding domain against ROR1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hudecek et al., CLIN CANCER RES 19(12):3153-3164 (2013); WO 2011159847; and US20130101607.

Bispecific CARs

In an embodiment a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody

molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope. In an embodiment the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In an
5 embodiment the first and second epitopes overlap. In an embodiment the first and second epitopes do not overlap. In an embodiment the first and second epitopes are on different antigens, e.g., different proteins (or different subunits of a multimeric protein). In an embodiment a bispecific antibody molecule comprises a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a first epitope and
10 a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody, or fragment thereof, having binding specificity for a first
15 epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a scFv, or fragment thereof, have binding specificity for a first epitope and a scFv, or fragment thereof, have binding specificity for a second epitope.

In certain embodiments, the antibody molecule is a multi-specific (*e.g.*, a bispecific or a
20 trispecific) antibody molecule. Protocols for generating bispecific or heterodimeric antibody molecules, and various configurations for bispecific antibody molecules, are described in, *e.g.*, paragraphs 455-458 of WO2015/142675, filed March 13, 2015, which is incorporated by reference in its entirety.

In one aspect, the bispecific antibody molecule is characterized by a first
25 immunoglobulin variable domain sequence, *e.g.*, a scFv, which has binding specificity for CD19, *e.g.*, comprises a scFv as described herein, or comprises the light chain CDRs and/or heavy chain CDRs from a scFv described herein, and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope on a different antigen.

Chimeric TCR

In one aspect, the antibodies and antibody fragments of the present invention (e.g., CD19 antibodies and fragments) can be grafted to one or more constant domain of a T cell receptor ("TCR") chain, for example, a TCR alpha or TCR beta chain, to create a chimeric TCR. Without
5 being bound by theory, it is believed that chimeric TCRs will signal through the TCR complex upon antigen binding. For example, an scFv as disclosed herein, can be grafted to the constant domain, e.g., at least a portion of the extracellular constant domain, the transmembrane domain and the cytoplasmic domain, of a TCR chain, for example, the TCR alpha chain and/or the TCR beta chain. As another example, an antibody fragment, for example a VL domain as described
10 herein, can be grafted to the constant domain of a TCR alpha chain, and an antibody fragment, for example a VH domain as described herein, can be grafted to the constant domain of a TCR beta chain (or alternatively, a VL domain may be grafted to the constant domain of the TCR beta chain and a VH domain may be grafted to a TCR alpha chain). As another example, the CDRs of an antibody or antibody fragment may be grafted into a TCR alpha and/or beta chain to create a
15 chimeric TCR. For example, the LCDRs disclosed herein may be grafted into the variable domain of a TCR alpha chain and the HCDRs disclosed herein may be grafted to the variable domain of a TCR beta chain, or vice versa. Such chimeric TCRs may be produced, e.g., by methods known in the art (For example, Willemsen RA et al, Gene Therapy 2000; 7: 1369–1377; Zhang T et al, Cancer Gene Ther 2004; 11: 487–496; Aggen et al, Gene Ther. 2012
20 Apr;19(4):365-74).

Non-Antibody Scaffolds

In embodiments, the antigen binding domain comprises a non-antibody scaffold, e.g., a fibronectin, ankyrin, domain antibody, lipocalin, small modular immuno-pharmaceutical,
25 maxybody, Protein A, or affilin. The non-antibody scaffold has the ability to bind to target antigen on a cell. In embodiments, the antigen binding domain is a polypeptide or fragment thereof of a naturally occurring protein expressed on a cell. In some embodiments, the antigen binding domain comprises a non-antibody scaffold. A wide variety of non-antibody scaffolds can be employed so long as the resulting polypeptide includes at least one binding region which
30 specifically binds to the target antigen on a target cell.

Non-antibody scaffolds include: fibronectin (Novartis, MA), ankyrin (Molecular Partners AG, Zurich, Switzerland), domain antibodies (Domantis, Ltd., Cambridge, MA, and Ablynx nv, Zwijnaarde, Belgium), lipocalin (Pieris Proteolab AG, Freising, Germany), small modular immuno-pharmaceuticals (Trubion Pharmaceuticals Inc., Seattle, WA), maxybodies (Avidia, Inc., Mountain View, CA), Protein A (Affibody AG, Sweden), and affilin (gamma-crystallin or ubiquitin) (Scil Proteins GmbH, Halle, Germany).

In an embodiment the antigen binding domain comprises the extracellular domain, or a counter-ligand binding fragment thereof, of molecule that binds a counterligand on the surface of a target cell.

Transmembrane Domain

In embodiments, a CAR described herein comprises a transmembrane domain that is fused to an extracellular sequence, e.g., an extracellular recognition element, which can comprise an antigen binding domain. In an embodiment, the transmembrane domain is one that naturally is associated with one of the domains in the CAR. In an embodiment, the transmembrane domain is one that is not naturally associated with one of the domains in the CAR.

A transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acid associated with the extracellular region of the protein from which the transmembrane was derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the extracellular region) and/or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the intracellular region).

In embodiments, the transmembrane domain is one which minimizes interactions with other elements, e.g., other transmembrane domains. In some instances, the transmembrane domain minimizes binding of such domains to the transmembrane domains of the same or different surface membrane proteins, e.g., to minimize interactions with other members of the receptor complex. Suitable examples can be derived by selection or modification of amino acid substitution of a known transmembrane domain. In an embodiment, the transmembrane domain is capable of promoting homodimerization with another CAR on the cell surface.

The transmembrane domain may comprise a naturally occurring, or a non-naturally occurring synthetic sequence. Where naturally occurring, the transmembrane domain may be derived from any membrane-bound or transmembrane protein.

Transmembrane regions suitable for use in molecules described herein may be derived
 5 from any one or more of e.g., the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3
 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86,
 CD134, CD137, CD154. In some embodiments, a transmembrane domain may include at least
 the transmembrane region(s) of, e.g., KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18),
 ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80
 10 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2R beta, IL2R gamma, IL7R α , ITGA1,
 VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE,
 CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2,
 CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96
 (Tactile), CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), CRTAM, Ly9
 15 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM
 (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp,
 NKG2D, NKG2C, or CD19. In an embodiment the transmembrane domain is derived from
 CD8. In an embodiment the transmembrane domain is derived from CD28. In one aspect, the
 transmembrane domain is a transmembrane domain from the sequence provided as SEQ ID NO:
 20 12 or SEQ ID NO: 42.

In an embodiment, a sequence, e.g., a hinge or spacer sequence, can be disposed between
 a transmembrane domain and another sequence or domain to which it is fused. In embodiments,
 a variety of human hinges (aka "spacers") can be employed as well, e.g., including but not
 limited to the human Ig (immunoglobulin) hinge. Optionally, a short oligo- or polypeptide linker,
 25 between 2 and 10 amino acids in length may form the linkage between the transmembrane
 domain and another domain, e.g., an intracellular signaling domain or costimulatory domain, of a
 CAR. A glycine-serine doublet provides a particularly suitable linker. In one aspect, the hinge or
 spacer is the amino acid sequence provided as SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.
 In one aspect, the hinge or spacer comprises a KIR2DS2 hinge.

In an embodiment, the transmembrane domain may be a non-naturally occurring sequence, in which case can comprise predominantly hydrophobic residues such as leucine and valine. In an embodiment, a triplet of phenylalanine, tryptophan and valine will be found at each end of a transmembrane domain.

5 Optionally, a short oligo- or polypeptide linker, between 2 and 10 amino acids in length may form the linkage between the transmembrane domain and the cytoplasmic region of the CAR. A glycine-serine doublet provides a particularly suitable linker. For example, in one aspect, the linker comprises the amino acid sequence of GGGGSGGGGS (SEQ ID NO:10). In some embodiments, the linker is encoded by a nucleotide sequence of
10 GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC (SEQ ID NO:11).

Cytoplasmic Domain

The cytoplasmic domain or region of the CAR includes an intracellular signaling domain. An intracellular signaling domain is generally responsible for activation of at least one of the
15 normal effector functions of the immune cell in which the CAR has been introduced.

Examples of intracellular signaling domains for use in the CAR of the invention include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivative or variant of these sequences and any recombinant sequence that has the same functional capability.

20 It is known that signals generated through the TCR alone are insufficient for full activation of the T cell and that a secondary and/or costimulatory signal is also required. Thus, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the TCR (primary intracellular signaling domains) and those that act in an antigen-independent manner to provide a
25 secondary or costimulatory signal (secondary cytoplasmic domain, e.g., a costimulatory domain).

Primary Signaling Domain

A primary signaling domain regulates primary activation of the TCR complex either in a stimulatory way, or in an inhibitory way. Primary intracellular signaling domains that act in a

stimulatory manner may contain signaling motifs which are known as immunoreceptor tyrosine-based activation motifs or ITAMs.

Examples of ITAM containing primary intracellular signaling domains that are of particular use in the invention include those of TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 (also known as "ICOS"), FcεRI, DAP10, DAP12, and CD66d. In one embodiment, a CAR of the invention comprises an intracellular signaling domain, e.g., a primary signaling domain of CD3-zeta, e.g., a CD3-zeta sequence described herein.

In one embodiment, a primary signaling domain comprises a modified ITAM domain, e.g., a mutated ITAM domain which has altered (e.g., increased or decreased) activity as compared to the native ITAM domain. In one embodiment, a primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an optimized and/or truncated ITAM-containing primary intracellular signaling domain. In an embodiment, a primary signaling domain comprises one, two, three, four or more ITAM motifs. Further examples of molecules containing a primary intracellular signaling domain that are of particular use in the invention include those of DAP10, DAP12, and CD32.

A primary intracellular signaling domain comprises a functional fragment, or analog, of a primary stimulatory molecule (e.g., CD3 zeta - GenBank Acc. No. BAG36664.1). The primary intracellular signaling domain can comprise the entire intracellular region or a fragment of the intracellular region which is sufficient for generation of an intracellular signal when an antigen binding domain to which it is fused binds cognate antigen. In embodiments the primary intracellular signaling domain has at least 70, 75, 80, 85, 90, 95, 98, or 99 % sequence identity with the entire intracellular region, or a fragment of the intracellular region which is sufficient for generation of an intracellular signal, of a naturally occurring primary stimulatory molecule, e.g., a human (GenBank Acc No. BAG36664.1), or other mammalian, e.g., a nonhuman species, e.g., rodent, monkey, ape or murine intracellular primary stimulatory molecule. In embodiments the primary intracellular signaling domain has at least 70, 75, 80, 85, 90, 95, 98, or 99 % sequence identity with SEQ ID NO: 18 or SEQ ID NO: 20.

In embodiments, the primary intracellular signaling domain, has at least 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identity with, or differs by no more than 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 amino acid residues from the corresponding residues of the entire intracellular region, or a fragment of the intracellular region which is sufficient for generation of an intracellular signal, of a naturally occurring human primary stimulatory molecule, e.g., a naturally occurring human primary stimulatory molecule disclosed herein.

Costimulatory Signaling Domain

The intracellular signalling domain of the CAR can comprise the CD3-zeta signalling domain by itself or it can be combined with any other desired intracellular signalling domain(s) useful in the context of a CAR of the invention. For example, the intracellular signalling domain of the CAR can comprise a CD3 zeta chain portion and a costimulatory signaling domain. The costimulatory signaling domain refers to a portion of the CAR comprising the intracellular domain of a costimulatory molecule. In one embodiment, the intracellular domain is designed to comprise the signaling domain of CD3-zeta and the signaling domain of CD28. In one aspect, the intracellular domain is designed to comprise the signaling domain of CD3-zeta and the signaling domain of ICOS.

A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligands that is required for an efficient response of lymphocytes to an antigen. Examples of such molecules include MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-

76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83, and the like. For example, CD27 costimulation has been demonstrated to enhance expansion, effector function, and survival of human CAR-expressing cell (e.g., T cell, NK cell) cells in vitro and augments human T cell persistence and antitumor activity in vivo (Song et al. BLOOD. 2012; 119(3):696-706). Further

5 examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2,

10 TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, NKG2D and NKG2C.

The intracellular signaling sequences within the cytoplasmic portion of the CAR of the

15 invention may be linked to each other in a random or specified order. Optionally, a short oligo- or polypeptide linker, for example, between 2 and 10 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) in length may form the linkage between intracellular signaling sequence. In one embodiment, a glycine-serine doublet can be used as a suitable linker. In one embodiment, a single amino acid, e.g., an alanine, a glycine, can be used as a suitable linker.

20 In one aspect, the intracellular signaling domain is designed to comprise two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains. In an embodiment, the two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains, are separated by a linker molecule, e.g., a linker molecule described herein. In one embodiment, the intracellular signaling domain comprises two costimulatory signaling domains. In some embodiments, the linker molecule is a

25 glycine residue. In some embodiments, the linker is an alanine residue.

A costimulatory domain comprises a functional fragment, or analog, of a costimulatory molecule (e.g., ICOS, CD28, or 4-1BB). It can comprise the entire intracellular region or a fragment of the intracellular region which is sufficient for generation of an intracellular signal, e.g., when an antigen binding domain to which it is fused binds cognate antigen. In

30 embodiments the costimulatory domain has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or

99 % sequence identity with the entire intracellular region, or a fragment of the intracellular region which is sufficient for generation of an intracellular signal, of a naturally occurring costimulatory molecule as described herein, e.g., a human, or other mammalian, e.g., a nonhuman species, e.g., rodent, monkey, ape or murine intracellular costimulatory molecule. In
 5 embodiments the costimulatory domain has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99 % sequence identity with SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 40, or SEQ ID NO: 44.

In embodiments the costimulatory signaling domain, has at least 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identity with, or differs by no more than 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1
 10 amino acid residues from the corresponding residues of the entire intracellular region, or a fragment of the intracellular region which is sufficient for generation of an intracellular signal, of, a naturally occurring human costimulatory molecule, e.g., a naturally occurring human costimulatory molecule disclosed herein.

Any of the CARs described herein can include one or more of the components listed in
 15 **Table 11.**

Table 11. Sequences of various components of CAR (aa – amino acids, na – nucleic acids that encodes the corresponding protein)

SEQ ID NO	description	Sequence
1	EF-1 promoter	CGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCACAGTCC CCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGG TGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTC CCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTT TTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTC CCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTT CCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGG GTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCTTCGCCTCGTGCTTGA GTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCAC CTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTGA TGACCTGCTGCGACGCTTTTTTCTGGCAAGATAGTCTTGTAATGCGGGCC AAGATCTGCACACTGGTATTTCTGGTTTTTGGGGCCGCGGGCGGCGACGGGG CCCGTGCGTCCCAGCGCACATGTTTCGGCGAGGCGGGCCTGCGAGCGCGGC CACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGC CTGGCCTCGCGCCCGCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCC GGTCGGCACCAAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTG

		CAGGGAGCTCAAATGGAGGACGCGCGCTCGGGAGAGCGGGCGGGTGA GTCACCCACACAAAGGAAAAGGGCCTTCCGTCCTCAGCCGTCGCTCATGT GACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCT TTTGGAGTACGTCGTCTTAGGTTGGGGGAGGGGTTTTATGCGATGGAGT TTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGAT GTAATTCTCCTTGGAAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCACTCTCAA GCCTCAGACAGTGGTTCAAAGTTTTTTCTTCCATTTCAAGGTGTCGTGA
2	Leader (aa)	MALPVTALLPLALLLHAARP
3	Leader (na)	ATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCTCTGGCTCTGCTGCTGCATGC CGCTAGACCC
4	CD 8 hinge (aa)	TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD
5	CD8 hinge (na)	ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCACCATCGCGTCG CAGCCCCTGTCCCTGCGCCAGAGGCGTGCCGCGCCAGCGGCGGGGGGCGCA GTGCACACGAGGGGGCTGGACTTCGCTGTGAT
6	Ig4 hinge (aa)	ESKYGPPCPPPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEV QFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALH NHYTQKSLSLSLGKM
7	Ig4 hinge (na)	GAGAGCAAGTACGGCCCTCCCTGCCCCCTTGCCCTGCCCCGAGTTCCTGG GCGGACCCAGCGTGTTCTGTTCCCCCAAGCCAAGGACACCCTGATGAT CAGCCGGACCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCAGGAGGA CCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGC CAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACCTACCGGGTGGTGTC CGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAATACAAGTG TAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAGAAAACCATCAGCAA GGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCTAGCCA AGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTT CTACCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCGAGAA CAACTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTG TACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAGGGCAACGTCTTT AGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCC TGAGCCTGTCCCTGGGCAAGATG
8	IgD hinge (aa)	RWPESPKAQASSVPTAQQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQ EERETKTPECPSTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLDKDAHLTWE VAGKVPTGGVEGLLERHSNGSQSHSRLTLPRSLWNAGTSVTCTLNHPSLPPQ RLMALREPAAQAPVKLSLNLASSDPPEAASWLLCEVSGFSPNILLMWLEDQR EVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLL NASRSLEVSIVTDH
9	IgD hinge (na)	AGGTGGCCCCGAAAGTCCCAAGGCCAGGCATCTAGTGTTCTACTGCACAGC CCCAGGCAGAAGGCAGCCTAGCCAAAGCTACTACTGCACCTGCCACTACGCG CAATACTGGCCGTGGCGGGAGGAGAGAGAAAAAGGAGAAAGAGAAAGAA GAACAGGAAGAGAGGGAGACCAAGACCCCTGAATGTCCATCCCATACCCAG CCGCTGGGCGTCTATCTCTTGACTCCCGCAGTACAGGACTTGTGGCTTAGAG ATAAGGCCACCTTTACATGTTTCGTGCTGGGCTCTGACCTGAAGGATGCCCA TTTGACTTGGGAGGTTGCCGGAAGGTACCCACAGGGGGGGTTGAGGAAG

		GGTTGCTGGAGCGCCATTCCAATGGCTCTCAGAGCCAGCACTCAAGACTCAC CCTTCCGAGATCCCTGTGGAACGCCGGGACCTCTGTCACATGTACTCTAAATC ATCCTAGCCTGCCCCACAGCGTCTGATGGCCCTTAGAGAGCCAGCCGCCCA GGCACCAGTTAAGCTTAGCCTGAATCTGCTCGCCAGTAGTGATCCCCCAGAG GCCGCCAGCTGGCTCTTATGCGAAGTGTCGGCTTTAGCCCCGCCAACATCT TGCTCATGTGGCTGGAGGACCAGCGAGAAGTGAACACCAGCGGCTTCGCTC CAGCCCGGCCCCACCCAGCCGGGTCTACCACATTCTGGGCCTGGAGTGT CTTAAGGGTCCCAGCACCACCTAGCCCCAGCCAGCCACATACACCTGTGT GTGTCCCATGAAGATAGCAGGACCCTGCTAAATGCTTCTAGGAGTCTGGAG GTTTCCTACGTGACTGACCATT
10	GS hinge/linker (aa)	GGGSGGGGS
11	GS hinge/linker (na)	GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC
12	CD8TM (aa)	IYWAPLAGTCGVLLSLVITLYC
13	CD8 TM (na)	ATCTACATCTGGGCGCCCTTGCCGGGACTTGTGGGGTCTTCTCCTGTCAC GGTTATCACCCCTTACTGC
14	4-1BB intracellular domain (aa)	KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
15	4-1BB intracellular domain (na)	AAACGGGGCAGAAAGAACTCCTGTATATATTCAAACAACCATTTATGAGAC CAGTACAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAG AAGAAGAAGGAGGATGTGAAGTG
16	CD27 (aa)	QRRKYRSNKGESPVPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP
17	CD27 (na)	AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCC CGCCGCCCCGGGCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCG ACTTCGCAGCCTATCGCTCC
18	CD3-zeta (aa)	RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPGEMGGKPRRK NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKHDGLYQGLSTATKDTYDAL HMQALPPR
19	CD3-zeta (na)	AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCTACAAGCAGGGCCA GAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGT TTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAA GGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGG CGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGGCAAG GGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTAC GACGCCCTTCACATGCAGGCCCTGCCCCCTCGC
20	CD3-zeta (aa)	RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPGEMGGKPRRK NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKHDGLYQGLSTATKDTYDAL HMQALPPR
21	CD3-zeta (na)	AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCTACCAGCAGGGCCA GAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGT TTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAA GGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGG

		CGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGAGGGGCAAG GGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTAC GACGCCCTTCACATGCAGGCCCTGCCCCCTCGC
22	linker	GGGS
23	linker	GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC
28	linker	(Gly-Gly-Gly-Ser) _n , where n = 1-10
29	linker	(Gly ₄ Ser) ₄
30	linker	(Gly ₄ Ser) ₃
31	linker	(Gly ₃ Ser)
32	polyA	A ₂₀₀₀
33	polyA	A ₁₅₀
34	polyA	A ₅₀₀₀
35	polyT	T ₁₀₀
36	polyT	T ₅₀₀₀
37	polyA	A ₆₄
38	polyA	A ₄₀₀

Combination of CARs

In one aspect, the CAR-expressing cell described herein can further comprise a second CAR, e.g., a second CAR that includes a different antigen binding domain, e.g., to the same target or a different target (e.g., a target other than a cancer associated antigen described herein or a different cancer associated antigen described herein, e.g., CD19, CD33, CLL-1, CD34, FLT3, or folate receptor beta). In one embodiment, the second CAR includes an antigen binding domain to a target expressed the same cancer cell type as the cancer associated antigen. In one embodiment, the CAR-expressing cell comprises a first CAR that targets a first antigen and includes an intracellular signaling domain having a costimulatory signaling domain but not a primary signaling domain, and a second CAR that targets a second, different, antigen and includes an intracellular signaling domain having a primary signaling domain but not a costimulatory signaling domain. While not wishing to be bound by theory, placement of a costimulatory signaling domain, e.g., 4-1BB, CD28, ICOS, CD27 or OX-40, onto the first CAR, and the primary signaling domain, e.g., CD3 zeta, on the second CAR can limit the CAR activity to cells where both targets are expressed. In one embodiment, the CAR expressing cell comprises a first cancer associated antigen CAR that includes an antigen binding domain that binds a target antigen described herein, a transmembrane domain and a costimulatory domain and a second CAR that targets a different target antigen (e.g., an antigen expressed on that same cancer cell type as the first target antigen) and includes an antigen binding domain, a

transmembrane domain and a primary signaling domain. In another embodiment, the CAR expressing cell comprises a first CAR that includes an antigen binding domain that binds a target antigen described herein, a transmembrane domain and a primary signaling domain and a second CAR that targets an antigen other than the first target antigen (e.g., an antigen expressed on the same cancer cell type as the first target antigen) and includes an antigen binding domain to the antigen, a transmembrane domain and a costimulatory signaling domain.

In one embodiment, the CAR-expressing cell comprises a CAR described herein (e.g., a CD19 CAR) and an inhibitory CAR. In one embodiment, the inhibitory CAR comprises an antigen binding domain that binds an antigen found on normal cells but not cancer cells, e.g., normal cells that also express CLL. In one embodiment, the inhibitory CAR comprises the antigen binding domain, a transmembrane domain and an intracellular domain of an inhibitory molecule. For example, the intracellular domain of the inhibitory CAR can be an intracellular domain of PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFRbeta).

In one embodiment, when the CAR-expressing cell comprises two or more different CARs, the antigen binding domains of the different CARs can be such that the antigen binding domains do not interact with one another. For example, a cell expressing a first and second CAR can have an antigen binding domain of the first CAR, e.g., as a fragment, e.g., an scFv, that does not form an association with the antigen binding domain of the second CAR, e.g., the antigen binding domain of the second CAR is a VHH.

In some embodiments, when present on the surface of a cell, binding of the antigen binding domain of the first CAR to its cognate antigen is not substantially reduced by the presence of the second CAR. In some embodiments, binding of the antigen binding domain of the first CAR to its cognate antigen in the presence of the second CAR is 85%, 90%, 95%, 96%, 97%, 98% or 99% of binding of the antigen binding domain of the first CAR to its cognate antigen in the absence of the second CAR.

In some embodiments, when present on the surface of a cell, the antigen binding domains of the first CAR said second CAR, associate with one another less than if both were scFv antigen binding domains. In some embodiments, the antigen binding domains of the first CAR and the second CAR, associate with one another 85%, 90%, 95%, 96%, 97%, 98% or 99% less than if
5 both were scFv antigen binding domains.

CAR-Expressing Cells

The CARs described herein are expressed on cells, e.g., immune effector cells, e.g., T cells. For example, a nucleic acid construct of a CAR described herein is transduced to a T cell.
10 In embodiments, the cells expressing the CARs described herein are an in vitro transcribed RNA CAR T cell.

Sources of Cells, e.g., T cells

Prior to expansion and genetic modification or other modification, a source of cells, e.g.,
15 immune effector cells, e.g., T cells or NK cells, can be obtained from a subject. Examples of subjects include humans, monkeys, chimpanzees, dogs, cats, mice, rats, and transgenic species thereof. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In some embodiments, the cells
20 obtained as described in this section are subjected to an assay described herein, e.g., one or more biomarkers are assayed.

In certain aspects of the present disclosure, immune effector cells, e.g., T cells or NK cells, can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as Ficoll™ separation. In one aspect, cells from the
25 circulating blood of an individual are obtained by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one aspect, the cells collected by apheresis may be washed to remove the plasma fraction and, optionally, to place the cells in an appropriate buffer or media for subsequent processing steps. In one embodiment, the cells are washed with

phosphate buffered saline (PBS). In an alternative embodiment, the wash solution lacks calcium and may lack magnesium or may lack many if not all divalent cations.

Initial activation steps in the absence of calcium can lead to magnified activation. As those of ordinary skill in the art would readily appreciate a washing step may be accomplished by methods known to those in the art, such as by using a semi-automated “flow-through” centrifuge (for example, the Cobe 2991 cell processor, the Baxter CytoMate, or the Haemonetics Cell Saver 5) according to the manufacturer’s instructions. After washing, the cells may be resuspended in a variety of biocompatible buffers, such as, for example, Ca-free, Mg-free PBS, PlasmaLyte A, or other saline solution with or without buffer. Alternatively, the undesirable components of the apheresis sample may be removed and the cells directly resuspended in culture media.

It is recognized that the methods of the application can utilize culture media conditions comprising 5% or less, for example 2%, human AB serum, and employ known culture media conditions and compositions, for example those described in Smith et al., “Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement” *Clinical & Translational Immunology* (2015) 4, e31; doi:10.1038/cti.2014.31.

In one aspect, T cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLL™ gradient or by counterflow centrifugal elutriation.

The methods described herein can include, e.g., selection of a specific subpopulation of immune effector cells, e.g., T cells, that are a T regulatory cell-depleted population, CD25+ depleted cells, using, e.g., a negative selection technique, e.g., described herein. In embodiments, the population of T regulatory depleted cells contains less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells.

In one embodiment, T regulatory cells, e.g., CD25+ T cells, are removed from the population using an anti-CD25 antibody, or fragment thereof, or a CD25-binding ligand, e.g., IL-2. In one embodiment, the anti-CD25 antibody, or fragment thereof, or CD25-binding ligand is conjugated to a substrate, e.g., a bead, or is otherwise coated on a substrate, e.g., a bead. In one

embodiment, the anti-CD25 antibody, or fragment thereof, is conjugated to a substrate as described herein.

In one embodiment, the T regulatory cells, e.g., CD25+ T cells, are removed from the population using CD25 depletion reagent from MiltenyiTM. In one embodiment, the ratio of
5 cells to CD25 depletion reagent is 1e7 cells to 20 uL, or 1e7 cells to 15 uL, or 1e7 cells to 10 uL, or 1e7 cells to 5 uL, or 1e7 cells to 2.5 uL, or 1e7 cells to 1.25 uL. In one embodiment, e.g., for T regulatory cells, e.g., CD25+ depletion, greater than 500 million cells/ml is used. In a further aspect, a concentration of cells of 600, 700, 800, or 900 million cells/ml is used.

In one embodiment, the population of immune effector cells to be depleted includes about
10 6×10^9 CD25+ T cells. In other aspects, the population of immune effector cells to be depleted include about 1×10^9 to 1×10^{10} CD25+ T cell, and any integer value in between. In one embodiment, the resulting population T regulatory depleted cells has 2×10^9 T regulatory cells, e.g., CD25+ cells, or less (e.g., 1×10^9 , 5×10^8 , 1×10^8 , 5×10^7 , 1×10^7 , or less CD25+ cells).

In one embodiment, the T regulatory cells, e.g., CD25+ cells, are removed from the
15 population using the CliniMAC system with a depletion tubing set, such as, e.g., tubing 162-01. In one embodiment, the CliniMAC system is run on a depletion setting such as, e.g., DEPLETION2.1.

Without wishing to be bound by a particular theory, decreasing the level of negative regulators of immune cells (e.g., decreasing the number of unwanted immune cells, e.g., T_{REG}
20 cells), in a subject prior to apheresis or during manufacturing of a CAR-expressing cell product can reduce the risk of subject relapse. In an embodiment, a patient is pre-treated with one or more therapies that reduce T_{REG} cells prior to collection of cells for CAR-expressing cell (e.g., T cell, NK cell) product manufacturing, thereby reducing the risk of patient relapse to CAR-expressing cell (e.g., T cell, NK cell) treatment (e.g., CTL019 treatment). Methods of depleting
25 T_{REG} cells are known in the art. Methods of decreasing T_{REG} cells include, but are not limited to, cyclophosphamide, anti-GITR antibody, CD25-depletion, and combinations thereof.

In some embodiments, the manufacturing methods comprise reducing the number of (e.g., depleting) T_{REG} cells prior to manufacturing of the CAR-expressing cell. For example, manufacturing methods comprise contacting the sample, e.g., the apheresis sample, with an anti-

GITR antibody and/or an anti-CD25 antibody (or fragment thereof, or a CD25-binding ligand), e.g., to deplete T_{REG} cells prior to manufacturing of the CAR-expressing cell (e.g., T cell, NK cell) product.

In an embodiment, a patient is pre-treated with cyclophosphamide prior to collection of cells for CAR-expressing cell (e.g., T cell, NK cell) product manufacturing, thereby reducing the risk of patient relapse to CAR-expressing cell treatment (e.g., CTL019 treatment). In an embodiment, a patient is pre-treated with an anti-GITR antibody prior to collection of cells for CAR-expressing cell (e.g., T cell, NK cell) product manufacturing, thereby reducing the risk of patient relapse to CAR-expressing cell treatment (e.g., CTL019 treatment).

In an embodiment, the CAR-expressing cell (e.g., T cell, NK cell) manufacturing process is modified to deplete T_{REG} cells prior to manufacturing of the CAR-expressing cell (e.g., T cell, NK cell) product (e.g., a CTL019 product). In an embodiment, CD25-depletion is used to deplete T_{REG} cells prior to manufacturing of the CAR-expressing cell (e.g., T cell, NK cell) product (e.g., a CTL019 product).

The methods described herein can include more than one selection step, e.g., more than one depletion step. Enrichment of a T cell population by negative selection can be accomplished, e.g., with a combination of antibodies directed to surface markers unique to the negatively selected cells. One method is cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected. For example, to enrich for CD4+ cells by negative selection, a monoclonal antibody cocktail can include antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8.

The methods described herein can further include removing cells from the population which express a tumor antigen, e.g., a tumor antigen that does not comprise CD25, e.g., CD19, CD30, CD38, CD123, CD20, CD14 or CD11b, to thereby provide a population of T regulatory depleted, e.g., CD25+ depleted, and tumor antigen depleted cells that are suitable for expression of a CAR, e.g., a CAR described herein. In one embodiment, tumor antigen expressing cells are removed simultaneously with the T regulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody, or fragment thereof, and an anti-tumor antigen antibody, or fragment thereof, can be

attached to the same substrate, e.g., bead, which can be used to remove the cells or an anti-CD25 antibody, or fragment thereof, or the anti-tumor antigen antibody, or fragment thereof, can be attached to separate beads, a mixture of which can be used to remove the cells. In other embodiments, the removal of T regulatory cells, e.g., CD25+ cells, and the removal of the tumor antigen expressing cells is sequential, and can occur, e.g., in either order.

Also provided are methods that include removing cells from the population which express a check point inhibitor, e.g., a check point inhibitor described herein, e.g., one or more of PD1+ cells, LAG3+ cells, and TIM3+ cells, to thereby provide a population of T regulatory depleted, e.g., CD25+ depleted cells, and check point inhibitor depleted cells, e.g., PD1+, LAG3+ and/or TIM3+ depleted cells. Exemplary check point inhibitors include B7-H1, B&-1, CD160, P1H, 2B4, PD1, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, TIGIT, CTLA-4, BTLA and LAIR1. In one embodiment, check point inhibitor expressing cells are removed simultaneously with the T regulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody, or fragment thereof, and an anti-check point inhibitor antibody, or fragment thereof, can be attached to the same bead which can be used to remove the cells, or an anti-CD25 antibody, or fragment thereof, and the anti-check point inhibitor antibody, or fragment thereof, can be attached to separate beads, a mixture of which can be used to remove the cells. In other embodiments, the removal of T regulatory cells, e.g., CD25+ cells, and the removal of the check point inhibitor expressing cells is sequential, and can occur, e.g., in either order.

Methods described herein can include a positive selection step. For example, T cells can be isolated by incubation with anti-CD3/anti-CD28 (e.g., 3x28)-conjugated beads, such as DYNABEADS® M-450 CD3/CD28 T, for a time period sufficient for positive selection of the desired T cells. In one embodiment, the time period is about 30 minutes. In a further embodiment, the time period ranges from 30 minutes to 36 hours or longer and all integer values there between. In a further embodiment, the time period is at least 1, 2, 3, 4, 5, or 6 hours. In yet another embodiment, the time period is 10 to 24 hours, e.g., 24 hours. Longer incubation times may be used to isolate T cells in any situation where there are few T cells as compared to other cell types, such in isolating tumor infiltrating lymphocytes (TIL) from tumor tissue or from immunocompromised individuals. Further, use of longer incubation times can increase the

efficiency of capture of CD8⁺ T cells. Thus, by simply shortening or lengthening the time T cells are allowed to bind to the CD3/CD28 beads and/or by increasing or decreasing the ratio of beads to T cells (as described further herein), subpopulations of T cells can be preferentially selected for or against at culture initiation or at other time points during the process. Additionally, by
5 increasing or decreasing the ratio of anti-CD3 and/or anti-CD28 antibodies on the beads or other surface, subpopulations of T cells can be preferentially selected for or against at culture initiation or at other desired time points.

In one embodiment, a T cell population can be selected that expresses one or more of IFN- γ , TNF α , IL-17A, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-21, CCL20, GM-CSF, IL-10, IL-13,
10 granzyme B, and perforin, or other appropriate molecules, e.g., other cytokines. Methods for screening for cell expression can be determined, e.g., by the methods described in PCT Publication No.: WO 2013/126712. In an embodiment, the T cell population expresses cytokine CCL20, IL-17a, IL-6, and combinations thereof.

For isolation of a desired population of cells by positive or negative selection, the
15 concentration of cells and surface (e.g., particles such as beads) can be varied. In certain aspects, it may be desirable to significantly decrease the volume in which beads and cells are mixed together (e.g., increase the concentration of cells), to ensure maximum contact of cells and beads. For example, in one aspect, a concentration of 10 billion cells/ml, 9 billion/ml, 8 billion/ml, 7 billion/ml, 6 billion/ml, or 5 billion/ml is used. In one aspect, a concentration of 1 billion
20 cells/ml is used. In yet one aspect, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further aspects, concentrations of 125 or 150 million cells/ml can be used.

Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that may weakly express target antigens of interest, such as CD28-negative T cells, or from samples
25 where there are many tumor cells present (e.g., leukemic blood, tumor tissue, etc.). Such populations of cells may have therapeutic value and would be desirable to obtain. For example, using high concentration of cells allows more efficient selection of CD8⁺ T cells that normally have weaker CD28 expression.

In a related aspect, it may be desirable to use lower concentrations of cells. By significantly diluting the mixture of T cells and surface (e.g., particles such as beads), interactions between the particles and cells is minimized. This selects for cells that express high amounts of desired antigens to be bound to the particles. For example, CD4+ T cells express higher levels of CD28 and are more efficiently captured than CD8+ T cells in dilute concentrations. In one aspect, the concentration of cells used is 5×10^6 /ml. In other aspects, the concentration used can be from about 1×10^5 /ml to 1×10^6 /ml, and any integer value in between.

In other aspects, the cells may be incubated on a rotator for varying lengths of time at varying speeds at either 2-10°C or at room temperature.

T cells for stimulation can also be frozen after a washing step. Wishing not to be bound by theory, the freeze and subsequent thaw step provides a more uniform product by removing granulocytes and to some extent monocytes in the cell population. After the washing step that removes plasma and platelets, the cells may be suspended in a freezing solution. While many freezing solutions and parameters are known in the art and will be useful in this context, one method involves using PBS containing 20% DMSO and 8% human serum albumin, or culture media containing 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin and 7.5% DMSO, or 31.25% Plasmalyte-A, 31.25% Dextrose 5%, 0.45% NaCl, 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin, and 7.5% DMSO or other suitable cell freezing media containing for example, Hespan and PlasmaLyte A, the cells then are frozen to -80°C at a rate of 1° per minute and stored in the vapor phase of a liquid nitrogen storage tank. Other methods of controlled freezing may be used as well as uncontrolled freezing immediately at -20° C or in liquid nitrogen.

In certain aspects, cryopreserved cells are thawed and washed as described herein and allowed to rest for one hour at room temperature prior to activation using the methods of the present invention.

Also contemplated in the context of the invention is the collection of blood samples or apheresis product from a subject at a time period prior to when the expanded cells as described herein might be needed. As such, the source of the cells to be expanded can be collected at any time point necessary, and desired cells, such as T cells, isolated and frozen for later use in

immune effector cell therapy for any number of diseases or conditions that would benefit from immune effector cell therapy, such as those described herein. In one aspect a blood sample or an apheresis is taken from a generally healthy subject. In certain aspects, a blood sample or an apheresis is taken from a generally healthy subject who is at risk of developing a disease, but
5 who has not yet developed a disease, and the cells of interest are isolated and frozen for later use. In certain aspects, the T cells may be expanded, frozen, and used at a later time. In certain aspects, samples are collected from a patient shortly after diagnosis of a particular disease as described herein but prior to any treatments. In a further aspect, the cells are isolated from a blood sample or an apheresis from a subject prior to any number of relevant treatment
10 modalities, including but not limited to treatment with agents such as natalizumab, efalizumab, antiviral agents, chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies, cytoxan, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and irradiation.

15 In a further aspect of the present invention, T cells are obtained from a patient directly following treatment that leaves the subject with functional T cells. In this regard, it has been observed that following certain cancer treatments, in particular treatments with drugs that damage the immune system, shortly after treatment during the period when patients would normally be recovering from the treatment, the quality of T cells obtained may be optimal or
20 improved for their ability to expand ex vivo. Likewise, following ex vivo manipulation using the methods described herein, these cells may be in a preferred state for enhanced engraftment and in vivo expansion. Thus, it is contemplated within the context of the present invention to collect blood cells, including T cells, dendritic cells, or other cells of the hematopoietic lineage, during this recovery phase. Further, in certain aspects, mobilization (for example, mobilization with
25 GM-CSF) and conditioning regimens can be used to create a condition in a subject wherein repopulation, recirculation, regeneration, and/or expansion of particular cell types is favored, especially during a defined window of time following therapy. Illustrative cell types include T cells, B cells, dendritic cells, and other cells of the immune system.

In one embodiment, the immune effector cells expressing a CAR molecule, e.g., a CAR
30 molecule described herein, are obtained from a subject that has received a low, immune

enhancing dose of an mTOR inhibitor. In an embodiment, the population of immune effector cells, e.g., T cells, to be engineered to express a CAR, are harvested after a sufficient time, or after sufficient dosing of the low, immune enhancing, dose of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells, or the ratio of PD1 negative immune effector cells, e.g., T cells/ PD1 positive immune effector cells, e.g., T cells, in the subject or harvested from the subject has been, at least transiently, increased.

In other embodiments, population of immune effector cells, e.g., T cells, which have, or will be engineered to express a CAR, can be treated ex vivo by contact with an amount of an mTOR inhibitor that increases the number of PD1 negative immune effector cells, e.g., T cells or increases the ratio of PD1 negative immune effector cells, e.g., T cells/ PD1 positive immune effector cells, e.g., T cells.

In one embodiment, a T cell population is diacylglycerol kinase (DGK)-deficient. DGK-deficient cells include cells that do not express DGK RNA or protein, or have reduced or inhibited DGK activity. DGK-deficient cells can be generated by genetic approaches, e.g., administering RNA-interfering agents, e.g., siRNA, shRNA, miRNA, to reduce or prevent DGK expression. Alternatively, DGK-deficient cells can be generated by treatment with DGK inhibitors described herein.

In one embodiment, a T cell population is Ikaros-deficient. Ikaros-deficient cells include cells that do not express Ikaros RNA or protein, or have reduced or inhibited Ikaros activity, Ikaros-deficient cells can be generated by genetic approaches, e.g., administering RNA-interfering agents, e.g., siRNA, shRNA, miRNA, to reduce or prevent Ikaros expression. Alternatively, Ikaros-deficient cells can be generated by treatment with Ikaros inhibitors, e.g., lenalidomide.

In embodiments, a T cell population is DGK-deficient and Ikaros-deficient, e.g., does not express DGK and Ikaros, or has reduced or inhibited DGK and Ikaros activity. Such DGK and Ikaros-deficient cells can be generated by any of the methods described herein.

Allogeneic CAR

In embodiments described herein, the immune effector cell can be an allogeneic immune effector cell, e.g., T cell. For example, the cell can be an allogeneic T cell, e.g., an allogeneic T cell lacking expression of a functional T cell receptor (TCR) and/or human leukocyte antigen (HLA), e.g., HLA class I and/or HLA class II.

A T cell lacking a functional TCR can be, e.g., engineered such that it does not express any functional TCR on its surface, engineered such that it does not express one or more subunits that comprise a functional TCR (e.g., engineered such that it does not express (or exhibits reduced expression) of TCR alpha, TCR beta, TCR gamma, TCR delta, TCR epsilon, and/or TCR zeta) or engineered such that it produces very little functional TCR on its surface. Alternatively, the T cell can express a substantially impaired TCR, e.g., by expression of mutated or truncated forms of one or more of the subunits of the TCR. The term “substantially impaired TCR” means that this TCR will not elicit an adverse immune reaction in a host.

A T cell described herein can be, e.g., engineered such that it does not express a functional HLA on its surface. For example, a T cell described herein, can be engineered such that cell surface expression HLA, e.g., HLA class I and/or HLA class II, is downregulated. In some embodiments, downregulation of HLA may be accomplished by reducing or eliminating expression of beta-2 microglobulin (B2M).

In some embodiments, the T cell can lack a functional TCR and a functional HLA, e.g., HLA class I and/or HLA class II.

Modified T cells that lack expression of a functional TCR and/or HLA can be obtained by any suitable means, including a knock out or knock down of one or more subunit of TCR or HLA. For example, the T cell can include a knock down of TCR and/or HLA using siRNA, shRNA, clustered regularly interspaced short palindromic repeats (CRISPR) transcription-activator like effector nuclease (TALEN), or zinc finger endonuclease (ZFN).

In some embodiments, the allogeneic cell can be a cell which does not express or expresses at low levels an inhibitory molecule, e.g. by any method described herein. For example, the cell can be a cell that does not express or expresses at low levels an inhibitory molecule, e.g., that can decrease the ability of a CAR-expressing cell to mount an immune

effector response. Examples of inhibitory molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFRbeta). Inhibition of an inhibitory molecule, e.g., by inhibition at the DNA, RNA or protein level, can optimize a CAR-expressing cell performance. In embodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA, a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription-activator like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN), e.g., as described herein, can be used.

siRNA and shRNA to inhibit TCR or HLA

In some embodiments, TCR expression and/or HLA expression can be inhibited using siRNA or shRNA that targets a nucleic acid encoding a TCR and/or HLA, and/or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta), in a cell, e.g., T cell.

Expression systems for siRNA and shRNAs, and exemplary shRNAs, are described, e.g., in paragraphs 649 and 650 of International Application WO2015/142675, filed March 13, 2015, which is incorporated by reference in its entirety.

CRISPR to inhibit TCR or HLA

“CRISPR” or “CRISPR to TCR and/or HLA” or “CRISPR to inhibit TCR and/or HLA” as used herein refers to a set of clustered regularly interspaced short palindromic repeats, or a system comprising such a set of repeats. “Cas”, as used herein, refers to a CRISPR-associated protein. A “CRISPR/Cas” system refers to a system derived from CRISPR and Cas which can be used to silence or mutate a TCR and/or HLA gene, and/or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3

and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta), in a cell, e.g., T cell.

The CRISPR/Cas system, and uses thereof, are described, e.g., in paragraphs 651-658 of International Application WO2015/142675, filed March 13, 2015, which is incorporated by reference in its entirety.

TALEN to inhibit TCR and/or HLA

“TALEN” or “TALEN to HLA and/or TCR” or “TALEN to inhibit HLA and/or TCR” refers to a transcription activator-like effector nuclease, an artificial nuclease which can be used to edit the HLA and/or TCR gene, and/or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta), in a cell, e.g., T cell.

TALENs, and uses thereof, are described, e.g., in paragraphs 659-665 of International Application WO2015/142675, filed March 13, 2015, which is incorporated by reference in its entirety.

Zinc finger nuclease to inhibit HLA and/or TCR

“ZFN” or “Zinc Finger Nuclease” or “ZFN to HLA and/or TCR” or “ZFN to inhibit HLA and/or TCR” refer to a zinc finger nuclease, an artificial nuclease which can be used to edit the HLA and/or TCR gene, and/or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta), in a cell, e.g., T cell.

ZFNs, and uses thereof, are described, e.g., in paragraphs 666-671 of International Application WO2015/142675, filed March 13, 2015, which is incorporated by reference in its entirety.

5 *Telomerase expression*

While not wishing to be bound by any particular theory, in some embodiments, a therapeutic T cell has short term persistence in a patient, due to shortened telomeres in the T cell; accordingly, transfection with a telomerase gene can lengthen the telomeres of the T cell and improve persistence of the T cell in the patient. See Carl June, “Adoptive T cell therapy for
10 cancer in the clinic”, Journal of Clinical Investigation, 117:1466-1476 (2007). Thus, in an embodiment, an immune effector cell, e.g., a T cell, ectopically expresses a telomerase subunit, e.g., the catalytic subunit of telomerase, e.g., TERT, e.g., hTERT. In some aspects, this disclosure provides a method of producing a CAR-expressing cell, comprising contacting a cell with a nucleic acid encoding a telomerase subunit, e.g., the catalytic subunit of telomerase, e.g.,
15 TERT, e.g., hTERT. The cell may be contacted with the nucleic acid before, simultaneous with, or after being contacted with a construct encoding a CAR.

In one aspect, the disclosure features a method of making a population of immune effector cells (e.g., T cells, NK cells). In an embodiment, the method comprises: providing a population of immune effector cells (e.g., T cells or NK cells), contacting the population of
20 immune effector cells with a nucleic acid encoding a CAR; and contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT, under conditions that allow for CAR and telomerase expression.

In an embodiment, the nucleic acid encoding the telomerase subunit is DNA. In an embodiment, the nucleic acid encoding the telomerase subunit comprises a promoter capable of
25 driving expression of the telomerase subunit.

In an embodiment, hTERT has the amino acid sequence of GenBank Protein ID AAC51724.1 (Meyerson et al., “hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization” Cell Volume 90, Issue 4, 22 August 1997, Pages 785–795) as set out in SEQ ID NO: 82 herein.

In an embodiment, the hTERT has a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 82. In an embodiment, the hTERT has a sequence of SEQ ID NO: 82. In an embodiment, the hTERT comprises a deletion (e.g., of no more than 5, 10, 15, 20, or 30 amino acids) at the N-terminus, the C-terminus, or both. In an
5 embodiment, the hTERT comprises a transgenic amino acid sequence (e.g., of no more than 5, 10, 15, 20, or 30 amino acids) at the N-terminus, the C-terminus, or both.

In an embodiment, the hTERT is encoded by the nucleic acid sequence of GenBank Accession No. AF018167 (Meyerson et al., "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization" Cell Volume 90,
10 Issue 4, 22 August 1997, Pages 785–795) as set out in SEQ ID NO: 83 herein.

In an embodiment, the hTERT is encoded by a nucleic acid having a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 83. In an embodiment, the hTERT is encoded by a nucleic acid of SEQ ID NO: 83.

15 **Activation and Expansion of Immune Effector Cells (e.g., T Cells)**

Immune effector cells such as T cells may be activated and expanded generally using methods as described, for example, in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No.
20 20060121005. In some embodiments, immune effector cells are subjected to an assay as described herein (e.g., one or more biomarkers are assayed) before, during, or after activation, or before, during, or after expansion.

Generally, a population of immune effector cells may be expanded by contact with a surface having attached thereto an agent that stimulates a CD3/TCR complex associated signal
25 and a ligand that stimulates a costimulatory molecule on the surface of the T cells. In particular, T cell populations may be stimulated as described herein, such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore. For co-stimulation of an accessory molecule on the surface of the T cells, a

ligand that binds the accessory molecule is used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells. To stimulate proliferation of either CD4⁺ T cells or CD8⁺ T cells, an anti-CD3 antibody and an anti-CD28 antibody can be used. Examples of an anti-CD28 antibody include 9.3, B-T3, XR-CD28 (Diacclone, Besançon, France) can be used as
5 can other methods commonly known in the art (Berg et al., Transplant Proc. 30(8):3975-3977, 1998; Haanen et al., J. Exp. Med. 190(9):13191328, 1999; Garland et al., J. Immunol Meth. 227(1-2):53-63, 1999).

In certain aspects, the primary stimulatory signal and the costimulatory signal for the T
10 cell may be provided by different protocols. For example, the agents providing each signal may be in solution or coupled to a surface. When coupled to a surface, the agents may be coupled to the same surface (i.e., in “cis” formation) or to separate surfaces (i.e., in “trans” formation). Alternatively, one agent may be coupled to a surface and the other agent in solution. In one aspect, the agent providing the costimulatory signal is bound to a cell surface and the agent
15 providing the primary activation signal is in solution or coupled to a surface. In certain aspects, both agents can be in solution. In one aspect, the agents may be in soluble form, and then cross-linked to a surface, such as a cell expressing Fc receptors or an antibody or other binding agent which will bind to the agents. In this regard, see for example, U.S. Patent Application Publication Nos. 20040101519 and 20060034810 for artificial antigen presenting cells (aAPCs)
20 that are contemplated for use in activating and expanding T cells in the present invention.

In one aspect, the two agents are immobilized on beads, either on the same bead, i.e., “cis,” or to separate beads, i.e., “trans.” By way of example, the agent providing the primary activation signal is an anti-CD3 antibody or an antigen-binding fragment thereof and the agent providing the costimulatory signal is an anti-CD28 antibody or antigen-binding fragment thereof;
25 and both agents are co-immobilized to the same bead in equivalent molecular amounts. In one aspect, a 1:1 ratio of each antibody bound to the beads for CD4⁺ T cell expansion and T cell growth is used. In certain aspects of the present invention, a ratio of anti CD3:CD28 antibodies bound to the beads is used such that an increase in T cell expansion is observed as compared to the expansion observed using a ratio of 1:1. In one particular aspect an increase of from about 1
30 to about 3 fold is observed as compared to the expansion observed using a ratio of 1:1. In one

aspect, the ratio of CD3:CD28 antibody bound to the beads ranges from 100:1 to 1:100 and all integer values there between. In one aspect, more anti-CD28 antibody is bound to the particles than anti-CD3 antibody, i.e., the ratio of CD3:CD28 is less than one. In certain aspects, the ratio of anti CD28 antibody to anti CD3 antibody bound to the beads is greater than 2:1. In one particular aspect, a 1:100 CD3:CD28 ratio of antibody bound to beads is used. In one aspect, a 1:75 CD3:CD28 ratio of antibody bound to beads is used. In a further aspect, a 1:50 CD3:CD28 ratio of antibody bound to beads is used. In one aspect, a 1:30 CD3:CD28 ratio of antibody bound to beads is used. In one preferred aspect, a 1:10 CD3:CD28 ratio of antibody bound to beads is used. In one aspect, a 1:3 CD3:CD28 ratio of antibody bound to the beads is used. In yet one aspect, a 3:1 CD3:CD28 ratio of antibody bound to the beads is used.

Ratios of particles to cells from 1:500 to 500:1 and any integer values in between may be used to stimulate T cells or other target cells. As those of ordinary skill in the art can readily appreciate, the ratio of particles to cells may depend on particle size relative to the target cell. For example, small sized beads could only bind a few cells, while larger beads could bind many. In certain aspects the ratio of cells to particles ranges from 1:100 to 100:1 and any integer values in-between and in further aspects the ratio comprises 1:9 to 9:1 and any integer values in between, can also be used to stimulate T cells. The ratio of anti-CD3- and anti-CD28-coupled particles to T cells that result in T cell stimulation can vary as noted above, however certain suitable values include 1:100, 1:50, 1:40, 1:30, 1:20, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, and 15:1 with one suitable ratio being at least 1:1 particles per T cell. In one aspect, a ratio of particles to cells of 1:1 or less is used. In one particular aspect, a suitable particle: cell ratio is 1:5. In further aspects, the ratio of particles to cells can be varied depending on the day of stimulation. For example, in one aspect, the ratio of particles to cells is from 1:1 to 10:1 on the first day and additional particles are added to the cells every day or every other day thereafter for up to 10 days, at final ratios of from 1:1 to 1:10 (based on cell counts on the day of addition). In one particular aspect, the ratio of particles to cells is 1:1 on the first day of stimulation and adjusted to 1:5 on the third and fifth days of stimulation. In one aspect, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:5 on the third and fifth days of stimulation. In one aspect, the ratio of particles to cells is 2:1 on the first day of stimulation and adjusted to 1:10 on the third and fifth

days of stimulation. In one aspect, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:10 on the third and fifth days of stimulation. One of skill in the art will appreciate that a variety of other ratios may be suitable for use in the present invention. In particular, ratios will vary depending on particle size and on cell size and type. In one aspect, the most typical ratios for use are in the neighborhood of 1:1, 2:1 and 3:1 on the first day.

In further aspects, the cells, such as T cells, are combined with agent-coated beads, the beads and the cells are subsequently separated, and then the cells are cultured. In an alternative aspect, prior to culture, the agent-coated beads and cells are not separated but are cultured together. In a further aspect, the beads and cells are first concentrated by application of a force, such as a magnetic force, resulting in increased ligation of cell surface markers, thereby inducing cell stimulation.

By way of example, cell surface proteins may be ligated by allowing paramagnetic beads to which anti-CD3 and anti-CD28 are attached (3x28 beads) to contact the T cells. In one aspect the cells (for example, 10^4 to 10^9 T cells) and beads (for example, DYNABEADS® M-450 CD3/CD28 T paramagnetic beads at a ratio of 1:1) are combined in a buffer, for example PBS (without divalent cations such as, calcium and magnesium). Again, those of ordinary skill in the art can readily appreciate any cell concentration may be used. For example, the target cell may be very rare in the sample and comprise only 0.01% of the sample or the entire sample (i.e., 100%) may comprise the target cell of interest. Accordingly, any cell number is within the context of the present invention. In certain aspects, it may be desirable to significantly decrease the volume in which particles and cells are mixed together (i.e., increase the concentration of cells), to ensure maximum contact of cells and particles. For example, in one aspect, a concentration of about 10 billion cells/ml, 9 billion/ml, 8 billion/ml, 7 billion/ml, 6 billion/ml, 5 billion/ml, or 2 billion cells/ml is used. In one aspect, greater than 100 million cells/ml is used. In a further aspect, a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In yet one aspect, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further aspects, concentrations of 125 or 150 million cells/ml can be used. Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that may weakly express target

antigens of interest, such as CD28-negative T cells. Such populations of cells may have therapeutic value and would be desirable to obtain in certain aspects. For example, using high concentration of cells allows more efficient selection of CD8+ T cells that normally have weaker CD28 expression.

5 In one embodiment, cells transduced with a nucleic acid encoding a CAR, e.g., a CAR described herein, are expanded, e.g., by a method described herein. In one embodiment, the cells are expanded in culture for a period of several hours (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 18, 21 hours) to about 14 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days). In one embodiment, the cells are expanded for a period of 4 to 9 days. In one embodiment, the cells are
10 expanded for a period of 8 days or less, e.g., 7, 6 or 5 days. In one embodiment, the cells, e.g., a CD19 CAR cell described herein, are expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions. Potency can be defined, e.g., by various T cell functions, e.g. proliferation, target cell killing, cytokine production, activation, migration, or combinations thereof. In one embodiment,
15 the cells, e.g., a CD19 CAR cell described herein, expanded for 5 days show at least a one, two, three or four fold increase in cells doublings upon antigen stimulation as compared to the same cells expanded in culture for 9 days under the same culture conditions. In one embodiment, the cells, e.g., the cells expressing a CD19 CAR described herein, are expanded in culture for 5 days, and the resulting cells exhibit higher proinflammatory cytokine production, e.g., IFN- γ and/or
20 GM-CSF levels, as compared to the same cells expanded in culture for 9 days under the same culture conditions. In one embodiment, the cells, e.g., a CD19 CAR cell described herein, expanded for 5 days show at least a one, two, three, four, five, tenfold or more increase in pg/ml of proinflammatory cytokine production, e.g., IFN- γ and/or GM-CSF levels, as compared to the same cells expanded in culture for 9 days under the same culture conditions.

25 Several cycles of stimulation may also be desired such that culture time of T cells can be 60 days or more. Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 15, (Lonza)) that may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN- γ , IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGF β , and TNF- α
30 or any other additives for the growth of cells known to the skilled artisan. Other additives for the

growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Media can include RPMI 1640, AIM-V, DMEM, MEM, α -MEM, F-12, X-Vivo 15, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells. Antibiotics, e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g., 37° C) and atmosphere (e.g., air plus 5% CO₂).

In one embodiment, the cells are expanded in an appropriate media (e.g., media described herein) that includes one or more interleukin that result in at least a 200-fold (e.g., 200-fold, 250-fold, 300-fold, 350-fold) increase in cells over a 14 day expansion period, e.g., as measured by a method described herein such as flow cytometry. In one embodiment, the cells are expanded in the presence IL-15 and/or IL-7 (e.g., IL-15 and IL-7).

In embodiments, methods described herein, e.g., CAR-expressing cell manufacturing methods, comprise removing T regulatory cells, e.g., CD25+ T cells, from a cell population, e.g., using an anti-CD25 antibody, or fragment thereof, or a CD25-binding ligand, IL-2. Methods of removing T regulatory cells, e.g., CD25+ T cells, from a cell population are described herein. In embodiments, the methods, e.g., manufacturing methods, further comprise contacting a cell population (e.g., a cell population in which T regulatory cells, such as CD25+ T cells, have been depleted; or a cell population that has previously contacted an anti-CD25 antibody, fragment thereof, or CD25-binding ligand) with IL-15 and/or IL-7. For example, the cell population (e.g., that has previously contacted an anti-CD25 antibody, fragment thereof, or CD25-binding ligand) is expanded in the presence of IL-15 and/or IL-7.

In some embodiments a CAR-expressing cell described herein is contacted with a composition comprising a interleukin-15 (IL-15) polypeptide, a interleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination of both a IL-15 polypeptide and a IL-15Ra polypeptide e.g., hetIL-15, during the manufacturing of the CAR-expressing cell, e.g., ex vivo. In embodiments, a CAR-expressing cell described herein is contacted with a composition comprising a IL-15 polypeptide during the manufacturing of the CAR-expressing cell, e.g., ex

vivo. In embodiments, a CAR-expressing cell described herein is contacted with a composition comprising a combination of both a IL-15 polypeptide and a IL-15 Ra polypeptide during the manufacturing of the CAR-expressing cell, e.g., ex vivo. In embodiments, a CAR-expressing cell described herein is contacted with a composition comprising hetIL-15 during the manufacturing of the CAR-expressing cell, e.g., ex vivo.

In one embodiment the CAR-expressing cell described herein is contacted with a composition comprising hetIL-15 during ex vivo expansion. In an embodiment, the CAR-expressing cell described herein is contacted with a composition comprising an IL-15 polypeptide during ex vivo expansion. In an embodiment, the CAR-expressing cell described herein is contacted with a composition comprising both an IL-15 polypeptide and an IL-15Ra polypeptide during ex vivo expansion. In one embodiment the contacting results in the survival and proliferation of a lymphocyte subpopulation, e.g., CD8+ T cells.

In one embodiment, the cells are cultured (e.g., expanded, simulated, and/or transduced) in media comprising serum. The serum may be, e.g., human AB serum (hAB). In some embodiments, the hAB serum is present at about 2%, about 5%, about 2-3%, about 3-4%, about 4-5%, or about 2-5%. As shown in Example 15 herein, 2% and 5% serum are each suitable levels that allow for many fold expansion of T cells. Furthermore, as shown in Smith et al., "Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement" Clinical & Translational Immunology (2015) 4, e31; doi:10.1038/cti.2014.31, medium containing 2% human AB serum is suitable for ex vivo expansion of T cells.

T cells that have been exposed to varied stimulation times may exhibit different characteristics. For example, typical blood or apheresed peripheral blood mononuclear cell products have a helper T cell population (TH, CD4+) that is greater than the cytotoxic or suppressor T cell population (TC, CD8+). Ex vivo expansion of T cells by stimulating CD3 and CD28 receptors produces a population of T cells that prior to about days 8-9 consists predominately of TH cells, while after about days 8-9, the population of T cells comprises an increasingly greater population of TC cells. Accordingly, depending on the purpose of treatment, infusing a subject with a T cell population comprising predominately of TH cells may be

advantageous. Similarly, if an antigen-specific subset of TC cells has been isolated it may be beneficial to expand this subset to a greater degree.

Further, in addition to CD4 and CD8 markers, other phenotypic markers vary significantly, but in large part, reproducibly during the course of the cell expansion process.

5 Thus, such reproducibility enables the ability to tailor an activated T cell product for specific purposes.

In some embodiments, cells transduced with a nucleic acid encoding a CAR, e.g., a CAR described herein, can be selected for administration based upon, e.g., protein expression levels of one or more of CCL20, GM-CSF, IFN γ , IL-10, IL-13, IL-17a, IL-2, IL-21, IL-4, IL-5, IL-6, IL-
10 9, TNF α and/or combinations thereof. In some embodiments, cells transduced with a nucleic acid encoding a CAR, e.g., a CAR described herein, can be selected for administration based upon, e.g., protein expression levels of CCL20, IL-17a, IL-6 and combinations thereof.

Once a CAR described herein is constructed, various assays can be used to evaluate the activity of the molecule, such as but not limited to, the ability to expand T cells following
15 antigen stimulation, sustain T cell expansion in the absence of re-stimulation, and anti-cancer activities in appropriate in vitro and animal models. Assays to evaluate the effects of a CAR are described in further detail below.

Western blot analysis of CAR expression in primary T cells can be used to detect the presence of monomers and dimers, e.g., as described in paragraph 695 of International
20 Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

In vitro expansion of CAR⁺ T cells following antigen stimulation can be measured by flow cytometry. For example, a mixture of CD4⁺ and CD8⁺ T cells are stimulated with α CD3/ α CD28 aAPCs followed by transduction with lentiviral vectors expressing GFP under the
25 control of the promoters to be analyzed. Exemplary promoters include the CMV IE gene, EF-1 α , ubiquitin C, or phosphoglycerokinase (PGK) promoters. GFP fluorescence is evaluated on day 6 of culture in the CD4⁺ and/or CD8⁺ T cell subsets by flow cytometry. See, e.g., Milone *ET AL.*, MOLECULAR THERAPY 17(8): 1453-1464 (2009). Alternatively, a mixture of CD4⁺ and CD8⁺ T cells are stimulated with α CD3/ α CD28 coated magnetic beads on day 0, and transduced with

CAR on day 1 using a bicistronic lentiviral vector expressing CAR along with eGFP using a 2A ribosomal skipping sequence. Cultures are re-stimulated with either a cancer associate antigen as described herein⁺ K562 cells (K562-a cancer associate antigen as described herein), wild-type K562 cells (K562 wild type) or K562 cells expressing hCD32 and 4-1BBL in the presence of
5 antiCD3 and anti-CD28 antibody (K562-BBL-3/28) following washing. Exogenous IL-2 is added to the cultures every other day at 100 IU/ml. GFP⁺ T cells are enumerated by flow cytometry using bead-based counting. See, *e.g.*, Milone *et al.*, MOLECULAR THERAPY 17(8): 1453-1464 (2009).

Sustained CAR⁺ T cell expansion in the absence of re-stimulation can also be measured.
10 See, *e.g.*, Milone *et al.*, MOLECULAR THERAPY 17(8): 1453-1464 (2009). Briefly, mean T cell volume (fl) is measured on day 8 of culture using a Coulter Multisizer III particle counter, a Nexcelom Cellometer Vision or Millipore Scepter, following stimulation with α CD3/ α CD28 coated magnetic beads on day 0, and transduction with the indicated CAR on day 1.

Animal models can also be used to measure a CAR-expressing cell (*e.g.*, T cell, NK cell)
15 activity, *e.g.*, as described in paragraph 698 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

Dose dependent CAR treatment response can be evaluated, *e.g.*, as described in paragraph 699 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

20 Assessment of cell proliferation and cytokine production has been previously described, *e.g.*, as described in paragraph 700 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

In another embodiment, potency of a cell (*e.g.*, T cell, NK cell) population (*e.g.* a CAR-expressing cell) product, *e.g.*, a CD19 CAR-expressing cell (*e.g.*, T cell, NK cell) cell product,
25 *e.g.*, CTL019 cells) is assessed using a Luminex® panel of cytokines to determine cytokine expression levels. Cell (*e.g.*, T cell, NK cell) populations (*e.g.*, a manufactured CAR-expressing cell) cell product, *e.g.*, a CD19 CAR-expressing cell product, *e.g.*, CTL019 cells) are activated *in vitro* by CD19-expressing K562 (K562-19) cells, which mimic CD19-expressing B cells in CLL. Following cell (*e.g.*, T cell, NK cell) activation, cytokine expression profiles are measured in the

co-cultured cell media and potency of activated cells (e.g., a CAR-expressing cell product, e.g., a CD19 CAR-expressing cell product, e.g., CTL019 cells) is correlated with expression of different cytokines including, but not limited to CCL-20/MIP-3a, GM-CSF, IFN γ , IL-10, IL-13, IL-17a, IL-2, IL-21, IL-4, IL-5, IL-6, IL-9, TNF α and/or combinations thereof.

5 In an embodiment, cytokine expression levels are informative with regards to the potency of a cell (e.g., T cell, NK cell) population (e.g., to kill tumor cells). In an embodiment, cytokine expression levels described herein are used to improve a cell (e.g., T cell, NK cell) population (e.g., a CAR-expressing cell product, e.g., a CD 19 CAR-expressing cell product, e.g., CTL019 cells) prior to infusion in patients. In an embodiment, cytokine expression levels described
10 herein provide an endpoint during optimization of the manufacturing process.

Cytotoxicity can be assessed by a standard ^{51}Cr -release assay, e.g., as described in paragraph 701 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

15 Imaging technologies can be used to evaluate specific trafficking and proliferation of CARs in tumor-bearing animal models, e.g., as described in paragraph 702 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

Other assays, including those described in the Example section herein as well as those that are known in the art can also be used to evaluate the CARs described herein.

20 Alternatively, or in combination to the methods disclosed herein, methods and compositions for one or more of: detection and/or quantification of CAR-expressing cells (e.g., *in vitro* or *in vivo* (e.g., clinical monitoring)); immune cell expansion and/or activation; and/or CAR-specific selection, that involve the use of a CAR ligand, are disclosed. In one exemplary embodiment, the CAR ligand is an antibody that binds to the CAR molecule, e.g., binds to the
25 extracellular antigen binding domain of CAR (e.g., an antibody that binds to the antigen binding domain, e.g., an anti-idiotypic antibody; or an antibody that binds to a constant region of the extracellular binding domain). In other embodiments, the CAR ligand is a CAR antigen molecule (e.g., a CAR antigen molecule as described herein).

In one aspect, a method for detecting and/or quantifying CAR-expressing cells is disclosed. For example, the CAR ligand can be used to detect and/or quantify CAR-expressing cells *in vitro* or *in vivo* (e.g., clinical monitoring of CAR-expressing cells in a patient, or dosing a patient). The method includes:

5 providing the CAR ligand (optionally, a labelled CAR ligand, e.g., a CAR ligand that includes a tag, a bead, a radioactive or fluorescent label);

 acquiring the CAR-expressing cell (e.g., acquiring a sample containing CAR-expressing cells, such as a manufacturing sample or a clinical sample);

 contacting the CAR-expressing cell with the CAR ligand under conditions where binding
10 occurs, thereby detecting the level (e.g., amount) of the CAR-expressing cells present. Binding of the CAR-expressing cell with the CAR ligand can be detected using standard techniques such as FACS, ELISA and the like.

In another aspect, a method of expanding and/or activating cells (e.g., immune effector cells) is disclosed. The method includes:

15 providing a CAR-expressing cell (e.g., a first CAR-expressing cell or a transiently expressing CAR cell);

 contacting said CAR-expressing cell with a CAR ligand, e.g., a CAR ligand as described herein), under conditions where immune cell expansion and/or proliferation occurs, thereby producing the activated and/or expanded cell population.

20 In certain embodiments, the CAR ligand is present on (e.g., is immobilized or attached to a substrate, e.g., a non-naturally occurring substrate). In some embodiments, the substrate is a non-cellular substrate. The non-cellular substrate can be a solid support chosen from, e.g., a plate (e.g., a microtiter plate), a membrane (e.g., a nitrocellulose membrane), a matrix, a chip or a bead. In embodiments, the CAR ligand is present in the substrate (e.g., on the substrate
25 surface). The CAR ligand can be immobilized, attached, or associated covalently or non-covalently (e.g., cross-linked) to the substrate. In one embodiment, the CAR ligand is attached (e.g., covalently attached) to a bead. In the aforesaid embodiments, the immune cell population can be expanded *in vitro* or *ex vivo*. The method can further include culturing the population of

immune cells in the presence of the ligand of the CAR molecule, e.g., using any of the methods described herein.

In other embodiments, the method of expanding and/or activating the cells further comprises addition of a second stimulatory molecule, e.g., CD28. For example, the CAR ligand and the second stimulatory molecule can be immobilized to a substrate, e.g., one or more beads, thereby providing increased cell expansion and/or activation.

In yet another aspect, a method for selecting or enriching for a CAR expressing cell is provided. The method includes contacting the CAR expressing cell with a CAR ligand as described herein; and selecting the cell on the basis of binding of the CAR ligand.

In yet other embodiments, a method for depleting, reducing and/or killing a CAR expressing cell is provided. The method includes contacting the CAR expressing cell with a CAR ligand as described herein; and targeting the cell on the basis of binding of the CAR ligand, thereby reducing the number, and/or killing, the CAR-expressing cell. In one embodiment, the CAR ligand is coupled to a toxic agent (e.g., a toxin or a cell ablative drug). In another embodiment, the anti-idiotypic antibody can cause effector cell activity, e.g., ADCC or ADC activities.

Exemplary anti-CAR antibodies that can be used in the methods disclosed herein are described, e.g., in WO 2014/190273 and by Jena et al., “Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T cells in Clinical Trials”, PLOS March 2013 8:3 e57838, the contents of which are incorporated by reference.

In some aspects and embodiments, the compositions and methods herein are optimized for a specific subset of T cells, e.g., as described in US Serial No. PCT/US2015/043219 filed July 31, 2015, the contents of which are incorporated herein by reference in their entirety. In some embodiments, the optimized subsets of T cells display an enhanced persistence compared to a control T cell, e.g., a T cell of a different type (e.g., CD8⁺ or CD4⁺) expressing the same construct.

In some embodiments, a CD4⁺ T cell comprises a CAR described herein, which CAR comprises an intracellular signaling domain suitable for (e.g., optimized for, e.g., leading to enhanced persistence in) a CD4⁺ T cell, e.g., an ICOS domain. In some embodiments, a CD8⁺ T

cell comprises a CAR described herein, which CAR comprises an intracellular signaling domain suitable for (e.g., optimized for, e.g., leading to enhanced persistence of) a CD8⁺ T cell, e.g., a 4-1BB domain, a CD28 domain, or another costimulatory domain other than an ICOS domain. In some embodiments, the CAR described herein comprises an antigen binding domain described
 5 herein, e.g., a CAR comprising an antigen binding domain.

In an aspect, described herein is a method of treating a subject, e.g., a subject having cancer. The method includes administering to said subject, an effective amount of:

1) a CD4⁺ T cell comprising a CAR (the CAR^{CD4+})

comprising:

10 an antigen binding domain, e.g., an antigen binding domain described herein;

a transmembrane domain; and

an intracellular signaling domain, e.g., a first costimulatory domain, e.g., an ICOS domain; and

2) a CD8⁺ T cell comprising a CAR (the CAR^{CD8+}) comprising:

15 an antigen binding domain, e.g., an antigen binding domain described herein;

a transmembrane domain; and

an intracellular signaling domain, e.g., a second costimulatory domain, e.g., a 4-1BB domain, a CD28 domain, or another costimulatory domain other than an ICOS domain;

wherein the CAR^{CD4+} and the CAR^{CD8+} differ from one another.

20 Optionally, the method further includes administering:

3) a second CD8⁺ T cell comprising a CAR (the second CAR^{CD8+}) comprising:

an antigen binding domain, e.g., an antigen binding domain described herein;

a transmembrane domain; and

an intracellular signaling domain, wherein the second CAR^{CD8+} comprises an intracellular
 25 signaling domain, e.g., a costimulatory signaling domain, not present on the CAR^{CD8+}, and, optionally, does not comprise an ICOS signaling domain.

RNA Transfection

Disclosed herein are methods for producing an in vitro transcribed RNA CAR. RNA CAR and methods of using the same are described, e.g., in paragraphs 553-570 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

In one embodiment, the in vitro transcribed RNA CAR can be introduced to a cell as a form of transient transfection. The RNA may have a 3' UTR, a 5' UTR, or both. The 5' UTR may contain a Kozak sequence. The RNA may comprise an IRES. The RNA may comprise a 5' cap. The RNA may comprise a polyA sequence. RNA can be produced using a DNA template that comprises a promoter, e.g., a T7, T7, or SP6 promoter. RNA can be introduced into target cells using any of a number of different methods, for instance, commercially available methods which include, but are not limited to, electroporation, the Gene Pulser II, Multiporator, cationic liposome mediated transfection using lipofection, polymer encapsulation, peptide mediated transfection, or biolistic particle delivery systems such as "gene guns".

Non-viral delivery methods

In some aspects, non-viral methods can be used to deliver a nucleic acid encoding a CAR described herein into a cell or tissue or a subject. Suitable non-viral delivery methods include transposons (e.g., Sleeping Beauty, piggyBac, and pT2-based transposons). Exemplary non-viral delivery methods and methods of using the same are described, e.g., in paragraphs 571-579 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

Methods of Manufacture/Production

In one aspect, methods of manufacturing a CAR-expressing cell according to the invention are disclosed herein (e.g., in "Source of Cells" and "Activation and Expansion of Cells").

In an embodiment, a method of manufacturing a CAR-expressing cell is provided. The method comprises:

providing a preparation of a CAR-expressing cell (e.g., a plurality of CAR-expressing immune effector cells, such as a T cells, or an NK cells) (e.g., a CD19 CAR-expressing cell as described herein, such as, e.g., CTL019);

acquiring a value for the level of (e.g., determining the level of expression of) one or more genes listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 to obtain a gene expression pattern for the sample;

(optionally) comparing the obtained gene expression pattern to that of a historical record of gene expression;

determining a difference between the obtained and historical gene expression; and

recording the determined difference in a quality control record.

In an embodiment, provided methods comprise steps of providing a CAR-expressing cell (e.g., T cell, NK cell) preparation (e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) as described herein, such as, e.g., CTL019);

determining the levels of expression of one or more genes listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, and KLRG1 to obtain a gene expression pattern (e.g., a gene signature) for the sample;

correlating the gene signature with patient response to a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g. a CD19 CAR-expressing cell (e.g., T cell, NK cell) as described herein, such as, e.g., CTL019);

and optimizing the CAR-expressing cell (e.g., T cell, NK cell) preparation based on the correlation of the gene signature and patient response prior to infusion into patients.

In an embodiment, provided methods comprise acquiring a value for the level (e.g., determining the expression level) of a cytokine, e.g., one or more cytokines listed in Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), and Table 17, Table 18, Table 20, secreted

by CAR-expressing cells (e.g., T cell, NK cell) in response to antigen recognition. In an embodiment, provided methods comprise determining the expression levels of one or more cytokines CCL20/MIP3a, IL-17a, IL-6 and/or combinations thereof, secreted by CAR-expressing cells (e.g., T cell, NK cell) in response to antigen recognition. In an embodiment, provided methods further comprise integration of cytokines secreted by CAR-expressing cells (e.g., T cells, NK cells), e.g., one or more cytokines listed in Table 14, Table 15 and Table 16, in a potency assay. In an embodiment, provided methods further comprise integration of cytokines CCL20/MIP3a, IL-17a, IL-6 and/or combinations thereof, in a potency assay.

In an embodiment, provided methods comprise integration of cytokines secreted by CAR-expressing cells (e.g., T cells, NK cells), e.g., one or more cytokines listed in Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), and Table 17 in a potency assay, and determining whether a CAR-expressing cell (e.g., T cell, NK cell) preparation (e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) as described herein, such as, e.g., CTL019) may have a clinical effect. In an embodiment, CCL20/MIP3a, IL-17a, IL-6 and/or combinations thereof are used in a potency assay to determine whether a CAR-expressing cell (e.g., T cell, NK cell) preparation (e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) as described herein, such as, e.g., CTL019) may have a clinical effect. In an embodiment, provided methods further comprise adjusting the CAR-expressing cell (e.g., T cell, NK cell) infusion dose to achieve clinical efficacy.

In an embodiment, provided methods comprise a step of providing a blood sample, e.g., a T cell sample, from a subject having cancer.

In an embodiment, provided methods further comprise a step of comparing the obtained gene expression pattern difference with that of a reference sample.

In an embodiment, a reference sample is a CAR-expressing cell (e.g., T cell, NK cell) preparation (e.g., a CD19 CAR-expressing cell as described herein, such as, e.g., CTL019) from a different batch of cells producing the therapeutic CAR-expressing cell preparation.

In an embodiment, a reference sample is a healthy donor sample with a manufactured CAR-expressing cell (e.g., T cell, NK cell) product (e.g., a CD19 CAR-expressing cell as described herein, such as, e.g., CTL019). In an embodiment, a reference sample is a healthy

donor sample with a manufactured CD19 CAR-expressing cell product, such as, e.g., CTL019 product.

In an embodiment, provided methods further comprise a step of recording the result of the comparing in a quality control record for the therapeutic CAR-expressing cell (e.g., T cell, NK cell) preparation.

In an embodiment, the determined difference is compared with a historical record of the reference sample.

In an embodiment, the CAR-expressing cell (e.g., T cell, NK cell) preparation is a CD19 CAR-expressing cell (e.g., CTL019) preparation.

In an embodiment, the CAR-expressing cell (e.g., T cell, NK cell) preparation comprises a CD19 CAR-expressing cell (e.g., CTL019) preparation.

In an embodiment, the CAR-expressing cell (e.g., T cell, NK cell) preparation consists of a CD19 CAR-expressing cell (e.g., CTL019) preparation.

In an aspect, a method is provided, comprising:
providing a blood sample, e.g., a T cell sample, from a subject having cancer;
determining the levels of expression of one or more genes listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, or KLRG1 to obtain a gene expression pattern for the sample;

comparing the obtained gene expression pattern to that of a reference value, e.g., a historical record of gene expression;
determining a difference between the obtained and the reference value; and
recording the determined difference in a quality control record.

The method can comprise a step of comparing the obtained gene expression pattern difference with that of a reference sample.

In some embodiments, the methods disclosed herein further include administering a T cell depleting agent after treatment with the cell (e.g., an immune effector cell as described herein), thereby reducing (e.g., depleting) the CAR-expressing cells (e.g., the CD19CAR-expressing cells). Such T cell depleting agents can be used to effectively deplete CAR-expressing cells (e.g., CD19CAR-expressing cells) to mitigate toxicity. In some embodiments,

the CAR-expressing cells were manufactured according to a method herein, e.g., assayed (e.g., before or after transfection or transduction) according to a method herein.

In some embodiments, the T cell depleting agent is administered one, two, three, four, or five weeks after administration of the cell, e.g., the population of immune effector cells,
5 described herein.

In one embodiment, the T cell depleting agent is an agent that depletes CAR-expressing cells, e.g., by inducing antibody dependent cell-mediated cytotoxicity (ADCC) and/or complement-induced cell death. For example, CAR-expressing cells described herein may also express an antigen (e.g., a target antigen) that is recognized by molecules capable of inducing
10 cell death, e.g., ADCC or complement-induced cell death. For example, CAR expressing cells described herein may also express a target protein (e.g., a receptor) capable of being targeted by an antibody or antibody fragment. Examples of such target proteins include, but are not limited to, EpCAM, VEGFR, integrins (e.g., integrins $\alpha\text{v}\beta 3$, $\alpha 4$, $\alpha\text{I}3/4\beta 3$, $\alpha 4\beta 7$, $\alpha 5\beta 1$, $\alpha\text{v}\beta 3$, αv), members of the TNF receptor superfamily (e.g., TRAIL-R1 , TRAIL-R2), PDGF Receptor,
15 interferon receptor, folate receptor, GPNMB, ICAM-1, HLA-DR, CEA, CA-125, MUC1, TAG-72, IL-6 receptor, 5T4, GD2, GD3, CD2, CD3, CD4, CD5, CD11 , CD11a/LFA-1, CD15, CD18/ITGB2, CD19, CD20, CD22, CD23/IgE Receptor, CD25, CD28, CD30, CD33, CD38, CD40, CD41 , CD44, CD51 , CD52, CD62L, CD74, CD80, CD125, CD147/basigin, CD152/CTLA-4, CD154/CD40L, CD195/CCR5, CD319/SLAMF7, and EGFR, and truncated
20 versions thereof (e.g., versions preserving one or more extracellular epitopes but lacking one or more regions within the cytoplasmic domain).

In some embodiments, the CAR expressing cell co-expresses the CAR and the target protein, e.g., naturally expresses the target protein or is engineered to express the target protein. For example, the cell, e.g., the population of immune effector cells, can include a nucleic acid
25 (e.g., vector) comprising the CAR nucleic acid (e.g., a CAR nucleic acid as described herein) and a nucleic acid encoding the target protein.

In one embodiment, the T cell depleting agent is a CD52 inhibitor, e.g., an anti-CD52 antibody molecule, e.g., alemtuzumab.

In other embodiments, the cell, e.g., the population of immune effector cells, expresses a
30 CAR molecule as described herein (e.g., CD19CAR) and the target protein recognized by the T

cell depleting agent. In one embodiment, the target protein is CD20. In embodiments where the target protein is CD20, the T cell depleting agent is an anti-CD20 antibody, e.g., rituximab.

In further embodiments of any of the aforesaid methods, the methods further include transplanting a cell, e.g., a hematopoietic stem cell, or a bone marrow, into the mammal.

5 In another aspect, the invention features a method of conditioning a mammal prior to cell transplantation. The method includes administering to the mammal an effective amount of the cell comprising a CAR nucleic acid or polypeptide, e.g., a CD19 CAR nucleic acid or polypeptide. In some embodiments, the cell transplantation is a stem cell transplantation, e.g., a hematopoietic stem cell transplantation, or a bone marrow transplantation. In other
10 embodiments, conditioning a subject prior to cell transplantation includes reducing the number of target-expressing cells in a subject, e.g., CD19-expressing normal cells or CD19-expressing cancer cells.

Nucleic Acid Constructs Encoding a CAR

15 Nucleic acid molecules encoding one or more CAR constructs can be introduced into an immune effector cell (e.g., a T cell) as described herein. In one aspect, the nucleic acid molecule is provided as a messenger RNA transcript. In one aspect, the nucleic acid molecule is provided as a DNA construct.

In some embodiments, a nucleic acid described herein is introduced into a cell that has
20 been assayed by a method described herein, e.g., one or more biomarkers has been assayed. In some embodiments, a cell comprising a nucleic acid described herein is assayed by a method described herein, e.g., one or more biomarkers has been assayed.

The nucleic acid molecules described herein can be a DNA molecule, an RNA molecule, or a combination thereof. In one embodiment, the nucleic acid molecule is an mRNA encoding a
25 CAR polypeptide as described herein. In other embodiments, the nucleic acid molecule is a vector that includes any of the aforesaid nucleic acid molecules.

Nucleic acid molecules can encode, e.g., a CAR molecule described herein, and can comprise, e.g., a nucleic acid sequence described herein, e.g., in **Table 11**, **Table 12** or **Table 13**.

The nucleic acid sequences coding for the desired molecules can be obtained using recombinant methods known in the art, such as, for example by screening libraries from cells expressing the gene, by deriving the gene from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques.

5 Alternatively, the gene of interest can be produced synthetically, rather than cloned.

Also described are vectors in which a nucleic acid of the present disclosure is inserted. Vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells. Lentiviral vectors have the added advantage over vectors derived from onco-
10 retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low immunogenicity. A retroviral vector may also be, e.g., a gammaretroviral vector. A gammaretroviral vector may include, e.g., a promoter, a packaging signal (ψ), a primer binding site (PBS), one or more (e.g., two) long terminal repeats (LTR), and a transgene of interest, e.g., a gene encoding a CAR. A
15 gammaretroviral vector may lack viral structural genes such as gag, pol, and env. Exemplary gammaretroviral vectors include Murine Leukemia Virus (MLV), Spleen-Focus Forming Virus (SFFV), and Myeloproliferative Sarcoma Virus (MPSV), and vectors derived therefrom. Other gammaretroviral vectors are described, e.g., in Tobias Maetzig et al., "Gammaretroviral Vectors: Biology, Technology and Application" *Viruses*. 2011 Jun; 3(6): 677–713.

20 In another embodiment, the vector comprising the nucleic acid encoding the desired CAR of the invention is an adenoviral vector (A5/35). In another embodiment, the expression of nucleic acids encoding CARs can be accomplished using of transposons such as sleeping beauty, CRISPR, CAS9, and zinc finger nucleases. See below June et al. 2009 *NATURE REVIEWS IMMUNOLOGY* 9.10: 704-716, is incorporated herein by reference.

25 In brief summary, the expression of natural or synthetic nucleic acids encoding CARs is typically achieved by operably linking a nucleic acid encoding the CAR polypeptide or portions thereof to a promoter, and incorporating the construct into an expression vector. The vectors can be suitable for replication and integration eukaryotes. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for
30 regulation of the expression of the desired nucleic acid sequence.

The expression constructs may also be used for nucleic acid immunization and gene therapy, using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g., U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466, incorporated by reference herein in their entireties. In another embodiment, the invention provides a gene therapy vector.

5 The nucleic acid can be cloned into a number of types of vectors. For example, the nucleic acid can be cloned into a vector including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus, and a cosmid. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.

Further, the expression vector may be provided to a cell in the form of a viral vector.

10 Viral vector technology is well known in the art and is described, for example, in Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1 -4, Cold Spring Harbor Press, NY), and in other virology and molecular biology manuals. Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno- associated viruses, herpes viruses, and lentiviruses. In general, a suitable vector contains an origin of

15 replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers, (e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193).

A number of viral based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. A

20 selected gene can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo. A number of retroviral systems are known in the art. In some embodiments, adenovirus vectors are used. A number of adenovirus vectors are known in the art. In one embodiment, lentivirus vectors are used.

25 Additional promoter elements, e.g., enhancers, regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the

thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription. Exemplary promoters include the CMV IE gene, EF-1 α , ubiquitin C, or phosphoglycerokinase (PGK)

5 promoters.

An example of a promoter that is capable of expressing a CAR transgene in a mammalian T cell is the EF1a promoter. The native EF1a promoter drives expression of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. The EF1a promoter has been extensively used in mammalian expression
10 plasmids and has been shown to be effective in driving CAR expression from transgenes cloned into a lentiviral vector. See, e.g., Milone et al., MOL. THER. 17(8): 1453–1464 (2009). In one aspect, the EF1a promoter comprises the sequence provided as SEQ ID NO:11.

Another example of a promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving
15 high levels of expression of any polynucleotide sequence operatively linked thereto. However, other constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma
20 virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the elongation factor-1 α promoter, the hemoglobin promoter, and the creatine kinase promoter. Further, the invention should not be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the invention. The use of an inducible promoter provides a molecular switch capable of turning on expression of the
25 polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to a metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.

Another example of a promoter is the phosphoglycerate kinase (PGK) promoter. In
30 embodiments, a truncated PGK promoter (e.g., a PGK promoter with one or more, e.g., 1, 2, 5,

10, 100, 200, 300, or 400, nucleotide deletions when compared to the wild-type PGK promoter sequence) may be desired.

A vector may also include, e.g., a signal sequence to facilitate secretion, a polyadenylation signal and transcription terminator (e.g., from Bovine Growth Hormone (BGH) gene), an element allowing episomal replication and replication in prokaryotes (e.g. SV40 origin and ColE1 or others known in the art) and/or elements to allow selection (e.g., ampicillin resistance gene and/or zeocin marker).

In order to assess the expression of a CAR polypeptide or portions thereof, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors. In other aspects, the selectable marker may be carried on a separate piece of DNA and used in a co- transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers include, for example, antibiotic-resistance genes, such as neo and the like.

Reporter genes are used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences. Reporter genes are described, e.g., in paragraph 599 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

In embodiments, the vector may comprise two or more nucleic acid sequences encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR, and a second CAR, e.g., an inhibitory CAR or a CAR that specifically binds to an antigen other than CD19. In such embodiments, the two or more nucleic acid sequences encoding the CAR are encoded by a single nucleic molecule in the same frame and as a single polypeptide chain. In this aspect, the two or more CARs, can, e.g., be separated by one or more peptide cleavage sites. (e.g., an auto-cleavage site or a substrate for an intracellular protease). Examples of peptide cleavage sites include T2A, P2A, E2A, or F2A sites.

Methods of introducing and expressing genes into a cell are known in the art. In the context of an expression vector, the vector can be readily introduced into a host cell, e.g.,

mammalian, bacterial, yeast, or insect cell by any method in the art. For example, the expression vector can be transferred into a host cell by physical, chemical, or biological means, e.g., those described in paragraphs 601-603 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

5 In the case where a non-viral delivery system is utilized, an exemplary delivery vehicle is a liposome. The use of lipid formulations is contemplated for the introduction of the nucleic acids into a host cell (in vitro, ex vivo or in vivo), and is described, e.g., in paragraphs 604-605 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

10 Regardless of the method used to introduce exogenous nucleic acids into a host cell or otherwise expose a cell to the inhibitor of the present invention, in order to confirm the presence of the recombinant DNA sequence in the host cell, a variety of assays may be performed. Such assays include, for example, “molecular biological” assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; “biochemical” assays, such as
15 detecting the presence or absence of a particular peptide, e.g., by immunological means (ELISAs and Western blots) or by assays described herein to identify agents falling within the scope of the invention.

Therapeutic Methods

20 In one aspect, the disclosure provides methods for treating a disease associated with expression of a tumor antigen described herein. In some embodiments, immune effector cells are assayed by a method described herein, e.g., one or more biomarkers is assayed, and the cells are administered to a subject as part of a treatment described herein. For example, the immune effector cells can be administered as part of a combination therapy described herein.

25 In one aspect, the present disclosure provides methods of treating cancer (e.g., a hematological cancer such as ALL and CLL) by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a CAR. In one embodiment, the cancer to be treated is a B cell malignancy. In one embodiment, the cancer to be treated is

ALL (acute lymphoblastic leukemia), CLL (chronic lymphocytic leukemia), DLBCL (diffuse large B-cell lymphoma), MCL (Mantle cell lymphoma, or MM (multiple myeloma).

In one aspect, the disclosure provides methods of treating cancer (e.g., a hematological cancer such as ALL and CLL) by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a CD19 CAR, wherein the cancer cells express CD19. In one embodiment, the cancer to be treated is a B cell malignancy. In one embodiment, the cancer to be treated is ALL (acute lymphoblastic leukemia), CLL (chronic lymphocytic leukemia), DLBCL (diffuse large B-cell lymphoma), MCL (Mantle cell lymphoma), Hodgkin lymphoma, or MM (multiple myeloma).

In one aspect, the present invention provides methods of treating cancer (e.g., a hematological cancer such as ALL and CLL) by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a CD22 CAR, wherein the cancer cells express CD22. In one embodiment, the cancer to be treated is a B cell malignancy. In one embodiment, the cancer to be treated is ALL (acute lymphoblastic leukemia), CLL (chronic lymphocytic leukemia), DLBCL (diffuse large B-cell lymphoma), MCL (Mantle cell lymphoma), Hodgkin lymphoma, or MM (multiple myeloma).

In one aspect, the present invention provides methods of treating cancer (e.g., a hematological cancer such as ALL and CLL) by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a CD20 CAR, wherein the cancer cells express CD20. In one embodiment, the cancer to be treated is a B cell malignancy. In one embodiment, the cancer to be treated is ALL (acute lymphoblastic leukemia), CLL (chronic lymphocytic leukemia), DLBCL (diffuse large B-cell lymphoma), MCL (Mantle cell lymphoma), Hodgkin lymphoma, or MM (multiple myeloma).

In one aspect, the present invention provides methods of treating cancer (e.g., a hematological cancer such as ALL and CLL) by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a ROR1 CAR, wherein the cancer cells express ROR1. In one embodiment, the cancer to be treated is a B cell malignancy. In one embodiment, the cancer to be treated is ALL (acute lymphoblastic leukemia), CLL

(chronic lymphocytic leukemia), DLBCL (diffuse large B-cell lymphoma), MCL (Mantle cell lymphoma), Hodgkin lymphoma, or MM (multiple myeloma).

The disclosure includes a type of cellular therapy where immune effector cells (e.g., T cells, NK cells) are genetically modified (e.g., via transduction of a lentiviral vector) to express a CAR and the CAR-expressing cell is infused to a recipient in need thereof. The infused cell is able to kill tumor cells in the recipient. Unlike antibody therapies, CAR-modified immune effector cells (e.g., T cells, NK cells) are able to replicate in vivo resulting in long-term persistence that can lead to sustained tumor control. CAR-expressing cells (e.g., T cells or NK cells) generated using lentiviral vectors will have stable CAR expression. In various aspects, the immune effector cells (e.g., T cells, NK cells) administered to the patient, or their progeny, persist in the patient for at least four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen month, fifteen months, sixteen months, seventeen months, eighteen months, nineteen months, twenty months, twenty-one months, twenty-two months, twenty-three months, two years, three years, four years, or five years after administration of the T cell to the patient.

The invention also includes a type of cellular therapy where immune effector cells (e.g., T cells, NK cells) are modified, e.g., by in vitro transcribed RNA, to transiently express a CAR and the CAR-expressing cell is infused to a recipient in need thereof. CAR-expressing cells (e.g., T cells, NK cells) generated through transduction of CAR RNA (e.g., by transfection or electroporation) transiently express RNA CARs for 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 days after transduction. The infused cell is able to kill tumor cells in the recipient. Thus, in various aspects, the immune effector cells (e.g., T cells, NK cells) administered to the patient, is present for less than one month, e.g., three weeks, two weeks, one week, after administration of the T cell to the patient.

In one aspect, the present disclosure provides methods of treating cancer (e.g., a hematological cancer such as ALL and CLL) by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a CAR, e.g., a CAR described herein.

In one embodiment, the present disclosure provides methods of treating cancer (e.g., a hematological cancer such as ALL and CLL) by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a CAR that specifically targets or binds to a tumor antigen (or cancer associated antigen) described herein, wherein the subject has been identified as a responder or partial responder. In other embodiments, the methods provide treating a cancer (e.g., a hematological cancer such as ALL and CLL) as a partial responder or non-responder by providing to the subject a cancer therapy other than a CAR therapy, e.g., providing the subject a treatment that is the standard of care for that particular type of cancer. In yet another embodiment, the method of treatment includes altering the manufacturing of a CAR-expressing cell to enrich for naïve T cells, e.g., as described herein, for a subject identified as a partial responder or non-responder prior to administering a CAR-expressing cell, e.g., a CAR-expressing cell described herein.

In one embodiment, the immune effector cells (e.g., T cells, NK cells) are engineered to express CD19 CAR, for treating a subject having cancer (e.g., a hematological cancer such as ALL and CLL), wherein the cancer cells express CD19. In one embodiment, the cancer to be treated is ALL or CLL. The CD19 CAR molecules to be expressed in an immune effector cell can comprise any anti-CD19 antigen binding domain in the art (e.g., those provided in **Table 12**) in combination with any of the CAR domains described herein to generate a full CAR construct. For example, the full CAR construct is a CAR listed in **Table 13**. **Table 13** provides the exemplary full CD19 CAR constructs generated using the various CAR domains (e.g., transmembrane and intracellular signaling domains) listed in **Table 12**, and the anti-CD19 antigen binding domains listed in **Table 12**. Amino acid sequences are designated (aa) and nucleic acid sequences are designated (nt).

Table 13. CD19 CAR Constructs

Name	Sequence
CAR 1	
104875	atggccctccctgtcaccgcccctgctgcttccgctggctcttctgctccacgcccgtcggcccgga
CAR 1 – Full - nt	aattgtgatgaccagtcacccgccactcttagcctttcaccgggtgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccgacaggctcctcgcttctgatctaccacaccagccggctccattctggaatccctgccagggttcagcggtagcgg

	<p>atctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttct gtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtgga ggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaactccaagaaagcggacc gggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccg attacgggggtgtcttggatcagacagccaccggggaagggcttggaatggattggagtgatttgg ggctctgagactacttactactcttcatccctcaagtcacgcgtcaccatctcaaaggacaactc taagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcg ctaagcattactattatggcgggagctacgcaatggattactggggacaggggtactctggtcacc gtgtccagcaccactaccccagcaccgaggccacccaccccggtcctaccatcgctcccagcc tctgtccctgcgtccggaggcatgtagaccgcagctggtggggccgtgcatacccggggtcttg acttcgctgcgatatctacatttggggccctctggctggtacttgcggggtcctgctgctttca ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaaccctt catgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggagg aaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcagggg cagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcg gagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtaca acgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcaga agaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc tcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 55)</p>
<p>104875 CAR 1 – Full - aa</p>	<p>MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc<u>rasqdiskyln</u>wyqqkpggap rlliy<u>htsrllhs</u>giparfsgsgsgtdytltlisslqpedfavyfc<u>qggntlpyt</u>fgggtkleikgg ggsggggsgggsgvqlqesgpglvkpsetlsltctvsgvslp<u>dygvs</u>wirqppgkglewig<u>viw</u> <u>gsettyyssslks</u>rvtiskdnsknqvsllkssvtaadtavyycak<u>hyyyggsyandy</u>wgqgtlvt vsstttpprptpaptiasqplslrpeacrpaaggavhtrglfacdiyiwaplagtcgvllls lvitlyckrgrklllyifkqpfmrpvqttqeedgcscrpfeeeeggcelrvkfrrsadapaykqg qnqlynelnlgrreeydvldkrrgrdpemggkprrrnpqeglynelqkdmaeyseigmkgerr rgkghdglyqglstatkdydalhmqalppr (SEQ ID NO: 56)</p>
CAR 2	
<p>104876 CAR 2 - Full - nt</p>	<p>atggccctccctgtcaccgccctgctgcttccgctggctcttctgtcctcacgccgctcgcccca aattgtgatgaccagtcaccgcactcttagcctttcaccgggtgagcgcgaaccctgtctt gcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccggacaggctcct cgcttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcgg atctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttct gtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtgga ggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaactccaagaaagcggacc gggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccg</p>

	<p>attacgggggtgtcttgatcagacagccaccggggaaggggtctggaatggattggagtgatttgg ggctctgagactacttactaccaatcatccctcaagtcacgcgtcaccatctcaaaggacaactc taagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcg ctaagcattactattatggcgggagctacgcaatggattactggggacaggggtactctggtcacc gtgtccagcaccactacccccagcaccgagggccacccaccccggtcctaccatcgctcccagcc tctgtccctgcgtccggaggcatgtagaccgcagctgggtggggccgtgcatacccggggtcttg acttcgctgcgatatctacatttgggcccctctggctggtagttgctgggggtcctgctgctttca ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaaccctt catgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggagg aaggcggtgcgaactgcgcgtgaaattcagccgcagcgagatgctccagcctacaagcagggg cagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcg gagaggacgggagccagaaatggcggggaagccgcgcagaaagaatccccaagagggcctgtaca acgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcaga agaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc tcttcacatgcaggccctgcccgcctcgg (SEQ ID NO: 57)</p>
<p>104876 CAR 2 - Full - aa</p>	<p>MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc<u>rasqdiskyl</u>nywqqkpggap rlliy<u>htsrllhs</u>giparfsgsgsgtdytlitisslqpedfavyfc<u>gggntlpyt</u>fgqgkcleikgg gsgsgggsgggsgsqvqlqesgpglvkpselstctvsgvslp<u>dygvs</u>wirpppgkglewig<u>viw</u> <u>gsettyyqsslks</u>rvtiskdnsknqvsllkssvtaadtavyycak<u>hyvyggsyamdy</u>wgggtlvt vssttppaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvllls lvitlyckrgrklllyifkqpfmrpvqttqeedgcscrfpееееggcelrvkfrsadapaykqg qnqlynelnlgrreeydvldkrrgrdpemggkprkrnpqeglynelqkdkmaeayseigmkgerr rgkghdglyqglstatkdttydalhmqalppr (SEQ ID NO: 58)</p>
CAR 3	
<p>104877 CAR 3 - Full - nt</p>	<p>atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgctcgcccaca agtccagcttcaagaatcagggcctgggtctggtagaagccatctgagactctgtccctcacttgca ccgtgagcggagtggtccctcccagactacggagtgagctggattagacagcctcccggaaagga ctggagtggtatcgagtgatttggggtagcgaaaccacttactattcatcttcctgaagtcacg ggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccg ctgacaccgccgtgtattactgtgccaaagcattactactatggagggtcctacgccatggactac tggggccagggaactctggctactgtgtcatctggtaggaggtagcggaggaggcgggagcgg tggaggtgggtccgaaatcgatgatgaccagagccctgcaaccctgtccctttctcccggggaac gggtaccctttcttgctgggcatcacaagatatctaaaatacctcaattggtatcaacagaag ccgggacaggccccctaggtcttctaccacacctctcgctgcatacggggattcccgcacg ctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccaggact tcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagctt</p>

	<p>gagatcaaaaccactactcccgctccaaggccacccacccctgccccgaccatcgctctcagcc gctttccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttg acttcgctgcgatatctacatttgggccctctggctggtacttgccgggtcctgctgctttca ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaaccctt catgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggagg aaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcagggg cagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcg gagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtaca acgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcaga agaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc tcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 59)</p>
<p>104877 CAR 3 – Full - aa</p>	<p>MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkg lewigviwgsettyyssslksrvtiskdnsknqvsllssvtaadtavyycakhyyyggsyamdy wgqgtlvtvssgggsgggsggggseivmtqspatlsispgeratlscrasqdiskylwnyqqk pgqaprlliyhtsrlhsqiparfsgsgsgtdytlitisslqpedfavyfcgggntlpytfgqgktl eiktttpprppptpaptiasqplslrpeacrpaaggavhtrglfacdiyiwaplagtcgvllls lvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpееееggcelrvkfsrsadapaykqg qnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdmaeyseigmkgerr rgkghdglyqglstatkdtaldhmqalppr (SEQ ID NO: 60)</p>
CAR 4	
<p>104878 CAR 4 – Full - nt</p>	<p>atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgctcgccaca agtccagcttcaagaatcagggcctggtctggtgaagccatctgagactctgtccctcacttgca ccgtgagcggagtgtccctcccagactacggagtgagctggattagacagcctcccgaaaggga ctggagtggatcgagtgatttgggtagcgaaaccacttactatcaatcttcctgaagtcacg ggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccg ctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactac tggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcgg tggagggtggctccgaaatcgtgatgaccagagccctgcaaccctgtccctttctccggggaac gggctaccctttcttgctcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaag ccgggacaggccctaggcttcttatctaccacacctctcgctgcatagcgggattcccgacg ctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccaggact tcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagctt gagatcaaaaccactactcccgctccaaggccacccacccctgccccgaccatcgctctcagcc gctttccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttg acttcgctgcgatatctacatttgggccctctggctggtacttgccgggtcctgctgctttca ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaaccctt</p>

	catgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggagg aaggcggtgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcagggg cagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcg gagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtaca acgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcaga agaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc tcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 61)
104878 CAR 4 – Full - aa	MALPVTALLLPLALLLHAARPqvqlqesgpglvkpssetlsltctvsgvslp <u>dygvs</u> wirqppgk lewig <u>viwgsettyyqsslks</u> rvtiskdnskqvslklssvtaadtavyycak <u>hyyyggsyamdy</u> wgqgtlvtvssgggsgggsgggsgggseivmtqspatlsispgeratlsc <u>rasqdiskyln</u> wyqqk pgqaprlliy <u>htsrlhs</u> giparfsgsgsgtdytltitisslqpedfavyfc <u>qqgntlpyt</u> fgqgtkl eiktttpprptpaptiasqplslrpeacrpaaggavhtrglfacdiyiwaplagtcgvllls lvitlyckrgrklllyifkqpfmrpvqttqeedgcscrpfeeeeggcelrvkfssadapaykqg qnqlynelnlgrreeydvldkrrgrdpemggkprrrnpqeglynelqkdmaeyseigmkgerr rgkghdglyqglstatkdydalhmqalppr (SEQ ID NO: 62)
CAR 5	
CAR5 scFv domain	eivmtqspatlsispgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgs sgsgtdytltitisslqpedfavyfcqqgntlpytfgqgtkleikgggsgggsgggsgggsgqv lqesgpglvkpssetlsltctvsgvslpdygvswirqppgkglewigviwgsettyyssslksrvt iskdnskqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss (SEQ ID NO: 63)
104879 CAR 5 – Full - nt	atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcgcccca aattgtgatgaccagtcacccgccactcttagcctttcaccgggtgagcgcgcaacctgtctt gcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccgacaggtcct cgcttctgctaccacaccagccggtccattctggaatccctgccaggttcagcggtagcgg atctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttct gtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtgga gggtggcagcgaggaggtgggtccggcggtggaggaagcggcgaggcgaggccaggtccaact ccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcg gagtgtctctccccgattacgggggtgtcttgatcagacagccaccggggaagggtctggaatgg attggagtgatttggggctctgagactacttactactcttcatccctcaagtcacgcgtcaccat ctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccg cgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacag ggtagtctgtcaccgtgtccagcaccactaccccagcaccgagggccaccaccccggtcctac catcgctcccagcctctgtccctgcgtccggaggcatgtagaccgcagctggtggggccgtgc

	ataccgggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggtg gtcctgctgcttttactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacat ctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggt tcccagaggaggaggaaggcggtgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacga cgtgctggacaagcgagagggacgggacccagaaatggcggggaagccgcgcagaaagaatcccc aagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatg aaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccacca ggacacctatgacgctcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 64)
104879 CAR 5 – Full - aa	MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc <u>rasqdiskyl</u> nwyyqkpgqap rlliy <u>htsrllhs</u> giparfsgsgsgtdytlitisslqpedefavyfc <u>gggntlpyt</u> fgqgkkleikgg ggsgggsgggsgggsgggsgvqlqesgpglvkpsetlsltctvsgvslp <u>dygvs</u> wirpppgkglew ig <u>viwgsettyysslks</u> rvtiskdnsknqvslklssvtaadtavyycak <u>hyyyggsyamy</u> wgq gtltvtssttppaprpptpaptiasqplslrpeacrpaaggavhtrglldfacdiyiwaplagtcg vlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrpfpeeeeggcelrvkfirsadap aykqggnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeyseigm kgerrrgkgghdglyqglstatkdydalhmqalppr (SEQ ID NO: 65)
CAR 6	
104880 CAR6 – Full - nt	atggccctccctgtcaccgcccctgctgcttccgctggctcttctgctccacgccgctcggcccga aattgtgatgaccagtcacccgccactcttagcctttcaccgggtgagcgcgcaaccctgtctt gcagagcctcccaagacatctcaaaataaccttaattggtatcaacagaagcccggacaggctcct cgcttctgatctaccacaccagccggtccattctggaatccctgccaggttcagcggtagcgg atctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttct gtcagcaagggaacaccctgcctacacctttggacagggcaccaagctcgagattaaaggtgga gggtggcagcggaggaggtgggtccggcggtggaggaagcggaggcggaggagccaggtccaact ccaagaaagcggaccgggtcttgtgaagccatcagaaactcttctactgacttgtagcgcg gagtgtctctccccgattacgggtgtcttgatcagacagccaccggggaagggtctggaatgg attggagtgatttggggctctgagactacttactaccaatcatccctcaagtcacgcgtcaccat ctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccg ccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacag ggtagtctggtcaccgtgtccagcaccactacccagcaccgaggccaccaccccggtcctac catcgccctcccagcctctgtccctgcgtccggaggcatgtagaccgcagctgggtggggccgtgc ataccgggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggtg gtcctgctgcttttactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacat ctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggt tcccagaggaggaggaaggcggtgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca

	gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacga cgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatcccc aagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatg aaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa ggacacctatgacgctcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 66)
104880 CAR6 – Full – aa	MALPVTALLLPLALLLHAARPeivmtqspatlsispgeratlsc <u>rasqdiskyl</u> nwyqqkpgqap rlliy <u>htsrllhs</u> giparfsgsgsgtdytlitisslqpedfavyfc <u>qggntlpyt</u> fgggtkleikgg ggsgggsgggsgggsgggsqvqlqesgpglvkpsetlsltctvsgvslp <u>dygvs</u> wirpppgkglew ig <u>viwgsettyyqsslks</u> rvtiskdnsknqvs1klssvtaadvayycak <u>hyvyggsyamy</u> wgg gtlvtvssttppaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcg vllslvitlyckrgrklliyifkqpfmrpvqttqeedgcscrpfpeeeeggcelrvkfrsadap aykqqgnqlynelnlgrreeydvldkrrgrdpemggkprkrnpqeglynelqdkmaeayseigm kgerrrgkghdglyqglstatkdydalhmqalppr (SEQ ID NO: 67)
CAR 7	
104881 CAR 7 Full - nt	atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgctcgcccaca agtccagcttcaagaatcagggcctggtctggtgaagccatctgagactctgtccctcacttgca ccgtgagcggagtgctccctcccagactacggagtgagctggattagacagcctcccgaaagga ctggagtggtcggagtgatttggggtagcgaaccacttactattcatcttcctgaagtcacg ggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccg ctgacaccgccgtgtattactgtgccaaagcattactactatggagggtcctacgccatggactac tggggccagggaactctgggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcgg tggaggtggctccggaggtggcggaagcgaaatcgtgatgacccagagccctgcaaccctgtccc tttctcccggggaacgggctaccctttcttgctggggcatcacaagatatctcaaaatacctcaat tggtatcaacagaagccgggacaggcccctaggcttcttatctaccacacctctcgctgcatag cgggattcccgcacgcttttagcgggtctggaagcgggaccgactacactctgacctctcatctc tccagcccaggacttcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggc cagggcaccaagcttgagatcaaaaccactactcccgtccaaggccaccacccctgccccgac catcgctctcagccgctttccctgcgtccggaggtcatgtagaccgcagctgggtggggcgtgc atacccggggtcttgacttcgcctgcgatctacatttgggcccctctgggtggtacttgccgg gtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacat ctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggt tcccagaggaggaggaaggcgggtgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacga cgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatcccc aagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatg aaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa

	ggacacctatgacgctcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 68)
104881 CAR 7 Full - aa	MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp <u>dygvs</u> wirqppgkg lewig <u>viwgsettyyssslks</u> rvtiskdnsknqvslklssvtaadtavyycak <u>hyvyggsyamdy</u> wgqgtlvtvssgggsgggsgggsgggsgggseivmtqspatlsispgeratlsc <u>rasqdiskyln</u> wyqqkpgqaprlly <u>htsrllhs</u> giparfsgsgsgtdytltisslqpedfavyfc <u>qggntlpyt</u> fg qgtnleiktttpprppptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcg vllslvitlyckrgrklllyifkqpfmrpvqttqeedgcscrfeeeeeggcclrvkfksrsadap aykqgnqlynelnlgrreedyvldkrrgrdpemggkprrknpqeglynelqkdkmaeyseigm kgerrrgkghdglyqglstatkdydalhmqalppr (SEQ ID NO: 69)
CAR 8	
104882 CAR 8 – Full - nt	atggctctgcccgtagccgcactcctcctgccactggctctgctgcttcacgccgctcgccaca agtcacgcttcaagaatcagggcctggctctggtgaagccatctgagactctgtccctcacttgca ccgtgagcggagtgccctcccagactacggagtgagctggattagacagcctcccggaaagga ctggagtgagtcggagtgatttgggtagcgaaaccacttactatcaatcttcctgaagtcacg ggtcaccatattcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccg ctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactac tggggccagggaactctggtcactgtgtcatctggtggaggagtagcggaggaggcgggagcgg tggaggtggctccggaggcgggtgggtcagaaatcgatgacccagagccctgcaaccctgtccc tttctcccgggaacgggctaccctttctgtcgggcatcacaagatatctcaaaatacctcaat tggtatcaacagaagccgggacagggccctaggcttcttatctaccacacctctcgccctgcatag cgggattcccgcacgcttttagcgggtctggaagcgggaccgactacactctgaccatctcatctc tccagcccaggacttcgccgtctacttctgccagcagggtaacacccctgccgtacaccttcggc cagggcaccaagcttgagatcaaaaccactactcccgtccaaggccaccacccctgccccgac catcgccctctcagccgctttccctgcgtccggaggcatgtagaccgcagctggtggggccgtgc ataccgggggtcttgacttcgcctgcgatatctacatttggggccctctggctggtacttgccgg gtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacat ctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccgg tcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacga cgtgctggacaagcggagaggacgggaccagaaatgggcgggaagccgcgcagaaagaatcccc aagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatg aaaggggaacgcagaagaggcaaggccacgacggactgtaccagggactcagcaccgccacca ggacacctatgacgctcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 70)
104882 CAR 8 –	MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp <u>dygvs</u> wirqppgkg lewig <u>viwgsettyyqssslks</u> rvtiskdnsknqvslklssvtaadtavyycak <u>hyvyggsyamdy</u>

Full - aa	<p>wgqgtlvtvssgggsgggsgggsgggsgggseivmtqspatlsispgeratlsc<u>rasqdiskyln</u> wyqqkpggaprlliy<u>htsrlhs</u>giparfsgsgsgtdytlitisslqpedfavyfc<u>gggntlpyt</u>fg qggtkleiktttppaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcg vllslvitlyckrgrklllyifkqpfmrpvqttqeedgcscrpfpeeeeggcelrvkf srsadap aykqggqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigm kgerrrgkghdglyqglstatkdydalhmqalppr (SEQ ID NO: 71)</p>
CAR 9	
105974 CAR 9 – Full - nt	<p>atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccga aattgtgatgacccagtcacccgccactcttagcctttcaccgggtgagcgcgaacccctgtctt gcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagccccggacaggctcct cgcttctgatctaccacaccagccggtccattctggaatccctgccaggttcagcggtagcgg atctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttct gtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtgga ggtggcagcggaggaggtgggtccggcgggtggaggaagcggaggcgggtgggagccaggtccaact ccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcg gagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatgg attggagtgatttggggctctgagactacttactacaactcatccctcaagtcacgcgtcaccat ctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccg ccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacag ggtactctggtcaccgtgtccagcaccactaccccagcaccgaggccaccaccccggtcctac catcgctcccagcctctgtccctgcgtccggaggcatgtagaccgcagctggtggggccgtgc ataccgggggtcttgacttcgcctgcgatatctacatttggggccctctgggtggtacttgcggg gtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacat ctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggt tcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacga cgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatcccc aagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatg aaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccacca ggacacctatgacgctcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 72)</p>
105974 CAR 9 – Full - aa	<p>MALPVTALLLPLALLLHAARPeivmtqspatlsispgeratlsc<u>rasqdiskyln</u>wyqqkpggap rlliy<u>htsrlhs</u>giparfsgsgsgtdytlitisslqpedfavyfc<u>gggntlpyt</u>fgqggtkleikgg ggsgggsgggsgggsgggsgvqlqesgpglvkpsetlsltctvsgvslp<u>dygvs</u>wirpppgkglew ig<u>viwgsettyynsslks</u>rvtiskdnsknqvsllkssvtaadtavyycak<u>hyvyggsyamdy</u>wgq gtlvtvsssttppaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcg vllslvitlyckrgrklllyifkqpfmrpvqttqeedgcscrpfpeeeeggcelrvkf srsadap</p>

	aykqgggnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeyseigm kgerrrrgkghdglyqglstatkdydalhmqalppr (SEQ ID NO: 73)
CAR10	
105975 CAR 10 Full - nt	atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccga aattgtgatgaccagtcacccgccactcttagcctttcaccgggtgagcgcgaaccctgtctt gcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccgacaggctcct cgccttctgatctaccacaccagccggctccattctggaatccctgccagggttcagcggtagcgg atctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttct gtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtgga gggtggcagcggaggaggtgggtccggcgggtggaggaagcggaggcgggtgggagccaggtccaact ccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcg gagtgtctctccccgattacgggggtgcttggatcagacagccaccggggaagggtctggaatgg attggagtgatttggggctctgagactacttactacaactcatccctcaagtcacgcgtcaccat ctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccg ccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacag ggtagctctggtcaccgtgtccagcaccactacccagcaccgaggccaccaccccggtcctac catcgctcccagcctctgtccctgcgtccggaggcatgtagaccgcagctgggtggggccgtgc ataccgggggtcttgacttcgctgcgatctacatttggggccctctggctggtagtgcggg gtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacat ctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccgggt tcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggctcggagagaggagtacga cgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatcccc aagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtag aaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa ggacacctatgacgctcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 74)
105975 CAR 10 Full - aa	MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLS C <u>RASQDISKYL</u> N WYQQKPGQAP RLLIY H <u>TSRLHS</u> GIPARFSGSGSGTDYTLTISSIQPEDFAVYFC <u>QOQNTLPYT</u> FGQGTKLEIKGG GGSGGGSGGGSGGGGSQVQLQESGPGLVKPSSETLSLTCTVSGVSLP <u>DYGV</u> S WIRQPPGKGLEW IG <u>VIWGSETTYNSSLKS</u> RVTIISKDNSKNQVSLKLSSVTAADTAVYYCAK <u>HYYYGGSYAMDY</u> WGQ GTLVTVSSTTTPAPRPPTPAPTIIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCG VLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAP AYKQGQNQLYNELNLGRREEYDVLDKRRGRDPGEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM KGERRRGKGHDLGYQGLSTATKDYDALHMALPPR (SEQ ID NO: 75)
CAR11	

105976 CAR 11 Full - nt	atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgctcgcccaca agtcacagcttcaagaatcagggcctggtctggtgaagccatctgagactctgtccctcacttgca ccgtgagcggagtgccctcccagactacggagtgagctggattagacagcctcccgaaagga ctggagtggtatcgagtgatttgggtagcgaaaccacttactataactcttccctgaagtcacg ggtcaccattttcaaaggataactcaaagaatcaagtgaagcctcaagctctcatcagtcaccgccg ctgacaccgccgtgtattactgtgccaaagcattactactatggagggctcctacgccatggactac tggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcgg tggaggtggctccggaggtggcggaagcgaaatcgatgatgacccagagccctgcaaccctgtccc tttctcccgggaacgggctaccctttcttgtcgggcatcacaagatatctcaaaatacctcaat tgggtatcaacagaagccgggacagggccctaggtcttcttatctaccacacctctcgccctgcatag cgggattcccgcacgcttttagcgggtctggaagcgggaccgactacactctgaccatctcatctc tccagcccagaggacttcgccgtctacttctgccagcagggtaacacccctgccgtacaccttcggc cagggcaccaagcttgagatcaaaaccactactcccgtccaaggccaccacccctgccccgac catcgccctctcagccgctttccctgcgtccggagggcatgtagaccgcagctggtggggccgtgc ataccgggggtcttgacttcgcctgcgatatctacatttggggccctctggctggtacttgccggg gtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacat ctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggt tcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacga cgtgctggacaagcggagaggacgggaccagaaatgggcgggaagccgcgcagaaagaatcccc aagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatg aaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccacca ggacacctatgacgctcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 76)
105976 CAR 11 Full - aa	MALPVTALLPLALLLHAARPQVQLQESGPGLVKPSSETLSLTCTVSGVSLP DYGVSWIRQPPGKG LEWIG VIWGSETTYNSSLKS RVTIISKDNSKNQVSLKLSSVTAADTAVYYCAK HYYYGGSYAMDY WGQGTILVTVSSGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLS C RASQDISKYL N WYQQKPGQAPRLLIY HTSRLHS GIPARFSGSGSGTDYTLTISSQLPEDFAVYFC QQGNTLPYTFG QGTELEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCG VLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAP AYKQGQNQLYNELNLGRREEYDVLDRRRGRDPEMGGKPRRKNPQEGLYNELQDKMAEAYSEIGM KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 77)
CAR12	
105977 CAR 12 – Full - nt	atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcgcccca aattgtgatgaccagtcacccgccactcttagcctttcaccgggtgagcgcgaaccctgtctt gcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccgacaggtcct cgcttctgatctaccacaccagccggtccattctggaatccctgccaggttcagcggtagcgg

	atctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttct gtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtgga ggtggcagcggaggaggtgggtccggcgggtggaggaagccaggtccaactccaagaaagcggacc gggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccg attacgggggtgtcttggatcagacagccaccggggaaggggtctggaatggattggagtgatttgg ggctctgagactacttactacaactcatccctcaagtcacgcgtcaccatctcaaaggacaactc taagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcg ctaagcattactattatggcgggagctacgcaatggattactggggacaggggtactctggtcacc gtgtccagcaccactaccccagcaccgagggccaccaccccggtcctaccatcgctcccagcc tctgtccctgcgtccggaggcatgtagaccgcagctgggtggggccgtgcatacccggggtcttg acttcgcctgcgatctctacatttgggcccctctggctggtagtgcgggtcctgctgctttca ctcgtgatcactctttactgtaagcgcgggtcggaagaagctgctgtacatctttaagcaaccctt catgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggagg aaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcagggg cagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcg gagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtaca acgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcaga agaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc tcttcacatgcaggccctgccgcctcgg (SEQ ID NO: 78)
105977 CAR 12 – Full - aa	MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSC <u>RASQDISKYLN</u> WYQQKPGQAP RLLIY <u>HTSRLHS</u> GIPARFSGSGSGTDYTLTISSLQPEDFAVYFC <u>QQGNTLPYT</u> FGQGTKLEIKGG GGSGGGGSGGGGSGVQLQESGPGLVKPSSETLSLTCTVSGVSLP <u>DYGVSWIR</u> QPPGKGLEWIG <u>VIW</u> <u>GSETTYNSSLKS</u> RVTIISKDNSKNQVSLKLSSVTAADTAVYYCAK <u>HYYYGGSYAMDY</u> WGQGLT VSTTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCVLLLS LVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQG QNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQDKMAEAYSEIGMKGERR RGKGDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 79)
CTL019	
CTL019 Full - nt	atggccttaccagtgaccgccttgtcctgccgtggccttgtgctccacgcccgccaggccgga catccagatgacacagactacatcctccctgtctgcctctctgggagacagagtcaccatcagtt gcagggcaagtcaggacattagtaaataatttaaattggtatcagcagaaaccagatggaactgtt aaactcctgatctaccatacatcaagattacactcaggagtcctcatcaaggttcagtggcagtg gtctggaacagattattctctcaccattagcaacctggagcaagaagatattgccacttactttt gccaacagggttaatacgttccgtacacgttcggaggggggaccaagctggagatcacaggtggc ggtggctcgggcgggtgggtgggtcgggtggcgcgatctgaggtgaaactgcaggagtcaggacc tggcctggtggcgccctcacagagcctgtccgtcacatgcactgtctcaggggtctcattaccg

	actatgggtgtaagctggattcgccagcctccacgaaagggctctggagtggctgggagtaatatgg ggtagtgaaaccacataactataattcagctctcaaatccagactgaccatcatcaaggacaactc caagagccaagttttcttaaaaatgaacagctctgcaaactgatgacacagccatttactactgtg ccaaacattattactacggtggtagctatgctatggactactggggccaaggaacctcagtcacc gtctcctcaaccacgacgcccagcgccgcgaccaccaacaccggcgcccaccatcgctcgagcc cctgtccctgcgcccagaggcgtgccggccagcggcgggggcgagtgacacgagggggctgg acttcgcctgtgatctacatctgggcgcccttgccgggacttggtgggtccttctcctgtca ctggttatcaccctttactgcaaacggggcagaaagaaactcctgtatatattcaacaaccatt tatgagaccagtacaaactactcaagaggaagatggctgtagctgccgatttccagaagaagaag aaggaggatgtgaactgagagtgaagttcagcaggagcgcagacgcccccgctacaagcagggc cagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttgacaagag acgtggccgggaccctgagatggggggaaaagccgagaaggaagaacccctcaggaaggcctgtaca atgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccgg aggggcaaggggcacgatggcctttaccagggctctcagtacagccaccaaggacacctacgacgc ccttcacatgcaggccctgccccctcgc (SEQ ID NO: 80)
CTL019 Full - aa	MALPVTALLLPLALLLHAARPdiqmtqttsslsaslgdrvtiscrasqdiskylnwyqqkpdgtv klliyhtsrhsgvpsrfsfsgsgsgtdysltisnleqediattyfcqqgntlpytfgggkkeitgg ggsggggsggggsevkqlqesgpglvapsqslsvtctvsgvslpdygvswirqprrkglewlgviw gsettyynsalksrhtiikdnsksqvflkmnslqtddtaiyycahyyyggsyamydgqgtsvt vssttppaprpptpaptiasqpplslrpeacrpaaggavhtrglfacdiyiwaplagtcgvllls lvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfeeeeeggcelrvkfrrsadapaykqg qnqlynelnlgrreeydvldkrrgrdpemggkprkrnpqeglynelqkdkmaeayseigmkgerr rgkghdglyqglstatkdtaldhmqalppr (SEQ ID NO: 81)

CD19 Associated Diseases and/or Disorders

In one aspect, the disclosure provides methods for treating cancer, e.g., a cancer associated with CD19 expression, with a CAR-expressing cell (e.g., T cell, NK cell) therapy.

- 5 Exemplary cancers include, but are not limited to e.g., one or more acute leukemias including but not limited to, e.g., B-cell acute lymphocytic leukemia (“B-ALL”), T-cell acute lymphocytic leukemia (“T-ALL”), acute lymphocytic leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL). Additional cancers or hematologic conditions associated with expression of
- 10 CD19 include, but are not limited to, e.g., B cell promyelocytic leukemia, blastic plasmacytoid

dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin
5 lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and "preleukemia" which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. Further, a disease associated with CD19 expression include, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative
10 diseases associated with expression of CD19.

In one embodiment, the disclosure provides methods for treating CLL.

In another embodiment, the disclosure provides methods for treating ALL.

In another embodiment, the disclosure provides methods for treating B-cell ALL.

In one aspect, the disclosure provides methods of treating a responder (e.g., a complete
15 responder and partial responder) having cancer (e.g., a hematological cancer such as ALL and CLL) with a CAR-expressing cell (e.g., T cell, NK cell) (e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) as described herein, such as, e.g., CTL019). In an embodiment, the disclosure provides methods of treating a responder (e.g., a complete responder and partial responder) with a CAR-expressing cell (e.g., T cell, NK cell) in combination with another therapeutic agent, e.g.,
20 another therapeutic agent described herein (e.g., another CAR, e.g., another CAR described herein, an inhibitory CAR, e.g., an inhibitory CAR described herein, a kinase inhibitor (e.g., a kinase inhibitor described herein, e.g., an mTOR inhibitor, a BTK inhibitor), a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein, a standard of care therapy, etc.). The combination can be, e.g., with any agent described herein. In an embodiment, after a CAR-
25 expressing cell (e.g., T cell, NK cell) treatment, e.g., an initial CAR-expressing cell (e.g., T cell, NK cell) treatment, a partial responder is tested by any one of the methods described herein, such as, e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) gene set signature, and if status has not changed and/or is down-graded to, e.g., a non-responder, then the subject is administered an alternative therapy, e.g., a standard of care for the particular cancer.

In one aspect, the disclosure provides methods of treating a non-responder having cancer (e.g., a hematological cancer such as ALL and CLL) with a CAR-expressing cell (e.g., T cell, NK cell) (e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) as described herein, such as, e.g., CTL019). In an embodiment, the disclosure provides methods of treating a non-responder with a CAR-expressing cell (e.g., T cell, NK cell) in combination with another therapeutic agent, e.g., another therapeutic agent described herein (e.g., another CAR, e.g., another CAR described herein, an inhibitory CAR, e.g., an inhibitory CAR described herein, a kinase inhibitor (e.g., a kinase inhibitor described herein, e.g., an mTOR inhibitor, a BTK inhibitor), a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein, a standard of care therapy, etc.). The combination can be, e.g., with any agent described herein. In an embodiment, after a CAR-expressing cell (e.g., T cell, NK cell) treatment, e.g., an initial CAR-expressing cell (e.g., T cell, NK cell) treatment, a non-responder is tested by any one of the methods described herein, such as, e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) gene set signature, and if status has changed and/or is up-graded to, e.g., a partial-responder, e.g., a complete responder, then the subject is administered an alternative therapy described herein.

In an embodiment, the disclosure provides methods of treating cancer (e.g., a hematological cancer such as ALL or CLL) comprising steps of: (1) identifying a partial responder subject and/or non-responder subject, (2) administering to the partial responder subject and/or non-responder subject an mTOR inhibitor described herein, such as, e.g., RAD001 and rapamycin, e.g., at a dose and/or dosing schedule described herein; and (3) administering a CAR (e.g., a CD19 CAR described herein, such as, e.g., CTL019), e.g., subsequent to the administration of the mTOR inhibitor, thus treating the cancer. In an embodiment, the method further includes administering the mTOR inhibitor and/or the CAR in combination with one or more checkpoint inhibitors described here, such as, e.g., a PD1 inhibitor.

In an embodiment, the disclosure provides methods of treating cancer (e.g., a hematological cancer such as ALL or CLL) comprising steps of: (1) identifying a partial responder subject (e.g., patient) and/or non-responder subject (e.g., patient), (2) enriching the T cell population of the partial responder subject and/or non-responder subject by selecting for a less exhausted and/or more naïve T cell population, (3) introducing (e.g., by transforming, transducing, infecting, electroporating, etc.) a CAR (e.g., a CD19 CAR described herein, such as,

e.g., CTL019) into said enriched T cell population thus transforming the subject's T cell population; and (4) administering the CAR-expressing T cell population into the partial responder subject and/or non-responder subject, thus treating the cancer.

In an embodiment, the disclosure provides methods of treating cancer (e.g., a hematological cancer such as ALL or CLL) comprising steps of: (1) identifying a partial responder subject (e.g., patient) and/or non-responder subject (e.g., patient), (2) reevaluating a partial responder subject and/or non-responder subject (e.g., patient) at a later time period for naïve T cells and/or less exhausted phenotype, and (3), e.g., if the subject has an increase in naïve T cells and/or a less exhausted phenotype, administering a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) as described herein, such as, e.g., CTL019), thus treating the cancer. In an embodiment, a later time period comprises at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 1 year, at least 2 years, at least 3 years, at least 4 years, at least 5 years, at least 6 years, at least 7 years, at least 8 years, at least 9 years, at least 10 years, or 11 years or more.

In an embodiment, the disclosure provides methods of treating cancer (e.g., a hematological cancer such as ALL or CLL) comprising the steps of (1) identifying partial responders and/or non-responders; and (2) treating with an alternative therapy, e.g., a standard of care for the particular cancer (e.g., the standard of care for ALL or CLL). In an embodiment, a partial responder is treated only with the standard of care (e.g., the standard of care for a hematological cancer such as ALL or CLL) in the absence of treatment with a CAR. In an embodiment, a non-responder is treated only with the standard of care (e.g., the standard of care for a hematological cancer such as ALL or CLL) in the absence of treatment with a CAR.

In an embodiment, standard of care for CLL includes, but is not limited to exemplary therapies described herein, e.g., described in **Table A**, and combinations thereof.

Table A: Exemplary therapies for CLL

First line $\geq$ 70 yrs with comorbidities	w/o del (11q) or del(17p)	del (17p)	del (11q)
Obinutuzumab + chlorambucil	X	X	X
Rituxan + chlorambucil	X		X
Rituxan	X		
Chlorambucil	X		
Fludarabine $\pm$ Rituxan	X	X	
Cladribine	X		
Bendamustine $\pm$ Rituxan	X		X
PCR (pentostatin, cyclophosphamide, Rituxan)	X		X
First Line < 70 years without significant comorbidities			
FCR (Fludarabine, cyclophosphamide, Rituxan)	X	X	X
FR (Fludarabine, Rituxan)	X	X	
PCR	X		X
Bendamustine $\pm$ Rituxan	X		X
Obinutuzumab + chlorambucil	X	X	X
Second line- Relapsed/Refractory $\geq$ 70 years			
Imbruvica	X	X	X
Reduced-dose FCR	X		X
Reduced-dose PCRR	X		X
Bendamustine $\pm$ Rituxan	X		X
Ofatumumab	X	X	X
Alemtuzumab + Rituxan	X	X	X
High dose methylprednisone (HDMP) + rituximab	X	X	X
Lenalidomide + Rituxan	X	X	X
Dose dense rituximab	X		X
Second line- Relapsed/Refractory < years without significant comorbidities			
Imbruvica	X	X	X

FCR (Fludarabine, cyclophosphamide, Rituxan)	X		X
PCR	X		X
Bendamustine ± Rituxan	X		X
Fludarabine + alemtuzumab	X		X
R-CHOP (Rituxan, cyclophosphamide, doxorubicin, vincristine, prednisone)	X	X	X
Ofatumumab	X	X	X
OFAR (oxaliplatin, Fludara, cytarabine, Rituxan)	X	X	X
HDMP + rituximab	X	X	X
Lenalidomide + Rituxan	X	X	X

In an embodiment, standard of care for CLL includes (1) radiation therapy, (2) chemotherapy, (3) surgery (e.g., removal of the spleen), (4) targeted therapy, (5) stem cell transplantation, and combinations thereof. In an embodiment, the standard of care comprises external radiation therapy. In an embodiment, the standard of care comprises internal radiation therapy (e.g., a radioactive substance sealed in needles, wires or catheters, for example, that are placed directly into or near the cancer).

In an embodiment, standard of care for ALL includes, but is not limited to exemplary therapies described herein, e.g., described in **Table B**, and combinations thereof.

10 **Table B: Exemplary therapies for ALL**

First Line
RCHOP (Rituxan, cyclophosphamide, doxorubicin, vincristine, prednisone)
Dose dense RCHOP 14 (category 3)
Dose adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + Rituxan
First Line Therapy for subjects with Poor left ventricular function or very frail
RCEPP (rituximab, cyclophosphamide, etoposide, prednisone, procarbazine)
RCEOP (rituximab, cyclophosphamide, etoposide, vincristine, prednisone)
RCNOP (rituximab, cyclophosphamide, mitoxantrone, vincristine, prednisone)
RCEOP (rituximab, cyclophosphamide, etoposide, vincristine, prednisone)

Dose adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + Rituxan
Second line- proceed to high dose therapy with autologous stem cell rescue
DHAP (dexamethasone, cisplatin, cytarabine) ± Rituxan
ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) ± Rituxan
GDP (gemcitabine, dexamethasone, cisplatin) ± Rituxan
GemOx (gemcitabine, oxaliplatin) ± Rituxan
ICE (ifosfamide, carboplatin, etoposide) + Rituxan
MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± Rituxan
Second-line therapy (non-candidates for high-dose therapy)
CEPP (cyclophosphamide, etoposide, prednisone, procarbazine) ± Rituxan
CEOP (cyclophosphamide, etoposide, vincristine, prednisone) ± Rituxan
DA-EPOCH ± Rituxan
Revlimid ± Rituxan
Rituxan
GemOx ± Rituxan
GDP ± Rituxan
Bendamustine + Rituxan

In an embodiment, standard of care for ALL includes (1) chemotherapy, (2) radiation therapy, (3) stem cell transplantation, (4) biological therapy, (5) targeted therapy, and combinations thereof.

- 5 In an embodiment, the standard of care includes, but is not limited to, fludarabine with cyclophosphamide (FC); fludarabine with rituximab (FR); fludarabine, cyclophosphamide, and rituximab (FCR); cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP); and combinations thereof. General chemotherapeutic agents considered for use include, but are not limited to anastrozole (Arimidex®), bicalutamide (Casodex®), bleomycin sulfate (Blenoxane®),
- 10 busulfan (Myleran®), busulfan injection (Busulfex®), capecitabine (Xeloda®), N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (Paraplatin®), carmustine (BiCNU®), chlorambucil (Leukeran®), cisplatin (Platinol®), cladribine (Leustatin®), cyclophosphamide (Cytosan® or Neosar®), cytarabine, cytosine arabinoside (Cytosar-U®), cytarabine liposome

injection (DepoCyt®), dacarbazine (DTIC-Dome®), dactinomycin (Actinomycin D, Cosmegen),
daunorubicin hydrochloride (Cerubidine®), daunorubicin citrate liposome injection
(DaunoXome®), dexamethasone, docetaxel (Taxotere®), doxorubicin hydrochloride
(Adriamycin®, Rubex®), etoposide (Vepesid®), fludarabine phosphate (Fludara®), 5-
5 fluorouracil (Adrucil®, Efudex®), flutamide (Eulexin®), tezacitibine, Gemcitabine
(difluorodeoxycytidine), hydroxyurea (Hydrea®), Idarubicin (Idamycin®), ifosfamide (IFEX®),
irinotecan (Camptosar®), L-asparaginase (ELSPAR®), leucovorin calcium, melphalan
(Alkeran®), 6-mercaptopurine (Purinethol®), methotrexate (Folex®), mitoxantrone
(Novantrone®), mylotarg, paclitaxel (Taxol®), phoenix (Yttrium90/MX-DTPA), pentostatin,
10 polifeprosan 20 with carmustine implant (Gliadel®), tamoxifen citrate (Nolvadex®), teniposide
(Vumon®), 6-thioguanine, thiotepa, tirapazamine (Tirazone®), topotecan hydrochloride for
injection (Hycamptin®), vinblastine (Velban®), vincristine (Oncovin®), vinorelbine
(Navelbine®), and combinations thereof.

In an embodiment, chemotherapy comprises an antimetabolite, including, but not limited
15 to, folic acid antagonists (also referred to herein as antifolates), pyrimidine analogs, purine
analogues and adenosine deaminase inhibitors): methotrexate (Rheumatrex®, Trexall®), 5-
fluorouracil (Adrucil®, Efudex®, Fluoroplex®), floxuridine (FUDF®), cytarabine (Cytosar-U®,
Tarabine PFS), 6-mercaptopurine (Puri-Nethol®), 6-thioguanine (Thioguanine Tabloid®),
fludarabine phosphate (Fludara®), pentostatin (Nipent®), pemetrexed (Alimta®), raltitrexed
20 (Tomudex®), cladribine (Leustatin®), clofarabine (Clofarex®, Clolar®), cytarabine liposomal
(also known as Liposomal Ara-C, DepoCyt™); decitabine (Dacogen®); hydroxyurea (Hydrea®,
Droxia™ and Mylocel™); mercaptopurine (Puri-Nethol®), pralatrexate (Folotyn™),
capecitabine (Xeloda®), nelarabine (Arranon®), azacitidine (Vidaza®) and gemcitabine
(Gemzar®). Suitable antimetabolites include, e.g., 5-fluorouracil (Adrucil®, Efudex®,
25 Fluoroplex®), floxuridine (FUDF®), capecitabine (Xeloda®), pemetrexed (Alimta®), raltitrexed
(Tomudex®) and gemcitabine (Gemzar®), and combinations thereof. In an embodiment, the
purine analogue is fludarabine.

In an embodiment, chemotherapy comprises an alkylating agent including, but not
limited to nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and
30 triazenes, uracil mustard (Aminouracil Mustard®, Chlorethaminacil®, Demethyldopan®,

Desmethyldopan®, Haemanthamine®, Nordopan®, Uracil nitrogen mustard®, Uracillost®, Uracilmostaza®, Uramustin®, Uramustine®), chlormethine (Mustargen®), cyclophosphamide (Cytoxan®, Neosar®, Clafen®, Endoxan®, Procytox®, Revimmune™), ifosfamide (Mitoxana®), melphalan (Alkeran®), Chlorambucil (Leukeran®), pipobroman (Amedel®, Vercyte®), triethylenemelamine (Hemel®, Hexalen®, Hexastat®), triethylenethiophosphoramine, Temozolomide (Temodar®), thiotepa (Thioplex®), busulfan (Busilvex®, Myleran®), carmustine (BiCNU®), lomustine (CeeNU®), streptozocin (Zanosar®), and Dacarbazine (DTIC-Dome®) and combinations thereof. Additional exemplary alkylating agents include, without limitation, Oxaliplatin (Eloxatin®); Temozolomide (Temodar® and Temodal®); Dactinomycin (also known as actinomycin-D, Cosmegen®); Melphalan (also known as L-PAM, L-sarcosine, and phenylalanine mustard, Alkeran®); Altretamine (also known as hexamethylmelamine (HMM), Hexalen®); Carmustine (BiCNU®); Bendamustine (Treanda®); Busulfan (Busulfex® and Myleran®); Carboplatin (Paraplatin®); Lomustine (also known as CCNU, CeeNU®); Cisplatin (also known as CDDP, Platinol® and Platinol®-AQ); Chlorambucil (Leukeran®); Cyclophosphamide (Cytoxan® and Neosar®); Dacarbazine (also known as DTIC, DIC and imidazole carboxamide, DTIC-Dome®); Altretamine (also known as hexamethylmelamine (HMM), Hexalen®); Ifosfamide (Ifex®); Prednimustine; Procarbazine (Matulane®); Mechlorethamine (also known as nitrogen mustard, mustine and mechlorethamine hydrochloride, Mustargen®); Streptozocin (Zanosar®); Thiotepa (also known as thiophosphoamide, TESP and TSPA, Thioplex®); Cyclophosphamide (Endoxan®, Cytoxan®, Neosar®, Procytox®, Revimmune®); Bendamustine HCl (Treanda®) and combinations thereof. In an embodiment, the alkylating agent is bendamustine. In an embodiment, the alkylating agent is cyclophosphamide.

In an embodiment, the chemotherapeutic agent is a kinase inhibitor, e.g., a tyrosine kinase inhibitor including, but not limited to, erlotinib hydrochloride (Tarceva®); linifanib (N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea, also known as ABT 869, available from Genentech); sunitinib malate (Sutent®); bosutinib (4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, also known as SKI-606, and described in US Patent No. 6,780,996); dasatinib (Sprycel®); pazopanib (Votrient®); sorafenib (Nexavar®); zactima (ZD6474); and imatinib or

imatinib mesylate (Gilevec® and Gleevec®). In one embodiment, the kinase inhibitor is a BTK inhibitor selected from ibrutinib (PCI-32765); GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13. In one embodiment, the kinase inhibitor is a CDK4 inhibitor selected from aloisine A; flavopiridol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3*S*,4*R*)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone; crizotinib (PF-02341066; 2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4*H*-1-benzopyran-4-one, hydrochloride (P276-00); 1-methyl-5-[[2-[5-(trifluoromethyl)-1*H*-imidazol-2-yl]-4-pyridinyl]oxy]-*N*-[4-(trifluoromethyl)phenyl]-1*H*-benzimidazol-2-amine (RAF265); indisulam (E7070); roscovitine (CYC202); palbociclib (PD0332991); dinaciclib (SCH727965); *N*-[5-[[5-*tert*-butyloxazol-2-yl)methyl]thio]thiazol-2-yl]piperidine-4-carboxamide (BMS 387032); 4-[[9-chloro-7-(2,6-difluorophenyl)-5*H*-pyrimido[5,4-*d*][2]benzazepin-2-yl]amino]-benzoic acid (MLN8054); 5-[3-(4,6-difluoro-1*H*-benzimidazol-2-yl)-1*H*-indazol-5-yl]-*N*-ethyl-4-methyl-3-pyridinemethanamine (AG-024322); 4-(2,6-dichlorobenzoylamino)-1*H*-pyrazole-3-carboxylic acid *N*-(piperidin-4-yl)amide (AT7519); 4-[2-methyl-1-(1-methylethyl)-1*H*-imidazol-5-yl]-*N*-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine (AZD5438); and XL281 (BMS908662). In one embodiment, the kinase inhibitor is an MNK inhibitor selected from CGP052088; 4-amino-3-(*p*-fluorophenylamino)-pyrazolo [3,4-*d*] pyrimidine (CGP57380); cercosporamide; ETC-1780445-2; and 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-*d*] pyrimidine.

In an embodiment, targeted therapy includes, but is not limited to an anti-CD20 antibody or functional fragment thereof, such as, e.g., rituximab (Riuxan® and MabThera®); tositumomab (Bexxar®); and ofatumumab (Arzerra®), and combinations thereof. In one embodiment, the targeted therapy includes, but is not limited to, an anti-CD52 antibody or functional fragment thereof such as, e.g., alemtuzumab (Campath®).

In an embodiment, biologic therapy comprises immunotherapy. Exemplary anthracyclines include, without limitation, doxorubicin (Adriamycin® and Rubex®); bleomycin (lenoxane®); daunorubicin (daunorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, Cerubidine®); daunorubicin liposomal (daunorubicin citrate liposome, DaunoXome®); mitoxantrone (DHAD, Novantrone®); epirubicin (Ellence™); idarubicin

(Idamycin®, Idamycin PFS®); mitomycin C (Mutamycin®); geldanamycin; herbimycin; ravidomycin; desacetylavidomycin and combinations thereof.

In an embodiment, stem cell transplantation comprises an autogeneic stem cell transplant. In an embodiment, stem cell transplantation comprises an allogenic stem cell transplant. In an
5 embodiment, stem cell transplantation comprises allogeneic bone marrow transplantation. In an embodiment, stem cell transplantation comprises a hematopoietic stem cell transplantation (HSCT). In an embodiment, hematopoietic stem cells are derived from various tissues including, but not limited to bone marrow, peripheral blood, umbilical cord blood, and combinations thereof.

10 In an embodiment, the provided methods comprise determining if the subject is identified as having a statistically significant difference in expression level of one or more markers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15 and Table 16, or a PD-1 biomarker, LAG-3 biomarker, TIM-3 biomarker, CD57 biomarker CD27
15 biomarker, CD122 biomarker, CD62L biomarker and a KLRG1 biomarker, relative to a reference level, and administering to the subject a therapeutically effective dose of a CAR-expressing cell, e.g., a T cell or NK cell. In an embodiment, a CAR-expressing cell (e.g., T cell, NK cell) is a CD19 CAR-expressing cell (e.g., T cell, NK cell) described herein such as, e.g., CTL019.

20 In one aspect, the disclosure provides methods for treating a disease associated with CD19 expression. In one aspect, the invention provides methods for treating a disease wherein part of the tumor is negative for CD19 and part of the tumor is positive for CD19. For example, provided methods are useful for treating subjects that have undergone treatment for a disease associated with elevated expression of CD19, wherein the subject that has undergone treatment for elevated levels of CD19 exhibits a disease associated with elevated levels of CD19.

25 In one aspect, provided methods comprise a vector comprising CD19 CAR operably linked to promoter for expression in mammalian cells (e.g., T cells or NK cells). In one aspect, provided methods comprise a recombinant cell (e.g., T cell or NK cell) expressing a CD19 CAR for use in treating CD19-expressing tumors, wherein the recombinant T cell expressing the CD19 CAR is termed a CD19 CAR-expressing cell. In one aspect, a CD19 CAR-expressing cell (e.g.,

T cell, NK cell) administered according to provided methods is capable of contacting a tumor cell with at least one CD19 CAR expressed on its surface such that the CAR-expressing cell targets the tumor cell and growth of the tumor is inhibited.

5 In one aspect, the disclosure features to a method of inhibiting growth of a CD19-expressing tumor cell, comprising contacting the tumor cell with a CD19 CAR-expressing cell (e.g., T cell, NK cell) described herein such that the CAR-expressing cell is activated in response to the antigen and targets the cancer cell, wherein the growth of the tumor is inhibited.

10 In one aspect, the disclosure includes a type of cellular therapy where T cells are genetically modified to express a CAR and the CAR-expressing cell (e.g., T cell, NK cell) is infused to a recipient in need thereof. The infused cell is able to kill tumor cells in the recipient. Unlike antibody therapies, CAR-modified cells (e.g., T cells or NK cells) are able to replicate in vivo resulting in long-term persistence that can lead to sustained tumor control. In various aspects, the cells administered to the patient, or their progeny, persist in the patient for at least four months, five months, six months, seven months, eight months, nine months, ten months, 15 eleven months, twelve months, thirteen months, fourteen month, fifteen months, sixteen months, seventeen months, eighteen months, nineteen months, twenty months, twenty-one months, twenty-two months, twenty-three months, two years, three years, four years, or five years after administration of the cell to the patient.

20 The disclosure also includes a type of cellular therapy where cells (e.g., T cells, NK cells) are modified, e.g., by in vitro transcribed RNA, to transiently express a chimeric antigen receptor (CAR) and the CAR-expressing cell (e.g., T cell, NK cell) is infused to a recipient in need thereof. The infused cell is able to kill tumor cells in the recipient. Thus, in various aspects, the cells administered to the patient, are present for less than one month, e.g., three weeks, two weeks, one week, after administration of the cell (e.g., T cell, NK cell) to the patient.

25 Without wishing to be bound by any particular theory, the anti-tumor immunity response elicited by the CAR-modified cells (e.g., T cells, NK cells) may be an active or a passive immune response, or alternatively may be due to a direct vs indirect immune response. In one aspect, the CAR transduced T cells exhibit specific proinflammatory cytokine secretion and potent cytolytic activity in response to human cancer cells expressing the CD19, resist soluble

CD19 inhibition, mediate bystander killing and mediate regression of an established human tumor. For example, antigen-less tumor cells within a heterogeneous field of CD19-expressing tumor may be susceptible to indirect destruction by CD19-redirected T cells that has previously reacted against adjacent antigen-positive cancer cells.

5 In one aspect, the fully-human CAR-modified cells (e.g., T cells, NK cells) described herein may be a type of vaccine for ex vivo immunization and/or in vivo therapy in a mammal. In one aspect, the mammal is a human.

 With respect to ex vivo immunization, at least one of the following occurs in vitro prior to administering the cell into a subject: i) expansion of the cells, ii) introducing a nucleic acid
10 encoding a CAR to the cells or iii) cryopreservation of the cells.

 Ex vivo procedures are well known in the art and are discussed more fully below. Briefly, cells are isolated from a subject (e.g., a human) and genetically modified (i.e., transduced or transfected in vitro) with a vector expressing a CAR disclosed herein. The CAR-modified cell can be administered to a mammalian recipient to provide a therapeutic benefit. The mammalian
15 recipient may be a human and the CAR-modified cell can be autologous with respect to the recipient. Alternatively, the cells can be allogeneic, syngeneic or xenogeneic with respect to the recipient.

Hematologic Cancer

 Hematological cancer conditions are types of cancer such as leukemia and malignant
20 lymphoproliferative conditions that affect blood, bone marrow and the lymphatic system.

 Leukemia can be classified as acute leukemia and chronic leukemia. Acute leukemia can be further classified as acute myelogenous leukemia (AML) and acute lymphoid leukemia (ALL). Chronic leukemia includes chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Other related conditions include myelodysplastic syndromes (MDS, formerly
25 known as “preleukemia”) which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells and risk of transformation to AML.

 Lymphoma is a group of blood cell tumors that develop from lymphocytes. Exemplary lymphomas include non-Hodgkin lymphoma and Hodgkin lymphoma.

The present disclosure provides for compositions and methods for treating cancer. In one aspect, the cancer is a hematologic cancer including but is not limited to a leukemia or a lymphoma. In one aspect, the CAR-expressing cells (e.g., T cells, NK cells) of the invention may be used to treat cancers and malignancies such as, but not limited to, e.g., acute leukemias including but not limited to, e.g., B-cell acute lymphoid leukemia ("B-ALL"), T-cell acute lymphoid leukemia ("T-ALL"), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL); additional hematologic cancers or hematologic conditions including, but not limited to, e.g., B cell promyelocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and "preleukemia" which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. Further a disease associated with CD19 expression includes, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases expressing CD19.

The present disclosure also provides methods for inhibiting the proliferation or reducing a CD19-expressing cell population, the methods comprising contacting a population of cells comprising a CD19-expressing cell with a CD19 CAR-expressing cell (e.g., T cell, NK cell) described herein that binds to the CD19-expressing cell. In a specific aspect, the disclosure provides methods for inhibiting the proliferation or reducing the population of cancer cells expressing CD19, the methods comprising contacting the CD19-expressing cancer cell population with a CD19 CAR-expressing cell (e.g., T cell, NK cell) described herein that binds to the CD19-expressing cell. In one aspect, the present disclosure provides methods for inhibiting the proliferation or reducing the population of cancer cells expressing CD19, the methods comprising contacting the CD19-expressing cancer cell population with a CD19 CAR-expressing cell (e.g., T cell, NK cell) described herein that binds to the CD19-expressing cell. In

certain aspects, the anti-CD19 CAR-expressing cell (e.g., T cell, NK cell) reduces the quantity, number, amount or percentage of cells and/or cancer cells by at least 25%, at least 30%, at least 40%, at least 50%, at least 65%, at least 75%, at least 85%, at least 95%, or at least 99% in a subject with or animal model for myeloid leukemia or another cancer associated with CD19-expressing cells relative to a negative control. In one aspect, the subject is a human.

The present disclosure also provides methods for preventing, treating and/or managing a disease associated with CD19-expressing cells (e.g., a hematologic cancer or atypical cancer expressing CD19), the methods comprising administering to a subject in need a CAR-expressing cell (e.g., T cell, NK cell) described herein that binds to the CD19-expressing cell. In one aspect, the subject is a human. Non-limiting examples of disorders associated with CD19-expressing cells include autoimmune disorders (such as lupus), inflammatory disorders (such as allergies and asthma) and cancers (such as hematological cancers or atypical cancers expressing CD19).

The present disclosure also provides methods for preventing, treating and/or managing a disease associated with CD19-expressing cells, the methods comprising administering to a subject in need a CD19 CAR-expressing cell (e.g., T cell, NK cell) described herein that binds to the CD19-expressing cell. In one aspect, the subject is a human.

The present disclosure provides methods for preventing relapse of cancer associated with CD19-expressing cells (e.g., a hematological cancer such as ALL and CLL), the methods comprising administering to a subject in need thereof a CD19 CAR-expressing cell (e.g., T cell, NK cell) described herein that binds to the CD19-expressing cell. In one aspect, the methods comprise administering to the subject in need thereof an effective amount of a CD19 CAR-expressing cell (e.g., T cell, NK cell) described herein that binds to the CD19-expressing cell in combination with an effective amount of another therapy.

Combination Therapy

It will be appreciated that any cancer therapy as described above and herein, can be administered in combination with one or more additional therapies to treat and/or reduce the symptoms of cancer described herein. The pharmaceutical compositions can be administered concurrently with, prior to, or subsequent to, one or more other additional therapies or

therapeutic agents. In an embodiment, a CAR-expressing cell described herein may be used in combination with other known agents and therapies. Administered “in combination”, as used herein, means that two (or more) different treatments are delivered to the subject during the course of the subject's affliction with the disorder, e.g., the two or more treatments are delivered after the subject has been diagnosed with the disorder and before the disorder has been cured or eliminated or treatment has ceased for other reasons. In some embodiments, the delivery of one treatment is still occurring when the delivery of the second begins, so that there is overlap in terms of administration. This is sometimes referred to herein as “simultaneous” or “concurrent delivery”. In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In some embodiments of either case, the treatment is more effective because of combined administration. For example, the second treatment is more effective, e.g., an equivalent effect is seen with less of the second treatment, or the second treatment reduces symptoms to a greater extent, than would be seen if the second treatment were administered in the absence of the first treatment or the analogous situation is seen with the first treatment. In some embodiments, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment delivered in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive. The delivery can be such that an effect of the first treatment delivered is still detectable when the second is delivered.

A CAR-expressing cell described herein and the at least one additional therapeutic agent can be administered simultaneously, in the same or in separate compositions, or sequentially. For sequential administration, the CAR-expressing cell described herein can be administered first, and the additional agent can be administered second, or the order of administration can be reversed.

The CAR therapy and/or other therapeutic agents, procedures or modalities can be administered during periods of active disorder, or during a period of remission or less active disease. The CAR therapy can be administered before the other treatment, concurrently with the treatment, post-treatment, or during remission of the disorder.

When administered in combination, the CAR therapy and the additional agent (e.g., second or third agent), or all, can be administered in an amount or dose that is higher, lower or

the same than the amount or dosage of each agent used individually, e.g., as a monotherapy. In certain embodiments, the administered amount or dosage of the CAR therapy, the additional agent (e.g., second or third agent), or all, is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50%) than the amount or dosage of each agent used individually, e.g., as a

5 monotherapy. In other embodiments, the amount or dosage of the CAR therapy, the additional agent (e.g., second or third agent), or all, that results in a desired effect (e.g., treatment of cancer) is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50% lower) than the amount or dosage of each agent used individually, e.g., as a monotherapy, required to achieve the same therapeutic effect.

10 In further aspects, a CAR-expressing cell described herein may be used in a treatment regimen in combination with surgery, chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, 15 cytokines, and irradiation peptide vaccine, such as that described in Izumoto et al. 2008 J NEUROSURG 108:963-971.

In one embodiment, a CAR-expressing cell described herein can be used in combination with a chemotherapeutic agent. Exemplary chemotherapeutic agents include those described in paragraphs 873-874 of International Application WO2015/142675, filed March 13, 2015, which 20 is herein incorporated by reference in its entirety, and combinations thereof.

Exemplary alkylating agents include, without limitation, those described in paragraph 875 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety, and combinations thereof.

Exemplary mTOR inhibitors include, without limitation, RAD001, temsirolimus; 25 ridaforolimus (formally known as deferolimus, (1*R*,2*R*,4*S*)-4-[(2*R*)-2 [(1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*, 23*S*,24*E*,26*E*,28*Z*,30*S*,32*S*,35*R*)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23, 29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxo-4-azatricyclo[30.3.1.0^{4,9}] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669, and described in PCT Publication

No. WO 03/064383); everolimus (Afinitor® or RAD001); rapamycin (AY22989, Sirolimus®); simapimod (CAS 164301-51-3); emsirolimus, (5-{2,4-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrido[2,3-*d*]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-Amino-8-[*trans*-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-*d*]pyrimidin-7(8*H*)-one (PF04691502, CAS 1013101-36-4); and *N*²-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4*H*-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L- α -aspartyl-L-serine- (SEQ ID NO: 91), inner salt (SF1126, CAS 936487-67-1), XL765 and combinations thereof.

Exemplary immunomodulators include, without limitation, those described in paragraph 882 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety, and combinations thereof.

Exemplary anthracyclines include, without limitation, those described in paragraph 883 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety, and combinations thereof.

Exemplary vinca alkaloids include, without limitation, those described in paragraph 884 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety, and combinations thereof.

Exemplary proteasome inhibitors include, without limitation, those described in paragraph 884 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety, and combinations thereof.

In some embodiments, a CAR-expressing cell described herein is administered in combination with an oncolytic virus. In embodiments, oncolytic viruses are capable of selectively replicating in and triggering the death of or slowing the growth of a cancer cell. In some cases, oncolytic viruses have no effect or a minimal effect on non-cancer cells. An oncolytic virus includes but is not limited to an oncolytic adenovirus, oncolytic Herpes Simplex Viruses, oncolytic retrovirus, oncolytic parvovirus, oncolytic vaccinia virus, oncolytic Sinbis virus, oncolytic influenza virus, or oncolytic RNA virus (e.g., oncolytic reovirus, oncolytic Newcastle Disease Virus (NDV), oncolytic measles virus, or oncolytic vesicular stomatitis virus (VSV)).

In an embodiment, cells expressing a CAR described herein are administered to a subject in combination with a molecule that decreases the Treg cell population. Methods that decrease the number of (e.g., deplete) Treg cells are known in the art and include, e.g., CD25 depletion, cyclophosphamide administration, modulating GITR function. Without wishing to be bound by
5 theory, it is believed that reducing the number of Treg cells in a subject prior to apheresis or prior to administration of a CAR-expressing cell described herein reduces the number of unwanted immune cells (e.g., Tregs) in the tumor microenvironment and reduces the subject's risk of relapse.

In one embodiment, a CAR expressing cell described herein are administered to a subject
10 in combination with a molecule targeting GITR and/or modulating GITR functions, such as a GITR agonist and/or a GITR antibody that depletes regulatory T cells (Tregs). In embodiments, cells expressing a CAR described herein are administered to a subject in combination with cyclophosphamide. In one embodiment, the GITR binding molecules and/or molecules modulating GITR functions (e.g., GITR agonist and/or Treg depleting GITR antibodies) are
15 administered prior to administration of the CAR-expressing cell. For example, in one embodiment, the GITR agonist can be administered prior to apheresis of the cells. In embodiments, cyclophosphamide is administered to the subject prior to administration (e.g., infusion or re-infusion) of the CAR-expressing cell or prior to apheresis of the cells. In
20 embodiments, cyclophosphamide and an anti-GITR antibody are administered to the subject prior to administration (e.g., infusion or re-infusion) of the CAR-expressing cell or prior to apheresis of the cells. In one embodiment, the subject has cancer (e.g., a solid cancer or a hematological cancer such as ALL or CLL). In an embodiment, the subject has CLL. In
25 embodiments, the subject has ALL. In embodiments, the subject has a solid cancer, e.g., a solid cancer described herein. Exemplary GITR agonists include, without limitation, GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies) such as, e.g., a GITR fusion protein described in U.S. Patent No.: 6,111,090, European Patent No.: 090505B1, U.S. Patent No.: 8,586,023, PCT Publication Nos.: WO 2010/003118 and 2011/090754, or an anti-GITR antibody described, e.g., in U.S. Patent No.: 7,025,962, European Patent No.: 1947183B1, U.S. Patent No.: 7,812,135, U.S. Patent No.: 8,388,967, U.S. Patent No.: 8,591,886, European
30 Patent No.: EP 1866339, PCT Publication No.: WO 2011/028683, PCT Publication No.: WO

2013/039954, PCT Publication No.: WO2005/007190, PCT Publication No.: WO 2007/133822, PCT Publication No.: WO2005/055808, PCT Publication No.: WO 99/40196, PCT Publication No.: WO 2001/03720, PCT Publication No.: WO99/20758, PCT Publication No.: WO2006/083289, PCT Publication No.: WO 2005/115451, U.S. Patent No.: 7,618,632, and PCT
5 Publication No.: WO 2011/051726.

In an embodiment, a CAR expressing cell described herein, such as, e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell), e.g., CTL019, is administered to a subject, e.g., a subject identified as a partial responder or non-responder, in combination with a GITR agonist, e.g., a GITR agonist described herein. In an embodiment, the GITR agonist is administered prior to the
10 CAR-expressing cell. For example, in an embodiment, the GITR agonist can be administered prior to apheresis of the cells. In an embodiment, the subject has cancer (e.g., a hematological cancer such as ALL and CLL). In an embodiment, the subject has ALL. In an embodiment, the subject has CLL.

In an embodiment, a CAR expressing cell described herein, such as, e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell), e.g., CTL019 is administered to a subject, e.g., a subject identified as a partial responder or non-responder, in combination with an mTOR inhibitor, e.g., an mTOR inhibitor described herein, e.g., a target of the rapamycin signaling pathway such as RAD001. In an embodiment, the mTOR inhibitor is administered prior to the CAR-expressing
15 cell. For example, in an embodiment, the mTOR inhibitor can be administered prior to apheresis of the cells. In an embodiment, the subject has cancer (e.g., a hematological cancer such as ALL and CLL). In an embodiment, the subject has ALL. In an embodiment, the subject has CLL.

Kinase Inhibitor

In one embodiment, a CAR-expressing cell described herein may be used in a treatment regimen in combination with a kinase inhibitor, e.g., a CDK4 inhibitor, a BTK inhibitor, an
25 MNK inhibitor, an mTOR inhibitor, an ITK inhibitor, etc. In one embodiment, the subject is a complete responder, and the subject is administered a treatment regimen that includes administration of a CAR-expressing cell described herein in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein, e.g., at a dose or dosing schedule described herein. In one embodiment, the subject is a partial responder or a non-responder, and the subject is

administered a treatment regimen that includes administration of a CAR-expressing cell described herein in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein, e.g., at a dose or dosing schedule described herein.

In an embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g., a CDK4 inhibitor described herein, e.g., a CDK4/6 inhibitor, such as, e.g., 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8*H*-pyrido[2,3-*d*]pyrimidin-7-one, hydrochloride (also referred to as palbociclib or PD0332991). In one embodiment, the kinase inhibitor is a BTK inhibitor, e.g., a BTK inhibitor described herein, such as, e.g., ibrutinib. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., an mTOR inhibitor described herein, such as, e.g., rapamycin, a rapamycin analog, OSI-027. The mTOR inhibitor can be, e.g., an mTORC1 inhibitor and/or an mTORC2 inhibitor, e.g., an mTORC1 inhibitor and/or mTORC2 inhibitor described herein. In one embodiment, the kinase inhibitor is a MNK inhibitor, e.g., a MNK inhibitor described herein, such as, e.g., 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-*d*]pyrimidine. The MNK inhibitor can be, e.g., a MNK1a, MNK1b, MNK2a and/or MNK2b inhibitor.

In one embodiment, the kinase inhibitor is a CDK4 inhibitor selected from aloisine A; flavopiridol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3*S*,4*R*)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone; crizotinib (PF-02341066; 2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4*H*-1-benzopyran-4-one, hydrochloride (P276-00); 1-methyl-5-[[2-[5-(trifluoromethyl)-1*H*-imidazol-2-yl]-4-pyridinyl]oxy]-*N*-[4-(trifluoromethyl)phenyl]-1*H*-benzimidazol-2-amine (RAF265); indisulam (E7070); roscovitine (CYC202); palbociclib (PD0332991); dinaciclib (SCH727965); *N*-[5-[[5-*tert*-butyloxazol-2-yl)methyl]thio]thiazol-2-yl]piperidine-4-carboxamide (BMS 387032); 4-[[9-chloro-7-(2,6-difluorophenyl)-5*H*-pyrimido[5,4-*d*][2]benzazepin-2-yl]amino]-benzoic acid (MLN8054); 5-[3-(4,6-difluoro-1*H*-benzimidazol-2-yl)-1*H*-indazol-5-yl]-*N*-ethyl-4-methyl-3-pyridinemethanamine (AG-024322); 4-(2,6-dichlorobenzoylamino)-1*H*-pyrazole-3-carboxylic acid *N*-(piperidin-4-yl)amide (AT7519); 4-[2-methyl-1-(1-methylethyl)-1*H*-imidazol-5-yl]-*N*-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine (AZD5438); and XL281 (BMS908662).

In one embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g., palbociclib (PD0332991), and the palbociclib is administered at a dose of about 50 mg, 60 mg, 70 mg, 75

mg, 80 mg, 90 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg (e.g., 75 mg, 100 mg or 125 mg) daily for a period of time, e.g., daily for 14-21 days of a 28 day cycle, or daily for 7-12 days of a 21 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of palbociclib are administered.

5 In one embodiment, the kinase inhibitor is a BTK inhibitor selected from ibrutinib (PCI-32765); GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13.

In one embodiment, the kinase inhibitor is a BTK inhibitor, e.g., ibrutinib (PCI-32765), and the ibrutinib is administered at a dose of about 250 mg, 300 mg, 350 mg, 400 mg, 420 mg,
10 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg (e.g., 250 mg, 420 mg or 560 mg) daily for a period of time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of ibrutinib are administered.


In one embodiment, the kinase inhibitor is an mTOR inhibitor selected from
15 temsirolimus; ridaforolimus (1*R*,2*R*,4*S*)-4-[(2*R*)-2 [(1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*,23*S*,24*E*,26*E*,28*Z*,30*S*,32*S*,35*R*)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23, 29,35-hexamethyl-2,3,10,14,20-penta-oxo-11,36-dioxo-4-azatricyclo[30.3.1.0^{4,9}] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669; everolimus (RAD001); rapamycin (AY22989); simapimod; (5-{2,4-
20 bis[(3*S*)-3-methylmorpholin-4-yl]pyrido[2,3-*d*]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-amino-8-[*trans*-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-*d*]pyrimidin-7(8*H*)-one (PF04691502); and *N*²-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4*H*-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L- α -aspartyl-L-serine-, inner salt (SF1126); and XL765.

25 In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., rapamycin, and the rapamycin is administered at a dose of about 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (e.g., 6 mg) daily for a period of time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of rapamycin are administered. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., everolimus

and the everolimus is administered at a dose of about 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg (e.g., 10 mg) daily for a period of time, e.g., daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of everolimus are administered.

- 5 In one embodiment, the kinase inhibitor is an MNK inhibitor selected from CGP052088; 4-amino-3-(p-fluorophenylamino)-pyrazolo [3,4-*d*] pyrimidine (CGP57380); cercosporamide; ETC-1780445-2; and 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-*d*] pyrimidine.

In some embodiments of the methods, uses, and compositions herein, the BTK inhibitor is a BTK inhibitor described in International Application WO/2015/079417, which is herein
 10 incorporated by reference in its entirety. For instance, in some embodiments, the BTK inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof;



wherein,

- 15 R1 is hydrogen, C1-C6 alkyl optionally substituted by hydroxy;

R2 is hydrogen or halogen;

R3 is hydrogen or halogen;

R4 is hydrogen;

R5 is hydrogen or halogen;

- 20 or R4 and R5 are attached to each other and stand for a bond, -CH₂-, -CH₂-CH₂-, -CH=CH-, -CH=CH-CH₂-, -CH₂-CH=CH-, or -CH₂-CH₂-CH₂-;

R6 and R7 stand independently from each other for H, C1-C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;

R8, R9, R, R', R10 and R11 independently from each other stand for H, or C1-C6 alkyl optionally substituted by C1-C6 alkoxy; or any two of R8, R9, R, R', R10 and R11 together with the carbon atom to which they are bound may form a 3 – 6 membered saturated carbocyclic ring;

R12 is hydrogen or C1-C6 alkyl optionally substituted by halogen or C1-C6 alkoxy;

or R12 and any one of R8, R9, R, R', R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C1-C6 alkyl or C1-C6 alkoxy;

n is 0 or 1; and

R13 is C2-C6 alkenyl optionally substituted by C1-C6 alkyl, C1-C6 alkoxy or N,N-di-C1-C6 alkyl amino; C2-C6 alkynyl optionally substituted by C1-C6 alkyl or C1-C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C1-C6 alkyl.

Low, Immune Enhancing, Dose of an mTOR Inhibitor

Methods described herein can use a low, immune enhancing, dose of an mTOR inhibitor e.g., an allosteric mTOR inhibitor, including rapalogs such as RAD001. Administration of a low, immune enhancing, dose of an mTOR inhibitor (e.g., a dose that is insufficient to completely suppress the immune system, but sufficient to improve immune function) can optimize the performance of immune effector cells, e.g., T cells or CAR-expressing cells, in the subject. Methods for measuring mTOR inhibition, dosages, treatment regimens, and suitable pharmaceutical compositions are described in U.S. Patent Application No. 2015/0140036, filed Nov. 13, 2014, hereby incorporated by reference.

In an embodiment, administration of a low, immune enhancing, dose of an mTOR inhibitor can result in one or more of the following:

- i) a decrease in the number of PD-1 positive immune effector cells;
- ii) an increase in the number of PD-1 negative immune effector cells;
- iii) an increase in the ratio of PD-1 negative immune effector cells / PD-1 positive immune effector cells;
- iv) an increase in the number of naive T cells;
- v) an increase in the expression of one or more of the following markers: CD62L^{high}, CD127^{high}, CD27⁺, and BCL2, e.g., on memory T cells, e.g., memory T cell precursors;

vi) a decrease in the expression of KLRG1, e.g., on memory T cells, e.g., memory T cell precursors; or

vii) an increase in the number of memory T cell precursors, e.g., cells with any one or combination of the following characteristics: increased CD62L^{high}, increased CD127^{high},
5 increased CD27⁺, decreased KLRG1, and increased BCL2;

and wherein any of the foregoing, e.g., i), ii), iii), iv), v), vi), or vii), occurs e.g., at least transiently, e.g., as compared to a non-treated subject.

In another embodiment, administration of a low, immune enhancing, dose of an mTOR inhibitor results in increased or prolonged proliferation of CAR-expressing cells, e.g., in culture
10 or in a subject, e.g., as compared to non-treated CAR-expressing cells or a non-treated subject. In embodiments, increased proliferation is associated with in an increase in the number of CAR-expressing cells. In another embodiment, administration of a low, immune enhancing, dose of an mTOR inhibitor results in increased killing of cancer cells by CAR-expressing cells, e.g., in culture or in a subject, e.g., as compared to non-treated CAR-expressing cells or a non-treated
15 subject. In embodiments, increased killing of cancer cells is associated with in a decrease in tumor volume.

In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with a low, immune enhancing dose of an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., RAD001, or a catalytic mTOR
20 inhibitor. For example, administration of the low, immune enhancing, dose of the mTOR inhibitor can be initiated prior to administration of a CAR-expressing cell described herein; completed prior to administration of a CAR-expressing cell described herein; initiated at the same time as administration of a CAR-expressing cell described herein; overlapping with administration of a CAR-expressing cell described herein; or continuing after administration of a
25 CAR-expressing cell described herein.

Alternatively or in addition, administration of a low, immune enhancing, dose of an mTOR inhibitor can optimize immune effector cells to be engineered to express a CAR molecule described herein. In such embodiments, administration of a low, immune enhancing, dose of an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, or a catalytic inhibitor, is initiated or
30 completed prior to harvest of immune effector cells, e.g., T cells or NK cells, to be engineered to express a CAR molecule described herein, from a subject.

In another embodiment, immune effector cells, e.g., T cells or NK cells, to be engineered to express a CAR molecule described herein, e.g., after harvest from a subject, or CAR-expressing immune effector cells, e.g., T cells or NK cells, e.g., prior to administration to a subject, can be cultured in the presence of a low, immune enhancing, dose of an mTOR inhibitor.


5 In an embodiment, administering to the subject a low, immune enhancing, dose of an mTOR inhibitor comprises administering, e.g., once per week, e.g., in an immediate release dosage form, 0.1 to 20, 0.5 to 10, 2.5 to 7.5, 3 to 6, or about 5, mgs of RAD001, or a bioequivalent dose thereof. In an embodiment, administering to the subject a low, immune enhancing, dose of an mTOR inhibitor comprises administering, e.g., once per week, e.g., in a
10 sustained release dosage form, 0.3 to 60, 1.5 to 30, 7.5 to 22.5, 9 to 18, or about 15 mgs of RAD001, or a bioequivalent dose thereof.

In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 5 but no more than 90%, at least 10 but no more than 90%, at least 15, but no more than 90%, at least 20 but no more than 90%, at least 30 but no more than 90%, at least
15 40 but no more than 90%, at least 50 but no more than 90%, at least 60 but no more than 90%, at least 70 but no more than 90%, at least 5 but no more than 80%, at least 10 but no more than 80%, at least 15, but no more than 80%, at least 20 but no more than 80%, at least 30 but no more than 80%, at least 40 but no more than 80%, at least 50 but no more than 80%, at least 60 but no more than 80%, at least 5 but no more than 70%, at least 10 but no more than 70%, at
20 least 15, but no more than 70%, at least 20 but no more than 70%, at least 30 but no more than 70%, at least 40 but no more than 70%, at least 50 but no more than 70%, at least 5 but no more than 60%, at least 10 but no more than 60%, at least 15, but no more than 60%, at least 20 but no more than 60%, at least 30 but no more than 60%, at least 40 but no more than 60%, at least 5 but no more than 50%, at least 10 but no more than 50%, at least 15, but no more than 50%, at
25 least 20 but no more than 50%, at least 30 but no more than 50%, at least 40 but no more than 50%, at least 5 but no more than 40%, at least 10 but no more than 40%, at least 15, but no more than 40%, at least 20 but no more than 40%, at least 30 but no more than 40%, at least 35 but no more than 40%, at least 5 but no more than 30%, at least 10 but no more than 30%, at least 15, but no more than 30%, at least 20 but no more than 30%, or at least 25 but no more than 30%.

5 measuring P70 S6 kinase activity by the Boulay assay, as described in U.S. Patent Application No. 2015/01240036, hereby incorporated by reference, or as described in U.S. Patent No. 7,727,950, hereby incorporated by reference; measuring the level of phosphorylated S6 by western blot; or evaluating a change in the ratio of PD1 negative immune effector cells to PD1 positive immune effector cells.

As used herein, the term “mTOR inhibitor” refers to a compound or ligand, or a pharmaceutically acceptable salt thereof, which inhibits the mTOR kinase in a cell. In an embodiment, an mTOR inhibitor is an allosteric inhibitor. Allosteric mTOR inhibitors include the neutral tricyclic compound rapamycin (sirolimus), rapamycin-related compounds, that is compounds having structural and functional similarity to rapamycin including, e.g., rapamycin derivatives, rapamycin analogs (also referred to as rapalogs) and other macrolide compounds that inhibit mTOR activity. In an embodiment, an mTOR inhibitor is a catalytic inhibitor.

Rapamycin is a known macrolide antibiotic produced by *Streptomyces hygroscopicus* having the structure shown in Formula A.



(A)

See, e.g., McAlpine, J.B., et al., J. Antibiotics (1991) 44: 688; Schreiber, S.L., et al., J. Am. Chem. Soc. (1991) 113: 7433; U.S. Patent No. 3,929,992. There are various numbering schemes proposed for rapamycin. To avoid confusion, when specific rapamycin analogs are
 5 named herein, the names are given with reference to rapamycin using the numbering scheme of formula A.

Rapamycin analogs useful in the invention are, for example, O-substituted analogs in which the hydroxyl group on the cyclohexyl ring of rapamycin is replaced by OR₁ in which R₁ is hydroxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl, or aminoalkyl; e.g. RAD001, also known as,
 10 everolimus as described in US 5,665,772 and WO94/09010 the contents of which are incorporated by reference. Other suitable rapamycin analogs include those substituted at the 26- or 28-position. The rapamycin analog may be an epimer of an analog mentioned above, particularly an epimer of an analog substituted in position 40, 28 or 26, and may optionally be further hydrogenated, e.g. as described in US 6,015,815, WO95/14023 and WO99/15530 the
 15 contents of which are incorporated by reference, e.g. ABT578 also known as zotarolimus or a rapamycin analog described in US 7,091,213, WO98/02441 and WO01/14387 the contents of which are incorporated by reference, e.g. AP23573 also known as ridaforolimus.

Examples of rapamycin analogs suitable for use in the present invention from US 5,665,772 include, but are not limited to, 40-O-benzyl-rapamycin, 40-O-(4'-
 20 hydroxymethyl)benzyl-rapamycin, 40-O-[4'-(1,2-dihydroxyethyl)]benzyl-rapamycin, 40-O-allyl-rapamycin, 40-O-[3'-(2,2-dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin, (2'E,4'S)-40-O-(4',5'-dihydroxypent-2'-en-1'-yl)-rapamycin, 40-O-(2-hydroxy)ethoxycarbonylmethyl-rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-(6-hydroxy)hexyl-rapamycin, 40-O-[2-(2-
 25 hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3S)-2,2-dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-dihydroxyprop-1-yl]-rapamycin, 40-O-(2-acetoxy)ethyl-rapamycin, 40-O-(2-nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-methyl-N'-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-dihydro-40-O-(2-
 30 hydroxy)ethyl-rapamycin, 40-O-(2-aminoethyl)-rapamycin, 40-O-(2-acetaminoethyl)-rapamycin, 40-O-(2-nicotinamidoethyl)-rapamycin, 40-O-(2-(N-methyl-imidazo-2'-

ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-tolylsulfonamidoethyl)-rapamycin and 40-O-[2-(4',5'-dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin.

Other rapamycin analogs useful in the present invention are analogs where the hydroxyl group on the cyclohexyl ring of rapamycin and/or the hydroxy group at the 28 position is replaced with an hydroxyester group are known, for example, rapamycin analogs found in US RE44,768, e.g. temsirolimus.

Other rapamycin analogs useful in the present invention include those wherein the methoxy group at the 16 position is replaced with another substituent, preferably (optionally hydroxy-substituted) alkynyloxy, benzyl, orthomethoxybenzyl or chlorobenzyl and/or wherein the methoxy group at the 39 position is deleted together with the 39 carbon so that the cyclohexyl ring of rapamycin becomes a cyclopentyl ring lacking the 39 position methoxy group; e.g. as described in WO95/16691 and WO96/41807 the contents of which are incorporated by reference. The analogs can be further modified such that the hydroxy at the 40-position of rapamycin is alkylated and/or the 32-carbonyl is reduced.

Rapamycin analogs from WO95/16691 include, but are not limited to, 16-demethoxy-16-(pent-2-ynyl)oxy-rapamycin, 16-demethoxy-16-(but-2-ynyl)oxy-rapamycin, 16-demethoxy-16-(propargyl)oxy-rapamycin, 16-demethoxy-16-(4-hydroxy-but-2-ynyl)oxy-rapamycin, 16-demethoxy-16-benzyloxy-40-O-(2-hydroxyethyl)-rapamycin, 16-demethoxy-16-benzyloxy-rapamycin, 16-demethoxy-16-ortho-methoxybenzyl-rapamycin, 16-demethoxy-40-O-(2-methoxyethyl)-16-pent-2-ynyl)oxy-rapamycin, 39-demethoxy-40-desoxy-39-formyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-hydroxymethyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-carboxy-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-(4-methyl-piperazin-1-yl)carbonyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-(morpholin-4-yl)carbonyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-[N-methyl, N-(2-pyridin-2-yl-ethyl)]carbamoyl-42-nor-rapamycin and 39-demethoxy-40-desoxy-39-(p-toluenesulfonylhydrazonomethyl)-42-nor-rapamycin.

Rapamycin analogs from WO96/41807 include, but are not limited to, 32-deoxo-rapamycin, 16-O-pent-2-ynyl-32-deoxo-rapamycin, 16-O-pent-2-ynyl-32-deoxo-40-O-(2-hydroxy-ethyl)-rapamycin, 16-O-pent-2-ynyl-32-(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin,

32(S)-dihydro-40-O-(2-methoxy)ethyl-rapamycin and 32(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin.

Another suitable rapamycin analog is umirolimus as described in US2005/0101624 the contents of which are incorporated by reference.

5 RAD001, otherwise known as everolimus (Afinitor®), has the chemical name (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxo-4-aza-tricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone

10 Further examples of allosteric mTOR inhibitors include sirolimus (rapamycin, AY-22989), 40-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin (also called temsirolimus or CCI-779) and ridaforolimus (AP-23573/MK-8669). Other examples of allosteric mTor inhibitors include zotarolimus (ABT578) and umirolimus.

15 Alternatively or additionally, catalytic, ATP-competitive mTOR inhibitors have been found to target the mTOR kinase domain directly and target both mTORC1 and mTORC2. These are also more effective inhibitors of mTORC1 than such allosteric mTOR inhibitors as rapamycin, because they modulate rapamycin-resistant mTORC1 outputs such as 4EBP1-T37/46 phosphorylation and cap-dependent translation.

Catalytic inhibitors include: BEZ235 or 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl)-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-phenyl]-propionitrile, or the monotosylate salt form. the synthesis of BEZ235 is described in WO2006/122806; CCG168 (otherwise known as AZD-8055, Chresta, C.M., et al., Cancer Res, 2010, 70(1), 288-298) which has the chemical name {5-[2,4-bis-((S)-3-methyl-morpholin-4-yl)-pyrido[2,3d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide (WO09104019); 3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (WO10051043 and WO2013023184); A N-(3-(N-(3-((3,5-dimethoxyphenyl)amino)quinoxaline-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide (WO07044729 and WO12006552); PKI-587 (Venkatesan, A.M., J. Med.Chem., 2010, 53, 2636-2645) which has the chemical name 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl]urea; GSK-2126458 (ACS Med. Chem. Lett., 2010, 1, 39-43) which has the chemical name 2,4-difluoro-N-{2-methoxy-5-[4-(4-pyridazinyl)-6-

quinolinyl]-3-pyridinyl}benzenesulfonamide;; 5-(9-isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine (WO10114484); (E)-N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide (WO12007926).

5 Further examples of catalytic mTOR inhibitors include 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one (WO2006/122806) and Ku-0063794 (Garcia-Martinez JM, et al., *Biochem J.*, 2009, 421(1), 29-42.. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).) WYE-354 is another example of a catalytic mTor inhibitor (Yu K, et al. (2009). *Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin.* *Cancer Res.* 69(15): 6232-6240).

mTOR inhibitors useful according to the present invention also include prodrugs, derivatives, pharmaceutically acceptable salts, or analogs thereof of any of the foregoing.

mTOR inhibitors, such as RAD001, may be formulated for delivery based on well-
15 established methods in the art based on the particular dosages described herein. In particular, US Patent 6,004,973 (incorporated herein by reference) provides examples of formulations useable with the mTOR inhibitors described herein.

Inhibitory Molecule Inhibitors/Checkpoint Inhibitors

20 In one embodiment, the subject can be administered an agent which enhances the activity of a CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits a checkpoint molecule. Checkpoint molecules, e.g., Programmed Death 1 (PD1), can, in some embodiments, decrease the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules, e.g., checkpoint molecules include PD1, PD-L1,
25 PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFRbeta). In embodiments, the CAR-expressing cell described herein comprises a switch costimulatory receptor, e.g., as described in WO 2013/019615, which is incorporated
30 herein by reference in its entirety.

The methods described herein can include administration of a CAR-expressing cell in combination with a checkpoint inhibitor. In one embodiment, the subject is a complete responder. In another embodiment, the subject is a partial responder or non-responder, and, e.g., in some embodiments, the checkpoint inhibitor is administered prior to the CAR-expressing cell, e.g., two weeks, 12 days, 10 days, 8 days, one week, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day before administration of the CAR-expressing cell. In some embodiments, the checkpoint inhibitor is administered concurrently with the CAR-expressing cell.

Inhibition of a checkpoint molecule, e.g., by inhibition at the DNA, RNA or protein level, can optimize a CAR-expressing cell performance. In embodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., a siRNA or shRNA, a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription-activator like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN), e.g., as described herein, can be used to inhibit expression of a checkpoint molecule in the CAR-expressing cell. In an embodiment, the inhibitor is a shRNA. In an embodiment, the checkpoint molecule is inhibited within a CAR-expressing cell. In these embodiments, a dsRNA molecule that inhibits expression of the checkpoint molecule is linked to the nucleic acid that encodes a component, e.g., all of the components, of the CAR.

In one embodiment, the inhibitor of an inhibitory signal can be, e.g., an antibody or antibody fragment that binds to a checkpoint molecule. For example, the agent can be an antibody or antibody fragment that binds to PD1, PD-L1, PD-L2 or CTLA4 (e.g., ipilimumab (also referred to as MDX-010 and MDX-101, and marketed as Yervoy®; Bristol-Myers Squibb; Tremelimumab (IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206). In an embodiment, the agent is an antibody or antibody fragment that binds to TIM3. In an embodiment, the agent is an antibody or antibody fragment that binds to LAG3. In an embodiment, the agent is an antibody or antibody fragment that binds to CEACAM.

PD1 is an inhibitory member of the CD28 family of receptors that also includes CD28, CTLA-4, ICOS, and BTLA. PD1 is expressed on activated B cells, T cells and myeloid cells (Agata et al. 1996 INT. IMMUNOL 8:765-75). Two ligands for PD1, PD-L1 and PD-L2 have been shown to downregulate T cell activation upon binding to PD1 (Freeman et al. 2000 J Exp Med

192:1027-34; Latchman et al. 2001 NAT IMMUNOL 2:261-8; Carter et al. 2002 EUR J IMMUNOL 32:634-43). PD-L1 is abundant in human cancers (Dong et al. 2003 J MOL MED 81:281-7; Blank et al. 2005 CANCER IMMUNOL. IMMUNOTHER. 54:307-314; Konishi et al. 2004 CLIN CANCER RES 10:5094). Immune suppression can be reversed by inhibiting the local interaction of PD1 with PD-L1.

Antibodies, antibody fragments, and other inhibitors of PD1, PD-L1 and PD-L2 are available in the art and may be used combination with a CAR described herein, e.g., a CD19 CAR described herein. For example, nivolumab (also referred to as BMS-936558 or MDX1106; Bristol-Myers Squibb) is a fully human IgG4 monoclonal antibody which specifically blocks PD1. Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD1 are disclosed in US 8,008,449 and WO2006/121168. Pidilizumab (CT-011; Cure Tech) is a humanized IgG1k monoclonal antibody that binds to PD1. Pidilizumab and other humanized anti-PD1 monoclonal antibodies are disclosed in WO2009/101611. Lambrolizumab (also referred to as MK03475; Merck) is a humanized IgG4 monoclonal antibody that binds to PD1.

Lambrolizumab and other humanized anti-PD1 antibodies are disclosed in US 8,354,509 and WO2009/114335. MDPL3280A (Genentech / Roche) is a human Fc optimized IgG1 monoclonal antibody that binds to PD-L1. MDPL3280A and other human monoclonal antibodies to PD-L1 are disclosed in U.S. Patent No.: 7,943,743 and U.S Publication No.: 20120039906. Other anti-PD-L1 binding agents include YW243.55.S70 (heavy and light chain variable regions are shown in SEQ ID NOs 20 and 21 in WO2010/077634) and MDX-1 105 (also referred to as BMS-936559, and, e.g., anti-PD-L1 binding agents disclosed in WO2007/005874). AMP-224 (B7-DCIg; Amplimmune; e.g., disclosed in WO2010/027827 and WO2011/066342), is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD1 and B7-H1. Other anti-PD1 antibodies include AMP 514 (Amplimmune), among others, e.g., anti-PD1 antibodies disclosed in US 8,609,089, US 2010028330, and/or US 20120114649.

In one embodiment, the anti-PD-1 antibody or fragment thereof is an anti-PD-1 antibody molecule as described in US 2015/0210769, entitled "Antibody Molecules to PD-1 and Uses Thereof," incorporated by reference in its entirety. In one embodiment, the anti-PD-1 antibody molecule includes at least one, two, three, four, five or six CDRs (or collectively all of the CDRs) from a heavy and light chain variable region from an antibody chosen from any of

BAP049-hum01, BAP049-hum02, BAP049-hum03, BAP049-hum04, BAP049-hum05, BAP049-hum06, BAP049-hum07, BAP049-hum08, BAP049-hum09, BAP049-hum10, BAP049-hum11, BAP049-hum12, BAP049-hum13, BAP049-hum14, BAP049-hum15, BAP049-hum16, BAP049-Clone-A, BAP049-Clone-B, BAP049-Clone-C, BAP049-Clone-D, or
 5 BAP049-Clone-E; or as described in Table 1 of US 2015/0210769, or encoded by the nucleotide sequence in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences; or closely related CDRs, e.g., CDRs which are identical or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g.,
 10 conservative substitutions).

In yet another embodiment, the anti-PD-1 antibody molecule comprises at least one, two, three or four variable regions from an antibody described herein, e.g., an antibody chosen from any of BAP049-hum01, BAP049-hum02, BAP049-hum03, BAP049-hum04, BAP049-hum05, BAP049-hum06, BAP049-hum07, BAP049-hum08, BAP049-hum09, BAP049-hum10,
 15 BAP049-hum11, BAP049-hum12, BAP049-hum13, BAP049-hum14, BAP049-hum15, BAP049-hum16, BAP049-Clone-A, BAP049-Clone-B, BAP049-Clone-C, BAP049-Clone-D, or BAP049-Clone-E; or as described in Table 1 of US 2015/0210769, or encoded by the nucleotide sequence in Table 1; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences.

TIM3 (T cell immunoglobulin-3) also negatively regulates T cell function, particularly in IFN-g-secreting CD4⁺ T helper 1 and CD8⁺ T cytotoxic 1 cells, and plays a critical role in T cell exhaustion. Inhibition of the interaction between TIM3 and its ligands, e.g., galectin-9 (Gal9), phosphatidylserine (PS), and HMGB1, can increase immune response. Antibodies, antibody fragments, and other inhibitors of TIM3 and its ligands are available in the art and may be used
 25 combination with a CD19 CAR described herein. For example, antibodies, antibody fragments, small molecules, or peptide inhibitors that target TIM3 binds to the IgV domain of TIM3 to inhibit interaction with its ligands. Antibodies and peptides that inhibit TIM3 are disclosed in WO2013/006490 and US20100247521. Other anti-TIM3 antibodies include humanized versions of RMT3-23 (disclosed in Ngiow et al., 2011, Cancer Res, 71:3540-3551), and clone 8B.2C12

(disclosed in Monney et al., 2002, Nature, 415:536-541). Bi-specific antibodies that inhibit TIM3 and PD-1 are disclosed in US20130156774.

In one embodiment, the anti-TIM3 antibody or fragment thereof is an anti- TIM3 antibody molecule as described in US 2015/0218274, entitled “Antibody Molecules to TIM3 and
5 Uses Thereof,” incorporated by reference in its entirety. In one embodiment, the anti- TIM3 antibody molecule includes at least one, two, three, four, five or six CDRs (or collectively all of the CDRs) from a heavy and light chain variable region from an antibody chosen from any of ABTIM3, ABTIM3-hum01, ABTIM3-hum02, ABTIM3-hum03, ABTIM3-hum04, ABTIM3-hum05, ABTIM3-hum06, ABTIM3-hum07, ABTIM3-hum08, ABTIM3-hum09, ABTIM3-
10 hum10, ABTIM3-hum11, ABTIM3-hum12, ABTIM3-hum13, ABTIM3-hum14, ABTIM3-hum15, ABTIM3-hum16, ABTIM3-hum17, ABTIM3-hum18, ABTIM3-hum19, ABTIM3-hum20, ABTIM3-hum21, ABTIM3-hum22, ABTIM3-hum23; or as described in Tables 1-4 of US 2015/0218274; or encoded by the nucleotide sequence in Tables 1-4; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher
15 identical) to any of the aforesaid sequences, or closely related CDRs, e.g., CDRs which are identical or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions).

In yet another embodiment, the anti- TIM3 antibody molecule comprises at least one, two, three or four variable regions from an antibody described herein, e.g., an antibody chosen
20 from any of ABTIM3, ABTIM3-hum01, ABTIM3-hum02, ABTIM3-hum03, ABTIM3-hum04, ABTIM3-hum05, ABTIM3-hum06, ABTIM3-hum07, ABTIM3-hum08, ABTIM3-hum09, ABTIM3-hum10, ABTIM3-hum11, ABTIM3-hum12, ABTIM3-hum13, ABTIM3-hum14, ABTIM3-hum15, ABTIM3-hum16, ABTIM3-hum17, ABTIM3-hum18, ABTIM3-hum19, ABTIM3-hum20, ABTIM3-hum21, ABTIM3-hum22, ABTIM3-hum23; or as described in
25 Tables 1-4 of US 2015/0218274; or encoded by the nucleotide sequence in Tables 1-4; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences.

In other embodiments, the agent which enhances the activity of a CAR-expressing cell is a CEACAM inhibitor (e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5 inhibitor). In one
30 embodiment, the inhibitor of CEACAM is an anti-CEACAM antibody molecule. Exemplary

anti-CEACAM-1 antibodies are described in WO 2010/125571, WO 2013/082366 WO 2014/059251 and WO 2014/022332, *e.g.*, a monoclonal antibody 34B1, 26H7, and 5F4; or a recombinant form thereof, as described in, *e.g.*, US 2004/0047858, US 7,132,255 and WO 99/052552. In other embodiments, the anti-CEACAM antibody binds to CEACAM-5 as described in, *e.g.*, Zheng et al. *PLoS One*. 2010 Sep 2;5(9). pii: e12529 (DOI:10.1371/journal.pone.0021146), or crossreacts with CEACAM-1 and CEACAM-5 as described in, *e.g.*, WO 2013/054331 and US 2014/0271618.

Without wishing to be bound by theory, carcinoembryonic antigen cell adhesion molecules (CEACAM), such as CEACAM-1 and CEACAM-5, are believed to mediate, at least in part, inhibition of an anti-tumor immune response (*see e.g.*, Markel et al. *J Immunol*. 2002 Mar 15;168(6):2803-10; Markel et al. *J Immunol*. 2006 Nov 1;177(9):6062-71; Markel et al. *Immunology*. 2009 Feb;126(2):186-200; Markel et al. *Cancer Immunol Immunother*. 2010 Feb;59(2):215-30; Ortenberg et al. *Mol Cancer Ther*. 2012 Jun;11(6):1300-10; Stern et al. *J Immunol*. 2005 Jun 1;174(11):6692-701; Zheng et al. *PLoS One*. 2010 Sep 2;5(9). pii: e12529).

For example, CEACAM-1 has been described as a heterophilic ligand for TIM-3 and as playing a role in TIM-3-mediated T cell tolerance and exhaustion (*see e.g.*, WO 2014/022332; Huang, et al. (2014) *Nature* doi:10.1038/nature13848). In embodiments, co-blockade of CEACAM-1 and TIM-3 has been shown to enhance an anti-tumor immune response in xenograft colorectal cancer models (*see e.g.*, WO 2014/022332; Huang, et al. (2014), *supra*). In other embodiments, co-blockade of CEACAM-1 and PD-1 reduce T cell tolerance as described, *e.g.*, in WO 2014/059251. Thus, CEACAM inhibitors can be used with the other immunomodulators described herein (*e.g.*, anti-PD-1 and/or anti-TIM-3 inhibitors) to enhance an immune response against a cancer, *e.g.*, a melanoma, a lung cancer (*e.g.*, NSCLC), a bladder cancer, a colon cancer an ovarian cancer, and other cancers as described herein.

LAG3 (lymphocyte activation gene-3 or CD223) is a cell surface molecule expressed on activated T cells and B cells that has been shown to play a role in CD8+ T cell exhaustion. Antibodies, antibody fragments, and other inhibitors of LAG3 and its ligands are available in the art and may be used combination with a CD19 CAR described herein. For example, BMS-986016 (Bristol-Myers Squibb) is a monoclonal antibody that targets LAG3. IMP701 (Immutep) is an antagonist LAG3 antibody and IMP731 (Immutep and GlaxoSmithKline) is a depleting

LAG3 antibody. Other LAG3 inhibitors include IMP321 (Immutep), which is a recombinant fusion protein of a soluble portion of LAG3 and Ig that binds to MHC class II molecules and activates antigen presenting cells (APC). Other antibodies are disclosed, e.g., in WO2010/019570.

5 In some embodiments, the agent which enhances the activity of a CAR-expressing cell can be, e.g., a fusion protein comprising a first domain and a second domain, wherein the first domain is a checkpoint molecule, or fragment thereof, and the second domain is a polypeptide that is associated with a positive signal, e.g., a polypeptide comprising an intracellular signaling domain as described herein (also referred to herein as an inhibitory CAR or iCAR). In some
10 embodiments, the polypeptide that is associated with a positive signal can include a costimulatory domain of CD28, CD27, ICOS, e.g., an intracellular signaling domain of CD28, CD27 and/or ICOS, and/or a primary signaling domain, e.g., of CD3 zeta, e.g., described herein. In one embodiment, the fusion protein is expressed by the same cell that expressed the CAR. In another embodiment, the fusion protein is expressed by a cell, e.g., a T cell that does not express
15 a CAR, e.g., a CD19 CAR.

In one embodiment, the extracellular domain (ECD) of a checkpoint molecule, e.g., a checkpoint molecule described herein such as, e.g., Programmed Death 1 (PD1), can be fused to a transmembrane domain and intracellular signaling domain described herein, e.g., an intracellular signaling domain comprising a costimulatory signaling domain such as, e.g., 41BB OX40, Cd28,
20 CD27, and/or a primary signaling domain, e.g., of CD3 zeta. In one embodiment, the inhibitory CAR, e.g., e.g., PD1 CAR, can be used in combination with another CAR, e.g., CD19CAR (e.g., a CD19RCAR). In one embodiment, the PD1 RCAR (or PD1 CAR) improves the persistence of the T cell. Examples of inhibitory molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT,
25 LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFRbeta). In one embodiment, the inhibitory molecule CAR comprises a first polypeptide, e.g., of an inhibitory molecule such as PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160,
30 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR,

A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFRbeta), or a fragment of any of these (e.g., at least a portion of an extracellular domain of any of these), and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27 or CD28, e.g., as described herein) and/or a primary
5 signaling domain (e.g., a CD3 zeta signaling domain described herein).

In one embodiment, the inhibitory molecule CAR comprises the extracellular domain (ECD) of PD1 fused to a transmembrane domain and intracellular signaling domains such as 41BB and CD3 zeta (also referred to herein as a PD1 CAR). In one embodiment, the PD1 CAR improves the persistence of the cell CAR-expressing cell. In one embodiment, the PD1 CAR
10 comprises the extracellular domain of PD1 indicated in SEQ ID NO: 44. In one embodiment, the PD1 CAR comprises, the amino acid sequence of SEQ ID NO:40.

In one embodiment, the PD1 CAR comprises the amino acid sequence provided as SEQ ID NO: 41.

In one embodiment, the PD1 CAR, e.g., the PD1 CAR described herein, is encoded by a
15 nucleic acid sequence provided as SEQ ID NO: 42, or at least the comprises the nucleic acid sequence encoding the extracellular domain of PD1 (provided as SEQ ID NO: 101).

In embodiments, the inhibitory extracellular domain, has at least 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identity with, or differs by no more than 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 amino acid residues from the corresponding residues of a naturally occurring human inhibitory
20 molecule, e.g., a naturally occurring human primary stimulatory molecule disclosed herein.

In an embodiment, a nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is operably linked to a promoter, e.g., a H1- or a U6-derived promoter such that the dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is
25 expressed, e.g., is expressed within a CAR-expressing cell. See e.g., Tiscornia G., "Development of Lentiviral Vectors Expressing siRNA," Chapter 3, in *Gene Transfer: Delivery and Expression of DNA and RNA* (eds. Friedmann and Rossi). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2007; Brummelkamp TR, *et al.* (2002) *Science* 296: 550–553; Miyagishi M, *et al.* (2002) *Nat. Biotechnol.* 19: 497–500. In an embodiment the nucleic
30 acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that

modulates or regulates, e.g., inhibits, T-cell function is present on the same vector, e.g., a lentiviral vector, that comprises a nucleic acid molecule that encodes a component, e.g., all of the components, of the CAR. In such an embodiment, the nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is located on the vector, e.g., the lentiviral vector, 5' - or 3' - to the nucleic acid that encodes a component, e.g., all of the components, of the CAR. The nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function can be transcribed in the same or different direction as the nucleic acid that encodes a component, e.g., all of the components, of the CAR.

In an embodiment the nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is present on a vector other than the vector that comprises a nucleic acid molecule that encodes a component, e.g., all of the components, of the CAR. In an embodiment, the nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is transiently expressed within a CAR-expressing cell. In an embodiment, the nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is stably integrated into the genome of a CAR-expressing cell. In an embodiment, the molecule that modulates or regulates, e.g., inhibits, T-cell function is PD-1.

In embodiments, the agent that enhances the activity of a CAR-expressing cell, e.g., inhibitor of an inhibitory molecule, is administered in combination with an allogeneic CAR, e.g., an allogeneic CAR described herein (e.g., described in the Allogeneic CAR section herein).

Natural Killer Cell Receptor (NKR) CARs

In an embodiment, the CAR molecule described herein comprises one or more components of a natural killer cell receptor (NKR), thereby forming an NKR-CAR. The NKR component can be a transmembrane domain, a hinge domain, or a cytoplasmic domain from any of the following natural killer cell receptors: killer cell immunoglobulin-like receptor (KIR), e.g., KIR2DL1, KIR2DL2/L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3,

KIR2DS4, DIR2DS5, KIR3DL1/S1, KIR3DL2, KIR3DL3, KIR2DP1, and KIR3DP1; natural cytotoxicity receptor (NCR), e.g., NKp30, NKp44, NKp46; signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, e.g., CD48, CD229, 2B4, CD84, NTB-A, CRACC, BLAME, and CD2F-10; Fc receptor (FcR), e.g., CD16, and CD64; and Ly49 receptors, e.g., LY49A, LY49C. The NKR-CAR molecules described herein may interact with an adaptor molecule or intracellular signaling domain, e.g., DAP12. Exemplary configurations and sequences of CAR molecules comprising NKR components are described in International Publication No. WO2014/145252, the contents of which are hereby incorporated by reference.

10 Split CAR

In some embodiments, the CAR-expressing cell uses a split CAR. The split CAR approach is described in more detail in publications WO2014/055442 and WO2014/055657, incorporated herein by reference. Briefly, a split CAR system comprises a cell expressing a first CAR having a first antigen binding domain and a costimulatory domain (e.g., 41BB), and the cell also expresses a second CAR having a second antigen binding domain and an intracellular signaling domain (e.g., CD3 zeta). When the cell encounters the first antigen, the costimulatory domain is activated, and the cell proliferates. When the cell encounters the second antigen, the intracellular signaling domain is activated and cell-killing activity begins. Thus, the CAR-expressing cell is only fully activated in the presence of both antigens.

20

Strategies for Regulating Chimeric Antigen Receptors

There are many ways CAR activities can be regulated. In some embodiments, a regulatable CAR (RCAR) where the CAR activity can be controlled is desirable to optimize the safety and efficacy of a CAR therapy. There are many ways CAR activities can be regulated. For example, inducible apoptosis using, e.g., a caspase fused to a dimerization domain (see, e.g., Di Stasa et al., N Engl. J. Med. 2011 Nov. 3; 365(18):1673-1683), can be used as a safety switch in the CAR therapy of the instant invention. In one embodiment, the cells (e.g., T cells or NK cells) expressing a CAR of the present invention further comprise an inducible apoptosis switch, wherein a human caspase (e.g., caspase 9) or a modified version is fused to a modification of the

human FKB protein that allows conditional dimerization. In the presence of a small molecule, such as a rapalog (e.g., AP 1903, AP20187), the inducible caspase (e.g., caspase 9) is activated and leads to the rapid apoptosis and death of the cells (e.g., T cells or NK cells) expressing a CAR of the present invention. Examples of a caspase-based inducible apoptosis switch (or one or more aspects of such a switch) have been described in, e.g., US2004040047; US20110286980; US20140255360; WO1997031899; WO2014151960; WO2014164348; WO2014197638; WO2014197638; all of which are incorporated by reference herein.

In another example, CAR-expressing cells can also express an inducible Caspase-9 (iCaspase-9) molecule that, upon administration of a dimerizer drug (e.g., rimiducid (also called AP1903 (Bellicum Pharmaceuticals) or AP20187 (Ariad)) leads to activation of the Caspase-9 and apoptosis of the cells. The iCaspase-9 molecule contains a chemical inducer of dimerization (CID) binding domain that mediates dimerization in the presence of a CID. This results in inducible and selective depletion of CAR-expressing cells. In some cases, the iCaspase-9 molecule is encoded by a nucleic acid molecule separate from the CAR-encoding vector(s). In some cases, the iCaspase-9 molecule is encoded by the same nucleic acid molecule as the CAR-encoding vector. The iCaspase-9 can provide a safety switch to avoid any toxicity of CAR-expressing cells. See, e.g., Song et al. Cancer Gene Ther. 2008; 15(10):667-75; Clinical Trial Id. No. NCT02107963; and Di Stasi et al. N. Engl. J. Med. 2011; 365:1673-83.

Alternative strategies for regulating the CAR therapy of the instant invention include utilizing small molecules or antibodies that deactivate or turn off CAR activity, e.g., by deleting CAR-expressing cells, e.g., by inducing antibody dependent cell-mediated cytotoxicity (ADCC). For example, CAR-expressing cells described herein may also express an antigen that is recognized by molecules capable of inducing cell death, e.g., ADCC or complement-induced cell death. For example, CAR expressing cells described herein may also express a receptor capable of being targeted by an antibody or antibody fragment. Examples of such receptors include EpCAM, VEGFR, integrins (e.g., integrins $\alpha\beta3$, $\alpha4$, $\alpha\beta4\beta3$, $\alpha4\beta7$, $\alpha5\beta1$, $\alpha\beta3$, αv), members of the TNF receptor superfamily (e.g., TRAIL-R1, TRAIL-R2), PDGF Receptor, interferon receptor, folate receptor, GPNMB, ICAM-1, HLA-DR, CEA, CA-125, MUC1, TAG-72, IL-6 receptor, 5T4, GD2, GD3, CD2, CD3, CD4, CD5, CD11a, CD11a/LFA-1, CD15, CD18/ITGB2, CD19, CD20, CD22, CD23/IgE Receptor, CD25, CD28, CD30, CD33, CD38,

CD40, CD41, CD44, CD51, CD52, CD62L, CD74, CD80, CD125, CD147/basigin, CD152/CTLA-4, CD154/CD40L, CD195/CCR5, CD319/SLAMF7, and EGFR, and truncated versions thereof (e.g., versions preserving one or more extracellular epitopes but lacking one or more regions within the cytoplasmic domain).

5 For example, a CAR-expressing cell described herein may also express a truncated epidermal growth factor receptor (EGFR) which lacks signaling capacity but retains the epitope that is recognized by molecules capable of inducing ADCC, e.g., cetuximab (ERBITUX®), such that administration of cetuximab induces ADCC and subsequent depletion of the CAR-expressing cells (see, e.g., WO2011/056894, and Jonnalagadda et al., Gene Ther. 2013; 20(8)853-860). Another strategy includes expressing a highly compact marker/suicide gene that
10 combines target epitopes from both CD32 and CD20 antigens in the CAR-expressing cells described herein, which binds rituximab, resulting in selective depletion of the CAR-expressing cells, e.g., by ADCC (see, e.g., Philip et al., Blood. 2014; 124(8)1277-1287). Other methods for depleting CAR-expressing cells described herein include administration of CAMPATH, a
15 monoclonal anti-CD52 antibody that selectively binds and targets mature lymphocytes, e.g., CAR-expressing cells, for destruction, e.g., by inducing ADCC. In other embodiments, the CAR-expressing cell can be selectively targeted using a CAR ligand, e.g., an anti-idiotypic antibody. In some embodiments, the anti-idiotypic antibody can cause effector cell activity, e.g., ADCC or ADC activities, thereby reducing the number of CAR-expressing cells. In other
20 embodiments, the CAR ligand, e.g., the anti-idiotypic antibody, can be coupled to an agent that induces cell killing, e.g., a toxin, thereby reducing the number of CAR-expressing cells. Alternatively, the CAR molecules themselves can be configured such that the activity can be regulated, e.g., turned on and off, as described below.

In other embodiments, a CAR-expressing cell described herein may also express a target
25 protein recognized by the T cell depleting agent. In one embodiment, the target protein is CD20 and the T cell depleting agent is an anti-CD20 antibody, e.g., rituximab. In such embodiment, the T cell depleting agent is administered once it is desirable to reduce or eliminate the CAR-expressing cell, e.g., to mitigate the CAR induced toxicity. In other embodiments, the T cell depleting agent is an anti-CD52 antibody, e.g., alemtuzumab, as described in the Examples
30 herein.

In other embodiments, an RCAR comprises a set of polypeptides, typically two in the

simplest embodiments, in which the components of a standard CAR described herein, e.g., an antigen binding domain and an intracellular signalling domain, are partitioned on separate polypeptides or members. In some embodiments, the set of polypeptides include a dimerization switch that, upon the presence of a dimerization molecule, can couple the polypeptides to one another, e.g., can couple an antigen binding domain to an intracellular signalling domain. In one embodiment, a CAR of the present invention utilizes a dimerization switch as those described in, e.g., WO2014127261, which is incorporated by reference herein. Additional description and exemplary configurations of such regulatable CARs are provided herein and in, e.g., paragraphs 527-551 of International Publication No. WO 2015/090229 filed March 13, 2015, which is incorporated by reference in its entirety. In some embodiments, an RCAR involves a switch domain, e.g., a FKBP switch domain, as set out SEQ ID NO: 92, or comprise a fragment of FKBP having the ability to bind with FRB, e.g., as set out in SEQ ID NO: 93. In some embodiments, the RCAR involves a switch domain comprising a FRB sequence, e.g., as set out in SEQ ID NO: 94, or a mutant FRB sequence, e.g., as set out in any of SEQ ID Nos. 95-100.

Co-expression of CAR with a Chemokine Receptor

In embodiments, the CAR-expressing cell described herein further comprises a chemokine receptor molecule. Transgenic expression of chemokine receptors CCR2b or CXCR2 in T cells enhances trafficking to CCL2- or CXCL1-secreting solid tumors including melanoma and neuroblastoma (Craddock et al., *J Immunother.* 2010 Oct; 33(8):780-8 and Kershaw et al., *Hum Gene Ther.* 2002 Nov 1; 13(16):1971-80). Thus, without wishing to be bound by theory, it is believed that chemokine receptors expressed in CAR-expressing cells that recognize chemokines secreted by tumors, e.g., solid tumors, can improve homing of the CAR-expressing cell to the tumor, facilitate the infiltration of the CAR-expressing cell to the tumor, and enhances antitumor efficacy of the CAR-expressing cell. The chemokine receptor molecule can comprise a naturally occurring or recombinant chemokine receptor or a chemokine-binding fragment thereof. A chemokine receptor molecule suitable for expression in a CAR-expressing cell described herein include a CXC chemokine receptor (e.g., CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, or CXCR7), a CC chemokine receptor (e.g., CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, or CCR11), a CX3C chemokine receptor (e.g.,

CX3CR1), a XC chemokine receptor (e.g., XCR1), or a chemokine-binding fragment thereof. In one embodiment, the chemokine receptor molecule to be expressed with a CAR described herein is selected based on the chemokine(s) secreted by the tumor. In one embodiment, the CAR-expressing cell described herein further comprises, e.g., expresses, a CCR2b receptor or a CXCR2 receptor. In an embodiment, the CAR described herein and the chemokine receptor molecule are on the same vector or are on two different vectors. In embodiments where the CAR described herein and the chemokine receptor molecule are on the same vector, the CAR and the chemokine receptor molecule are each under control of two different promoters or are under the control of the same promoter.

Split CAR

In some embodiments, the CAR-expressing cell uses a split CAR. The split CAR approach is described in more detail in publications WO2014/055442 and WO2014/055657. Briefly, a split CAR system comprises a cell expressing a first CAR having a first antigen binding domain and a costimulatory domain (e.g., 41BB), and the cell also expresses a second CAR having a second antigen binding domain and an intracellular signaling domain (e.g., CD3 zeta). When the cell encounters the first antigen, the costimulatory domain is activated, and the cell proliferates. When the cell encounters the second antigen, the intracellular signaling domain is activated and cell-killing activity begins. Thus, the CAR-expressing cell is only fully activated in the presence of both antigens.

Pharmaceutical Compositions and Treatments

Pharmaceutical compositions may comprise a CAR-expressing cell, e.g., a plurality of CAR-expressing cells, as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g.,

aluminum hydroxide); and preservatives. Compositions can be, e.g., formulated for intravenous administration.

Pharmaceutical compositions of the present disclosure may be administered in a manner appropriate to the disease to be treated (or prevented). The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease, although appropriate dosages may be determined by clinical trials.

In one embodiment, the pharmaceutical composition is substantially free of, e.g., there are no detectable levels of a contaminant, e.g., a contaminant described in paragraph 1009 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

When "an immunologically effective amount," "an anti-tumor effective amount," "a tumor-inhibiting effective amount," or "therapeutic amount" is indicated, the precise amount of the compositions of the present invention to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject). It can generally be stated that a pharmaceutical composition comprising the immune effector cells (e.g., T cells, NK cells) described herein may be administered at a dosage of 10^4 to 10^9 cells/kg body weight, in some instances 10^5 to 10^6 cells/kg body weight, including all integer values within those ranges. T cell compositions may also be administered multiple times at these dosages. The cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., NEW ENG. J. OF MED. 319:1676, 1988).

In some embodiments, a dose of CAR cells (e.g., CD19 CAR cells) comprises about 1×10^6 , 1.1×10^6 , 2×10^6 , 3.6×10^6 , 5×10^6 , 1×10^7 , 1.8×10^7 , 2×10^7 , 5×10^7 , 1×10^8 , 2×10^8 , or 5×10^8 cells/kg. In some embodiments, a dose of CAR cells (e.g., CD19 CAR cells) comprises at least about 1×10^6 , 1.1×10^6 , 2×10^6 , 3.6×10^6 , 5×10^6 , 1×10^7 , 1.8×10^7 , 2×10^7 , 5×10^7 , 1×10^8 , 2×10^8 , or 5×10^8 cells/kg. In some embodiments, a dose of CAR cells (e.g., CD19 CAR cells) comprises up to about 1×10^6 , 1.1×10^6 , 2×10^6 , 3.6×10^6 , 5×10^6 , 1×10^7 , 1.8×10^7 , 2×10^7 , 5×10^7 , 1×10^8 , 2×10^8 , or 5×10^8 cells/kg. In some embodiments, a dose of CAR cells

(e.g., CD19 CAR cells) comprises about 1.1×10^6 – 1.8×10^7 cells/kg. In some embodiments, a dose of CAR cells (e.g., CD19 CAR cells) comprises about 1×10^7 , 2×10^7 , 5×10^7 , 1×10^8 , 2×10^8 , 5×10^8 , 1×10^9 , 2×10^9 , or 5×10^9 cells. In some embodiments, a dose of CAR cells (e.g., CD19 CAR cells) comprises at least about 1×10^7 , 2×10^7 , 5×10^7 , 1×10^8 , 2×10^8 , 5×10^8 , 1×10^9 , 2×10^9 , or 5×10^9 cells. In some embodiments, a dose of CAR cells (e.g., CD19 CAR cells) comprises up to about 1×10^7 , 2×10^7 , 5×10^7 , 1×10^8 , 2×10^8 , 5×10^8 , 1×10^9 , 2×10^9 , or 5×10^9 cells.

In certain aspects, it may be desired to administer activated immune effector cells (e.g., T cells, NK cells) to a subject and then subsequently redraw blood (or have an apheresis performed), activate immune effector cells (e.g., T cells, NK cells) therefrom according to the present disclosure, and reinfuse the patient with these activated and expanded immune effector cells (e.g., T cells, NK cells). This process can be carried out multiple times every few weeks. In certain aspects, immune effector cells (e.g., T cells, NK cells) can be activated from blood draws of from 10cc to 400cc. In certain aspects, immune effector cells (e.g., T cells, NK cells) are activated from blood draws of 20cc, 30cc, 40cc, 50cc, 60cc, 70cc, 80cc, 90cc, or 100cc.

The administration of the subject compositions may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient trans arterially, subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (i.v.) injection, or intraperitoneally. In one aspect, the T cell compositions described herein are administered to a patient by intradermal or subcutaneous injection. In one aspect, the T cell compositions described herein are administered by i.v. injection. The compositions of immune effector cells (e.g., T cells, NK cells) may be injected directly into a tumor, lymph node, or site of infection.

In a particular exemplary aspect, subjects may undergo leukapheresis, wherein leukocytes are collected, enriched, or depleted ex vivo to select and/or isolate the cells of interest, e.g., T cells. These T cell isolates may be expanded by methods known in the art and treated such that one or more CAR constructs described herein may be introduced, thereby creating a CAR T cell of the present disclosure. Subjects in need thereof may subsequently undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain

aspects, following or concurrent with the transplant, subjects receive an infusion of the expanded CAR T cells described herein. In an additional aspect, expanded cells are administered before or following surgery.

The dosage of the above treatments to be administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. The scaling of dosages for human administration can be performed according to art-accepted practices. The dose for CAMPATH, for example, will generally be in the range 1 to about 100 mg for an adult patient, usually administered daily for a period between 1 and 30 days. A suitable daily dose is 1 to 10 mg per day although in some instances larger doses of up to 40 mg per day may be used (described in U.S. Patent No. 6,120,766).

In one embodiment, the CAR is introduced into immune effector cells (e.g., T cells, NK cells), e.g., using in vitro transcription, and the subject (e.g., human) receives an initial administration of CAR immune effector cells (e.g., T cells, NK cells) of the invention, and one or more subsequent administrations of the CAR immune effector cells (e.g., T cells, NK cells) of the invention, wherein the one or more subsequent administrations are administered less than 15 days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days after the previous administration. In one embodiment, more than one administration of the CAR immune effector cells (e.g., T cells, NK cells) described herein are administered to the subject (e.g., human) per week, e.g., 2, 3, or 4 administrations of the CAR immune effector cells (e.g., T cells, NK cells) of the invention are administered per week. In one embodiment, the subject (e.g., human subject) receives more than one administration of the CAR immune effector cells (e.g., T cells, NK cells) per week (e.g., 2, 3 or 4 administrations per week) (also referred to herein as a cycle), followed by a week of no CAR immune effector cells (e.g., T cells, NK cells) administrations, and then one or more additional administration of the CAR immune effector cells (e.g., T cells, NK cells) (e.g., more than one administration of the CAR immune effector cells (e.g., T cells, NK cells) per week) is administered to the subject. In another embodiment, the subject (e.g., human subject) receives more than one cycle of CAR immune effector cells (e.g., T cells, NK cells), and the time between each cycle is less than 10, 9, 8, 7, 6, 5, 4, or 3 days. In one embodiment, the CAR immune effector cells (e.g., T cells, NK cells) are administered every other day for 3 administrations per week. In one embodiment, the CAR immune effector cells (e.g., T cells, NK

cells) described herein are administered for at least two, three, four, five, six, seven, eight or more weeks.

In one aspect, CAR-expressing cells (e.g., T cells, NK cells) as described herein such as, e.g., CD19 CAR-expressing cells, e.g., CTL019 are generated using lentiviral viral vectors, such as lentivirus. CAR-expressing cells generated that way can have stable CAR expression.

In one aspect, CAR-expressing cells (e.g., T cells, NK cells) transiently express CAR vectors for 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 days after transduction. Transient expression of CARs can be effected by RNA CAR vector delivery. In one aspect, the CAR RNA is transduced into the cell by electroporation.

A potential issue that can arise in patients being treated using transiently expressing CAR cells, e.g., T cells (particularly with murine scFv bearing CAR-expressing cells (e.g., T cells, NK cells)) is anaphylaxis after multiple treatments. Without being bound by this theory, it is believed that such an anaphylactic response might be caused by a patient developing humoral anti-CAR response, i.e., anti-CAR antibodies having an anti-IgE isotype. It is thought that a patient's antibody producing cells undergo a class switch from IgG isotype (that does not cause anaphylaxis) to IgE isotype when there is a ten to fourteen day break in exposure to antigen.

If a patient is at high risk of generating an anti-CAR antibody response during the course of transient CAR therapy (such as those generated by RNA transductions), CAR-expressing cell (e.g., T cell, NK cell) infusion breaks should not last more than ten to fourteen days.

In some embodiments of any of the aforesaid methods, the method further includes administering one or more doses of a cell (e.g., an immune cell containing a CAR nucleic acid or CAR polypeptide as described herein), to a mammal (e.g., a mammal having a cancer, e.g., a mammal that is or is identified as being a responder, complete responder, partial responder, non-responder, relapser, or non-relapser according to the methods herein). In some embodiments, the one or more doses of CAR cells (e.g., CD19 CAR cells) comprises at least about 1×10^6 , 5×10^6 , 1×10^7 , 2×10^7 , 5×10^7 , 1×10^8 , 2×10^8 , 5×10^8 , 1×10^9 , 2×10^9 , or 5×10^9 cells.

In one embodiment, up to 10, 9, 8, 7, 6, 5, 4, 3, or 2 doses of cells are administered. In other embodiments, one, two, three, four, five or 6 doses of the cells are administered to the mammal, e.g., in a treatment interval of one, two, three, four or more weeks. In one

embodiment, up to 6 doses are administered in two weeks. The doses may be the same or different. In one embodiment, a lower dose is administered initially, followed by one or more higher doses. In one exemplary embodiment, the lower dose is about 1×10^5 to 1×10^9 cells/kg, or 1×10^6 to 1×10^8 cells/kg; and the higher dose is about 2×10^5 to 2×10^9 cells/kg or 2×10^6 to 2×10^8 cells/kg, followed by 3-6 doses of about 4×10^5 to 4×10^9 cells/kg, or 4×10^6 to 4×10^8 cells/kg.

In one embodiment, the one or more doses of the cells are administered after one or more lymphodepleting therapies, e.g., a lymphodepleting chemotherapy. In one embodiment, the lymphodepleting therapy includes a chemotherapy (e.g., cyclophosphamide).

In one embodiment, the one or more doses is followed by a cell transplant, e.g., an allogeneic hematopoietic stem cell transplant. For example, the allogeneic hematopoietic stem cell transplant occurs between about 20 to about 35 days, e.g., between about 23 and 33 days.

Biopolymer delivery methods

In some embodiments, one or more CAR-expressing cells as disclosed herein can be administered or delivered to the subject via a biopolymer scaffold, e.g., a biopolymer implant. Biopolymer scaffolds can support or enhance the delivery, expansion, and/or dispersion of the CAR-expressing cells described herein. A biopolymer scaffold comprises a biocompatible (e.g., does not substantially induce an inflammatory or immune response) and/or a biodegradable polymer that can be naturally occurring or synthetic. Exemplary biopolymers are described, e.g., in paragraphs 1004-1006 of International Application WO2015/142675, filed March 13, 2015, which is herein incorporated by reference in its entirety.

Exemplary Computer System

Various computer systems can be specially configured to leverage information returned on potential cancer responder status indicators (for example, ALL and CLL responder status indicator as described herein such as, e.g., complete responder, partial responder, non-responder). In some embodiments, the computer system can determine and present information on confidence levels associated with various bio-markers and/or indicators for cancer (e.g. a

hematological cancer) such as ALL and CLL. For example, the computer systems can evaluate whether a test conducted on a subject indicates a gene signature of a complete responder, partial responder or non-responder, along with a degree of confidence associated with the subject responder classification. In further examples, the system can provide an indication and/or
5 recommendation on increasing the degree of confidence associated with the predicted responder classification. For example, the system can be configured to evaluate any tests and tested biomarkers and/or indicators of cancer that have been performed for a subject against another characteristic identified as independent and/or additive of the existing data. In an embodiment, the system can be configured to evaluate any tests and tested biomarkers and/or cancer indicators
10 (e.g., a hematological cancer such as CLL and ALL) that have been performed for a subject against another characteristic identified as independent and/or additive of the existing data. The system can determine when an additional biomarker and/or indicator (e.g., gene signature) would increase confidence associated with, for example, a change in responder classification. The system can recommend testing of any identified characteristic accordingly.

15 In some embodiments, an interactive system for identification, assessment and/or treatment of a subject having cancer (e.g., a hematological cancer such as ALL and CLL) can be provided. In an embodiment, an interactive system for identification, assessment and/or treatment of a subject having cancer (e.g., a hematological cancer such as ALL and CLL) can be provided. According to one embodiment, the system can be configured to accept user input
20 regarding degree of confidence of a subject assessment. Responsive to the user entered degree of confidence, the system can determine test characteristics to include in an evaluation model. In one example, the system includes specification of independent indicators for disease activity in a subject (e.g., patient) population. The system can be configured to estimate a degree of confidence in a determination of disease activity or a prediction of future disease activity based
25 on what independent indicators are used. The system can be further configured to determined and/or recommend various combinations of the determined independent indicators to improve a degree of confidence in an evaluation.

According to another aspect, a computer system can be specially configured to evaluate indicators for cancer (e.g., a hematological cancer such as ALL and CLL). In an embodiment, a
30 computer system can be specially configured to evaluate indicators for ALL and/or CLL. The

system can be configured to generate a multivariate model, wherein the multivariate model excludes correlated indicators. In some examples, the system can be configured to identify correlated indicators responsive to evaluating returned test results within a subject (e.g., patient) population having one or more of the indicators. For example, the system can execute regression model analysis to control for various parameters, including, for example, subject age, race, sex, and the presence of other indicators. Responsive to eliminating correlated indicators, the system can generate a model of one or more independent indicators. In some embodiments, the system can be configured to select various combinations of the one or more independent indicators and can further access evaluations (including, for example, evaluating the combination directly) to present information on a confidence level associated with respective selections. The system selected models can be used to generate an expected change in disease activity with the determined confidence level.

In an embodiment, the disclosure provides a system for evaluating cancer (e.g., a hematological cancer such as ALL and CLL) in a subject, comprising:

at least one processor operatively connected to a memory, the at least one processor when executing is configured to:

acquire a value of responder status that comprises a measure of a CD19 CAR-expressing cell (e.g., T cell, NK cell) gene set signature and a combination of one or more of:

a biomarker listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15, Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, a CD27 biomarker, a CD45RO biomarker, a PD-1 biomarker, a LAG-3 biomarker, a TIM-3 biomarker, an IL2RA biomarker, an IL21 biomarker, a CD4 biomarker, a CD8 biomarker, a TH1+ helper T cell gene set signature, a TH2+ helper T cell gene set signature, and a memory T cell (e.g., a CD8+ memory T cell, e.g., a naïve T cell (T_N), e.g. a memory stem cell (T_{SCM}), e.g. a central memory T cell (T_{CM}), e.g. an effector memory T cell (T_{EM})) gene set signature; and

responsive to a determination of the value of responder status, perform one, two, three, four or more of:

identify the subject as a complete responder, partial responder, or non-responder;

recommend a CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy as described herein, such as, e.g., CTL019);

recommend a selection or alteration of a dosing of a CAR-expressing cell (e.g., T cell, NK cell) therapy; or

an alternative therapy, e.g., a standard of care for the particular cancer.

In an embodiment, the invention provides a system for evaluating cancer (e.g., a
5 hematological cancer such as ALL and CLL) in a subject, comprising: at least one processor
operatively connected to a memory, the at least one processor when executing is configured to:
acquire a value of responder status that comprises a measure of a CD19 CAR-expressing cell
(e.g., T cell, NK cell) gene set signature and a combination of one or more of: a biomarker listed
in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14, Table 15,
10 Table 16 (e.g., CCL20, IL-17a and/or IL-6), Table 17, Table 18, Table 20, PD-1, LAG-3, TIM-3,
CD57, CD27, CD122, CD62L, and KLRG1; and responsive to a determination of the value of
responder status, perform one, two, three, four or more of: identify the subject as a complete
responder, partial responder, or non-responder; recommend a CAR-expressing cell therapy (e.g.,
a CD19 CAR-expressing cell therapy as described herein, such as, e.g., CTL019); recommend a
15 selection or alteration of a dosing of a CAR-expressing cell therapy; or an alternative therapy.

FIG. 16 is a block diagram of a distributed computer system 200, in which various
aspects and functions in accord with the present disclosure may be practiced. The distributed
computer system 200 may include one or more computer systems. For example, as illustrated,
the distributed computer system 200 includes three computer systems 202, 204 and 206. As
20 shown, the computer systems 202, 204 and 206 are interconnected by, and may exchange data
through, a communication network 208. The network 208 may include any communication
network through which computer systems may exchange data. To exchange data via the network
208, the computer systems 202, 204, and 206 and the network 208 may use various methods,
protocols and standards including, among others, token ring, Ethernet, Wireless Ethernet,
25 Bluetooth, radio signaling, infra-red signaling, TCP/IP, UDP, HTTP, FTP, SNMP, SMS, MMS,
SS2, JSON, XML, REST, SOAP, CORBA IIOP, RMI, DCOM and Web Services.

According to some embodiments, the functions and operations discussed for identifying,
treating or preventing cancer (e.g., a hematological cancer such as ALL and CLL) in a subject
can be executed on computer systems 202, 204 and 206 individually and/or in combination. For

example, the computer systems 202, 204, and 206 support, for example, participation in a collaborative operations, which may include analyzing treatment data captured on a patient population. In one alternative, a single computer system (e.g., 202) can analyze treatment data captured on a subject (e.g., patient) population to develop characterization models and/or identify independent indicators for disease activity. The computer systems 202, 204 and 206 may include personal computing devices such as cellular telephones, smart phones, tablets, etc., and may also include desktop computers, laptop computers, etc.

Various aspects and functions in accord with the present disclosure may be implemented as specialized hardware or software executing in one or more computer systems including the computer system 202 shown in **FIG. 16**. In one embodiment, computer system 202 is a computing device specially configured to execute the processes and/or operations discussed above. For example, the system can present user interfaces to end-users that present treatment information, diagnostic information, and confidence levels associated with biomarkers and/or genetic indicators, among other options. As depicted, the computer system 202 includes at least one processor 210 (e.g., a single core or a multi-core processor), a memory 212, a bus 214, input/output interfaces (e.g., 216) and storage 218. The processor 210, may include one or more microprocessors or other types of controllers, and can perform a series of instructions that manipulate data (e.g., treatment data, testing data, etc.). As shown, the processor 210 is connected to other system components, including a memory 212, by an interconnection element (e.g., the bus 214).

The memory 212 and/or storage 218 may be used for storing programs and data during operation of the computer system 202. For example, the memory 212 may be a relatively high performance, volatile, random access memory such as a dynamic random access memory (DRAM) or static memory (SRAM). In addition, the memory 212 may include any device for storing data, such as a disk drive or other non-volatile storage device, such as flash memory, solid state, or phase-change memory (PCM). In further embodiments, the functions and operations discussed with respect to identifying, treating or preventing cancer (e.g., ALL and/or CLL) in a subject can be embodied in an application that is executed on the computer system 202 from the memory 212 and/or the storage 218.

Computer system 202 also includes one or more interfaces 216 such as input devices, output devices, and combination input/output devices. The interfaces 216 may receive input, provide output, or both. The storage 218 may include a computer-readable and computer-writeable nonvolatile storage medium in which instructions are stored that define a program to be
5 executed by the processor. The storage system 218 also may include information that is recorded, on or in, the medium, and this information may be processed by the application. A medium that can be used with various embodiments may include, for example, optical disk, magnetic disk or flash memory, SSD, among others.

Further, the invention is not limited to a particular memory system or storage system.
10 Although the computer system 202 is shown by way of example as one type of computer system upon which various functions for identifying, treating or preventing cancer (e.g., a hematological cancer such as ALL and CLL) in a subject may be practiced, aspects of the invention are not limited to being implemented on the computer system, shown in **FIG. 16**. Various aspects and functions in accord with the present invention may be practiced on one or more computers
15 having different architectures or components than that shown in **FIG. 16**.

In some embodiments, the computer system 202 may include an operating system that manages at least a portion of the hardware components (e.g., input/output devices, touch screens, cameras, etc.) included in computer system 202. One or more processors or controllers, such as processor 210, may execute an operating system which may be, among others, a Windows-based
20 operating system (e.g., Windows NT, ME, XP, Vista, 2, 8, or RT) available from the Microsoft Corporation, an operating system available from Apple Computer (e.g., MAC OS, including System X), one of many Linux-based operating system distributions (for example, the Enterprise Linux operating system available from Red Hat Inc.), a Solaris operating system available from Sun Microsystems, or a UNIX operating systems available from various sources. Many other
25 operating systems may be used, including operating systems designed for personal computing devices (e.g., iOS, Android, etc.) and embodiments are not limited to any particular operating system.

According to one embodiment, the processor and operating system together define a computing platform on which applications may be executed. Additionally, various functions for
30 identifying, treating or preventing cancer (e.g., a hematological cancer such as ALL and CLL) in

a subject may be implemented in a non-programmed environment (for example, documents created in HTML, XML or other format that, when viewed in a window of a browser program, render aspects of a graphical-user interface or perform other functions). Further, various embodiments in accord with aspects of the present disclosure may be implemented as

5 programmed or non-programmed components, or any combination thereof. Thus, the disclosure is not limited to a specific programming language and any suitable programming language could also be used.

EXEMPLIFICATION

10 The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

15 Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples specifically point out various aspects of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

20

Example 1: Identification of Novel Transcriptional gene signatures that predict subject response to CD19 CAR-Expressing Cell Therapy in Chronic Lymphoid Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL) using Whole Genome RNAseq and Unbiased Feature Selection

25 The present Example describes the identification of novel transcriptional gene signatures that predict patient response to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019 therapy) in Chronic Lymphoid Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL), for use in accordance with the present invention.

Among other things, the present Example describes novel gene signatures based on mRNA expression levels of selected genes in apheresis and manufactured CD19 CAR-expressing cell (e.g., T cell, NK cell) product samples (e.g., CTL019) prior to re-infusion.

In particular, the present Example describes methods of unbiased feature selection to discover novel gene signatures that predict patient response to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019) in CLL and ALL, for use in accordance with the present invention.

Novel gene signatures based on mRNA expression levels in apheresis and manufactured CD19 CAR-expressing cell product samples prior to re-infusion have been identified that predict patient response to CD19 CAR-expressing cell therapy in Chronic Lymphoid Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL). The identified signatures were discovered in a whole genome RNAseq study of manufactured product samples which included 7 ALL subject samples and 21 CLL subject samples. ALL subject samples (7 total) were taken from subjects (e.g., patients) with complete response to CD19 CAR-expressing cell therapy. CLL subject samples (21 total) were stratified as follows: biological samples were taken from 2 patients that were complete responders (CRs) to CTL019 therapy, 6 patients that were partial responders (PRs), and 13 non-responders (NRs). The gene signatures were then investigated in a subset of the above patients where samples were collected at apheresis. Several gene signatures discriminating responders from non-responders in manufactured product and apheresis samples were discovered and are described further in Example 2. Healthy donor samples with manufactured product (i.e., reference samples) were acquired and used as a reference level.

Novel gene signatures were then discovered using various data analytical approaches: 1) unbiased feature selection; 2) gene set analysis; and 3) differential expression analysis of selected genes of interest. Gene set analysis (2) and differential expression analysis (3) are discussed in further detail in Example 2.

Novel gene signatures derived from unbiased feature selection were discovered by determining which genes were differentially expressed between the CRs and NRs and between CRs and PRs. Genes were defined as differentially expressed if their differential expression was

statistically significant with a FDR p-value cutoff of 0.1. The gene lists for the CR vs NR comparison (N=128) and CR vs PR comparison (N=34) are tabulated in **Table 1A-B**.

Without wishing to be bound by a particular theory, these data indicate that the differentiation state of T cells in apheresis or CD19 CAR-expressing cell (e.g., T cell, NK cell) product (e.g., CTL019) correlate with subject response (i.e., CR, PR, or NR). Gene signatures for T cells from CR are in a more unstimulated/undifferentiated state. In addition, memory T cell subsets are differentially enriched between CRs versus NRs, with CRs showing similarity to naive T cells (T_N) and T memory stem cells (T_{SCM}). An exemplary schematic illustrating the progression of a naïve T cell (T_N) through the memory T cell subset stages, into an effector memory T cell (T_{EM}) is shown in FIG. 3).

Complete responders to CTL019 therapy have a significantly higher % of CD8+ T cells that express the co-stimulatory molecule CD27 but lack the antigen-experienced T cell marker CD45RO compared to the non-responders. In an embodiment, the threshold for this discrimination was 7% CD27+ CD45RO- cells in the CD8+ population. In an embodiment, a complete responder is defined as 7% or greater CD27+ CD45RO- cells in the CD8+ population. Without wishing to be bound by a particular theory, the state of memory T cells in CTL019 samples is likely a major component of response (FIG. 3).

These data demonstrate that CRs are more like resting T_{EFF} cells, resting T_{REG} cells, naïve CD4 cells, unstimulated memory cells and early memory T cells, whereas NRs are more like activated T_{EFF} cells, activated T_{REG} cells, activated TH1 and TH2 cells, stimulated memory cells, and late T memory cells.

Table 1A: Comparison of Complete Responders (CR) vs. Non-responders (NR)

Gene	Unigene	Accession No.	FDR
C16orf74	Hs.461655	NM_206967	6.47E-05
uc021oxm			1.67E-03
uc021ygq			2.83E-03
uc021oxp			3.31E-03
SNED1	Hs.471834	NM_001080437	9.55E-03
ADAM19	Hs.483944	NM_033274	1.34E-02

FAIM2	Hs.567424	NM_012306	1.82E-02
WHAMMP2			1.82E-02
LOC730091	Hs.659905		1.84E-02
TCF7	Hs.573153	NM_201633, NM_201632, NM_001134851, NM_001134852, NM_213648, NM_003202, NM_201634	1.84E-02
TTLL2	Hs.520554	NM_031949	1.84E-02
LY9	Hs.403857	NM_002348, NM_001033667	2.03E-02
uc021tnc			2.13E-02
TRIL	Hs.21572	NM_014817	2.28E-02
uc004crn			2.28E-02
DPEP2	Hs.372633	NM_022355	2.28E-02
GZMB	Hs.1051	NM_004131	2.35E-02
FAM102A	Hs.568044	NM_203305, NM_001035254	2.35E-02
ALS2CL	Hs.517937	NM_147129	2.35E-02
EPHA4	Hs.371218	NM_004438	2.35E-02
IKBIP	Hs.252543	NM_201612, NM_201613, NM_153687	2.88E-02
HBEGF	Hs.799	NM_001945	2.88E-02
LHFPL3	Hs.659164	NM_199000	2.88E-02
RCAN2	Hs.440168	NM_005822	2.97E-02
MFGE8	Hs.3745	NM_005928, NM_001114614	2.97E-02
IL24	Hs.723317, Hs.58831	NM_006850, NM_181339	2.97E-02
FAIM3	Hs.723317, Hs.58831	NM_001142472, NM_001142473, NM_005449	2.97E-02
CDKN1B	Hs.238990	NM_004064	2.99E-02
AQP3	Hs.234642	NM_004925	3.06E-02
GPR155	Hs.516604	NM_001033045, NM_152529	3.06E-02
HS6ST2	Hs.385956	NM_147175, NM_001077188	3.25E-02
SNORD85			3.25E-02
uc022cci			3.25E-02
GSTM1	Hs.301961	NM_000561, NM_146421	3.27E-02
VSIG1	Hs.177164	NM_001170553, NM_182607	3.86E-02
VIPR1	Hs.348500	NM_004624	3.86E-02
RCAN3	Hs.656799	NM_013441	4.45E-02
ADHFE1	Hs.720023	NM_144650	4.49E-02
HSPH1	Hs.36927	NM_006644	4.62E-02
ENPP6	Hs.297814	NM_153343	4.74E-02
RORC	Hs.607993, Hs.256022	NM_005060, NM_001001523	4.83E-02
TRIB2	Hs.627749, Hs.467751	NM_021643	4.96E-02
LRP8	Hs.576154	NM_001018054, NM_004631, NM_033300, NM_017522	4.96E-02
RGS17	Hs.166313	NM_012419	5.05E-02

TAAR3	Hs.679662		5.18E-02
C5orf41	Hs.484195	NM_153607, NM_001168394,NM_001168393	5.27E-02
MIR3183			5.27E-02
LTA	Hs.36	NM_001159740, NM_000595	5.27E-02
KLHL24	Hs.407709	NM_017644	5.28E-02
PIK3IP1	Hs.26670	NM_001135911, NM_052880	5.28E-02
MAP3K1	Hs.653654	NM_005921	5.29E-02
VWC2L	Hs.534834	NM_001080500	5.29E-02
IDI2-AS1			5.29E-02
DUSP4	Hs.417962	NM_001394, NM_057158	5.29E-02
SKIL	Hs.581632	NM_001145098, NM_001145097, NM_005414	5.77E-02
uc021oxf			5.86E-02
AMICA1	Hs.16291	NM_153206, NM_001098526	5.86E-02
TP53INP1	Hs.492261	NM_001135733, NM_033285	5.86E-02
GDAP1L1	Hs.517059	NM_024034	6.00E-02
HK2	Hs.591588, Hs.406266	NM_000189	6.43E-02
CBLL1	Hs.592271	NM_024814	6.44E-02
PSD3	Hs.434255	NM_015310, NM_206909	6.44E-02
PUS7	Hs.520619	NM_019042	6.44E-02
MSMO1			6.63E-02
IDI1	Hs.283652	NM_004508	6.63E-02
HRH4	Hs.287388	NM_001160166, NM_021624, NM_001143828	6.73E-02
FAM19A1	Hs.655061	NM_213609	6.73E-02
EHD4	Hs.143703	NM_139265	6.73E-02
PVR	Hs.171844	NM_001135768, NM_006505, NM_001135770, NM_001135769	6.74E-02
MIR1293			6.74E-02
WDR64	Hs.723441	NM_144625	6.74E-02
CDKN1A	Hs.370771	NM_078467, NM_000389	6.74E-02
CACNA1I	Hs.125116	NM_021096, NM_001003406	6.75E-02
C21orf63	Hs.208358	NM_058187	6.75E-02
FLJ41649	Hs.654837		9.72E-02
MPP7	Hs.499159	NM_173496	9.82E-02
POP1	Hs.252828	NM_001145861, NM_001145860, NM_015029	9.82E-02
CALCOCO1	Hs.156667	NM_020898, NM_001143682	9.82E-02
COL5A3	Hs.235368	NM_015719	9.82E-02
LHFP	Hs.507798	NM_005780	9.82E-02
CTSO	Hs.75262	NM_001334	9.82E-02
LEF1	Hs.555947	NM_001166119, NM_001130713,	9.82E-02

		NM_001130714, NM_016269	
RNASET2	Hs.720966, Hs.529989	NM_003730	9.89E-02

Table 1B: Comparison of Complete responders (CR) vs. Partial responders (PR)

Gene	Unigene	Accession No.	FDR
uc021oxm			0.000511026
uc021oxp			0.000511026
SPTB	Hs.417303	NM_000347, NM_001024858	0.019052239
ALS2CL	Hs.517937	NM_147129, NM_182775	0.025286191
TCF7	Hs.573153	NM_201633, NM_201632, NM_001134851, NM_001134852, NM_213648, NM_003202, NM_201634	0.025286191
TRIL	Hs.21572	NM_014817	0.025286191
WDR86	Hs.647083	NM_198285	0.025286191
ACSM2B	Hs.567879, Hs.298252	NM_182617, NM_001105069	0.044953527
DUSP4	Hs.417962	NM_001394, NM_057158	0.044953527
EFHC1	Hs.403171	NM_018100	0.044953527
HS6ST2	Hs.385956	NM_147175, NM_001077188	0.044953527
TRIB2	Hs.627749, Hs.467751	NM_021643	0.047492472
SQLE	Hs.71465	NM_003129	0.053797924
PRR5-ARHGAP8	Hs.720401, Hs.102336	NM_001017530, NM_181333, NM_181334, NM_181335, NM_015366, NM_001017526, NM_001017529, NM_001017528	0.053797924
C16orf74	Hs.461655	NM_206967	0.056452084
TMIE	Hs.185777	NM_147196	0.056452084
LOC100131176	Hs.659231		0.056452084
VSIG1	Hs.177164	NM_001170553, NM_182607	0.056452084
MIR3194			0.056452084
RAP1GAP2	Hs.499659	NM_015085, NM_001100398	0.057016164
FLJ13197	Hs.29725		0.084544923
TSPEAR			0.084544923
uc021zdn			0.084544923
RASA3	Hs.593075	NM_007368	0.084544923
OLIG3	Hs.195398	NM_175747	0.084544923
GPR155	Hs.516604	NM_001033045, NM_152529	0.084544923
uc021ygq			0.084544923
FAM19A1	Hs.655061	NM_213609	0.084544923
LY9	Hs.403857	NM_002348, NM_001033667	0.084544923
ANKRD20A5P			0.084544923

C21orf15	Hs.580910		0.08962672
ADHFE1	Hs.720023	NM_144650	0.08962672
MIR1293			0.098706653
LOC730091	Hs.659905		0.098706653

Example 2: Identification of Novel Transcriptional gene signatures which predict subject response to CD19 CAR-Expressing Cell Therapy in Chronic Lymphoid Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL) using Gene Set Analysis and Differential

5 Expression Analysis

The present Example describes the identification of novel transcriptional gene signatures that predict patient response to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019) in CLL and ALL, for use in accordance with the present invention.

10 In particular, the present Example describes methods of Gene Set Analysis to discover novel gene signatures, for use in accordance with the present invention.

Among other things, the present Example describes novel gene signatures based on Gene Set Analysis, that are predictive of patient response to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019). Gene set analysis was performed on gene sets described in Example 1, and with gene sets from three additional datasets. **FIG. 2A** depicts an exemplary
15 histogram comparing the number of samples analyzed in a whole genome CTL019 RNAseq analysis. p= product; a=apheresis. Gene sets were sourced from (1) additional experiments were based on gene sets by Szabo *et al.* (described herein); (2) gene sets published by Abbas *et al.* in GENOME RESEARCH 2005; and (3) gene sets published by Gattinoni *et al.* in NATURE MEDICINE 2011. Each of these gene sets are described in further detail below.

20 Szabo *et al.* gene sets that were used in the Gene Set Analysis are provided in **Table 2**. Human CD4+ T cells were purified from PBMCs (5 normal donors, males, ages 18-28, with no known allergies or infections). CD4+ CD25+ (T reg) and CD4+ CD25- (T effector) T cells were isolated and anti-CD3/CD28 stimulated for 0 or 16 hours to yield 4 conditions: (1) T reg 0 hours; (2) T reg 16 hours; (3) T effector 0 hours; and (4) T effector 16 hours. Two gene sets were
25 derived for each condition: one set of genes whose expression levels were up-regulated in that condition relative to all others and another set of genes whose expression levels were down-

regulated in that condition relative to all others. The number of genes in each gene set was determined by a fold change cutoff (see **Table 2**).

Table 2: Gene sets comprised of genes up or down regulated in T_{REG} and T_{EFF} at resting and activation (Szabo data set)

Table 2	
Gene Set	Number of Genes
Downregulated T _{REG} vs T _{EFF} 0h (FC3 p<0.05)	120
Downregulated T _{REG} vs T _{EFF} 16h (FC3 p<0.05)	139
Downregulated T _{EFF} 16h vs 0h (FC7 p<0.05)	246
Upregulated T _{REG} vs T _{EFF} 16h (FC4 p<0.05)	254
Upregulated T _{REG} vs T _{EFF} 0h (FC4 p<0.05)	135
Upregulated T _{EFF} 16h vs 0h (FC9 p<0.05)	347
Upregulated T _{REG} 16h vs 0h (FC8 p<0.05)	226

5

Exemplary genes according to Table 2 downregulated in Treg compared with Teff at 0h include ABCB1, ACSL6, ADAMTS10, ADD2, AIF1, AIF1, AIF1, AIF1, AK5, AKR1E2, ALS2CL, ANK3, ANKRD55, APBA2, AREG, ATHL1, AXIN2, B4GALNT4, BACH2, BCL7A, BEND5, BHLHE40, BPGM, C10orf47, C16orf54, C1orf228, C2orf89, CA6, CACHD1, CACNA1I, CCL5, CELA1, CHD7, CHI3L2, COL18A1, COL6A1, CR2, CYB561, CYSLTR1, D4S234E, DACT1, DENND5A, DHRS3, DLG4, DLL1, DPYSL4, DSC1, EDAR, EMR1, EMR4P, ENC1, EPHA1, FCGBP, FHIT, GADD45G, GIPC3, GIPC3, GPR125, GPR160, H1F0, HDGFRP3, HIPK2, IFITM5, KCNQ1, KLF5, KLHL29, KRT72, KRT73, LASS6, LRRC24, MAN1C1, ME3, MMP28, MTUS1, NBL1, NELL2, NEO1, NKG7, NLRP6, NME4, NOG, NOSIP, NPAS2, NRCAM, OBSCN, OSBPL5, PCSK5, PDZD4, PECAM1, PLLP, PLXDC1, PPFIBP2, PRKAR1B, PTK2, RHOB, RMRP, RNF157, SATB1, SCML4, SDK2, SEC14L2, SEC14L2, SLC15A3, SLC22A17, SLC22A23, SLC40A1, SNTB1, SORBS3, SOX8, ST6GALNAC1, TCF7, TCF7, THEMIS, TMIGD2, VIPR1, WNT10B, WNT7A, ZNF467, ZNF516, and ZNF609.

20

Exemplary genes according to Table 2 downregulated in Treg compared to Teff 16h include IL2, TNFSF8, NELL2, G0S2, IRF8, IFNG, IGFBP4, GPR125, CD200, GPR81, ADD2, IL21, SNORD86, TMCC2, C1orf228, SLC15A3, IL22, LRRN3, GPR171, FASLG, GZMH,

NHS, MCOLN2, BACH2, TAGAP, MPZL2, PRAGMIN, DACT1, CXCL10, SLAMF6, PHGDH, CSF2, PRSS23, UHRF1, PLAC8, ISM1, BTLA, CDC20, GFOD1, HSD11B1, ME3, ZNF704, DHRS3, CXCL13, CCND1, NBL1, CRTAM, MAP6D1, H1F0, CDT1, CCL4, LIF, CD84, TRAT1, MIR155, SLAMF7, AIF1, AIF1, AIF1, AIF1, PRG4, VWCE, CHEK1,
 5 SH2D4A, MCM10, RHOU, NPAS2, NFIX, STAP1, DTL, C16orf59, CSDA, GINS2, FAM117B, ABCB1, CLC, PHEX, GDF10, RAB13, BCL7A, MAMLD1, SHF, LPIN2, AHI1, CCND3, HDGFRP3, MIR155HG, PVR, CDCA5, RRAS2, SIPA1L2, RASL10B, GAL, SNORD88C, SNORD18B, CDC6, SRD5A3, ORC6L, B3GNT5, ANK3, MCM2, MIR25, RHOBTB3, TNF, TERT, CSDAP1, CCDC64, CDC25A, ZNF367, MCM7, CASP10, LTA,
 10 MCM4, AFF3, FMNL2, TNFRSF21, AXIN2, CHD7, FABP5, XRCC2, CGREF1, CCL4L1, CCL4L2, B4GALNT4, DSCC1, CD97, PTPRK, RAD54L, EPB41L3, MYO1B, ORC1L, CHML, ZWINT, MAD2L1, NDST1, C11orf82, BEGAIN, CD55, and FABP5L3.

Exemplary genes according to Table 2 downregulated in Teff at 16 h vs 0 h include ABCA7, ABCG1, ABTB1, ACCS, ADAMTS10, ADD3, AK5, ALS2CL, AMT, ANKRD55,
 15 ANXA1, AQP3, AREG, ARL4C, ARRDC2, ARRDC3, BBC3, BCL9L, BIN2, BNIP3L, BTG1, BTN3A1, C10orf110, C11orf21, C11orf35, C14orf181, C16orf54, C16orf74, C17orf108, C1orf162, C1QTNF6, C20orf111, C20orf112, C5orf39, C5orf41, C5orf41, CACNA1I, CAPS, CBX4, CCNL1, CDC14A, CDC42BPG, CECR1, CFP, CHI3L2, CITED4, CLK1, CRIP2, CSGALNACT1, CTSF, CTSW, CXCR4, CYTH4, DCHS1, DDIT3, DDX60L, DISC1, DISC1,
 20 DISC1, DISC1, DPEP2, DPYD, DUSP1, DUSP8, EDAR, EMR4P, EPHA4, EPHX1, EPHX2, ERMN, ERP27, EVI2B, FAM13A, FAM13AOS, FAM46C, FAM65B, FBXO32, FHIT, FLT3LG, FOS, FOSB, FRAT1, FYB, GABARAPL1, GABARAPL3, GADD45B, GOLGA7B, GPA33, GPRASP1, GRASP, GSTM2, GZMA, GZMK, HBP1, HERPUD2, HIST1H1C, HIST1H3A, HPCAL4, HSD17B11, ID1, IDUA, IER2, IFI44, IL10RA, IL11RA, IRF2BP2,
 25 IRS2, ITGA6, JMY, JUN, JUNB, JUND, KCNQ1, KIAA1370, KIAA1683, KLF2, KLF3, KLF4, KLF5, KLF6, KLHL24, KLHL3, KLRB1, KRT72, KRT73, LIME1, LOC100128071, LOC100289511, LOC282997, LOC283070, LOC338799, LOC728392, LTBP3, MAL, MAP2K6, MDS2, MEGF6, MEGF6, MFGE8, MIR1909, MMP28, MOAP1, MXD4, MYADM, MYLIP, MYO15B, NFKBIZ, NLRC3, NLRP1, NOG, NR1D2, NR1D2, NR3C2, P2RY8,
 30 PBXIP1, PCSK5, PDE4D, PDZD4, PER1, PGAM2, PGCP, PHF1, PHF1, PIK3IP1, PIK3R5, PIM1, PION, PLCD1, PLCH2, PLCL1, PLEKHB1, PLK2, PLXDC1, PNRC1, PPP1R15A,

ProSAPiP1, RAB37, RAP1GAP2, RARRES3, RASA3, RASGRP2, REM2, RGS1, RGS2, RNF125, SAMD3, SCML4, SEC31B, SIGIRR, SIK1, SLC2A3, SLC2A4RG, SLC2A4RG, SLC9A9, SLFN5, SMAD7, SMPD1, SNORA11, SORL1, SOX4, SULT1B1, SYNE1, SYTL1, TCEA3, TCF7, TCF7, TCP11L2, THEMIS, TMC8, TMEM63A, TMEM71, TMIGD2, 5 TNFAIP3, TNNT3, TP53INP2, TPM2, TRANK1, TRIB2, TSC22D3, TSPAN18, TSPAN18, TSPAN32, TSSK3, TXK, TXNIP, UNC84B, UTRN, VIPR1, VSIG1, VSIG1, WHAMM, WNT10B, WNT7A, XAF1, XYLT1, XYLT1, YPEL2, YPEL3, YPEL5, ZBP1, ZBTB10, ZFP36, ZFP36L2, ZMAT1, ZNF331, and ZNF815.

Exemplary genes according to Table 2 upregulated in Treg v Teff at 16 h FC include

10 ZBTB32, LRRC32, STAMBPL1, SNX10, LOC389333, ZNF193, GCNT1, FAS, GK3P, NTRK1, FREQ, IL1R1, CRADD, GNA15, RAB33A, IL18R1, CX3CR1, TNFRSF1B, APOBEC3G, FOXP3, SEPT11, CD70, IL1RL1, NIPA1, PANX2, CHST2, NEDD9, ACOT9, PDGFA, MAST4, TNFRSF8, PHLPP1, IL2RB, CTLA4, SYTL3, ZC3H12C, PTPRJ, UBASH3B, METRNL, PRDM1, SEPT3, TNFRSF18, WNT10A, CCR8, C18orf1, CSF1, CD80, 15 GALNT4, GALNT4, IL1RL2, ADPRH, ZNF282, APOBEC3C, HS3ST3B1, EPAS1, RBKS, KAT2B, C9orf167, TYMP, IL1RAP, C2CD4A, CD68, ABHD4, MICAL2, C6orf145, DUSP16, LRIG1, CASK, EPSTI1, TNFRSF12A, IGSF3, SPATS2L, SPATS2L, MAF, CD58, KLHDC7B, ZBTB38, LAYN, IL1R2, HIP1, ITGB8, ITGB8, IKZF2, LGMN, XIRP1, GPR19, SAMD9L, PRF1, JAKMIP1, MGC29506, ADAM8, HLF, COL9A2, NDRG1, SAMHD1, AKAP5, 20 RNF213, RNF213, APAF1, STX1A, SSH1, SSH1, CCRL2, CCR6, CSF2RB, HAVCR2, KLF5, MX1, ACTA2, OAS3, EMP1, CTNNAL1, MGC12916, CCL17, FOSL2, SAT1, TRPV2, PRIC285, SOCS2, ETV7, TIGIT, RASAL1, OPTN, MGST2, GPR68, MYO1G, PTPLA, TNFRSF11A, ANXA2, IRF5, C14orf139, CAPN2, LFNG, IL12RB1, MYO1E, GLRX, DENND3, ANXA2P2, NQO1, C10orf128, ANTXR2, ANTXR2, SLC26A11, FLVCR2, PREX1, 25 SLC2A8, CDKN2A, TMEM149, SYT11, TOX, TOX2, FUT7, ANXA2P1, FAM129B, DFNB31, TMPRSS6, IL1RN, ISG15, CDKN1B, FAM129A, TST, HDAC9, TMEM110, SMPD1, CDKN1A, C17orf67, ANXA2P3, MPST, IRF7, LMCD1, SNX24, HMOX1, ATP2B4, FCER2, HPGD, RASGRP4, FAM164A, IFI6, FAM110C, XKRX, PBX4, NTNG2, CST7, BASP1, C14orf49, GLIPR1, DHRS2, TWIST1, SPSB1, CYTH4, CADM1, ITIH4, LOC541471, 30 CGA, LOC645166, PARP12, NINJ2, MICAL1, OAS1, HLA-DRB4, LGALS3, OASL, CORO2A, HLA-DRB3, KIAA1370, HERC6, STAC, MSC, CCR5, SUOX, RHOC, HLA-

DQB2, PDE4A, LOC100302650, XAF1, FCRL3, RTKN2, GLIPR2, HLA-DRB1, IL13, P2RY10, IL10, CXCR6, LSP1, ACP5, SLC1A4, FXYD7, TRIB2, LMNA, HLA-DPA1, MEOX1, LGALS1, HLA-DRB5, IL10RA, HLA-DRA, CARD16, IL5, RGS1, HLA-DQA2, AKR1C3, IL4, HLA-DMA, GPR55, AQP3, MUSTN1, P2RY8, FANK1, IL9, CCNG2,
 5 ADAM12, LOC654342, IL17A, PPP2R2B, and FAM46C.

Exemplary genes according to Table 2 upregulated Treg vs Teff at 0h FC4 include C12orf75, SELPLG, SWAP70, RGS1, PRR11, SPATS2L, SPATS2L, TSHR, C14orf145, CASP8, SYT11, ACTN4, ANXA5, GLRX, HLA-DMB, PMCH, RAB11FIP1, IL32, FAM160B1, SHMT2, FRMD4B, CCR3, TNFRSF13B, NTNG2, CLDND1, BARD1, FCER1G,
 10 TYMS, ATP1B1, GJB6, FGL2, TK1, SLC2A8, CDKN2A, SKAP2, GPR55, CDCA7, S100A4, GDPD5, PMAIP1, ACOT9, CEP55, SGMS1, ADPRH, AKAP2, HDAC9, IKZF4, CARD17, VAV3, OBFC2A, ITGB1, CIITA, SETD7, HLA-DMA, CCR10, KIAA0101, SLC14A1, PTTG3P, DUSP10, FAM164A, PYHIN1, MYO1F, SLC1A4, MYBL2, PTTG1, RRM2, TP53INP1, CCR5, ST8SIA6, TOX, BFSP2, ITPRIPL1, NCAPH, HLA-DPB2, SYT4, NINJ2,
 15 FAM46C, CCR4, GBP5, C15orf53, LMCD1, MKI67, NUSAP1, PDE4A, E2F2, CD58, ARHGEF12, LOC100188949, FAS, HLA-DPB1, SELP, WEE1, HLA-DPA1, FCRL1, ICA1, CNTNAP1, OAS1, METTL7A, CCR6, HLA-DRB4, ANXA2P3, STAM, HLA-DQB2, LGALS1, ANXA2, PI16, DUSP4, LAYN, ANXA2P2, PTPLA, ANXA2P1, ZNF365, LAIR2, LOC541471, RASGRP4, BCAS1, UTS2, MIAT, PRDM1, SEMA3G, FAM129A, HPGD,
 20 NCF4, LGALS3, CEACAM4, JAKMIP1, TIGIT, HLA-DRA, IKZF2, HLA-DRB1, FANK1, RTKN2, TRIB1, FCRL3, and FOXP3.

Exemplary genes according to Table 2 upregulated in Teff at 16 h v 0 h include AARS, ABCF2, ACOT7, ACTL6A, AHSA1, AIM2, AIMP2, ALAS1, ALDH1B1, ANKRD13B, APOL1, ARMCX3, ASPHD2, B3GNT5, B4GALT2, B4GALT5, BATF, BATF3, BCAT2,
 25 BCL2L1, BOP1, BTLA, BYSL, C11orf75, C15orf23, C15orf63, C16orf59, C17orf79, C17orf96, C1orf163, C3orf26, C4orf43, C8orf30A, C9orf64, CAD, CBR1, CCDC56, CCDC86, CCL20, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, CCNB1, CCND2, CCT3, CCT5, CCT6A, CCT7, CD109, CD200, CD274, CD3EAP, CD40LG, CD82, CDC20, CDC45L, CDC6, CDK4, CDT1, CENPM, CETN3, CHAC2, CHEK1, CISD1, CISH, CKS1B, COPB2, CORO1C, CSF2,
 30 CTNNA1, CTPS, CTTN, DARS2, DCAF12, DCTPP1, DHCR24, DKC1, DTL, E2F1, EBNA1BP2, ECE2, EDARADD, EEF1E1, EGR2, EIF2B3, EIF2S1, EIF5B, EIF6, ENO1,

ESPL1, EXOSC3, EXOSC4, F5, F5, FABP5, FABP5L3, FADS1, FAM40B, FARSA, FASLG, FDPS, FKBP4, FKBP4, FOSL1, FREQ, G0S2, G3BP1, GALE, GAR1, GART, GEM, GEMIN6, GEMIN7, GFOD1, GINS1, GINS2, GLRX2, GNG8, GNPDA1, GPATCH4, GPN3, GPR171, GTF2H2D, HIVEP3, HMGCS1, HN1L, HNRNPAB, HSPD1, HSPE1, HYAL2, IARS, IER3, IFNG, IFRD2, IGFBP4, IL12RB2, IL15RA, IL17F, IL2, IL21, IL22, IL2RA, IL3, IRF4, IRF8, ISOC2, KCNK5, KEAP1, KIAA0020, KIAA0664, LAG3, LAPTM4B, LARP4, LIF, LOC286016, LOC344967, LOC442308, LOC728402, LRP8, LSM2, LTA, LYAR, MANF, MATK, MCM10, MCM2, MCM3, MCM4, METTL13, MIR1182, MIR155, MIR155HG, MIR621, MPV17L2, MPZL2, MRM1, MRPL12, MRPL15, MRPL17, MRPL35, MRPL51, MRPS17, MRPS23, MRTO4, MTCH2, MTHFD1L, MTHFD2, MYOF, NAB2, NDFIP2, NDUFAF1, NFE2L3, NFKBIL2, NLN, NME1, NME1-NME2, NOLC1, NOP16, NPTX1, NT5DC2, NUDCD1, NUP43, NUP62, OTUD7B, PACSIN3, PAICS, PAK1IP1, PAM, PDCD1, PDCD2L, PDIA4, PDIA6, PEA15, PFAS, PFDN6, PFDN6, PFKM, PFKP, PGAM1, PGAM4, PHB, PHF6, PKM2, PLAGL2, PNPO, POLD2, POLE2, POLR3K, POP1, PPIL1, PPP1R14B, PRDX1, PRDX3, PRDX4, PRMT1, PRMT5, PRSS23, PSAT1, PSMA3, PSMA5, PSMA6, PSMB3, PSMB5, PSMD1, PSMD11, PSMD14, PTGFRN, PTMS, PTRH1, PTRH2, PUS7, PYCR1, PYCRL, RARS, RBBP8, RCC1, RPF2, RPP25, RRP1, RRP9, RUVBL1, RUVBL2, SAMD4A, SCD, SDC4, SECTM1, SEH1L, SEMA7A, SFT2D1, SFXN1, SH2D2A, SHF, SHMT2, SIPA1L2, SLAMF1, SLC1A5, SLC27A2, SLC27A4, SLC29A1, SLC38A5, SLC39A14, SLC43A3, SLC6A9, SLCO4A1, SNORA18, SNORD17, SORD, SPR, SQLE, SRM, SRXN1, STIP1, STT3A, TALDO1, TAP1, TBKBP1, TBL3, TBX21, TIMM8B, TIMM8B, TIPIN, TMCC2, TMEM165, TMEM194A, TMEM208, TMEM97, TNF, TNFAIP8L2, TNFRSF4, TNFRSF9, TNFSF14, TOMM40, TPI1, TRIP10, TRIP13, TTLL12, TUBA1B, TUBB, TUBB, TUBB, TUBG1, TXN, TXNDC5, UBE2T, UCK2, UGDH, UHRF1, UMPS, UTP6, VDAC1, VDR, WARS, WDR12, WDR18, WDR3, WDR4, WDR77, YIF1A, YWHAG, ZBED2, ZDHHC16, ZNF593, ZNF607, and ZWINT.

Exemplary genes according to Table 2 upregulated in Treg 16h vs 0h Fc8 include AARS, ACOT7, AGRN, AHSA1, AIM2, AIMP2, ALAS1, ALDH1B1, APOL1, APOL2, B4GALT2, BATF, BATF3, BCL2A1, BCL2L1, BOP1, BYSL, C17orf96, C2CD4A, C5orf32, C9orf64, CCDC86, CCL17, CCL20, CCT5, CD3EAP, CD40LG, CD68, CD7, CDK2AP2, CDK4, CHAC2, CHPF, CISD1, CISH, COPB2, CRIM1, CSF1, CTLA4, CTSL1, CTTN, DCTPP1,

DHCR24, EBI3, EBNA1BP2, ECE2, EDARADD, EGR2, EMP1, ENO1, EPAS1, EXOSC4, FABP5, FAH, FAM40B, FARSA, FKBP4, FKBP4, FLT1, FLT1, FOSL1, FREQ, G6PD, GALE, GART, GCLM, GEM, GK, GNPDA1, GPR56, HIVEP3, HMGCS1, HMOX1, HN1L, HSPA1A, HSPA1B, HSPD1, HSPE1, HYAL2, IER3, IFRD2, IKBIP, IL10, IL12RB2, IL13, IL15RA, IL17A, IL1R1, IL1R2, IL1RL2, IL1RN, IL2RA, IL3, IL4, IL4I1, IL5, IL9, IRF4, KCNK5, LAG3, LAPTM4B, LIF, LOC344967, LOC389333, LOC442308, LRRC32, LRRC61, LTA, LYAR, MANF, MATK, METRNL, METTL13, MGC29506, MICAL2, MIR1182, MIR155, MIR155HG, MLEC, MRPL12, MRTO4, MTHFD1L, MYOF, NAB2, NDFIP2, NDUFAF1, NKG7, NLN, NME1, NME1-NME2, NOP16, NPM3, NUDCD1, PAICS, PANX2, PDCD1, PDGFA, PDIA4, PDIA6, PFAS, PGAM4, PHB, PNPO, POP1, PPIL1, PPPDE2, PRDX1, PRDX3, PRDX4, PRKAR1B, PRMT1, PRMT5, PSAT1, PSMB5, PSMD1, PSMD11, PTGFRN, PTRH1, PUS7, PYCR1, RASAL1, RBBP8, RCC1, SC4MOL, SCD, SDC4, SECTM1, SEH1L, SEMA7A, SETP11, SERPINE2, SERPINH1, SH2D2A, SLC16A13, SLC16A3, SLC1A5, SLC27A2, SLC27A4, SLC29A1, SLC38A5, SLC39A1, SLC39A14, SLC43A3, SLCO4A1, SOCS1, SPHK1, SPINT1, SQLE, SRM, SRXN1, STIP1, STT3A, TBKBP1, TBX21, TMPRSS6, TNF, TNFRSF11A, TNFRSF12A, TNFRSF18, TNFRSF1B, TNFRSF4, TNFRSF8, TNFRSF9, TNFSF14, TOMM40, TRIP10, TTLL12, TUBB, TUBB, TUBB, TXN, TYMP, UCK2, UGDH, VDR, VTRNA1-3, WARS, WDR12, WDR4, WDR77, XIRP1, YWHAG, ZBED2, ZBTB32, ZDHHC16, and ZNF282.

An exemplary list of the T_{REG} genes upregulated at 16h include AIM2, ALAS1, BATF, C5orf32, CCL17, CD40LG, CHAC2, CSF1, CTSL1, EBNA1BP2, EDARADD, EMP1, EPAS1, FABP5, FAM40B, FKBP4, FOSL1, GCLM, GK, GPR56, HMOX1, HSPD1, HSPE1, IKBIP, IL10, IL13, IL15RA, IL1RN, IL2RA, IL3, IL4, IL5, IL9, KCNK5, LTA, MANF, MIR1182, MIR155, MIR155HG, MYOF, NDUFAF1, NLN, NME1, NME1-NME2, PANX2, PDIA6, PGAM4, PPIL1, PPPDE2, PRDX4, PRKAR1B, PSMD1, PSMD11, PUS7, RBBP8, SLC27A2, SLC39A14, SLC43A3, SRXN1, STIP1, STT3A, TBX21, TNFRSF11A, TNFRSF1B, TNFRSF8, TNFRSF9, TXN, UCK2, VDR, VTRNA1-3, WDR12, YWHAG, ZDHHC16, and ZNF282. The upregulated expression may be determined, e.g., by measuring RNA levels for the indicated genes.

An exemplary list of the T_{EFF} genes upregulated at 16h include AIM2, ALAS1, B4GALT5, BATF, C3orf26, C4orf43, CCL3, CCL4, CCT3, CCT7, CD40LG, CHAC2, CSF2, CTNNA1, EBNA1BP2, EDARADD, EEF1E1, EIF2B3, EIF2S1, FABP5, FAM40B, FKBP4, FOSL1, GFOD1, GLRX2, HSPD1, HSPE1, IFNG, IL15RA, IL21, IL2RA, IL3, KCNK5, KIAA0020, LARP4, LRP8, LTA, MANF, MIR1182, MIR155, MIR155HG, MTCH2, MYOF, NDUFAF1, NLN, NME1, NME1-NME2, OTUD7B, PAM, PDIA6, PEA15, PFKM, PGAM1, PGAM4, PPIL1, PRDX4, PRSS23, PSMD1, PSMD11, PSMD14, PTRH2, PUS7, RBBP8, RPF2, RPP25, SFXN1, SLC27A2, SLC39A14, SLC43A3, SORD, SPR, SRXN1, STIP1, STT3A, TBX21, TMCC2, TMEM165, TNFRSF9, TXN, TXNDC5, UCK2, VDR, WDR12, YWHAG, and ZDHHC16.

The Abbas gene sets compared the expression profiles of 17 immune cell types and identified genes uniquely expressed in certain cell types relative to others. The select Abbas gene sets that were included in the Gene Set Analysis are listed in **Table 3** and include CD4+ T cells naïve and resting, CD8+ T cells naïve and resting, helper Th1 at 12 hours, helper Th1 at 48 hours, helper Th2 at 12 hours, helper Th2 at 48 hours, memory T resting (naïve) cells, and memory T activated cells.

Table 3: Gene sets comprised of gene up or down regulated resting and activated T-cell subtypes (Abbas data set)

Table 3	
Gene Set	Number of genes
Downregulated CD8 vs CD4 Naïve T-cells	200
Downregulated Naïve CD4 vs 12H activated Th1	200
Downregulated Naïve CD4 vs 48H activated Th1	200
Downregulated Naïve CD4 vs 12H activated Th2	200
Downregulated Naïve CD4 vs 48H activated Th2	200
Downregulated Th1 vs Th2 12H activated	200
Downregulated Th1 vs Th2 48H activated	200
Downregulated unstimulated vs stimulated memory T-cells	200
Upregulated CD8 vs CD4 Naïve T-cells	200
Upregulated Naïve CD4 vs 12H activated Th1	200
Upregulated Naïve CD4 vs 48H activated Th1	200

Table 3	
Gene Set	Number of genes
Upregulated Naïve CD4 vs 12H activated Th2	200
Upregulated Naïve CD4 vs 48H activated Th2	200
Upregulated Th1 vs Th2 12H activated	200
Upregulated Th1 vs Th2 48H activated	200
Upregulated unstimulated vs stimulated memory T-cells	200

The Gattinoni gene sets compared the expression profiles of various CD8+ memory T cell subsets. Specifically, immune cells were isolated from healthy donors and the following CD8+ T memory subsets were purified: T_N (naïve), T_{SCM} (memory stem cells), T_{CM} (central memory), T_{EM} (effector memory). Gene sets were defined by comparing between all pairs of groups (e.g. T_{SCM} vs. T_N) and by identifying those genes that either progressively increased or decreased across the 4 conditions in order from T_N → T_{SCM} → T_{CM} → T_{EM}. The select gene sets from Gattinoni *et al.* that were considered in the Gene Set Analysis are tabulated in **Table 4**.

Table 4: Gene sets comprised of gene up or down regulated resting and activated T-cell subtypes (Gattinoni data set)

Table 4	
Gene Set	Number of genes
T _{CM} vs T _{EM}	29
T _N vs T _{CM}	148
T _N vs T _{EM}	212
T _{SCM} vs T _{CM}	19
T _{SCM} vs T _{EM}	75
T _{SCM} vs T _N	73
Progressively down	208
Progressively up	32

Each gene set (e.g., ALL and CLL RNAseq gene sets, Szabo gene sets, Abbas gene sets, and Gattinoni gene sets) was evaluated to determine its association with subject response (i.e., CR, PR, or NR) in the following manner: a meta-gene was calculated for each subject, where the meta-gene score for subject *j* was defined as

$$m_j = \sum_{i=1}^G \frac{x_{ij} - \mu(x_{.j})}{\sigma(x_{.j})}$$

where x_{ij} is the expression value of gene i in subject j for a given gene set $n=1,...,G$; $\mu(x_{.j})$ is the mean of genes $1,...,G$ in subject j ; and $\sigma(x_{.j})$ is the standard deviation of genes $1,...,G$ in subject j .

- 5 A 3-group statistical model was applied to each gene set to determine whether the meta-gene was statistically different between the CLL product CRs, PRs, and NRs. A schematic illustrating this approach is given in **FIG. 2B**. CRs are more like resting T_{EFF} cells, whereas NR are more like activated T_{EFF} cells. CTL019 NR samples are in a more activated state than CR samples. Gene sets that were found to be significantly altered and predictive of patient response to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019) are listed in **Table 5**.
- 10

Table 5: Gene sets that are enriched in CLL samples

Table 5					
Gene Set	Source	CRs	NRs	Product	Apheresis
T _{EFF} 16h vs 0h	Szabo	T _{EFF} oh	T _{EFF} 16h	X	X
T _{REG} 16h vs 0h	Szabo	T _{REG} oh	T _{REG} 16h	X	X
T _{REG} vs T _{EFF} 16h	Szabo	T _{EFF}	T _{REG}	X	X
Naïve CD4 vs 12H act Th1	Abbas	Naïve CD4	Th1	X	X
Naïve CD4 vs 12H act Th2	Abbas	Naïve CD4	Th2	X	X
Naïve CD4 vs 48H act Th1	Abbas	Naïve CD4	Th1	X	X
Naïve CD4 vs 48H act Th2	Abbas	Naïve CD4	Th2	X	X
Unstim vs stim memory	Abbas	Unstimulated	Stimulated	X	
T _{SCM} vs T _{EM}	Gattinoni	T _{SCM}	T _{EM}	X	
T _{SCM} vs T _{CM}	Gattinoni	T _{SCM}	T _{CM}	X	
T _{CM} vs T _{EM}	Gattinoni	T _{EM}	T _{CM}	X	
Progressively down	Gattinoni	Early stage	Late stage	X	X

FIG. 3 depicts an exemplary schematic of memory T cell precursors and subsets. Without wishing to be bound by a particular theory, the state of memory T cells in CTL019 samples is likely a major component of response.

For a subset of the patients in the manufactured product study described in Example 1, whole genome RNAseq was also performed on T cells collected by apheresis. The gene sets described above were evaluated in these 14 apheresed samples (2 CRs, 3 PRs, and 9 NRs). Gene sets that were found to be significantly altered and predictive of patient response to CTL019 therapy are tabulated in **Table 5**.

Whole genome RNAseq was performed on 7 ALL manufactured product CR samples and 4 ALL apheresis CR samples. Meta-gene scores for each gene set were calculated for the ALL samples as described above for the CLL samples. Gene sets with meta-gene scores correlating with the expected pattern of response in product and apheresis samples (ALL → CLL CR → CLL PR → CLL NR) are tabulated in **Table 6**. Gene sets marked with * in **Table 6** are also correlated with response in apheresis samples.

Table 6: Gene sets correlating to response over product ALL and CLL samples (ALL → CLL CR → CLL PR → CLL NR)

Table 6
Gene Set
Downregulated Treg vs Teff 0h (FC3 p<0.05)*
Downregulated Treg vs Teff 16h (FC3 p<0.05)
Upregulated Treg vs Teff 0h (FC4 p<0.05)*
Upregulated Treg vs Teff 16h (FC4 p<0.05)
TCMvsTEM down gene set
TCMvsTEM up gene set
TNvsTCM down gene set*
TNvsTCM up gene set*
TNvsTEM down gene set*
TNvsTEM up gene set*
TSCMvsTCM down gene set*
TSCMvsTCM up gene set*

TSCMvsTEM up gene set*
TSCMvsTN down gene set*
TSCMvsTN up gene set*
Progressively down*
Progressively up*
Downregulated CD8 vs CD4 Naïve T-cells*
Upregulated Naïve CD4 vs 12H activated Th1
Upregulated Naïve CD4 vs 48H activated Th1
Upregulated Naïve CD4 vs 12H activated Th2
Upregulated Naïve CD4 vs 48H activated Th2*
Downregulated Th1 vs Th2 12H activated

For example, the meta-gene score for the gene set comprised of genes upregulated in T_{SCM} in comparison to T_{CM} is found to be correlated with response in both apheresis and product samples, **FIG. 4**. The meta-gene scores from healthy donor samples with manufactured product are included in the plot to serve as a reference point. The x-axis is samples by response group where a=apheresis and p=product. The y-axis is normalized meta-gene expression scores. Gene sets enriched in CLL CRs (e.g., CTL019 CRs) are also enriched in acute lymphoblastic leukemias (ALLs). ALL and CLL CRs are enriched in T stem cell (T_{SCM}) subset specific genes, whereas CLL PRs and NRs are enriched in T central memory (T_{CM}) subset genes. The same pattern is seen in apheresis as in product samples. ALL expression patterns are most similar to CLL CRs and are even more extreme in the direction of resting/unstimulated/early memory T cells.

FIG. 5A depicts an exemplary result from a Principle Component Analysis (PCA) of CTL019 samples. This exemplary PCA result illustrates that CRs, ALL and Normal samples cluster separately from PRs and NRs. **FIG. 5B** depicts an exemplary result from a PCA of CTL019 and apheresis samples. This exemplary PCA result illustrates that CRs, ALL and Normal samples cluster separately from PRs and NRs and from the apheresis cluster.

FIG. 6 depicts an exemplary schematic depicting immunophenotyping of apheresis and product samples.

Manufactured CTL019 product (e.g., genetically engineered CAR19-expressing T cells obtained from CLL patients) classified as complete responders (CR), partial responders (PR), non-responders (NR), or pending were assessed for expression of immune checkpoint inhibitor molecules, such as PD-1, LAG3, and TIM3.

5 CD 19 CAR-expressing cells (e.g., T cells, NK cells) from CLL patients (e.g., manufactured product) with different responses to CAR-expressing cell therapy were analyzed by flow cytometry to determine percentages of CD4+ and CD8+ T cells. The CD19 CAR-expressing cells were from: patients that responded to CAR-expressing cell therapy (CR) (n=5); patients that partially responded to CAR-expressing cell therapy (n=8), patients that did not
10 respond to CAR-expressing cell therapy (NR) (n=19); and patients that were pending, e.g., not yet assigned to a group (NA) (n=3). Cells were labeled with antibodies that specifically recognize CD4, CD8, the CAR19 molecule, and immune checkpoint molecules PD-1, LAG3, and TIM3, and secondary antibodies conjugated to fluoresceins, according to standard methods for flow cytometry analysis known in the art. Expression of each marker, e.g., CD4+, CD8+, etc., was
15 determined by flow cytometry analysis software, and subpopulations (e.g., CD4+ T cells, CD8+ T cells, or CAR19-expressing T cells) were further analyzed for the expression of immune checkpoint molecules PD-1, LAG3, and TIM3.

Using the methods and analysis described above, the percentage of CD4-expressing cells and CD8-expressing cells was determined for each patient in each response group. As described
20 above, 36 manufactured CTL019 samples from CLL patients were analyzed, and included 5 CR, 8 PR, 19NR and 3 pending. **FIG. 7A** depicts an exemplary result illustrating percent CD4+ cells and patient response. Partial responders were shown to have a statistically significant greater percentage of CD4+ cells. **FIG. 7B** depicts an exemplary result illustrating percent CD8+ cells and patient response. Complete responders were shown to have a statistically significant great
25 percentage of CD8+ cells.

An example of the flow cytometry profiles analysis used to determine surface marker expression is shown in **FIG. 8A** and **8B**. Cells expressing CD4+ were determined using flow cytometry, and were further analyzed for CAR19 and PD-1 expression, such that the x-axis of the profiles indicate CAR19 expression (the top left (Q5) and bottom left (Q8) quadrants show
30 the CAR19-negative CD4+ cells, while the top right (Q6) and bottom right (Q7) quadrants show

the CAR19-expressing CD4+ cells) and the y-axis shows PD-1 expression (the bottom left (Q8) and right (Q7) quadrants show the PD-1 negative CD4+ cells and the top left (Q5) and right (Q6) quadrants show the PD-1-expressing CD4+ cells). In the CD4+ population from a CAR-expressing cell (e.g., T cell, NK cell) responder, 44.7% of the CD4+ cells overall expressed PD-1, and about 22.3% of the CAR19-expressing cells were PD-1 positive, while 27.2% of CAR19-expressing cells were PD-1 negative (FIG. 8A). In contrast, in the CD4+ population from a non-responder, there was a significant decrease in CAR19-expressing cells overall (about 15.3% compared to the 49.5% in CR), with 14.7% of the CAR19-expressing cells being PD-1 positive while only 0.64% were PD-1 negative (FIG. 8B). Comparison between the profiles in FIG. 8A and FIG. 8B shows that a much higher percentage of the CD4+ cells from a non-responder express PD-1 (about 92.9%) compared to the CAR-expressing cell responder (about 44.7%).

Using the methods and analysis described above, the percentage of PD-1 expressing (PD-1+) cells of the CD4+ population and the CD8+ population was determined for each patient in each response group. Non-responders were shown to have a greater percentage of PD-1+ cells in both the CD4+ (FIG. 8C) and CD8+ (FIG. 8D) populations compared to those that responded to CAR therapy (CR); the increase of average PD-1 percentage was statistically significant for both CD4+ and CD8+ populations. Partial responders (PR) exhibited higher percentages of PD-1+ cells than responders (CR) in both CD4+ (FIG. 8C) and CD8+ (FIG. 8D) populations.

Further analysis was performed to determine the distribution of cells expressing PD-1, LAG3, and TIM3 from patients with different responses to CAR therapy. Representative cell profile analysis for PD-1, LAG3, and TIM3 expression in the CD4+ population are shown in FIG. 9 and FIG. 10. The cell populations were first analyzed for CAR19+ expression. The CAR19+ population was then analyzed for PD-1 and LAG3 expression (FIG. 9) or PD-1 and TIM3 expression (FIG. 10). In the LAG3+ population from a CAR-expressing cell (e.g., T cell, NK cell) responder, 36.1% of the CAR19+ cells overall expressed PD-1, and about 7.3% of the LAG3-expressing cells were PD-1 positive, while 5.9% of LAG3-expressing cells were PD-1 negative (FIG. 9). In contrast, in the CAR19+ population from a non-responder, there was a significant increase in LAG3-expressing cells overall (about 69.7% compared to the 13.2% in CR), with 67.3% of the LAG3-expressing cells being CAR19+ positive while only 2.41% were PD-1 negative (FIG. 9). Comparison between the CR and NR flow cytometry profiles in FIG. 9

show that a much higher percentage of the LAG3+ cells from a non-responder express PD-1 (about 67.3%) compared to the CAR-expressing cell (e.g., T cell, NK cell) responder (about 7.3%).

Using the methods and analysis described above, the percentage of PD-1 and LAG-3
5 expressing (PD-1+/LAG-3+) cells of the CAR19+ population was determined for each patient in each response group. Non-responders were shown to have a greater percentage of PD-1+/LAG-3+ cells in the CAR19+ populations compared to those that responded to CAR therapy (CR) (FIG. 9); the increase of average PD-1/LAG-3 percentage was statistically significant for the CAR19+ population. Partial responders (PR) exhibited higher percentages of PD-1+/LAG-3+
10 cells than responders (CR) in the CAR19 + (FIG. 9) population. In an embodiment, NR products exhibit an exhausted phenotype of PD1+ CAR+ and co-expression of LAG3.

Next, the CAR19+ population was analyzed for PD-1 and TIM-3 expression (FIG. 10). In the TIM+ population from a CAR-expressing cell (e.g., T cell, NK cell) responder, 28.5% of the CAR19+ cells overall expressed PD-1 (FIG. 10). In contrast, in the CAR19+ population
15 from a non-responder, there was a significant increase in TIM3+/PD1+ cells, with 83.3% of the CAR19+-expressing cells being TIM3+/PD1+ (FIG. 10).

Using the methods and analysis described above, the percentage of PD-1 and TIM-3
expressing (PD-1+/TIM-3+) cells of the CAR19+ population was determined for each patient in each response group. Non-responders were shown to have a greater percentage of PD-1+/TIM-3+ cells in the CAR19+ populations compared to those that responded to CAR therapy (CR)
20 (FIG. 10); the increase of average PD-1/TIM-3 percentage was statistically significant for the CAR19+ population. Partial responders (PR) exhibited higher percentages of PD-1+/TIM-3+ cells than responders (CR) in the CAR19 + (FIG. 10) population. In an embodiment, NR products exhibit an exhausted phenotype of PD1+ CAR+ and co-expression of TIM3.

25 Cells expressing CD4+ and CD8+ were determined using flow cytometry, and were further analyzed for CD27+ expression. Using the methods and analysis described above, the percentage of CD27 expressing (CD27+) cells of the CD4+ population and the CD8+ population was determined for each patient in each response group. Complete responders (CR) and partial responders (PR) were shown to have a greater percentage of CD27+ cells in both the CD4+

(FIG. 11A) and CD8+ (FIG. 11B) populations compared to non-responders (NR); the increase of average CD27 percentage was statistically significant for both CD4+ and CD8+ populations. Partial responders (PR) exhibited higher percentages of CD27+ cells than complete responders (CR) in CD4+ (FIG. 11A) populations. Complete responders (CR) exhibited higher percentages of CD27+ cells than partial responders (PR) in CD8+ (FIG. 11B) populations. In an embodiment, CD27 levels in a CAR product correlate with patient response. In an embodiment, CRs CD8+ cells display higher percentages of CD27+ cells as compared to PRs and NRs.

FIG. 12 depicts an exemplary multi-color flow cytometry analysis result identifying correlates of response in apheresis samples. 26 apheresed samples from CLL patients were analyzed. Samples included 4 CR, 6 PR, 14NR and 1 patient was not infused.

FIG. 13 depicts an exemplary multi-color flow cytometry analysis result illustrating a correlation between a younger T cell phenotype and response to CTL019 therapy. These data demonstrate that the percentage of CD27+ CD45RO- in CD8+ T cells is predictive of which CLL patients will undergo a complete response to CTL019.

FIG. 14 depicts an exemplary analysis of apheresis in a human patient prior to CTL019 therapy. Exemplary results illustrate that while patient 1000-00045 presented with very few T cells, 27% of the T cells were CD8+ CD27+ CD45RO-.

FIG. 15 depicts an exemplary result of a patient response (patient 1000-00045) to CTL019 therapy. CD8+ CD27+ CD45RO- T cells were a positive predictor of the patient response to CTL019 therapy. These exemplary results illustrate that a good prognostic phenotype in apheresis is a high percentage of CD8+ CD27+ CD45RO- T cells (young phenotype). A poor prognostic phenotype in CTL019 product is a high percentage of PD1+ CAR+ and LAG3+ or TIM3+ T cells (exhausted phenotype).

Significant gene sets from the analyses above were refined to a subset of genes within the gene sets that are significantly differentially expressed between ALL CRs/CLL CRs and CLL NRs as well as following the expected expression pattern of increasing or decreasing from ALL → CLL CR → CLL PR → CLL NR. An exemplary listing of genes that were significantly differentially expressed are listed in **Table 7A**. **Table 7A** is an exemplary list of biomarkers whose expression values predict patient response to CTL019 therapy. **Table 7A** was further

refined to produce a flow cytometry biomarker gene panel by selecting for genes that are cell surface markers. Exemplary cell surface genes that predict patient response to CTL019 therapy are shown in **Table 8**.

5 **Table 7A: Exemplary genes that predict patient response to CTL019 therapy**

Table 7A		
Gene	Unigene	Accession No.
ABCA7	Hs.134514	NM_019112
ABTB1	Hs.107812	NM_172027, NM_172028, NM_032548
ACOT9	Hs.298885	NM_001037171, NM_001033583
ACTA2	Hs.500483	NM_001141945, NM_001613
ADAMTS10	Hs.657508	NM_030957
ADD3	Hs.501012	NM_016824, NM_019903, NM_001121
ADPRH	Hs.99884	NM_001125
AEBP1	Hs.439463	NM_001129
AES	Hs.515053	NM_198970, NM_198969, NM_001130
AIM2	Hs.281898	NM_004833
ALAS1	Hs.476308	NM_199166, NM_000688
ALPK1	Hs.652825	NM_025144, NM_001102406
ALS2CL	Hs.517937	NM_147129, NM_182775
AMD1	Hs.159118	NM_001634, NM_001033059
ANKRD55	Hs.436214	NM_024669, NM_001039935
ANKZF1	Hs.437647	NM_018089, NM_001042410
ANTXR2	Hs.162963, Hs.720941	NM_001145794, NM_058172
ANXA2	Hs.591361, Hs.546235, Hs.511605	NM_004039, NM_001136015, NM_001002858, NM_001002857
ANXA2P2	Hs.534301	
AP1G2	Hs.343244	NM_003917
AP1M1	Hs.71040	NM_032493, NM_001130524
AP2A2	Hs.19121	NM_012305
APAF1	Hs.552567	NM_181869, NM_181868, NM_013229, NM_001160, NM_181861
APBA2	Hs.721380, Hs.618112	NM_001130414, NM_005503
APBB3	Hs.529449	NM_133174, NM_133173, NM_133172, NM_006051
AQP3	Hs.234642	NM_004925
ARFGAP2	Hs.436204	NM_032389
ARHGAP33	Hs.515364	NM_052948
ARHGEF1	Hs.631550	NM_004706, NM_199002, NM_198977

ARHGEF11	Hs.516954	NM_198236, NM_014784
ARHGEF18	Hs.465761	NM_001130955, NM_015318
ARL4C	Hs.723194, Hs.111554	NM_005737
ARPC5L	Hs.132499	NM_030978
ARRB1	Hs.625320, Hs.503284	NM_020251, NM_004041
ARRDC2	Hs.515249	NM_015683, NM_001025604
ARSB	Hs.604199, Hs.149103	NM_000046, NM_198709
ATOX1	Hs.125213	NM_004045
ATP13A3	Hs.529609	NM_024524
ATP1B3	Hs.477789	NM_001679
ATP2A2	Hs.506759	NM_001135765, NM_170665, NM_001681
ATP2B4	Hs.343522, Hs.511311	NM_001001396, NM_001684
ATP8B4	Hs.511311	NM_024837
ATXN7L3B	Hs.744849	NM_001136262
AVEN	Hs.555966	NM_020371
B4GALT5	Hs.370487	NM_004776
BATF	Hs.509964	NM_006399
BCL9L	Hs.414740	NM_182557
BEND5	Hs.475348	NM_024603
BEX4	Hs.184736	NM_001080425, NM_001127688
BIN1	Hs.193163	NM_139350, NM_139348, NM_139349, NM_139343, NM_004305, NM_139345, NM_139344, NM_139347, NM_139351, NM_139346
BNIP3L	Hs.131226	NM_004331
BTN3A1	Hs.191510	NM_001145008, NM_007048, NM_194441, NM_001145009
C10orf128	Hs.385493	NM_001010863
C11orf10	Hs.437779	NM_014206
C11orf21	Hs.559181	NM_001142946
C11orf35	Hs.669395	NM_173573
C12orf5	Hs.504545	NM_020375
C16orf54	Hs.331095	NM_175900
C16orf74	Hs.461655	NM_206967
C17orf48	Hs.47668	NM_020233
C17orf67	Hs.658949	NM_001085430
C19orf29	Hs.267446	NM_001080543, NM_021231
C1QBP	Hs.555866	NM_001212
C20orf11	Hs.353013	NM_017896
C20orf112	Hs.516978	NM_080616
C21orf2	Hs.517331	NM_004928
C2orf67	Hs.591638, Hs.282260	NM_152519

C3orf26		NM_001167924, NM_032359
C4orf43		NM_018352
C5orf13	Hs.483067, Hs.36053, Hs.694860	NM_001142475, NM_001142476, NM_004772, NM_001142482, NM_001142477, NM_001142483, NM_001142478, NM_001142474, NM_001142481, NM_001142479, NM_001142480
C5orf30	Hs.482976	NM_033211
C5orf32	Hs.529798	NM_032412
C5orf39	Hs.529385, Hs.721020	NM_001014279
CABIN1	Hs.517478	NM_012295
CACHD1	Hs.443891	NM_020925
CADM1	Hs.370510	NM_014333, NM_001098517
CAPG	Hs.516155	NM_001747
CAPS	Hs.584744	NM_004058, NM_080590
CASK	Hs.495984	NM_001126054, NM_001126055, NM_003688
CBX4	Hs.405046	NM_003655
CCDC47	Hs.202011	NM_020198
CCL17	Hs.546294	NM_002987
CCL3	Hs.514107	NM_002983
CCL4	Hs.75703	NM_002984
CCR1	Hs.301921	NM_001295
CCT2	Hs.189772	NM_006431
CCT3	Hs.491494	NM_001008800, NM_005998, NM_001008883
CCT7	Hs.368149	NM_001009570, NM_006429, NM_001166284, NM_001166285
CD248	Hs.195727	NM_020404
CD40LG	Hs.592244	NM_000074
CD58	Hs.34341	NM_001144822, NM_001779
CD70	Hs.715224, Hs.501497	NM_001252
CD80	Hs.838	NM_005191
CDC123	Hs.412842	NM_006023
CDC25B	Hs.153752	NM_004358, NM_021872, NM_021873
CDC42BPG	Hs.293590	NM_017525
CDK7	Hs.184298	NM_001799
CDKN1A	Hs.370771	NM_078467, NM_000389
CDKN2A	Hs.512599	NM_058197, NM_058195, NM_000077
CERK	Hs.200668	NM_022766
CFP	Hs.53155	NM_001145252, NM_002621
CHAC2	Hs.585944	NM_001008708
CHI3L2	Hs.514840	NM_001025199, NM_001025197, NM_004000
CHMP7	Hs.5019	NM_152272
CLDND1	Hs.531371	NM_001040181, NM_001040183, NM_001040200, NM_001040199, NM_001040182, NM_019895

CLTC	Hs.491351	NM_004859
CNN3	Hs.483454	NM_001839
CNOT8	Hs.26703	NM_004779
CNPY3	Hs.414099	NM_006586
COQ3	Hs.713623	NM_017421
CSF1	Hs.591402	NM_000757, NM_172212, NM_172211, NM_172210
CSF2	Hs.1349	NM_000758
CSNK2A1	Hs.654675, Hs.644056	NM_001895, NM_177560, NM_177559
CST7	Hs.143212	NM_003650
CTC1	Hs.156055	NM_025099
CTDSP1	Hs.444468	NM_182642, NM_021198
CTDSP2	Hs.524530	XM_001720210, XM_001722552, XM_002344384, XM_001725997, NM_005730
CTNNA1	Hs.656653, Hs.445981	NM_001903
CTSL1	Hs.418123	NM_001912, NM_145918
CUL9	Hs.485434	NM_015089
CUTA	Hs.520070	NM_001014433, NM_001014840, NM_015921, NM_001014838, NM_001014837
CYFIP1	Hs.26704	NM_014608, NM_001033028
CYP2J2	Hs.152096	NM_000775
DBP	Hs.414480, Hs.528006	NM_001352
DCAF11	Hs.525251	NM_001163484, NM_181357, NM_025230
DCBLD2	Hs.203691	NM_080927
DCHS1	Hs.199850	NM_003737
DCTN6	Hs.158427	NM_006571
DDX10	Hs.591931	NM_004398
DENND2D	Hs.557850	NM_024901
DENND5A	Hs.501857	NM_015213
DERL1	Hs.241576	NM_001134671, NM_024295
DFNB31	Hs.93836	NM_001083885, NM_015404
DGKD	Hs.471675	NM_152879, NM_003648
DGKZ	Hs.502461	NM_001105540, NM_003646, NM_201533, NM_201532
DHRS2	Hs.272499	NM_182908, NM_005794
DIABLO	Hs.169611	NM_138929, NM_019887
DNAJB6	Hs.490745	NM_005494, NM_058246
DPEP2	Hs.372633	NM_022355
DUSP22	Hs.29106	NM_020185, XM_001718070
E2F6	Hs.603093	NM_198256
EBNA1BP2	Hs.346868	NM_006824, NM_001159936
EDARADD	Hs.352224	NM_080738, NM_145861

EED	Hs.503510	NM_152991, NM_003797
EEF1E1	Hs.602353, Hs.723203	NM_004280, NM_001135650
EGFL6	Hs.12844	NM_001167890, NM_015507
EHD1	Hs.523774	NM_006795
EIF2B3	Hs.533549	NM_001166588, NM_020365
EIF2S1	Hs.151777	NM_004094
ELL2	Hs.708710, Hs.192221	NM_012081
EMP1	Hs.436298	NM_001423
EPAS1	Hs.468410	NM_001430
EPHA4	Hs.371218	NM_004438
EPHX1	Hs.89649	NM_001136018, NM_000120
EPPK1	Hs.200412	NM_031308
ERGIC2	Hs.339453	NM_016570
ERGIC3	Hs.472558	NM_015966, NM_198398
ERP29	Hs.75841	NM_001034025, NM_006817
ETFA	Hs.39925	NM_001127716, NM_000126
ETNK1	Hs.29464	NM_001039481, NM_018638
ETV7	Hs.272398	NM_016135
FAAH	Hs.720143	NM_001441
FABP5	Hs.408061	NM_001444
FAF2	Hs.484242	NM_014613
FAIM3	Hs.723317, Hs.58831	NM_001142472, NM_001142473, NM_005449
FAM117B	Hs.471130	NM_173511
FAM134B	Hs.711125	NM_001034850, NM_019000
FAM13A	Hs.97270	NM_014883, NM_001015045
FAM193B	Hs.484289	NM_019057
FAM40B	Hs.489988	NM_020704, NM_001134336
FAM63A	Hs.723127	NM_018379, NM_001163260, NM_001163259, NM_001163258, NM_001040217
FAM65B	Hs.559459	NM_014722, NM_015864
FANCL	Hs.720331	NM_001114636, NM_018062
FANK1	Hs.352591	NM_145235
FAR2	Hs.298851	NM_018099
FAU	Hs.387208	NM_001997
FCER1G	Hs.433300	NM_004106
FCER2	Hs.465778	NM_002002
FCGBP	Hs.111732	NM_003890, XM_001717543
FCHO1	Hs.96485	NM_001161358, NM_001161357, NM_001161359, NM_015122
FCRL3	Hs.292449	NM_052939
FGD3	Hs.411081	NM_033086, NM_001083536
FGF9	Hs.111	NM_002010

FKBP4	Hs.713721, Hs.524183	NM_002014
FLOT2	Hs.514038	NM_004475
FLT3LG	Hs.428	NM_001459
FLVCR2	Hs.615289, Hs.509966	NM_017791
FOSL1	Hs.283565	NM_005438
FOSL2	Hs.596972, Hs.220971	NM_005253
FRAT1	Hs.126057	NM_005479
GAL3ST4	Hs.44856	NM_024637
GALNT4	Hs.713979, Hs.25130	NM_003774
GCLM	Hs.315562	NM_002061
GCNT1	Hs.521568	NM_001490, NM_001097633, NM_001097635, NM_001097634, NM_001097636
GFOD1	Hs.484686	NM_018988
GFPT1	Hs.580300	NM_002056
GIPC3	Hs.266873	NM_133261
GK	Hs.1466, Hs.654557	NM_001128127, NM_000167, NM_203391
GLRX2	Hs.458283	NM_016066, NM_197962
GMEB2	Hs.473286	NM_012384
GNAI1	Hs.134587	NM_002069
GPA33	Hs.651244	NM_005814
GPD1L	Hs.82432	NM_015141
GPKOW	Hs.503666	NM_015698
GPR125	Hs.99195	NM_145290
GPR56	Hs.513633	NM_001145773, NM_001145774, NM_001145771, NM_001145772, NM_005682, NM_201525, NM_001145770, NM_201524
GPSM3	Hs.520046	NM_022107
GRAP	Hs.567416	NM_006613
GRASP	Hs.407202	NM_181711
GTF2A2	Hs.512934	NM_004492
HAVCR1	Hs.129711	NM_001099414, NM_012206
HBS1L	Hs.378532	NM_001145207, NM_001145158, NM_006620
HDAC9	Hs.196054	NM_014707, NM_178423, NM_178425, NM_058176, NM_058177
HIGD1A	Hs.711098, Hs.593134, Hs.7917	NM_014056, NM_001099669, NM_001099668
HIP1	Hs.329266, Hs.619089	NM_005338
HLA-DMA	Hs.351279	NM_006120
HLA-DPA1	Hs.347270	NM_033554
HLA-DQA2	Hs.591798	NM_020056
HLA-DQB2	Hs.719990	NM_001198858, NM_001300790
HLA-DRA	Hs.520048	NM_019111
HLA-DRB1	Hs.716081, Hs.696211, Hs.723344, Hs.534322	NM_002124, NM_021983, XM_002346251

HLA-DRB5	Hs.534322	NM_002125
HLF	Hs.196952	NM_002126
HMOX1	Hs.517581	NM_002133
HSPD1	Hs.595053, Hs.723164	NM_199440, NM_002156
HSPE1	Hs.1197	NM_002157
HYI	Hs.709864	NM_031207
ICAM3	Hs.654563	NM_002162
IDUA	Hs.89560	NM_000203
IER2	Hs.501629	NM_004907
IFNAR2	Hs.708195	NM_207584, NM_207585, NM_000874
IFNG	Hs.856	NM_207585
IGF1R	Hs.643120, Hs.714012	NM_000875
IGSF3	Hs.171057	NM_001007237, NM_001542
IGSF9B	Hs.204121	NM_014987
IKBIP	Hs.252543	NM_201612, NM_201613, NM_153687
IL10	Hs.193717	NM_000572
IL11RA	Hs.591088	NM_004512, NM_147162, NM_001142784
IL13	Hs.845	NM_002188
IL15RA	Hs.524117	NM_002189, NM_172200
IL1RAP	Hs.478673	NM_134470, NM_001167930, NM_001167928, NM_001167929, NM_002182
IL1RL1	Hs.66	NM_003856, NM_016232
IL1RN	Hs.81134	NM_000577, NM_173841, NM_173842, NM_173843
IL21	Hs.567559	NM_021803
IL2RA	Hs.231367	NM_000417
IL2RB	Hs.474787	NM_000878
IL3	Hs.694	NM_000588
IL4	Hs.73917	NM_000589, NM_172348
IL5	Hs.2247	NM_000879
IL6ST	Hs.532082	NM_002184, NM_175767
IL9	Hs.960	NM_000590
ING4	Hs.524210	NM_001127583, NM_001127582, NM_001127586, NM_001127585, NM_001127584, NM_016162
INPP5A	Hs.523360, Hs.715308	NM_005539
INTS1	Hs.532188	NM_001080453
IRF2BP2	Hs.350268	NM_001077397, NM_182972
ISOC1	Hs.483296	NM_016048
ITGA6	Hs.133397	NM_001079818, NM_000210
ITPKB	Hs.528087, Hs.659396	NM_002221
ITPR3	Hs.65758	NM_002224
JAKMIP1	Hs.479066	NM_144720, NM_001099433

KAT8	Hs.533803	NM_032188, NM_182958
KCNK5	Hs.444448	NM_003740
KCTD12	Hs.644125	NM_138444
KIAA0020	Hs.493309	NM_014878
KIAA0141	Hs.210532	NM_014773, NM_001142603
KIAA0664L3	Hs.715792	
KIAA0748	Hs.33187	NM_001098815, NM_001136030
KIAA1257	Hs.518247	NM_020741
KIAA1279	Hs.279580	NM_015634
KIAA1683	Hs.313471	NM_025249, NM_001145305, NM_001145304
KIAA1797	Hs.136247	NM_017794
KIF3A	Hs.43670	NM_007054
KIT	Hs.479754	NM_001093772, NM_000222, XM_001724747, XM_936229
KLF2	Hs.107740	NM_016270
KLF3	Hs.298658	NM_016531
KPNA3	Hs.527919	NM_002267
KRT72	Hs.662013	NM_080747, NM_001146226, NM_001146225
KRT73	Hs.55410	NM_175068
LAIR1	Hs.572535	NM_002287, NM_021706
LARP4	Hs.26613	NM_199188, NM_199190, NM_052879, NM_001170808, NM_001170803, NM_001170804
LDLRAP1	Hs.590911	NM_015627
LEF1	Hs.555947	NM_001166119, NM_001130713, NM_001130714, NM_016269
LGMN	Hs.18069	NM_001008530, NM_005606
LIMA1	Hs.525419	NM_001113547, NM_001113546, NM_016357, NM_017806
LIME1	Hs.233220	NM_017806
LMBR1L	Hs.272838	NM_018113
LMNA	Hs.594444	NM_005572, NM_170708, NM_170707
LMO7	Hs.207631	NM_015842, NM_005358
LOC100289511	Hs.729250	XM_002347442, XM_002343308, XM_002344795
LOC100302650	Hs.729719	
LOC282997	Hs.599931	
LOC283174	Hs.504370	
LOC338799	Hs.524804	
LOC541471	Hs.652166, Hs.652426, Hs.560805	
LOC728392	Hs.104305	NM_001162371
LRCH4	Hs.719669, Hs.125742	NM_002319
LRP8	Hs.576154	NM_001018054, NM_004631, NM_033300, NM_017522
LRRN1	Hs.163244	NM_020873

LSM14B	Hs.105379	NM_144703
LTA	Hs.36	NM_001159740, NM_000595
LTBP3	Hs.289019	NM_001130144, NM_001164266, NM_021070
LYPD3	Hs.631594	NM_014400
MAF	Hs.134859	NM_005360, NM_001031804
MAL	Hs.80395	NM_022438, NM_022439, NM_002371, NM_022440
MAMLD1	Hs.20136	NM_005491
MANF	Hs.436446	NM_006010
MAP2K6	Hs.463978	NM_002758
MAP4K2	Hs.534341	NM_004579
MARCKSL1	Hs.75061	NM_023009
MCF2L	Hs.170422, Hs.597691	NM_001112732, NM_024979
MDS2	Hs.523369	
MED28	Hs.434075, Hs.644788	NM_025205
MED6	Hs.497353	NM_005466
MEGF6	Hs.593645	NM_001409
MEOX1	Hs.438	NM_001040002, NM_013999, NM_004527
MFGE8	Hs.3745	NM_005928, NM_001114614
MINPP1	Hs.121260	NM_004897
MIR1182		
MIR155		
MIR155HG	Hs.697120	
MLXIP	Hs.721711, Hs.437153	NM_014938
MOB1A	Hs.602092	NM_018221
MPI	Hs.75694	NM_002435
MPRIP	Hs.462341, Hs.646854	NM_201274, NM_015134
MRPL13	Hs.333823	NM_014078
MRPL22	Hs.483924	NM_014180, NM_001014990
MRPL33	Hs.515879	NM_145330, NM_004891
MRPL39	Hs.420696	NM_017446, NM_080794
MRPL42	Hs.199579	NM_014050, NM_172177, NM_172178
MRPS28	Hs.521124	NM_014018
MSC	Hs.442619	NM_005098
MSL1	Hs.532786	NM_001012241
MTCH2	Hs.269944	NM_014342
MYADM	Hs.380906	NM_001020819, NM_001020818, NM_001020821, NM_001020820, NM_138373
MYCBP2	Hs.591221	NM_015057
MYO15B	Hs.390817	
MYOF	Hs.602086	NM_013451, NM_133337
MZF1	Hs.399810	NM_198055, NM_003422

NAA50	Hs.596074	NM_025146
NCKAP1	Hs.603732	NM_205842, NM_013436
NDRG2	Hs.525205	NM_201540, NM_201541, NM_201539, NM_201538, NM_201537, NM_201536, NM_201535, NM_016250
NDUFAB1	Hs.189716	NM_005003
NDUFAF1	Hs.106529	NM_016013
NDUFV2	Hs.464572	NM_021074
NEDD9	Hs.37982	NM_182966, NM_001142393, NM_006403
NEK7	Hs.723303, Hs.24119	NM_133494
NELL2	Hs.505326	NM_006159, NM_001145110, NM_001145108, NM_001145109, NM_001145107
NFATC1	Hs.701518, Hs.534074	NM_172388, NM_172387, NM_172389, NM_006162, NM_172390
NIPA1	Hs.511797	NM_144599, NM_001142275
NIPAL3	Hs.523442	NM_020448
NLN	Hs.247460	NM_020726
NME1	Hs.463456	NM_198175, NM_001018138, NM_000269, NM_001018139, NM_002512, NM_001018137, NM_001018136
NME1-NME2	Hs.463456	NM_198175, NM_001018138, NM_001018139, NM_001018137, NM_001018136, NM_000269, NM_002512
NME7	Hs.706952	NM_013330, NM_197972
NPEPPS	Hs.443837, Hs.449880	NM_006310, XM_001725441, XM_001725426
NQO1	Hs.406515	NM_001025434, NM_001025433, NM_000903
NRCAM	Hs.21422	NM_001037132, NM_001037133, NM_005010
NSDHL	Hs.57698	NM_015922, NM_001129765
NSMAF	Hs.372000	NM_003580, NM_001144772
NT5DC3	Hs.48428	NM_001031701
NUBP1	Hs.81469	NM_002484
NUCB2	Hs.654599	NM_005013
NUMA1	Hs.325978	NM_006185
NUP153	Hs.601591, Hs.718703	NM_005124
OASL	Hs.118633	NM_198213, NM_003733
ODC1	Hs.467701	NM_002539
OLFM2	Hs.169743	NM_058164
OSBPL7	Hs.463320	NM_145798
OTUD7B	Hs.98322	NM_020205
P2RY8	Hs.111377	NM_178129
P4HA2	Hs.519568	NM_001017974, NM_001017973, NM_001142598, NM_001142599, NM_004199
PAM	Hs.369430	NM_138766, NM_000919, NM_138822, NM_138821
PAN2	Hs.273397	NM_014871, NM_001166279, NM_001127460

PANX2	Hs.440092	NM_001160300, NM_052839
PAPD7	Hs.481542	NM_006999, NM_001171806, NM_001171805
PARK7	Hs.419640	NM_007262, NM_001123377
PBX4	Hs.466257	NM_025245
PCIF1	Hs.716563	NM_022104
PCSK5	Hs.368542	NM_006200
PDE4A	Hs.89901	NM_001111308, NM_006202, NM_001111307, NM_001111309
PDIA6	Hs.212102	NM_005742
PDK1	Hs.470633	NM_002610
PEA15	Hs.517216	NM_003768
PFKM	Hs.75160	NM_001166688, NM_001166686, NM_001166687, NM_000289
PGAM1	Hs.592599, Hs.632918	NM_002629
PGAM2	Hs.632642	NM_000290
PGAM4	Hs.632822	NM_001029891
PHKA2	Hs.54941	NM_000292
PHLPP1	Hs.465337	NM_194449
PHLPP2	Hs.709458	NM_015020
PICALM	Hs.163893	NM_001008660, NM_007166
PIK3R5	Hs.278901	NM_001142633, NM_014308
PIP4K2A	Hs.57079	NM_005028
PITPNM2	Hs.272759	NM_020845
PLAA	Hs.27182	NM_001031689
PLCG1	Hs.268177	NM_182811, NM_002660
PLCH2	Hs.170156	NM_014638
PNISR	Hs.520287, Hs.644863	NM_015491, NM_032870,
POMP	Hs.268742	NM_015932
PPFIBP2	Hs.655714	NM_003621
PPIL1	Hs.27693	NM_016059
PPP2R1B	Hs.584790	NM_002716, NM_181699
PPP2R2B	Hs.655213	NM_181676, NM_181675, NM_181674, NM_181678, NM_181677, NM_004576, NM_001127381
PPP6R2	Hs.449098, Hs.733531, Hs.740776	NM_001242898, NM_001242899, NM_001242900, NM_014678
PPPDE2	Hs.570455	NM_015704
PRDM1	Hs.436023	NM_182907, NM_001198
PRDX4	Hs.83383	NM_006406
PREP	Hs.436564	NM_002726
PRKAR1B	Hs.520851	NM_001164760, NM_002735, NM_001164758, NM_001164759, NM_001164762, NM_001164761
PRKCZ	Hs.496255	NM_001033581, NM_002744, NM_001033582

PRR5	Hs.720401, Hs.102336	NM_001017530, NM_181333, NM_181334, NM_181335, NM_015366, NM_001017526, NM_001017529, NM_001017528
PRSS23	Hs.25338	NM_007173
PSMA1	Hs.102798	NM_001143937, NM_148976, NM_002786
PSMB1	Hs.352768	NM_002793
PSMC2	Hs.437366	NM_002803
PSMD1	Hs.3887	NM_002807
PSMD11	Hs.655396	NM_002815
PSMD14	Hs.567410	NM_005805
PSMD5	Hs.193725	NM_005047
PTP4A3	Hs.43666	NM_007079, NM_032611
PTPLA	Hs.114062	NM_014241
PTPN6	Hs.63489	NM_002831, NM_080548, NM_080549
PTRH2	Hs.12677	NM_016077
PUS7	Hs.520619	NM_019042
PYCARD	Hs.499094	NM_145182, NM_013258
R3HDM2	Hs.443673	NM_014925
RAB1A	Hs.310645	NM_004161, NM_015543
RAB21	Hs.524590	NM_014999
RAB23	Hs.555016	NM_016277, NM_183227
RAB33A	Hs.654356	NM_004794
RAB37	Hs.351413	NM_001163990, NM_001163989, NM_175738, NM_001006638
RAB43	Hs.546542, Hs.723723	XM_001723593, XM_001720383, XM_001724346, NM_198490, XM_002342369
RABGGTB	Hs.78948	NM_004582
RAD50	Hs.655835	NM_133482, NM_005732
RAPGEF6	Hs.483329	NM_001164386, NM_001164387, NM_001164388, NM_001164389, NM_001164390, NM_016340
RASA3	Hs.593075	NM_007368
RASGRP2	Hs.99491	NM_153819, NM_001098670, NM_001098671
RBBP8	Hs.546282	NM_002894, NM_203292, NM_203291
RBKS	Hs.11916	NM_022128
REEP5	Hs.429608	NM_005669
RGS1	Hs.75256	NM_002922
RGS14	Hs.9347	NM_006480
RHOT2	Hs.513242	NM_138769
RNF19A	Hs.292882	NM_015435, NM_183419
RNF213	Hs.195642	NM_020914, NM_020954, XM_002343588
RNF34	Hs.292804	NM_194271, NM_025126
RPF2	Hs.372265	NM_032194
RPP25	Hs.8562	NM_017793

RYBP	Hs.7910	NM_012234
S1PR1	Hs.154210	NM_001400
S1PR4	Hs.662006	NM_003775
SCML4	Hs.486109	NM_198081
SDHB	Hs.465924	NM_003000
SDK2	Hs.435719	NM_001144952
SEC24D	Hs.189641	NM_014822
SEC31B	Hs.18889	NM_015490
SELL	Hs.728756	NM_000655
SELP	Hs.73800	NM_003005
SEPT11	Hs.128199	NM_018243
SEPT3	Hs.120483	NM_019106, NM_145733
SEPT9	Hs.440932	NM_001113491, NM_001113492, NM_001113493, NM_001113494, NM_001113495, NM_001113496, NM_001293695, NM_001293696, NM_001293697, NM_001293698, NM_006640,
SERPINF1	Hs.532768	NM_002615
SERPINF2	Hs.159509	NM_001165920, NM_001165921, NM_000934
SF1	Hs.502829	NM_004630, NM_201995, NM_201997, NM_201998
SFXN1	Hs.369440	NM_022754
SH2B1	Hs.723196	NM_001145797, NM_015503, NM_001145795, NM_001145796, NM_001145812
SHC1	Hs.433795	NM_001130040, NM_003029, NM_001130041, NM_183001
SIGIRR	Hs.501624	NM_021805, NM_001135054, NM_001135053
SIRPG	Hs.590883	NM_080816, NM_018556, NM_001039508
SLC16A1	Hs.75231	NM_001166496, NM_003051
SLC16A10	Hs.591327	NM_018593
SLC1A4	Hs.654352	NM_003038, NM_001135581
SLC24A6	Hs.286194	NM_024959
SLC25A17	Hs.474938	NM_006358
SLC25A32	Hs.607819	NM_030780
SLC26A11	Hs.4866	NM_173626, NM_001166348, NM_001166347, NM_001166349
SLC27A2	Hs.720807	NM_003645, NM_001159629
SLC2A1	Hs.473721	NM_006516
SLC2A4RG	Hs.435126	NM_020062
SLC2A8	Hs.179522	NM_014580
SLC35F2	Hs.524014	NM_017515
SLC39A14	Hs.491232	NM_001128431, NM_015359, NM_001135153, NM_001135154
SLC39A8	Hs.288034	NM_022154, NM_001135148, NM_001135147, NM_001135146

SLC40A1	Hs.643005	NM_014585
SLC43A3	Hs.99962	NM_199329, NM_017611, NM_014096
SLIRP	Hs.655105	NM_001267863, NM_001267864, NM_031210
SNPH	Hs.713451, Hs.323833	NM_014723, NM_001136566
SNRK	Hs.476052	NM_017719, NM_001100594
SNRPG	Hs.631639, Hs.654528, Hs.516076, Hs.465167	NM_003096, XM_002347904, NM_001146693, XM_002343626, XM_001723258
SNX24	Hs.483200	NM_014035
SOAT1	Hs.496383	NM_003101
SORD	Hs.878, Hs.633539	NM_003104
SOX4	Hs.643910	NM_003107
SP140L	Hs.662198	NM_138402
SPATS2L	Hs.120323	NM_001100424, NM_001100423, NM_001100422, NM_015535
SPG7	Hs.185597	NM_003119, NM_199367
SPR	Hs.301540	NM_003124
SPSB3	Hs.592080	NM_080861
SPTBN1	Hs.503178, Hs.705692	NM_003128, NM_178313
SRGN	Hs.1908	NM_002727
SRSF5	Hs.632326	NM_001039465, NM_006925
SRXN1	Hs.719997, Hs.516830	NM_080725
SSH1	Hs.199763	NM_001161331, NM_001161330, NM_018984
ST8SIA4	Hs.308628	NM_175052, NM_005668
STAC	Hs.56045	NM_003149
STAT6	Hs.524518	NM_003153
STIP1	Hs.337295	NM_006819
STMN3	Hs.639609	NM_015894
STRAP	Hs.504895	NM_007178
STT3A	Hs.504237	NM_152713
STX16	Hs.307913	NM_001134772, NM_001134773, NM_003763, NM_001001433
SULT1B1	Hs.129742	NM_014465
SUN1	Hs.438072	NM_001171944, NM_001171946, NM_001171945, NM_001130965, NM_025154
SUN2	Hs.517622	NM_015374
SVIL	Hs.499209	NM_003174, NM_021738
SYT11	Hs.32984	NM_152280
SYTL1	Hs.469175	NM_032872
SYTL3	Hs.436977	NM_001009991
TACC3	Hs.104019	NM_006342
TANK	Hs.132257	NM_004180, NM_133484
TBCC	Hs.75064	NM_003192

TBX21	Hs.272409	NM_013351
TCEA3	Hs.446354	NM_003196
TCF20	Hs.475018	NM_181492, NM_005650
TCF7	Hs.573153	NM_201633, NM_201632, NM_001134851, NM_001134852, NM_213648, NM_003202, NM_201634
TFRC	Hs.529618	NM_001128148, NM_003234
THNSL1	Hs.645274	NM_024838
TIGIT	Hs.421750	NM_173799
TIMD4	Hs.334907	NM_001146726, NM_138379
TJP3	Hs.25527	NM_014428
TMC6	Hs.632227	NM_001127198, NM_007267
TMC8	Hs.592102	NM_152468
TMCC2	Hs.6360	NM_014858
TMED2	Hs.75914, Hs.592682	NM_006815
TMEM110	Hs.556077, Hs.705605	NM_198563, NM_205853
TMEM123	Hs.503709	NM_052932
TMEM165	Hs.479766	NM_018475
TMEM220	Hs.462230	NM_001004313
TMEM33	Hs.31082	NM_018126
TMEM63A	Hs.119387	NM_014698
TMEM66	Hs.521487	NM_016127
TMEM70	Hs.106650	NM_017866, NM_001040613
TMEM71	Hs.293842	NM_144649, NM_001145153
TMIGD2	Hs.263928	NM_001169126, NM_144615
TNFRSF11A	Hs.204044	NM_003839
TNFRSF1B	Hs.256278	NM_001066
TNFRSF8	Hs.1314	NM_152942, NM_001243
TNFRSF9	Hs.654459	NM_001561
TNNT3	Hs.73454	NM_006757, NM_001042782, NM_001042780, NM_001042781
TOP2B	Hs.475733	NM_001068
TPM2	Hs.300772	NM_213674, NM_003289, NM_001145822
TRAPPC6A	Hs.466929	NM_024108
TRIB2	Hs.627749, Hs.467751	NM_021643
TRIM22	Hs.501778, Hs.684559	NM_006074
TRIP12	Hs.591633	NM_004238
TRMT5	Hs.380159	NM_020810
TSC2	Hs.90303	NM_001077183, NM_001114382, NM_000548
TSPAN18	Hs.592575, Hs.385634	NM_001031730, NM_130783
TSPAN32	Hs.271954	NM_139022
TTC4	Hs.720251	NM_004623

TTC9	Hs.79170	NM_015351
TTN	Hs.134602	NM_133432, NM_133379, NM_133378, NM_133437, NM_003319
TWIST1	Hs.66744	NM_000474
TXK	Hs.479669	NM_003328
TXN	Hs.435136	NM_003329
TXNDC5	Hs.719272, Hs.150837	NM_001145549, NM_201280, NM_030810
UBASH3B	Hs.444075	NM_032873
UBE2E2	Hs.595802, Hs.475688	NM_152653
UBE2Z	Hs.514297	NM_023079
UCHL3	Hs.162241	NM_006002
UCK2	Hs.458360	NM_012474
UHRF1BP1L	Hs.620701	NM_001006947, NM_015054
USP19	Hs.255596	NM_006677
USP53	Hs.595368, Hs.431081	NM_019050
UXS1	Hs.469561	NM_025076
UXT	Hs.172791	NM_004182, NM_153477
VDR	Hs.524368	NM_001017535, NM_000376
VILL	Hs.103665	NM_015873
VIPR1	Hs.348500	NM_004624
VSIG1	Hs.177164	NM_001170553, NM_182607
VTRNA1-3		
WDR12	Hs.73291	NM_018256
WNT7A	Hs.72290	NM_004625
WRB	Hs.198308	NM_001146218, NM_004627
XAF1	Hs.441975	NM_017523, NM_199139
YPEL3	Hs.513491	NM_031477, NM_001145524
YWHAE	Hs.591239, Hs.513851	NM_006761
YWHAG	Hs.520974	NM_012479
ZBTB22	Hs.206770	NM_005453, NM_001145338
ZBTB38	Hs.723156	NM_001080412
ZC3H12C	Hs.376289	NM_033390
ZDHHC16	Hs.76662	NM_032327, NM_198046, NM_198045, NM_198044, NM_198043
ZFP36L2	Hs.503093	NM_006887
ZGPAT	Hs.590868	NM_181485, NM_001083113, NM_032527
ZMAT1	Hs.496512	NM_032441, NM_001011657
ZNF193	Hs.100921	NM_006299
ZNF238	Hs.69997	NM_205768, NM_006352
ZNF282	Hs.657701	NM_003575
ZNF331	Hs.185674	NM_018555, NM_001079907, NM_001079906
ZNF506	Hs.351906	NM_001145404, NM_001099269

ZNF542	Hs.467326	
ZNF673	Hs.632800	NM_017776, NM_001129900, NM_001129898, NM_001129899
ZNF688	Hs.301463, Hs.513509	NM_152458, NM_145271, NM_001024683
ZNF710	Hs.459311	NM_198526
ZNF83	Hs.710125, Hs.665751, Hs.467210, Hs.659798	NM_018300, NM_001105550, NM_001105552, NM_001105551, NM_001105554, NM_001105553, NM_001105549
ZSWIM1	Hs.517075	NM_080603

The most significant genes in **Table 7A** were defined as those with 1) an absolute fold change between ALL CRs/CLL CRs and CLL NRs of greater than 2 and 2) a p-value on the correlation of response and expression of less than 0.01. Thirty-four genes, listed in **Table 7B** below, met this criteria and the expression of these genes were measured on four additional platforms to compare and validate the findings from RNAseq. The four platforms were OpenArray, Fluidigm, Nanostring, and qPCR. Results from this cross-platform comparison experiment confirmed the results and conclusions described herein. Table 7B also indicates whether each gene is upregulated in complete responders (CR) relative to non-responders, or upregulated in non-responders (NR) relative to complete responders. An exemplary publication disclosing the sequence of each gene is also given in Table 7B, and each publication is incorporated by reference in its entirety, including all nucleic acid and protein sequences therein.

Table 7B. Selected genes from Table 7A

Gene	Unigene	Accession No.	Exemplary publication	Upregulated in CR or NR
ALS2CL	Hs.517937	NM_147129, NM_182775	Jouan et al., Behav Brain Funct 9, 9 (2013)	CR
AQP3	Hs.234642	NM_004925	Xie et al., Arch. Dermatol. Res. 305 (5), 397-406 (2013)	CR
C16orf74	Hs.461655	NM_206967	Kim et al., PLoS ONE 5 (12), E15260 (2010)	CR
CCL17	Hs.546294	NM_002987	Lee et al, Pediatr. Res. 74 (5), 545-551 (2013)	NR
CD248	Hs.195727	NM_020404	Kontseikova et al., Int. J. Oncol. 41 (4), 1365-1372 (2012)	CR
CSF2	Hs.1349	NM_000758	Sawada et al., J. Exp. Med. 211 (2), 263-280 (Feb 2014)	NR
DHRS2	Hs.272499	NM_182908, NM_005794	Prunotto et al., J Proteomics 82, 193-229 (2013)	NR
DPEP2	Hs.372633	NM_022355	Willer et al., Nat. Genet. 40 (2), 161-169 (2008)	CR

EPAS1	Hs.468410	NM_001430	Mathew et al., Proc. Natl. Acad. Sci. U.S.A. 111 (1), 291-296 (Jan 2014)	NR
EPHA4	Hs.371218	NM_004438	Xu et al., Proc. Natl. Acad. Sci. U.S.A. 110 (36), 14634-14639 (2013)	CR
FAIM3	Hs.723317, Hs.58831	NM_001142472, NM_001142473, NM_005449	Murakami et al., J. Immunol. 189 (2), 587-597 (2012)	CR
FAM134B	Hs.711125	NM_001034850, NM_019000	Murphy et al., J. Neurol. Neurosurg. Psychiatr. 83 (1), 119-120 (2012)	CR
GPA33	Hs.651244	NM_005814	Deng et al. PLoS ONE 8 (11), E79629 (2013)	CR
IL13	Hs.845	NM_002188	Jiang et al., Am. J. Physiol. Endocrinol. Metab. 305 (11), E1359-E1366 (2013)	NR
IL3	Hs.694	NM_000588	Miyake et al., Cytokine 64 (1), 86-89 (2013)	NR
IL9	Hs.960	NM_000590	Jabeen et al., J. Clin. Invest. 123 (11), 4641-4653 (2013)	NR
KRT72	Hs.662013	NM_080747, NM_001146226, NM_001146225	Principe et al., Proteomics 13 (10-11), 1667-1671 (2013)	CR
KRT73	Hs.55410	NM_175068	De Mateo et al., Proteomics 11 (13), 2714-2726 (2011)	CR
LTA	Hs.36	NM_001159740, NM_000595	Stuart et al., Twin Res Hum Genet 16 (6), 1079-1086 (2013)	NR
MCF2L	Hs.170422, Hs.597691	NM_001112732, NM_024979	Valdes et al., Ann. Rheum. Dis. 71 (9), 1537-1540 (2012)	CR
MDS2	Hs.523369		Meyer et al., PLoS Genet. 6 (8) (2010)	CR
MEGF6	Hs.593645	NM_001409	Nakayama et al. Genomics 51 (1), 27-34 (1998)	CR
MIR155			Weber et al., FEBS J. 272 (1), 59-73 (2005)	NR
PPFIBP2	Hs.655714	NM_003621	Bohm et al., Oncol. Rep. 28 (2), 429-438 (2012)	CR
SCML4	Hs.486109	NM_198081	Vieira et al., Genet. Med. 10 (9), 668-674 (2008)	CR
SDK2	Hs.435719	NM_001144952	Otowa et al., J. Hum. Genet. 54 (2), 122-126 (2009)	CR
SPR	Hs.301540	NM_003124	Yang et al., J. Biol. Chem. 288 (26), 19221-19237 (2013)	NR
SULT1B1	Hs.129742	NM_014465	Ross et al., Nat. Genet. 41 (12), 1345-1349 (2009)	CR
TCF7	Hs.573153	NM_201633, NM_201632, NM_001134851, NM_001134852, NM_213648, NM_003202, NM_201634	Nikuseva-Martic et al., Pathol. Oncol. Res. 19 (3), 545-551 (2013)	CR

TNFRSF8	Hs.1314	NM_152942, NM_001243	Yao et al., Am. J. Surg. Pathol. 37 (9), 1407-1412 (2013)	NR
TSPAN18	Hs.592575, Hs.385634	NM_001031730, NM_130783	Yuan et al., PLoS ONE 8 (3), E58785 (2013)	CR
TWIST1	Hs.66744	NM_000474	Zhou et al., J. Exp. Clin. Cancer Res. 33, 12 (Jan 2014)	NR
VIPR1	Hs.348500	NM_004624	Bono et al., Cancer Cell 23 (4), 477-488 (2013)	CR
VSIG1	Hs.177164	NM_001170553, NM_182607	Chen et al., J Surg Oncol 106 (3), 286-293 (2012)	CR

Cell surface markers differentiating memory T cell subsets that are described in Maus et al. (ANNU. REV. IMMUNOL. 2014) and were not included in the Gattinoni gene sets were also evaluated. Among other things, KLRG1 was identified as a gene whose expression increases in apheresis samples from ALL → CLL CR → CLL PR → CLL NR. KLRG1 expression values predict patient response to CTL019 therapy. At least CD57, CD27, CD122, and CD62L were identified as biomarkers of response in the product samples. Among other things CD57, CD27, CD122, and CD62L expression values predict patient response to CTL019 therapy.

In an embodiment, a complete responder (CR) gene signature comprises one or more biomarker profiles described in **Table 9**.

Table 9: Exemplary biomarker profile of a complete responder to CAR19 therapy

Table 9: Exemplary biomarker profile of a complete responder to CAR19 therapy	
CD27+	PD1-
CD8+	LAG3-
	TIM3-
	KLRG1-
Exemplary CR cell-types	
Resting T effector cells (T _{EM})	
Resting T _{REG}	
Naïve CD4+	
Unstimulated memory T cells (T _{SCM})	
Early memory T cells	

In an embodiment, a non-responder (NR) gene signature comprises one or more biomarker profiles described in **Table 10**.

Table 10: Exemplary biomarker profile of a non-responder to CAR19 therapy

Table 10: Exemplary biomarker profile of a non-responder to CAR19 therapy	
PD1+	CD27-
LAG3+	
TIM3+	
KLRG1+	
Exemplary NR cell-types	
Activated T effector cells (T _{EM})	
Activated T _{REG}	
Activated T _{HI}	
Resting T _{H2}	
Stimulated memory T cells (T _{SCM})	
Late memory T cells	

Based on the biological understanding, combinations of genes from unbiased feature selection, gene sets, and selected genes of interest could be used to further differentiate NR's, PR's, and CR's.

The previously described work was expanded upon in a study of 35 CLL subject samples. This group of 35 subjects includes the 21 CLL subjects in the previous study, for a total of 5 CRs, 9 PRs, and 21 NRs. In this study manufactured CD19 CAR-expressing cell product samples were collected and cultured overnight with control beads. Novel gene signatures based on mRNA expression levels have been identified that predict patient response. The gene lists for the CR vs NR comparison (N=185) is tabulated in **Table 18**.

Table 18. Gene lists for the CR vs NR comparison

Gene	Unigene	Accession No.	FDR
ABCB1	Hs.489033	NM_000927	0.0492
ACSL1	Hs.406678	NM_001995, NM_001286711, NM_001286708, NM_001286710, NM_001286712	0.0362
ADAM12		NM_003474, NM_001288973, NM_021641, NM_001288974, NM_001288975	0.0089
ADAM23		NM_003812	0.0185
ADCY1	Hs.192215	NM_001281768, NM_021116	0.0203
AFAP1	Hs.529369	NM_198595, NM_001134647	0.0884
AGRN	Hs.273330	NM_198576, NM_001305275	0.0212

ANKRD33B	Hs.26039	NM_001164440	0.0097
APLP2	Hs.370247	NM_001142277, NM_001642, NM_001142278, NM_001142276, NM_001243299	0.0429
AQPEP			0.0615
ARHGAP32	Hs.440379	NM_001142685, NM_014715	0.0675
ART3	Hs.731997	NM_001130017, NM_001130016, NM_001130016, NM_001179	0.0890
ATN1	Hs.143766	NM_001007026, NM_001940	0.0675
ATP9A	Hs.649234	NM_006045	0.0029
B4GALNT1	Hs.159481	NM_001478, NM_001276468, NM_001276469	0.0104
B4GALT6		NM_004775	0.0965
C1orf198	Hs.520494	NM_032800, NM_001136494, NM_001136495	0.0047
C21orf63			0.0029
C5orf39			0.0047
C9orf142		NM_183241	0.0870
CACNB2	Hs.59093	NM_201596, NM_201593, NM_201597, NM_201571, NM_001167945, NM_201572, NM_000724, NM_201590, NM_201570	0.0615
CAMK2G		NM_001222, NM_172173, NM_172169, NM_172170, NM_001204492, NM_172171	0.0675
CAMSAP2	Hs.23585	NM_203459, NM_001297708, NM_001297707	0.0797
CCDC74A	Hs.351461	NM_138770, NM_001258304, NM_001258306, NM_001258305	0.0492
CCL22	Hs.534347	NM_002990	0.0666
CCL5		NM_002985, NM_001278736	0.0615
CD109	Hs.399891	NM_133493, NM_001159588, NM_001159587	0.0423
CD200		NM_001004196, NM_005944	0.0299
CD27	Hs.355307	NM_001242	0.0225
CD52		NM_001803	0.0172
CDKN1A	Hs.370771	NM_000389, NM_001220778, NM_001220777, NM_078467	0.0450
CERS6	Hs.743222	NM_203463, NM_001256126	0.0384
CHST2	Hs.8786	NM_004267	0.0063
CNTNAP2	Hs.655684	NM_014141	0.0872
CPA5	Hs.567642	NM_001127442, NM_080385, NM_001127441	0.0433
CPM	Hs.654387	NM_001005502, NM_198320, NM_001874, NM_001005502, NM_198320, NM_001874	0.0466
CR1		NM_000573, NM_000651	0.0891
CTNNA1	Hs.445981, Hs.740112	NM_001903, NM_001290310, NM_001290309, NM_001290307, NM_001290312	0.0148
CXCL9	Hs.77367	NM_002416	0.0299
CXCR5		NM_001716	0.0939
DBN1		NM_004395, NM_080881	0.0492
DEPDC7	Hs.280990	NM_001077242, NM_139160	0.0256

DIRC3			0.0890
DLG2	Hs.367656	NM_001364, NM_001142702, NM_001142699, NM_001142700, NM_001300983, NM_001206769	0.0085
DNAJC12	Hs.260720	NM_021800, NM_201262	0.0891
DRAM1	Hs.525634	NM_018370	0.0376
DSG2	Hs.412597	NM_001943	0.0384
DUSP4		NM_001394, NM_057158	0.0148
EBI3		NM_005755	0.0063
EEF1A2	Hs.433839	NM_001958	0.0497
EEF1DP3			0.0939
EHD4		NM_139265	0.0415
EMP1		NM_001423	0.0541
ENPP2	Hs.190977	NM_006209, NM_001130863, NM_001040092	0.0870
EPAS1	Hs.468410	NM_001430	0.0149
ERP29		NM_006817, NM_001034025	0.0615
EVC	Hs.646899	NM_001306090, NM_153717, NM_001306092	0.0666
EVI5	Hs.594434	NM_005665, NM_001308248	0.0373
FADS2		NM_001281501, NM_001281502, NM_004265	0.0764
FAM134B	Hs.481704	NM_019000, NM_001034850	0.0452
FAM40B			0.0148
FAM65C	Hs.372578	NM_001290268, NM_080829	0.0615
FASN	Hs.83190	NM_004104	0.0884
FKBP11		NM_001143781, NM_016594, NM_001143782	0.0407
FLT1	Hs.594454	NM_002019, NM_001160030, NM_001159920, NM_001160031	0.0699
FLT3LG		NM_001204502, NM_001459, NM_001278637, NM_001278638, NM_001204503	0.0408
FOXP1		NM_032682, NM_001244816, NM_001244815, NM_001244814, NM_001244808, NM_001244812, NM_001012505, NM_001244813, NM_001244810	0.0615
FSCN1	Hs.118400	NM_003088	0.0694
GAS8	Hs.431792, Hs.739124	NM_001481, NM_001286209, NM_001286205, NM_001286208	0.0811
GEM	Hs.654463	NM_181702, NM_005261	0.0275
GNA12	Hs.487341	NM_007353, NM_001282441, NM_001282440	0.0360
GPR56			0.0122
GZMA		NM_006144	0.0805
HCST		NM_014266, NM_001007469	0.0212
HDC	Hs.1481	NM_002112, NM_001306146	0.0890
HSH2D	Hs.631617	NM_032855	0.0243
IL1A		NM_000575	0.0148
IL1RN		NM_173843, NM_173841, NM_000577, NM_173842	0.0615

IL26	Hs.272350	NM_018402	0.0718
ILDR2	Hs.133153, Hs.730291	NM_199351	0.0860
KLRB1	Hs.169824	NM_002258	0.0074
KLRC3	Hs.654362	NM_002261, NM_007333	0.0035
LHFP	Hs.507798	NM_005780	0.0053
LIFR	Hs.133421, Hs.616721	NM_002310, NM_001127671	0.0362
LINC00476			0.0299
LMCD1		NM_014583, NM_001278235, NM_001278233, NM_001278234	0.0423
LMNA	Hs.594444	NM_001282625, NM_005572, NM_170707, NM_001282626, NM_001257374, NM_001282624, NM_170708	0.0677
LOC347411			0.0407
LOC619207			0.0407
LRIG3		NM_001136051, NM_153377	0.0746
LRP1B	Hs.656461	NM_018557	0.0615
LRRC4C	Hs.745123	NM_001258419, NM_020929	0.0733
LY9	Hs.403857	NM_001261456, NM_001261457, NM_002348, NM_001033667	0.0615
MAST2	Hs.319481	NM_015112	0.0959
MGAT4A	Hs.177576	NM_001160154, NM_012214	0.0085
MOB1B	Hs.691454	NM_173468, NM_001244766	0.0441
MRPL54		NM_172251	0.0910
MYOF	Hs.602086	NM_133337, NM_013451	0.0615
NAB2	Hs.159223	NM_005967	0.0373
NCDN	Hs.121870	NM_001014841, NM_001014839, NM_014284	0.0876
NCKAP1	Hs.603732	NM_013436, NM_205842	0.0299
NCR3		NM_147130, NM_001145466, NM_001145467	0.0595
NDUFA12	Hs.674965	NM_018838, NM_001258338	0.0936
NEDD4L	Hs.185677	NM_001243960, NM_001144967, NM_015277, NM_001144971, NM_001144968, NM_001144969, NM_001144970, NM_001144966, NM_001144964, NM_001144965	0.0333
NEURL3	Hs.149219	NM_001285485, NM_001285486	0.0821
NINL	Hs.631508	NM_025176	0.0709
NOSIP	Hs.7236	NM_001270960, NM_015953	0.0001
NRP2	Hs.471200	NM_201266, NM_201264, NM_201267, NM_003872, NM_018534, NM_201279	0.0926
OSMR	Hs.120658	NM_001168355, NM_003999	0.0432
PANX2	Hs.440092	NM_001160300, NM_052839	0.0376
PCBP3	Hs.736936	NM_020528, NM_001130141	0.0089
PHKA1	Hs.201379	NM_002637, NM_001122670, NM_001172436	0.0130

PITPNC1	Hs.591185	NM_181671, NM_012417	0.0373
PLXNB2	Hs.3989	NM_012401	0.0148
PLXNB3	Hs.632833	NM_005393, NM_001163257	0.0981
PMCH		NM_002674	0.0383
POU2AF1	Hs.654525, Hs.733573, Hs.739353	NM_006235	0.0376
PPARG	Hs.162646	NM_138712, NM_005037, NM_138711, NM_015869	0.0821
PPCDC	Hs.458922, Hs.640486	NM_021823, NM_001301103, NM_001301101, NM_001301102, NM_001301104, NM_001301105	0.0224
PRDM1	Hs.436023	NM_001198, NM_182907	0.0376
PRKCDBP		NM_145040	0.0615
PRR5		NM_015366, NM_001198721, NM_181333, NM_001017528, NM_001017530, NM_001017529	0.0384
PSEN2	Hs.25363	NM_000447, NM_012486	0.0299
PTPN6	Hs.63489	NM_080548, NM_002831, NM_080549	0.0733
PTPRCAP		NM_005608	0.0521
PTPRD	Hs.446083	NM_002839, NM_130391, NM_001171025, NM_130393, NM_001040712, NM_130392	0.0141
PVR		NM_006505, NM_001135769, NM_001135768, NM_001135770	0.0149
RABL3	Hs.444360	NM_173825	0.0733
RBMV1E		NM_001006118	0.0089
RGL1	Hs.497148	NM_001297669, NM_015149, NM_001297670, NM_001297671, NM_001297672	0.0891
RNASE4		NM_001282193, NM_001282192, NM_002937, NM_194431	0.0860
RORC	Hs.256022	NM_001001523, NM_005060	0.0027
RPS28		NM_001031	0.0763
S100A4		NM_019554, NM_002961	0.0047
SCARB1		NM_001082959, NM_005505	0.0327
SCD	Hs.558396	NM_005063	0.0870
SCML4		NM_001286408, NM_001286409, NM_198081	0.0860
SDC1	Hs.224607	NM_002997, NM_001006946	0.0299
SDK2	Hs.435719	NM_001144952	0.0981
SEPT3	Hs.120483	NM_145733, NM_019106	0.0582
SEPT5-GP1BB			0.0107
SGPP2	Hs.591604	NM_152386	0.0347
SH2B2	Hs.489448	NM_020979	0.0373
SH3TC1	Hs.479116, Hs.630085	NM_018986	0.0205
SKAP1	Hs.316931	NM_003726, NM_001075099	0.0661
SLC13A3	Hs.655498	NM_022829, NM_001193340, NM_001193339, NM_001193342, NM_001011554	0.0254

SLC22A17	Hs.373498	NM_001289050, NM_016609, NM_020372	0.0944
SLC27A2	Hs.11729	NM_003645, NM_001159629	0.0811
SLC29A1	Hs.25450	NM_001304463, NM_001078175, NM_001078177, NM_001304465, NM_001304466, NM_001304462	0.0150
SLC41A2		NM_032148	0.0936
SLC43A3	Hs.99962	NM_014096, NM_001278201, NM_199329, NM_017611, NM_001278206	0.0423
SLC4A10	Hs.333958	NM_022058, NM_001178015, NM_001178016	0.0376
SOAT2	Hs.656544	NM_003578	0.0130
SORCS3	Hs.671950	NM_014978	0.0876
SPIRE1	Hs.515283	NM_001128626, NM_020148, NM_001128627	0.0615
SPNS3		NM_182538	0.0001
SPOCK1	Hs.582184, Hs.596136	NM_004598	0.0718
SRCIN1	Hs.448872	NM_025248	0.0661
SSBP3	Hs.733025	NM_145716, NM_001009955, NM_018070	0.0376
STX8		NM_004853	0.0937
SULT2B1	Hs.369331	NM_177973, NM_004605	0.0150
TERT	Hs.492203	NM_198253, NM_001193376, NM_005424	0.0765
TIE1	Hs.78824	NM_005424, NM_001253357	0.0931
TLE4		NM_007005, NM_001282760, NM_001282748, NM_001282749, NM_001282753	0.0891
TMOD1	Hs.404289	NM_003275, NM_001166116	0.0308
TNFRSF19		NM_148957, NM_018647, NM_001204458, NM_001204459	0.0224
TNFRSF4	Hs.129780	NM_003327	0.0884
TOB1	Hs.744946	NM_005749, NM_001243885, NM_001243877	0.0945
TOX2	Hs.26608	NM_001098797, NM_001098796, NM_032883, NM_001098798	0.0347
TRIB2	Hs.467751	NM_021643	0.0666
TSKU	Hs.8361	NM_015516, NM_001258210	0.0027
TSPAN13		NM_014399	0.0376
TTBK1	Hs.485436	NM_032538	0.0027
TTC39C	Hs.733420	NM_153211, NM_001243425, NM_001135993, NM_001292030	0.0172
TUBB6	Hs.193491, Hs.744066	NM_001303524, NM_032525, NM_001303529, NM_001303526, NM_001303525	0.0271
uc001acl			0.0212
uc004aex			0.0299
uc010eif			0.0243
uc021oxp			0.0595
USP44		NM_032147, NM_001042403, NM_001278393	0.0666
XYLT1	Hs.22907	NM_022166	0.0890
ZBTB20		NM_001164343, NM_001164347, NM_001164345,	0.0148

		NM_001164342, NM_015642, NM_001164344, NM_001164346	
ZBTB32	Hs.99430, Hs.736841	NM_014383	0.0384
ZNF219	Hs.250493	NM_016423, NM_001102454, NM_001101672	0.0860
ZNF683	Hs.353208	NM_001114759, NM_173574, NM_001307925	0.0205

Gene set analyses were performed to predict patient response to CD19 CAR-expressing cell therapy (e.g., CTL019). Gene set analysis was performed on gene sets described in Example 1, and with gene sets from three additional datasets described in Example 2 (Szabo et al., Abbas et al., and Gattinoni et al.). Each gene set was evaluated to determine its association with subject response (i.e. CR, PR, or NR) as described in Example 2. Gene sets found to be significantly altered and predictive of patient response to CD19 CAR-expressing cell therapy (e.g., CTL019) are listed in **Table 19**.

Table 19. Gene sets predictive of patient response to CAR therapy

Gene Set	Source	CRs	NRs
Treg vs Teff 0h	Szabo	Teff 0h	Treg 0h
Treg vs Teff 16h	Szabo	Teff 16h	Treg 16h
Teff 16h vs 0h	Szabo	Teff 0h	Teff 16h
Treg 16h vs 0h	Szabo	Treg 0h	Treg 16h
Naïve CD4 vs 12h act Th2	Abbas	Naïve CD4	Th2
Naïve CD4 vs 48h act Th2	Abbas	Naïve CD4	Th2
Naïve CD4 vs 12h act Th1	Abbas	Naïve CD4	Th1
Unstim vs stim memory	Abbas	Unstimulated	Stimulated
Progressively down	Gattinoni	Early stage	Late stage

Significant gene sets from the analyses above were refined to a subset of genes within the gene sets that are significantly differentially expressed between the CRs and NRs. An exemplary listing of genes that were significantly differentially expressed are listed in **Table 20**. **Table 20** is an exemplary list of biomarkers whose expression values predict patient response to CTL019 therapy. **Table 20** can be further refined into a smaller list of high confidence biomarkers by setting a stricter FDR. For instance, using a FDR of 0.10 will results in a list of 265 genes and a FDR of 0.01 will result in a list of 27 genes.

Table 20. Exemplary biomarkers for predicting patient response to CAR therapy

Gene	Unigene	Accession No.	FDR
ABCB1	Hs.489033	NM_000927	0.0147
ABTB1	Hs.107812	NM_172027, NM_032548	0.156
ACACA		NM_198834, NM_198837, NM_198836, NM_198839, NM_198838	0.226
ACSL1	Hs.406678	NM_001995, NM_001286711, NM_001286708, NM_001286710, NM_001286712	0.0211
ACSS2	Hs.517034	NM_001242393, NM_018677, NM_001076552	0.189
ACTN1	Hs.509765	NM_001102, NM_001130004, NM_001130005	0.137
ADAM12		NM_003474, NM_001288973, NM_021641, NM_001288974, NM_001288975	0.00259
ADAM7	Hs.116147	NM_003817	0.249
ADD3		NM_019903, NM_016824, NM_001121	0.243
ADH7	Hs.389	NM_001166504, NM_000673	0.179
AES	Hs.515053	NM_198969, NM_001130, NM_198970	0.0307
AGRN	Hs.273330	NM_198576, NM_001305275	0.00795
AHCYL1	Hs.743973	NM_006621, NM_001242675, NM_001242676, NM_001242673, NM_001242674	0.24
AHI1		NM_001134830, NM_017651, NM_001134831, NM_001134832	0.106
AIM2		NM_004833	0.224
AK5	Hs.559718	NM_174858, NM_012093	0.21
AKR1C3		NM_003739, NM_001253908	0.212
ALDH18A1	Hs.500645	NM_002860, NM_001017423	0.234
ALG5		NM_013338, NM_001142364	0.171
ALOX5AP		NM_001629, NM_001204406	0.0878
ALPP	Hs.284255	NM_001632	0.218
ANAPC13	Hs.106909	NM_001242374, NM_015391, NM_001242375	0.246
ANKRD10		NM_017664, NM_001286721	0.229
ANKRD6		NM_001242813, NM_001242809, NM_014942, NM_001242811, NM_001242814	0.0842
ANXA2P3			0.219
AP1G2	Hs.343244, Hs.740123	NM_001282475, NM_001282474, NM_003917	0.0756
APOA2		NM_001643	0.0265
APOBEC3C		NM_014508	0.11
APP	Hs.434980	NM_000484, NM_001136129, NM_201414, NM_001204303, NM_201413, NM_001204302, NM_001136016, NM_001136130, NM_001204301, NM_001136131	0.129
AQP3	Hs.234642	NM_004925	0.0645
ARFRP1	Hs.389277, Hs.661969	NM_001267549, NM_001134758, NM_001267544, NM_001267546, NM_001267545, NM_001267547, NM_003224, NM_001267548	0.112

ARHGEF18	Hs.465761	NM_015318, NM_001130955	0.207
ARID5A		NM_212481	0.184
ARL4C	Hs.111554, Hs.730678	NM_001282431, NM_005737	0.091
ARNTL2		NM_001248003, NM_001248005, NM_001248002, NM_001248004, NM_020183	0.0709
ARRDC2	Hs.515249	NM_001025604, NM_001286826, NM_015683	0.248
ATF7IP2	Hs.513343, Hs.742019	NM_024997, NM_001256160	0.0661
ATP6V1B2	Hs.295917	NM_001693	0.171
ATP8A2		NM_016529	0.222
AURKAIP1		NM_017900, NM_001127230, NM_001127229	0.207
AUTS2	Hs.21631	NM_001127231, NM_015570, NM_001127232	0.158
B4GALT7	Hs.455109	NM_007255	0.115
BACH2	Hs.269764	NM_021813, NM_001170794	0.115
BANP	Hs.461705, Hs.690969	NM_001173541, NM_079837, NM_001173540, NM_017869, NM_001173543, NM_001173539, NM_001173542	0.236
BARD1		NM_000465, NM_001282549, NM_001282543, NM_001282548, NM_001282545	0.232
BASP1	Hs.201641	NM_006317, NM_001271606	0.137
BCL11B	Hs.709690	NM_001282237, NM_138576, NM_001282238, NM_022898	0.134
BCOR		NM_017745, NM_001123384, NM_001123385, NM_001123383	0.22
BEX4	Hs.184736	NM_001080425, NM_001127688	0.218
BFSP1	Hs.129702	NM_001195, NM_001161705, NM_001278607, NM_001278606, NM_001278608	0.186
BHLHE40		NM_003670	0.224
BIN1	Hs.193163	NM_139344, NM_139348, NM_139351, NM_139346, NM_139347, NM_139349, NM_139345, NM_004305, NM_139343, NM_139350	0.192
BIN2	Hs.14770	NM_001290008, NM_001290009, NM_016293, NM_001290007	0.094
BIRC3		NM_182962, NM_001165	0.127
BUB1	Hs.469649	NM_001278617, NM_004336, NM_001278616	0.141
C11orf21	Hs.559181	NM_001142946	0.0679
C11orf48			0.103
C11orf67			0.227
C11orf82			0.196
C14orf49			0.217
C16orf45	Hs.738182	NM_033201, NM_001142469	0.181
C16orf74		NM_206967	0.197
C17orf53	Hs.437059	NM_024032, NM_001171251	0.185
C17orf66			0.229
C1orf162	Hs.288010	NM_174896, NM_001300834	0.135

C1orf54		NM_001301040, NM_001301039, NM_024579, NM_001301042	0.212
C20orf111			0.0568
C20orf112			0.102
C2orf28			0.24
C2orf89			0.159
C5orf30	Hs.482976	NM_033211	0.207
C5orf39			0.00226
C7orf10			0.162
C7orf59			0.0455
C9orf23			0.0943
CA6		NM_001215, NM_001270500, NM_001270501	0.0798
CAMK1		NM_003656	0.215
CAMK2G		NM_001222, NM_172173, NM_172169, NM_172170, NM_001204492, NM_172171	0.0175
CAMK4		NM_001744	0.0524
CAPG	Hs.687978	NM_001747, NM_001256140, NM_001256139	0.0735
CAPS		NM_080590, NM_004058	0.0524
CARM1		NM_199141	0.162
CBLB	Hs.430589	NM_170662	0.061
CCDC47	Hs.202011	NM_020198	0.104
CCDC56			0.0674
CCL20	Hs.75498	NM_001130046, NM_004591	0.249
CCL4L1			0.0434
CCL5		NM_002985, NM_001278736	0.015
CCNB1	Hs.23960	NM_031966	0.195
CCND3		NM_001760, NM_001287427, NM_001136126, NM_001136017, NM_001136125, NM_001287434	0.0618
CCR6		NM_031409, NM_004367	0.0767
CD109	Hs.399891	NM_133493, NM_001159588, NM_001159587	0.013
CD200		NM_001004196, NM_005944	0.00952
CD22	Hs.579691, Hs.716252	NM_001185099, NM_001771, NM_001185100, NM_001278417, NM_001185101	0.124
CD244	Hs.157872	NM_016382, NM_001166663, NM_001166664	0.0605
CD248	Hs.195727	NM_020404	0.0548
CD3D		NM_000732, NM_001040651	0.0455
CD4		NM_000616	0.166
CD5	Hs.58685	NM_014207	0.0926
CD55		NM_000574, NM_001300903, NM_001300904, NM_001300902, NM_001114752	0.139
CD68	Hs.647419	NM_001251, NM_001040059	0.144

CD80	Hs.838	NM_005191	0.061
CDC14A	Hs.127411	NM_033312, NM_033313, NM_003672	0.149
CDC25B	Hs.153752	NM_001287519, NM_001287520, NM_021873, NM_004358, NM_001287522, NM_021872, NM_001287518, NM_001287516, NM_001287517	0.136
CDC42BPB	Hs.654634	NM_006035	0.0835
CDC42EP3	Hs.369574, Hs.689535	NM_006449, NM_001270437, NM_001270438, NM_001270436	0.126
CDC6		NM_001254	0.201
CDKN1A	Hs.370771	NM_000389, NM_001220778, NM_001220777, NM_078467	0.013
CDKN2D	Hs.435051	NM_079421, NM_001800	0.218
CDT1		NM_030928	0.195
CECR1	Hs.170310	NM_177405, NM_001282228, NM_001282227, NM_001282229, NM_001282226, NM_001282225	0.147
CEMP1		NM_001048212	0.179
CEP55	Hs.14559	NM_001127182, NM_018131	0.241
CFH	Hs.363396	NM_000186, NM_001014975	0.158
CFHR2		NM_005666	0.074
CGREF1	Hs.159525	NM_001166240, NM_006569, NM_001166239	0.201
CHEK1	Hs.24529	NM_001114121, NM_001274, NM_001244846, NM_001114122	0.136
CHL1	Hs.148909, Hs.731409	NM_006614, NM_001253387, NM_001253388	0.226
CHMP7	Hs.5019	NM_152272	0.0594
CHST11	Hs.17569	NM_001173982, NM_018413	0.149
CHST12	Hs.744987	NM_001243794, NM_001243795, NM_018641	0.192
CHST2	Hs.8786	NM_004267	0.00226
CHSY1	Hs.110488, Hs.734921	NM_014918	0.11
CLCA2	Hs.241551	NM_006536	0.172
CMAHP			0.0642
CNPY3		NM_006586	0.0605
COL18A1	Hs.517356	NM_130445, NM_030582, NM_130444	0.189
COL6A1	Hs.474053	NM_001848	0.201
CORO1C	Hs.330384	NM_014325, NM_001276471, NM_001105237	0.0566
COX4I1		NM_001861	0.222
CRADD	Hs.591016, Hs.719191	NM_003805	0.144
CRKL	Hs.5613	NM_005207	0.201
CSGALNACT1	Hs.613729	NM_001130518, NM_018371	0.0589
CSNK2A1		NM_001895, NM_177559, NM_177560	0.171
CSTB		NM_000100	0.0477

CSTF2		NM_001325, NM_001306206	0.158
CTDSP1	Hs.444468	NM_001206878, NM_182642, NM_021198	0.195
CTNNA1	Hs.445981, Hs.740112	NM_001903, NM_001290310, NM_001290309, NM_001290307, NM_001290312	0.00562
CTNNA2	Hs.167368	NM_004389, NM_001282598, NM_001164883, NM_001282597, NM_001282600, NM_001282599	0.145
CTNNAL1		NM_001286974, NM_003798	0.124
CTNNBIP1	Hs.463759	NM_020248, NM_001012329	0.091
CTNND2	Hs.314543	NM_001332, NM_001288717, NM_001288715, NM_001288716	0.226
CTSF	Hs.11590	NM_003793	0.224
CTSW	Hs.416848	NM_001335	0.0929
CTTN	Hs.596164	NM_138565, NM_005231, NM_001184740	0.0642
CUX1	Hs.191482	NM_181500, NM_001202546, NM_001202544, NM_001202543, NM_001202545, NM_181552, NM_001913	0.137
CXCL13	Hs.100431	NM_006419	0.192
CYB561	Hs.355264	NM_001017917, NM_001915, NM_001017916	0.208
CYFIP1	Hs.26704	NM_014608, NM_001033028, NM_001287810	0.192
D4S234E			0.224
DAB1	Hs.477370	NM_021080	0.0455
DAXX		NM_001141969, NM_001254717, NM_001141970, NM_001350	0.192
DBN1		NM_004395, NM_080881	0.0127
DENND2D		NM_024901, NM_001271833	0.0882
DENND3	Hs.18166	NM_014957	0.223
DEPDC7	Hs.280990	NM_001077242, NM_139160	0.00865
DGKD	Hs.471675	NM_152879, NM_003648	0.0524
DGKI	Hs.737768	NM_004717	0.0596
DHCR24	Hs.498727	NM_014762	0.0843
DIXDC1	Hs.655626	NM_001278542, NM_001037954, NM_033425	0.224
DLG2	Hs.367656	NM_001364, NM_001142702, NM_001142699, NM_001142700, NM_001300983, NM_001206769	0.00226
DMRT1	Hs.98586	NM_021951	0.0589
DNAJB5	Hs.237506	NM_001135004, NM_012266, NM_001135005	0.0843
DNAJC6	Hs.647643	NM_014787, NM_001256864, NM_001256865	0.219
DNM1	Hs.522413	NM_004408, NM_001005336, NM_001288737, NM_001288738, NM_001288739	0.244
DOCK7	Hs.744927	NM_033407, NM_001272000, NM_001272002, NM_001271999, NM_001272001	0.061
DONSON		NM_017613	0.0754
DPEP2	Hs.372633	NM_022355	0.11
DPP7		NM_013379	0.236
DPYD	Hs.335034	NM_000110, NM_001160301	0.133

DPYSL2	Hs.593187	NM_001197293, NM_001386, NM_001244604	0.106
DSN1	Hs.632268	NM_001145318, NM_001145315, NM_001145317, NM_001145316, NM_024918	0.0767
DTL	Hs.656473	NM_016448, NM_001286229, NM_001286230	0.234
DUSP10	Hs.497822	NM_007207	0.162
DUSP16		NM_030640	0.238
DUSP22		NM_020185, NM_001286555	0.0735
DUSP4		NM_001394, NM_057158	0.00463
DVL2	Hs.118640	NM_004422	0.0847
DYNLL1	Hs.5120	NM_001037494, NM_001037495, NM_003746	0.195
EAPP	Hs.433269	NM_018453	0.246
EBI3		NM_005755	0.00226
EBI3			0.00226
EED		NM_003797, NM_152991, NM_001308007	0.0798
EEF1D		NM_001195203, NM_032378, NM_001130056, NM_001289950, NM_001960, NM_001130053, NM_001130055, NM_001130057	0.101
EFS	Hs.24587	NM_005864, NM_032459, NM_001277174	0.0594
EGFL6	Hs.12844	NM_015507, NM_001167890	0.229
EIF2C4			0.158
ELL2	Hs.192221	NM_012081	0.0455
EMB	Hs.561411	NM_198449	0.24
EMP1		NM_001423	0.0144
ENPP2	Hs.190977	NM_006209, NM_001130863, NM_001040092	0.0275
EPAS1	Hs.468410	NM_001430	0.00636
EPB41L4B	Hs.591901	NM_019114, NM_018424	0.172
EPHA4	Hs.371218	NM_001304536, NM_001304537, NM_004438	0.157
ERGIC3		NM_015966, NM_198398	0.207
ERI2	Hs.248437	NM_080663, NM_001142725	0.0552
ERP29		NM_006817, NM_001034025	0.0113
ESPL1	Hs.153479	NM_012291	0.236
ESR1	Hs.208124	NM_001291230, NM_001122741, NM_001291241, NM_000125, NM_001122742, NM_001122740	0.192
ESRRG		NM_001134285, NM_001243511, NM_001243518, NM_001438, NM_001243514, NM_001243513, NM_206595, NM_001243506, NM_001243510, NM_001243507, NM_001243512, NM_001243509, NM_001243515, NM_001243519, NM_206594	0.195
ETV3		NM_001145312, NM_005240	0.208
EVI5	Hs.594434	NM_005665, NM_001308248	0.0127
FADS1	Hs.503546, Hs.739285	NM_013402	0.16
FADS2		NM_001281501, NM_001281502, NM_004265	0.0243

FAH		NM_000137	0.131
FAIM2	Hs.567424	NM_012306	0.215
FAIM3			0.128
FAM125B			0.0735
FAM134B	Hs.481704	NM_019000, NM_001034850	0.0128
FAM134C	Hs.632262	NM_178126	0.107
FAM40B			0.00562
FAM46C	Hs.356216	NM_017709	0.241
FAM65B	Hs.559459	NM_014722, NM_015864, NM_001286447, NM_001286445, NM_001286446	0.0965
FANCI	Hs.513126	NM_018193, NM_001113378	0.133
FAU		NM_001997	0.137
FDPS		NM_001135822, NM_001242824, NM_002004, NM_001135821, NM_001242825	0.0852
FGD3	Hs.411081	NM_001083536, NM_001286993, NM_033086	0.125
FGF21	Hs.283015	NM_019113	0.249
FHIT	Hs.655995	NM_002012, NM_001166243	0.0505
FKBP11		NM_001143781, NM_016594, NM_001143782	0.0128
FLI1	Hs.504281	NM_002017, NM_001167681, NM_001271012, NM_001271010	0.0965
FLT1	Hs.594454	NM_002019, NM_001160030, NM_001159920, NM_001160031	0.0243
FLT3LG		NM_001204502, NM_001459, NM_001278637, NM_001278638, NM_001204503	0.0124
FLVCR2	Hs.509966	NM_017791, NM_001195283	0.149
FMNL2	Hs.654630	NM_052905	0.171
FNBP1		NM_015033	0.142
FOXN3		NM_001085471, NM_005197	0.207
FOXP1		NM_032682, NM_001244816, NM_001244815, NM_001244814, NM_001244808, NM_001244812, NM_001012505, NM_001244813, NM_001244810	0.015
FXYD5		NM_014164, NM_144779, NM_001164605	0.0852
FXYD7		NM_022006	0.189
G0S2		NM_015714	0.0594
GAB2	Hs.429434	NM_012296, NM_080491	0.0532
GAB3	Hs.496982	NM_080612, NM_001282283, NM_001081573	0.136
GABARAPL1	Hs.524250	NM_031412	0.162
GAD2		NM_001134366, NM_000818	0.129
GARS	Hs.404321	NM_002047	0.109
GATM	Hs.75335	NM_001482	0.124
GBP5	Hs.513726	NM_052942, NM_001134486	0.168
GCET2			0.243

GEM	Hs.654463	NM_181702, NM_005261	0.00795
GK	Hs.1466	NM_203391, NM_001128127, NM_000167, NM_001205019	0.0432
GLCCI1	Hs.131673	NM_138426	0.211
GLIPR2	Hs.493819	NM_001287010, NM_001287013, NM_022343, NM_001287011, NM_001287014, NM_001287012	0.0466
GMNN		NM_001251990, NM_001251989, NM_015895, NM_001251991	0.215
GNG4	Hs.159711	NM_004485, NM_001098722, NM_001098721	0.101
GNLY		NM_006433, NM_001302758, NM_012483	0.184
GPC1		NM_002081	0.186
GPD1L	Hs.82432	NM_015141	0.099
GPKOW		NM_015698	0.167
GPR114			0.17
GPR56			0.00463
GPRC5C	Hs.446438	NM_022036, NM_018653	0.158
GPRIN3		NM_198281	0.215
GPSM3	Hs.520046	NM_001276501, NM_022107	0.122
GRAMD3	Hs.363558, Hs.664026	NM_001146319, NM_023927, NM_001146322, NM_001146321, NM_001146320	0.0594
GRAP		NM_006613	0.158
GTF3C4		NM_012204	0.231
GTPBP1	Hs.276925	NM_004286	0.0665
GYG1	Hs.477892, Hs.727448	NM_004130, NM_001184720, NM_001184721	0.124
GZMA		NM_006144	0.0211
GZMH		NM_001270780, NM_033423, NM_001270781	0.159
H19	Hs.533566		0.151
H1FO	Hs.745024	NM_005318	0.0432
HAO2	Hs.659767	NM_001005783, NM_016527	0.17
HBS1L	Hs.378532	NM_006620, NM_001145158, NM_001145207	0.0528
HERPUD2		NM_022373	0.236
HKDC1	Hs.522988	NM_025130	0.236
HLA-DPA1	Hs.347270	NM_033554, NM_001242524, NM_001242525	0.158
HLA-DQA2		NM_020056, NM_002122	0.179
HLA-DQB2	Hs.731563	NM_001198858, NM_001300790	0.226
HLA-DRB5		NM_002125	0.0645
HMGCR	Hs.628096	NM_000859, NM_001130996	0.0466
HMGCS1		NM_001098272, NM_002130	0.0666
HNRPLL			0.0566
HOXC8		NM_022658	0.142
HPGD	Hs.596913	NM_000860, NM_001145816, NM_001256301,	0.0276

		NM_001256306, NM_001256307, NM_001256305	
HPS5	Hs.437599	NM_007216, NM_181507, NM_181508	0.167
HSD11B1		NM_005525, NM_001206741, NM_181755	0.0502
HSD17B11	Hs.594923	NM_016245	0.156
HSD17B12	Hs.132513	NM_016142	0.143
HSPA1L	Hs.690634	NM_005527	0.193
HSPD1		NM_002156, NM_199440	0.139
ICAM1	Hs.643447	NM_000201	0.132
ICAM2		NM_000873, NM_001099789, NM_001099788, NM_001099786, NM_001099787	0.0847
ICAM3	Hs.654563	NM_002162	0.229
IER2	Hs.501629	NM_004907	0.158
IER3		NM_003897	0.206
IFI44		NM_006417	0.223
IFIH1	Hs.163173	NM_022168	0.0524
IGBP1	Hs.496267	NM_001551	0.151
IGSF3	Hs.171057	NM_001007237, NM_001542	0.0466
IL17RA	Hs.48353	NM_014339, NM_001289905	0.135
IL1A		NM_000575	0.00562
IL1RAP	Hs.478673	NM_001167929, NM_001167928, NM_002182, NM_134470, NM_001167930, NM_001167931	0.0524
IL1RAPL1	Hs.658912	NM_014271	0.167
IL1RN		NM_173843, NM_173841, NM_000577, NM_173842	0.0168
IL21		NM_021803, NM_001207006	0.167
IL32		NM_001012718, NM_004221, NM_001012633, NM_001012631, NM_001012635, NM_001012634, NM_001012632, NM_001012636	0.177
IL8			0.234
INPP4B		NM_003866, NM_001101669	0.0965
IRF4		NM_002460, NM_001195286	0.142
IRF6	Hs.591415	NM_006147, NM_001206696	0.0699
IRF8		NM_002163	0.114
ISG20	Hs.459265	NM_001303234, NM_001303233, NM_002201, NM_001303237	0.0354
ITGA6	Hs.133397	NM_000210, NM_001079818	0.0441
ITGAE	Hs.513867	NM_002208	0.192
ITPA		NM_033453, NM_181493, NM_001267623	0.16
ITPK1		NM_001142594, NM_001142593, NM_014216	0.12
JUN	Hs.696684	NM_002228	0.141
JUNB	Hs.25292	NM_002229	0.0455
KAZALD1	Hs.733496	NM_030929	0.214

KCNK1		NM_002245	0.104
KCNK5	Hs.444448	NM_003740	0.246
KCNQ1		NM_000218, NM_181798	0.205
KIFC1	Hs.436912	NM_002263	0.234
KIT	Hs.479754	NM_001093772, NM_000222	0.0466
KLF2	Hs.744182	NM_016270	0.166
KLF3	Hs.298658	NM_016531	0.24
KLF4	Hs.376206	NM_004235	0.136
KLF7	Hs.59908	NM_003709, NM_001270943, NM_001270942, NM_001270944	0.203
KLRB1	Hs.169824	NM_002258	0.00226
KLRC1	Hs.512576	NM_001304448, NM_002259, NM_213657, NM_007328, NM_213658	0.0455
KLRD1	Hs.562457, Hs.668357	NM_002262, NM_007334, NM_001114396	0.158
KRT72	Hs.662013	NM_001146225, NM_001146226, NM_080747	0.212
LAIR1		NM_001289026, NM_001289027, NM_002287, NM_021706, NM_001289025, NM_001289023	0.238
LAMB3	Hs.497636	NM_000228, NM_001127641, NM_001017402	0.0642
LCLAT1	Hs.468048	NM_001304445, NM_001002257, NM_182551	0.234
LIF	Hs.2250	NM_002309, NM_001257135	0.0837
LIMA1	Hs.525419	NM_001243775, NM_001113546, NM_016357, NM_001113547	0.0774
LITAF	Hs.459940	NM_001136473, NM_004862, NM_001136472	0.0747
LMCD1		NM_014583, NM_001278235, NM_001278233, NM_001278234	0.0127
LMNA	Hs.594444	NM_001282625, NM_005572, NM_170707, NM_001282626, NM_001257374, NM_001282624, NM_170708	0.0166
LMNB2	Hs.538286	NM_032737	0.144
LOC282997			0.198
LOC728392			0.12
LOC728855			0.0567
LRRC16A	Hs.649550	NM_001173977, NM_017640	0.0756
LSAMP	Hs.26409	NM_002338	0.223
LTA	Hs.36	NM_001159740, NM_000595	0.135
LYAR	Hs.425427	NM_017816, NM_001145725	0.0882
MAP2K5		NM_145160, NM_002757, NM_001206804	0.107
MAP2K6	Hs.463978	NM_002758	0.0594
MATK	Hs.631845	NM_139354, NM_139355, NM_002378	0.177
MBP	Hs.551713	NM_001025081, NM_001025090, NM_001025092, NM_002385, NM_001025100, NM_001025101	0.192
MCAM		NM_006500	0.245
MCM10	Hs.198363	NM_018518, NM_182751	0.232

MCM2	Hs.477481	NM_004526	0.119
MCM4		NM_182746, NM_005914	0.144
MCTP2	Hs.33368	NM_001159643, NM_018349, NM_001159644	0.147
ME3	Hs.199743	NM_001014811, NM_001161586, NM_006680	0.136
MEST		NM_177524, NM_001253901, NM_001253902, NM_001253900, NM_002402, NM_177525	0.192
METTL13	Hs.494705	NM_014955, NM_001007239, NM_015935	0.207
METTL7A	Hs.744021	NM_014033	0.0605
MFNG	Hs.517603	NM_002405, NM_001166343	0.061
MGAT4C	Hs.589093, Hs.739389	NM_013244	0.0544
MICAL2	Hs.501928, Hs.735627	NM_014632, NM_001282663, NM_001282665, NM_001282666, NM_001282667, NM_001282664	0.158
MID1IP1	Hs.522605	NM_001098790, NM_021242, NM_001098791	0.229
MIR155HG	Hs.697120		0.0386
MIS18A	Hs.190518	NM_018944	0.0906
MLEC	Hs.701392, Hs.744910	NM_001303627, NM_014730, NM_001303628	0.244
MLH1	Hs.195364	NM_000249, NM_001258271, NM_001258274, NM_001167618, NM_001167617, NM_001167619, NM_001258273	0.159
MMP19		NM_002429, NM_001272101	0.165
MPP1	Hs.496984	NM_001166460, NM_002436, NM_001166461, NM_001166462	0.212
MRC2	Hs.7835	NM_006039	0.215
MRPL39		NM_017446, NM_080794	0.151
MRPS17	Hs.44298	NM_015969	0.0524
MT1G		NM_005950, NM_001301267	0.214
MTHFD1	Hs.652308	NM_005956	0.0524
MTHFD2		NM_006636	0.0924
MTMR4	Hs.514373	NM_004687	0.171
MYB	Hs.606320, Hs.626299	NM_001130173, NM_001130172, NM_005375, NM_001161657, NM_001161656, NM_001161658, NM_001161659, NM_001161660	0.0528
MYL6		NM_021019, NM_079423	0.137
MYO1C	Hs.286226	NM_001080779, NM_001080950, NM_033375	0.128
MYO1F	Hs.465818	NM_012335	0.0965
MYOF	Hs.602086	NM_133337, NM_013451	0.0243
NAB2	Hs.159223	NM_005967	0.0128
NCAPD2	Hs.5719	NM_014865	0.233
NCAPD3		NM_015261	0.236
NCAPH		NM_015341, NM_001281710, NM_001281711, NM_001281712	0.17
NCKAP1	Hs.603732	NM_013436, NM_205842	0.0111

NDFIP2	Hs.525093	NM_001161407, NM_019080	0.0528
NELL2	Hs.505326	NM_001145108, NM_006159, NM_001145110, NM_001145107, NM_001145109	0.0558
NFKBIZ	Hs.319171	NM_001005474, NM_031419	0.181
NHSL2	Hs.397836, Hs.660859	NM_001013627	0.192
NINJ2		NM_016533, NM_001294345, NM_001294346	0.061
NKG7		NM_005601	0.123
NKIRAS1	Hs.173202	NM_020345	0.201
NMT2		NM_004808, NM_001308295	0.0842
NOG	Hs.248201	NM_005450	0.171
NOSIP	Hs.7236	NM_001270960, NM_015953	3.65E-05
NPC2	Hs.433222	NM_006432	0.156
NPY		NM_000905	0.0466
NR1D2	Hs.37288	NM_001145425, NM_005126	0.139
NR2E1	Hs.157688	NM_003269, NM_001286102	0.0871
NR3C2	Hs.163924	NM_000901, NM_001166104	0.0645
NR4A3	Hs.279522	NM_173199, NM_006981, NM_173200	0.171
NSMCE1	Hs.284295	NM_145080	0.0711
NUP205	Hs.743250	NM_015135	0.162
OASL		NM_003733, NM_198213, NM_001261825	0.192
ODC1		NM_002539, NM_001287188, NM_001287190, NM_001287189	0.139
OLFM2		NM_058164, NM_001304348, NM_001304347	0.229
ORC6		NM_014321	0.0798
OSBPL8	Hs.430849	NM_020841, NM_001003712	0.227
OTUD7B		NM_020205	0.0487
P2RX4		NM_002560, NM_001256796, NM_001261397, NM_001261398	0.0671
P4HA2	Hs.519568	NM_001142598, NM_001142599, NM_001017974, NM_001017973, NM_004199	0.107
PACSIN3	Hs.334639	NM_016223, NM_001184974, NM_001184975	0.226
PAICS	Hs.518774	NM_001079525, NM_001079524, NM_006452	0.167
PAM	Hs.369430, Hs.738567	NM_001177306, NM_138822, NM_138821, NM_000919, NM_138766	0.218
PANX2	Hs.440092	NM_001160300, NM_052839	0.0128
PARP8	Hs.369581	NM_001178055, NM_024615, NM_001178056	0.122
PBX4	Hs.466257	NM_025245	0.211
PCSK5	Hs.368542	NM_006200, NM_001190482	0.0473
PDCD1	Hs.158297	NM_005018	0.0747
PDE10A	Hs.348762, Hs.638546	NM_006661, NM_001130690	0.215
PDGFRB	Hs.509067	NM_002609	0.0628

PECAM1	Hs.376675	NM_000442	0.0666
PELP1	Hs.744899	NM_014389, NM_001278241	0.192
PER1	Hs.445534	NM_002616	0.0674
PEX16		NM_057174, NM_004813	0.0666
PFDN5		NM_002624, NM_145897	0.135
PFKM	Hs.75160	NM_001166686, NM_000289, NM_001166688, NM_001166687	0.0961
PGAP1	Hs.229988	NM_024989	0.158
PGCP			0.186
PHEX		NM_001282754, NM_000444	0.149
PHF6	Hs.356501	NM_032458, NM_001015877, NM_032335	0.202
PHLPP1	Hs.465337	NM_194449	0.0853
PIK3C2G	Hs.22500	NM_001288772, NM_001288774, NM_004570	0.0629
PINK1	Hs.389171	NM_032409	0.24
PION			0.187
PITPNC1	Hs.591185	NM_181671, NM_012417	0.00827
PKMYT1	Hs.732385, Hs.734466	NM_182687, NM_004203, NM_001258451, NM_001258450	0.246
PLAC8	Hs.546392	NM_016619, NM_001130716, NM_001130715	0.0653
PLAGL2	Hs.154104	NM_002657	0.174
PLCG2		NM_002661	0.118
PLCL1		NM_006226	0.107
PLCL2	Hs.202010, Hs.741267	NM_001144382, NM_015184	0.141
PLIN2		NM_001122	0.0747
PLK2	Hs.398157	NM_006622, NM_001252226	0.205
PLXNB2	Hs.3989	NM_012401	0.0064
PLXND1	Hs.301685	NM_015103	0.229
PMAIP1	Hs.96	NM_021127	0.0316
PMCH		NM_002674	0.0126
PNLIPRP1	Hs.73923	NM_006229, NM_001303135	0.137
PNMA1	Hs.194709	NM_006029	0.11
POU2AF1	Hs.654525, Hs.733573	NM_006235	0.0127
POU6F1	Hs.555886	NM_002702	0.229
PPCDC	Hs.458922, Hs.640486	NM_021823, NM_001301103, NM_001301101, NM_001301102, NM_001301104, NM_001301105	0.00748
PPFIBP2	Hs.655714, Hs.739217	NM_003621, NM_001256568, NM_001256569	0.0544
PPP1R15A	Hs.631593	NM_014330	0.0645
PPP2R2B	Hs.739387	NM_181678, NM_181674, NM_181675, NM_181676, NM_001271899, NM_181677, NM_001271900, NM_001271948	0.061

PPP2R3C	Hs.530712	NM_017917, NM_001305156, NM_001305155	0.167
PPP2R5C	Hs.368264, Hs.679341	NM_001161726, NM_178586, NM_178587, NM_002719, NM_001161725	0.158
PPP3CA	Hs.435512	NM_000944, NM_001130692, NM_001130691	0.0679
PQBP1		NM_001167990, NM_005710, NM_001032384, NM_144495, NM_001032381, NM_001167989, NM_001032382, NM_001032383	0.141
PRC1	Hs.366401	NM_003981, NM_199413, NM_001267580	0.0642
PRDM1	Hs.436023	NM_001198, NM_182907	0.0127
PRF1	Hs.2200	NM_001083116, NM_005041	0.192
PRKAR1B	Hs.520851	NM_001164761, NM_001164758, NM_002735, NM_001164760, NM_001164759, NM_001164762	0.167
PRKCDBP		NM_145040	0.0181
PRKCH	Hs.333907, Hs.630857	NM_006255	0.0889
PRKCQ	Hs.498570	NM_006257, NM_001282644, NM_001242413, NM_001282645	0.115
PRKD3	Hs.660757	NM_005813	0.195
PRKG2	Hs.570833	NM_001282485, NM_006259, NM_001282483, NM_001282482, NM_001282481, NM_001282480	0.205
PRNP	Hs.472010	NM_001080121, NM_001271561, NM_001080122, NM_000311, NM_183079, NM_001080123	0.236
PRR5		NM_015366, NM_001198721, NM_181333, NM_001017528, NM_001017530, NM_001017529	0.0135
PRSS23	Hs.25338, Hs.729257	NM_001293180, NM_001293178, NM_007173, NM_001293179	0.158
PSMA5	Hs.485246	NM_002790, NM_001199773, NM_001199774, NM_001199772	0.213
PSMB9		NM_002800	0.234
PSMC2	Hs.437366	NM_001204453, NM_002803	0.246
PSMD11		NM_001270482, NM_002815	0.206
PSMD14	Hs.740477	NM_005805	0.131
PTGFRN	Hs.418093	NM_020440	0.215
PTPN12	Hs.61812	NM_002835, NM_001131008, NM_001131009	0.205
PTPN14	Hs.193557, Hs.688910	NM_005401	0.124
PTPN3	Hs.436429, Hs.698275	NM_001145368, NM_002829, NM_001145369, NM_001145370	0.135
PTPN4	Hs.469809	NM_002830	0.187
PTPN6	Hs.63489	NM_080548, NM_002831, NM_080549	0.0174
PTTG1		NM_004219, NM_001282383, NM_001282382	0.235
PUS7	Hs.520619	NM_019042	0.127
PVR		NM_006505, NM_001135769, NM_001135768, NM_001135770	0.0064
PYCARD		NM_013258, NM_145182	0.0843
PYCR1		NM_006907, NM_153824, NM_001282279, NM_001282281, NM_001282280	0.235

RAB37		NM_175738, NM_001163989, NM_001006638, NM_001163990	0.192
RACGAP1	Hs.505469	NM_013277, NM_001126104, NM_001126103	0.167
RAD51		NM_001164270, NM_002875, NM_133487, NM_001164269	0.246
RAP1GAP2	Hs.499659, Hs.685132	NM_015085, NM_001100398	0.167
RARRES3		NM_004585	0.116
RASAL1	Hs.528693	NM_001193520, NM_004658, NM_001193521, NM_001301202	0.125
RASGEF1A	Hs.125293	NM_001282862, NM_145313	0.0831
RASGRP2	Hs.99491	NM_001098671, NM_001098670, NM_153819	0.115
RASGRP4	Hs.130434	NM_001146202, NM_001146204, NM_001146205, NM_170604, NM_001146207, NM_001146203, NM_001146206	0.129
RBMS1	Hs.470412, Hs.654231	NM_016836, NM_002897	0.0466
REEP2		NM_001271803, NM_016606	0.135
REPIN1	Hs.647086	NM_001099695, NM_014374, NM_013400, NM_001099696	0.243
RGS1	Hs.75256	NM_002922	0.149
RGS12		NM_198229, NM_002926, NM_198227	0.192
RGS9	Hs.664380	NM_001165933, NM_001081955, NM_003835	0.222
RHOB	Hs.502876	NM_004040	0.0842
RNF125	Hs.633703	NM_017831	0.135
RNF19A	Hs.292882, Hs.735657	NM_015435, NM_183419, NM_001280539	0.0544
RPLP2		NM_001004	0.111
RPS20		NM_001146227, NM_001023	0.189
RPS27		NM_001030	0.0505
RPS28		NM_001031	0.0135
RPS6KA3	Hs.445387	NM_004586	0.189
RSAD2	Hs.17518	NM_080657	0.229
RTF1	Hs.511096	NM_015138	0.219
RYBP		NM_012234	0.156
S100A4		NM_019554, NM_002961	0.00133
S1PR1	Hs.154210	NM_001400	0.151
S1PR4	Hs.662006, Hs.688059	NM_003775	0.0505
SALL2	Hs.416358, Hs.745364	NM_005407, NM_001291446, NM_001291447	0.0685
SCD	Hs.558396	NM_005063	0.0265
SCGB1A1		NM_003357	0.152
SCML4		NM_001286408, NM_001286409, NM_198081	0.0243
SDC4	Hs.632267	NM_002999	0.156

SDK2	Hs.435719	NM_001144952	0.0307
SECTM1	Hs.558009	NM_003004	0.0735
SELPLG		NM_003006, NM_001206609	0.245
SEMA3B	Hs.82222	NM_001290060, NM_001005914, NM_001290061, NM_001290063, NM_001290062, NM_004636	0.0477
SEPT3	Hs.120483	NM_145733, NM_019106	0.0175
SERPINF1		NM_002615	0.11
SERPINF2	Hs.159509	NM_001165921, NM_001165920, NM_000934	0.21
SFMBT2	Hs.407983	NM_001018039, NM_001029880	0.0871
SFXN1		NM_022754	0.174
SGCB	Hs.438953	NM_000232	0.12
SGTB	Hs.482301	NM_019072	0.246
SH2B2	Hs.489448	NM_020979	0.0127
SHF	Hs.310399	NM_001301169, NM_001301168, NM_138356, NM_001301170, NM_001301171	0.0567
SIGIRR	Hs.501624	NM_001135054, NM_021805, NM_001135053	0.143
SIGLEC9	Hs.245828	NM_014441, NM_001198558	0.246
SIPA1L1	Hs.654657	NM_001284245, NM_015556, NM_001284247, NM_001284246	0.215
SKAP1	Hs.316931	NM_003726, NM_001075099	0.0127
SLA2	Hs.713578	NM_032214, NM_175077	0.227
SLAMF1		NM_003037	0.246
SLC11A1	Hs.591607	NM_000578	0.144
SLC14A1		NM_001308278, NM_015865, NM_001146036, NM_001128588, NM_001308279, NM_001146037	0.243
SLC16A1	Hs.75231	NM_003051, NM_001166496	0.18
SLC1A4	Hs.654352	NM_001193493, NM_003038	0.246
SLC1A5	Hs.631582	NM_005628, NM_001145145, NM_001145144	0.218
SLC22A17	Hs.373498	NM_001289050, NM_016609, NM_020372	0.0366
SLC25A20	Hs.13845	NM_000387	0.22
SLC27A2	Hs.11729	NM_003645, NM_001159629	0.0274
SLC29A1	Hs.25450	NM_001304463, NM_001078175, NM_001078177, NM_001304465, NM_001304466, NM_001304462	0.00562
SLC2A1	Hs.473721	NM_006516	0.0507
SLC2A3	Hs.419240	NM_006931	0.192
SLC35F2	Hs.524014	NM_017515	0.0567
SLC39A1	Hs.7854	NM_001271958, NM_001271957, NM_014437, NM_001271959, NM_001271960, NM_001271961	0.144
SLC39A14	Hs.491232	NM_015359, NM_001135154, NM_001128431, NM_001135153	0.156
SLC43A1	Hs.591952	NM_003627, NM_001198810	0.192
SLC43A3	Hs.99962	NM_014096, NM_001278201, NM_199329, NM_017611, NM_001278206	0.015

SLC46A3		NM_181785, NM_001135919	0.0767
SLCO3A1	Hs.311187	NM_013272, NM_001145044	0.151
SMAP2	Hs.15200	NM_022733, NM_001198978, NM_001198980, NM_001198979	0.164
SMTN		NM_134270, NM_006932, NM_134269, NM_001207018, NM_001207017	0.162
SMYD5	Hs.631882	NM_006062	0.246
SNAI2	Hs.360174	NM_003068	0.0502
SNTB1	Hs.46701	NM_021021	0.162
SNTG1		NM_001287813, NM_018967, NM_001287814	0.0585
SORD		NM_003104	0.0455
SPATA7		NM_018418, NM_001040428	0.0965
SPATS2L	Hs.120323, Hs.734045	NM_001282735, NM_015535, NM_001100422, NM_001282743, NM_001100424, NM_001100423, NM_001282744	0.061
SPINK2		NM_021114, NM_001271718, NM_001271720, NM_001271722, NM_001271721	0.0642
SPINT1	Hs.233950	NM_003710, NM_001032367, NM_181642	0.246
SPSB3	Hs.592080	NM_080861	0.122
SQLE	Hs.71465	NM_003129	0.0502
SREK1IP1	Hs.69504	NM_173829	0.163
SSBP3	Hs.733025	NM_145716, NM_001009955, NM_018070	0.0112
SSH1		NM_018984, NM_001161330, NM_001161331	0.163
SSR2		NM_003145	0.0544
ST6GALNAC 2	Hs.592105	NM_006456	0.224
ST8SIA1	Hs.408614	NM_003034	0.0699
STAMBP	Hs.469018, Hs.732857	NM_213622, NM_006463, NM_201647	0.11
STAP1	Hs.435579	NM_012108	0.0685
STAT6	Hs.524518	NM_003153, NM_001178078, NM_001178081, NM_001178079, NM_001178080	0.158
STIL	Hs.525198, Hs.673209	NM_001282936, NM_003035, NM_001048166, NM_001282937, NM_001282939, NM_001282938	0.205
STIP1	Hs.337295, Hs.618350	NM_001282652, NM_006819, NM_001282653	0.223
STK38	Hs.409578	NM_001305102, NM_007271	0.0924
STMN3		NM_015894, NM_001276310	0.0735
STOM		NM_004099, NM_001270526, NM_198194, NM_001270527	0.112
STX1A	Hs.647024	NM_004603, NM_001165903	0.222
STX6	Hs.518417	NM_005819, NM_001286210	0.236
SV2A	Hs.516153	NM_014849	0.216
SVIL	Hs.499209	NM_003174, NM_021738	0.243
SYT1	Hs.310545	NM_001135805, NM_005639, NM_001291901,	0.0645

		NM_001135806	
SYTL1		NM_032872, NM_001193308	0.23
SYTL2	Hs.369520	NM_206929, NM_206930, NM_001162951, NM_001162952, NM_001289610, NM_001289608, NM_032943, NM_001162953	0.0502
SYTL3		NM_001242395, NM_001009991, NM_001242384, NM_001242394	0.129
TAF7	Hs.438838	NM_005642	0.0836
TARP			0.22
TARS		NM_001258437, NM_152295, NM_001258438	0.158
TBCC		NM_003192	0.246
TBX15	Hs.146196	NM_152380	0.00865
TCEAL4		NM_001300901, NM_024863, NM_001006935, NM_001006937	0.0594
TCF7		NM_003202, NM_201634, NM_001134851, NM_213648, NM_201632	0.114
TERT	Hs.492203	NM_198253, NM_001193376	0.0311
TGFB1	Hs.645227	NM_000660	0.12
TGFBR3		NM_001195684, NM_001195683, NM_003243	0.188
TIGIT	Hs.421750	NM_173799	0.234
TJP3	Hs.25527	NM_001267560, NM_001267561	0.248
TLE4		NM_007005, NM_001282760, NM_001282748, NM_001282749, NM_001282753	0.0302
TMEM194A			0.106
TMEM212	Hs.642307	NM_001164436	0.102
TMEM48			0.171
TMEM5	Hs.216386	NM_014254, NM_001278237	0.178
TMEM71	Hs.293842	NM_144649, NM_001145153	0.234
TMEM80		NM_001042463, NM_174940, NM_001276274, NM_001276253	0.246
TMEM9B		NM_001286094, NM_020644, NM_001286095	0.192
TMPRSS6	Hs.370885	NM_153609, NM_001289001, NM_001289000	0.0585
TNFAIP1	Hs.76090	NM_021137	0.167
TNFRSF11A		NM_001270951, NM_003839, NM_001278268, NM_001270949, NM_001270950	0.0605
TNFRSF18	Hs.212680	NM_148901, NM_004195, NM_148902	0.0366
TNFRSF25	Hs.462529	NM_148967, NM_148970, NM_148966, NM_003790, NM_148965	0.163
TNFRSF4	Hs.129780	NM_003327	0.0337
TNFRSF8	Hs.1314	NM_001243, NM_001281430	0.106
TNFRSF9	Hs.86447	NM_001561	0.0524
TOX2	Hs.26608	NM_001098797, NM_001098796, NM_032883, NM_001098798	0.0107
TP53INP2	Hs.516994	NM_021202	0.139

TPCN1	Hs.524763	NM_017901, NM_001143819, NM_001301214	0.181
TPK1	Hs.660232	NM_022445, NM_001042482	0.24
TPMT	Hs.444319	NM_000367	0.232
TRAPPC6A		NM_024108, NM_001270893, NM_001270891, NM_001270892	0.0638
TRIB1	Hs.444947	NM_025195, NM_001282985	0.074
TRIB2	Hs.467751	NM_021643	0.0181
TRIM25	Hs.528952	NM_005082	0.143
TRIP10	Hs.515094	NM_004240, NM_001288962, NM_001288963	0.149
TRPM3		NM_001007471, NM_020952, NM_206946, NM_206945, NM_001007470, NM_206948, NM_024971, NM_206944, NM_206947	0.195
TSPAN18	Hs.385634	NM_130783	0.129
TSPAN32		NM_139022	0.0502
TTC21B	Hs.310672	NM_024753	0.243
TTC39C	Hs.733420	NM_153211, NM_001243425, NM_001135993, NM_001292030	0.00494
TTL4	Hs.471405	NM_014640	0.158
TUBB	Hs.636480	NM_001293213, NM_178014, NM_001293215, NM_001293216, NM_001293212	0.236
TUBB2B	Hs.300701	NM_178012	0.0386
TUBB6	Hs.193491, Hs.744066	NM_001303524, NM_032525, NM_001303529, NM_001303526, NM_001303525	0.00952
UBA52	Hs.5308	NM_003333, NM_001033930	0.0902
UBASH3B	Hs.444075	NM_032873	0.0666
UBL3	Hs.145575	NM_007106	0.0929
UHRF1BP1L	Hs.620701	NM_015054, NM_001006947	0.0666
UNC119	Hs.410455	NM_005148, NM_054035	0.168
URGCP	Hs.663312	NM_017920, NM_001077664, NM_001290075, NM_001290076, NM_001077663	0.141
USP22	Hs.462492	NM_015276	0.0745
USP25		NM_013396, NM_001283042, NM_001283041	0.232
USP51	Hs.40061	NM_201286	0.186
UXS1	Hs.730756	NM_001253875, NM_025076, NM_001253876	0.167
UXT		NM_004182, NM_153477	0.0826
VDAC3		NM_001135694, NM_005662	0.158
VDR	Hs.524368	NM_001017535, NM_001017536, NM_000376	0.124
VIPR1	Hs.348500, Hs.683175	NM_001251882, NM_001251885, NM_004624, NM_001251883, NM_001251884	0.0642
VNN2	Hs.293130, Hs.740120	NM_004665, NM_078488, NM_001242350	0.129
VSIG1	Hs.177164	NM_182607, NM_001170553	0.0709
WASF2	Hs.469244	NM_006990, NM_001201404	0.137

WEE1		NM_003390, NM_001143976	0.0594
WIP1	Hs.463964	NM_017983	0.171
WNT10A	Hs.121540	NM_025216	0.0502
XYLT1	Hs.22907	NM_022166	0.0278
YPEL1		NM_013313	0.195
YWHAG	Hs.744840	NM_012479	0.0783
ZBP1	Hs.302123	NM_001160417, NM_030776, NM_001160418, NM_001160419	0.218
ZBTB20		NM_001164343, NM_001164347, NM_001164345, NM_001164342, NM_015642, NM_001164344, NM_001164346	0.00562
ZBTB32	Hs.99430, Hs.736841	NM_014383	0.0128
ZC3H12A	Hs.656294	NM_025079	0.198
ZC3H12C	Hs.376289	NM_033390	0.0628
ZC3H12D		NM_207360	0.0709
ZEB2	Hs.34871	NM_014795, NM_001171653	0.0594
ZFP161			0.0965
ZFP36L2	Hs.503093	NM_006887	0.218
ZHX2	Hs.377090	NM_014943	0.144
ZNF267		NM_003414	0.127
ZNF282	Hs.729056	NM_003575, NM_001303481	0.121
ZNF506		NM_001099269, NM_001145404	0.195
ZNF587	Hs.744891	NM_032828, NM_001204817	0.236
ZNF652		NM_014897, NM_001145365	0.0429
ZNF688		NM_145271, NM_001024683	0.229
ZNF704	Hs.434957, Hs.730558	NM_001033723	0.215
ZNRF1	Hs.427284	NM_032268	0.164

Example 3: Prognostic Flow Cytometry-based assays

Prognostic flow cytometry-based assays are developed to screen subjects with cancer (e.g., patients with a hematological cancer such as ALL and CLL) for CAR-expressing cell (e.g., T cell, NK cell) therapy, e.g., CD19 CAR-expressing cell therapy as described herein such as, e.g., CTL019 therapy. In some embodiments, subjects are participating in clinical trials.

A sample (e.g., a blood sample) is isolated from a patient and a fluorescent flow cytometry-based assay is performed screening for one or more cell surface or secreted

biomarkers described in Examples 1 and 2. An exemplary list of markers that are measured, e.g., by flow cytometry if cell surface-expressed, or by ELISA if secreted, and whose expression values predict patient response to CAR-expressing cell (e.g., T cell, NK cell) therapy, e.g., CD19 CAR-expressing cell therapy as described herein such as, e.g., CTL019 therapy includes, but is not limited to, genes listed in **Table 8**.

Table 8: Exemplary markers measured that predict patient response to CAR-expressing cell therapy

Gene	Unigene	Accession No.
ATP1B3	Hs.477789	NM_001679
CCL17	Hs.546294	NM_002987
CCL3	Hs.514107	NM_002983
CCL4	Hs.75703	NM_002984
CCR1	Hs.301921	NM_001295
CD40LG	Hs.592244	NM_000074
CD58	Hs.34341	NM_001144822, NM_001779
CD70	Hs.715224, Hs.501497	NM_001252
CD80	Hs.838	NM_005191
CSF1	Hs.591402	NM_000757, NM_172212, NM_172211, NM_172210
FCER2	Hs.465778	NM_002002
GPR56	Hs.513633	NM_001145773, NM_001145774, NM_001145771, NM_001145772, NM_005682, NM_201525, NM_001145770
HAVCR1	Hs.129711	NM_001099414, NM_012206
HLA-DMA	Hs.351279	NM_006120
HLA-DPA1	Hs.347270	NM_033554
HLA-DRA	Hs.520048	NM_019111
HLA-DRB1	Hs.716081, Hs.696211, Hs.723344, Hs.534322	NM_002124, NM_021983, XM_002346251
HLA-DRB5	Hs.534322	NM_002125
ICAM3	Hs.654563	NM_002162
IFNAR2	Hs.708195	NM_207584, NM_207585, NM_000874
IFNG	Hs.856	NM_207585
IGF1R	Hs.643120, Hs.714012	NM_000875
IL10	Hs.193717	NM_000572
IL13	Hs.845	NM_002188
IL15RA	Hs.524117	NM_002189, NM_172200
IL21	Hs.567559	NM_021803
IL2RA	Hs.231367	NM_000417
IL2RB	Hs.474787	NM_000878

IL3	Hs.694	NM_000588
IL4	Hs.73917	NM_000589, NM_172348
IL5	Hs.2247	NM_000879
IL6ST	Hs.532082	NM_002184, NM_175767
IL9	Hs.960	NM_000590
ITGA6	Hs.133397	NM_000210, NM_001079818
KIT	Hs.479754	NM_000222, NM_001093772
LAIR1	Hs.572535	NM_001289023, NM_001289025, NM_001289026, NM_001289027, NM_002287, NM_021706
NFATC1	Hs.534074, Hs.701518	NM_001278669, NM_001278670, NM_001278672, NM_001278673, NM_001278675, NM_006162, NM_172387, NM_172388, NM_172389, NM_172390
SELL	Hs.728756	NM_000655
SELP	Hs.73800	NM_003005
SIRPG	Hs.590883	NM_001039508, NM_018556, NM_080816
STAT6	Hs.524518	NM_001178078, NM_001178079, NM_001178080, NM_001178081, NM_003153
TFRC	Hs.529618	NM_001128148, NM_003234
TIMD4	Hs.334907	NM_001146726, NM_138379
TNFRSF1B	Hs.256278	NM_001066
TNFRSF9	Hs.86447, Hs.738942	NM_001561

Example 4: Classifiers to Predict Class Membership

Based on the biological understanding, combinations of genes from unbiased feature selection, gene sets, and selected genes of interest are used to further differentiate complete responders from partial responders and non-responders. In an embodiment, combinations of genes from unbiased feature selection, gene sets, and selected genes of interest are used to further differentiate relapsers from non-relapsers. In an embodiment, classifiers are built based on all genes to predict class membership. In an embodiment, predictions of class membership further differentiate NR's, PR's, and CR's. In an embodiment, predictions of class membership further differentiate relapsers from non-relapsers. Alternatively or additionally, a classifier is built which uses a subset of predetermined significant features. Significant features include, but are not limited to, enriched meta-gene, a subset of significantly differentially expressed genes in the meta-genes, and combinations thereof.

Example 5: Cytokine Expression Signatures Predictive of CAR-Expressing Cell Potency

The present example describes the identification of exemplary cytokine expression signatures that predict patient response to CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., a CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy, e.g., a CTL019 therapy) in Chronic Lymphoid Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL), for use in accordance with the present invention.

Among other things, the present Example describes novel cytokine expression signatures that predict the potency of manufactured CAR-expressing cell (e.g., T cell, NK cell) cell products based on secreted cytokine profiles following activation *in vitro*.

In an embodiment, novel cytokine expression signatures described herein predict the potency of manufactured CAR-expressing cell (e.g., T cell, NK cell) products to kill target tumor cells.

In an embodiment, novel cytokine expression signatures described herein are correlated with patient response to CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g. CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy, e.g., a CTL019 CAR-expressing cell therapy) in CLL to improve the CAR-expressing cell product prior to infusion in patients.

In an embodiment, novel cytokine expression signatures described herein are used to assess manufactured CAR-expressing cell (e.g., T cell, NK cell) products (e.g., CD19 CAR-expressing cell products, e.g., CTL019 product). In an embodiment, novel cytokine expression signatures described herein provide an endpoint in manufacturing process optimization.

Novel cytokine expression signatures based on cytokine protein expression levels in manufactured CD19 CAR-expressing cell (e.g., T cell, NK cell) product samples prior to re-infusion have been identified that predict patient response to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy in Chronic Lymphoid Leukemia (CLL). The identified signatures were discovered in a cytokine protein expression study of manufactured product samples prepared from 21 CLL subject samples. CLL subject samples (21 total) were stratified as follows: CTL019 manufactured product was derived from 6 patients that were complete responders (CRs) to CTL019 therapy, 5 patients that were partial responders (PRs), and 10 non-responders (NRs).

Several cytokine expression signatures discriminating responders from non-responders in manufactured product were discovered using a Luminex® panel of 13 cytokines.

The potency of CTL019 manufactured products from 21 CLL patients were assessed in a tumor cell killing assay. Briefly, manufactured CTL019 products were “activated” *in vitro* by CD19-expressing K562 (K562-19 cells). Without wishing to be bound by a particular theory, CD19 expressing K562 cells (e.g., K562-19 cells) mimic leukemic CD19 expressing B-cells in CLL patients. CTL019 cells are engineered to identify and kill cells that express CD19 antigen on their cell surface and CTL019-mediated killing of K562-19 cells serves as a proxy for assessing potency of CTL019-mediated killing of tumor cells.

Following CTL019 product activation, cytokine protein expression profiles were measured in the co-cultured media using a Luminex® panel of cytokines. The expression profiles of exemplary cytokines were measured and the potency of CTL019 cell products was correlated with the expression of different cytokines. Exemplary cytokines considered in this analysis are provided in **Table 14**.

Table 14: Exemplary cytokines

Cytokine	Entrez ID	Official Gene Symbol
CCL-20 / MIP-3a	6364	CCL20
GM-CSF	1437	CSF2
IFN γ	3458	IFNG
IL-10	3586	IL10
IL-13	3596	IL13
IL-17a	3605	IL17A
IL-2	3558	IL2
IL-21	59067	IL21
IL-4	3565	IL4
IL-5	3567	IL5
IL-6	3569	IL6
IL-9	3578	IL9
TNF α	7124	TNF

Novel cytokine expression profiles were then discovered using various data analytical approaches including 1) bi-clustering analysis; and 2) univariate analysis.

Cytokine expression data derived from the Luminex® assay were log-normalized and subjected to bi-clustering analyses (hierarchical clustering was performed using the complete linkage method). Bi-clustering analyses of cytokine expression in stimulated CTL019 products and CLL patients yield four major clusters (a cut-off distance ≤ 1.0 , resulted in 4 clusters as shown in FIG. 17) and distinct subgroups of CRs/PRs and NRs were identified. An exemplary heatmap of bi-clustering of cytokine expression in stimulated CTL019 products and CLL patients is shown in **FIG. 17**. Surprisingly, two clusters (Cluster 1 and Cluster 3) were almost exclusively comprised of CRs and PRs, whereas the other two clusters (Cluster 2 and Cluster 4) contained predominantly NRs. On average, cytokine expression levels were higher in CRs/PRs versus NRs (**FIG. 17**).

Next, a 3-group univariate analysis using ANOVA (analysis of variance) was performed that compared CRs versus PRs versus NRs. Statistical significance was determined using a p-value cut-off of 0.05. Statistical significance (e.g., p-values) of different cytokines to distinguish CRs, PRs and NRs are listed in **Table 15**.

Table 15: Statistical significance of different cytokines to distinguish CRs, PRs and NRs in a 3-group univariate analysis using ANOVA

Cytokine	p-value
CCL20/MIP3a	0.001838
IL-17a	0.001857
IL-6	0.006017
TNF α	0.013499
IL-2	0.034397
IL-21	0.055684
IL-5	0.075396
IL-10	0.08935
IL-9	0.098761
IFN γ	0.137263
GM-CSF	0.191839
IL-4	0.197774

IL-13	0.222134
-------	----------

The 3-group model of univariate analysis identified 5 cytokines, e.g., IL-17a, CCL-20/MIP3a, IL-6, IL-2, and TNF α , as statistically significant markers of response to CTL019 therapy in CLL patients (**FIG. 18** and **Table 15**). Exemplary results of log-normalized expressions of statistically significant cytokines that distinguish CRs, PRs and NRs in CLL patients are shown in **FIG. 18**.

Manufactured CTL019 product was evaluated by flow cytometry to determine percentages of CAR+ cells. The 5 cytokines identified in the 3-group model of univariate analysis were further correlated to the percentage of CAR+ cells in each of the manufactured CTL019 products. Exemplary correlation coefficients and corresponding p-values of cytokine expression (derived from Luminex® panel discussed above) and percentages of CAR+ cells (determined by flow cytometry) are provided in **Table 16**.

Table 16: Correlation coefficients and corresponding p-values of cytokine expression and percentage of CAR+ cells

Cytokine	Correlation coefficient	p.value
IL-17a	0.278349	0.221794
IL-10	0.390318	0.08024
CCL20/MIP3a	0.395273	0.076147
IL-5	0.494758	0.022598
IL-4	0.525982	0.014321
TNF α	0.539276	0.011642
GM-CSF	0.588262	0.005032
IL-6	0.631841	0.002122
IFN γ	0.660738	0.001112
IL-2	0.661608	0.001089
IL-21	0.674378	0.0008
IL-9	0.70858	0.000324
IL-13	7.53E-01	8.19E-05

The percentage of CAR+ cells in CTL019 product represents transduction efficiency. In CLL, the percent of CAR+ cells at pre-harvest levels distinguish responders (e.g., complete responders and partial responders) from non-responders (NR). **FIG. 21** depicts an exemplary scatter plot showing percent of CAR+ cells (i.e., transduction rate) at pre-harvest for complete

responders (CR) in red, partial responders (PR) in blue and non-responders (NR) in red. Transduction efficiencies were measured pre-harvest and correlated with subject response (e.g., CR, PR, or NR). The solid line represents a 15% transduction efficiency that separates the majority of non-responders from responders. Without wishing to be bound to a particular theory, these data indicate that pre-harvest CAR transduction efficiency is a marker of response to CAR-expressing cell (e.g., T cell, NK cell) therapy in CLL.

Correlation analysis of IL17a with CCL20 cytokine expression was performed, and their association with clinical response was evaluated by scatter plot analyses. **FIG. 19A** depicts an exemplary scatter plot showing log-normalized correlation of IL17A (y-axis) and CCL20 (x-axis) expression with a correlation coefficient of 0.928 and corresponding p-value of 1.36e-09. Dashed lines represent the classification boundary for separating NRs from CRs/PRs. Each dot in **FIG. 19A** represents a CLL patient, and the cross-hatch (NR), black (PR) and white (CR) represent the clinical response. Classification boundary in **FIG. 19A** demonstrates that the combination of IL-17a and CCL20 separates almost all NRs from CRs/PRs, and PRs in turn are clustered separately from CRs. Among other things, these data demonstrate CAR+ cell expression of one or more cytokines listed in **Table 16** predict clinical response.

Surprisingly, IL-17a and CCL-20 expression levels were *not* correlated with the percentage of CAR+ cells in the CTL019 product (representing transduction efficiency). Without wishing to be bound by a particular theory, these data indicate IL-17a and CCL-20 cytokine expression levels are informative (e.g., predictive of response) with regard to potency of a manufactured CAR-expressing cell (e.g., T cell, NK cell) product, e.g., a manufactured CD19 CAR-expressing cell product, in several ways. First, cytokine signatures are correlated with patient response to CTL019 CAR-expressing cell therapy in CLL. Therefore, cytokine signatures described herein can be used to improve and/or modify CAR-expressing cell (e.g., T cell, NK cell) product (e.g., a CD19 CAR-expressing cell product such as, e.g., CTL019) prior to infusion in patients, for greater clinical efficacy. Second, cytokine signatures described herein can be used to assess manufactured CAR-expressing cell (e.g., T cell, NK cell) products thereby providing, among other things, an end point in manufacturing process optimization.

In an embodiment, cytokine signatures described herein define the potency of a CAR-expressing cell (e.g., T cell, NK cell) product. In an embodiment, cytokine signatures described

herein are markers of response to a CAR-expressing cell (e.g., T cell, NK cell) product in a hematological cancer (e.g., CLL or ALL).

In an embodiment, cytokine signatures described herein predict subject response to a CAR-expressing cell (e.g., T cell, NK cell) product.

5 In an embodiment, cytokine signatures described in **Table 16** predict subject response to a CAR-expressing cell (e.g., T cell, NK cell) product.

In an embodiment, IL-17a and CCL-20 expression levels predict subject response to a CAR-expressing cell (e.g., T cell, NK cell) product.

**Example 6: Identification of Factors that Predict Subject Relapse to CD19 CAR-
10 Expressing Cell Therapy in B-cell Acute Lymphocytic Leukemia (B-ALL)**

The present Example describes, among other things, the identification of novel transcriptional gene signatures that predict patient relapse to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019 therapy) in B cell Acute Lymphocytic Leukemia (B-ALL), for use in accordance with the present invention.

15 Among other things, the present Example describes novel gene signatures based on mRNA expression levels of selected genes in the patient prior to CD19 CAR-expressing cell (e.g., T cell, NK cell) treatment (e.g., CTL019) (apheresis or bone marrow) or in manufactured CD19 CAR-expressing cell (e.g., T cell, NK cell) product samples (e.g., CTL019) prior to re-infusion. In an embodiment, the present example describes novel gene signatures that
20 discriminate relapsers to CTL019 therapy in B-ALL from non-relapsers to CTL019 therapy in B-ALL.

The present Example describes methods of unbiased feature selection to discover novel gene signatures that predict subject relapse to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019) in B-ALL, for use in accordance with the present invention.

25 The present Example also describes methods of Gene Set Analysis to discover novel gene signatures, for use in accordance with the present invention.

Novel gene signatures based on mRNA expression levels in manufactured CD19 CAR-expressing cell (e.g., T cell, NK cell) product samples prior to re-infusion were identified that

predict subject relapse to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy in B cell Acute Lymphocytic Leukemia (B-ALL). The identified signatures were discovered in a whole genome RNAseq study of manufactured product samples which included 7 B-ALL subject samples. B-ALL subject samples (7 total) were stratified as follows: biological samples were taken from 4 subjects who did not relapse (“non-relapsers”) following CTL019 therapy, and 3 subjects who did relapse (“relapsers”) following CTL019 therapy. Several gene signatures discriminating responders from non-responders, and relapsers from non-relapsers, in manufactured product samples were discovered and are described further in detail below.

Novel gene signatures were then discovered using various data analytical approaches: 1) unbiased feature selection; 2) gene set analysis; and 3) differential expression analysis of selected genes of interest.

Novel gene signatures derived from unbiased feature selection were discovered by determining which genes were differentially expressed between the 2-group comparison of relapsers and non-relapsers which compared the 3 relapsers to the 4 non-relapsers. Genes were defined as differentially expressed if their differential expression was statistically significant in the 2-group comparison with a FDR p-value cutoff of 0.25. The gene list for the relapser versus non-relapser comparison (N=17) is tabulated in **Table 17**. 2-group statistical models were applied to determine whether the meta-gene was statistically different between the groups, similar to the approach illustrated in **FIG. 2B**. **FIG. 2B** depicts an exemplary heat map of genes upregulated in activated T_{EFF} versus resting T_{EFF} cells for complete responders (CR), partial responders (PR), and non-responders (NR).

Without wishing to be bound by a particular theory, these data indicate that the differentiation state of T cells in CD19 CAR-expressing cell (e.g., T cell, NK cell) product (e.g., CTL019) correlate with subject response (i.e., CR, PR, or NR) and predict subject relapse to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019 therapy) in B-ALL. As described in Example 1, complete responders gene signatures are more like *resting* T_{REG} and T_{EFF} cells. Among other things, gene signatures for relapsers (e.g., a complete responder that relapses to CTL019 therapy) contain genes upregulated in T_{REG} versus T_{EFF} cells at resting. Without wishing to be bound by a particular theory, these data indicate that relapsers to CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019) in B-ALL have higher levels of

T_{REG} compared to non-relapsers to CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019). **FIG. 21** depicts exemplary results illustrating that T_{REG} are differentially enriched in relapsers (R) versus non-relapsers, e.g., relapsers express high levels of T_{REG} genes compared to complete responders (CR) (e.g., non-relapsers). An exemplary publication or sequence number disclosing the sequence of each gene is also given in Table 17, and each publication is

5 incorporated by reference in its entirety, including all nucleic acid and protein sequences therein.

Table 17: Exemplary Genes that Predict Patient Relapse to CTL019 Therapy

Table 17					
Gene	miRBase	Unigene	Accession No.	FDR	Exemplary Publication
MIR199A1	MI0000242		NR_029586.1	2.11E-05	Landgraf et al., Cell 129 (7), 1401-1414 (2007)
PPIAL4D		Hs.730589	NM_001164261.1	3.94E-05	SEQ ID NO: 102
MIR1203	MI0006335		NR_031607.1	4.63E-03	Marton et al., Leukemia 22 (2), 330-338 (2008)
uc021ovp				6.73E-03	SEQ ID NO: 103
ITM2C		Hs.111577	NM_001012514.2 NM_001012516.2 NM_001287240.1 NM_001287241.1 NM_030926.5	1.17E-01	Yoshida et al., Int. J. Mol. Med. 25 (4), 649-656 (2010)
HLA-DQB1		Hs.409934 Hs.534322	NM_001243961.1 NM_001243962.1 NM_002123.4	1.17E-01	Pankuweit et al., Gene 531 (2), 180-183 (2013)
TTY10		Hs.461175	NR_001542.1	1.25E-01	Derrien et al., Genome Res. 22 (9), 1775-1789 (2012)
TXLNG2P		Hs.522863	NR_045128.1 NR_045129.1	2.27E-01	Prakash et al., PLoS ONE 5 (10), E13284 (2010)
MIR4650-1	MI0017277		NR_039793.1	2.27E-01	Persson et al., Cancer Res. 71 (1), 78-86 (2011)
KDM5D		Hs.80358	NM_001146705.1 NM_001146706.1 NM_004653.4	2.27E-01	Kim et al., J. Am. Soc. Nephrol. 20 (9), 2025-2033 (2009)
USP9Y		Hs.598540	NM_004654.3	2.27E-01	Luddi et al., N. Engl. J. Med. 360 (9), 881-885 (2009)
PRKY		Hs.584730	NR_028062.1	2.27E-01	Hogan et al., Clin Med Res 7 (3), 69-84 (2009)
RPS4Y2		Hs.367761	NM_001039567.2	2.27E-01	Ye et al., BMC Bioinformatics 13, 134

					(2012)
RPS4Y1		Hs.282376	NM_001008.3	2.27E-01	Eljaafari et al., J. Immunol. 190 (1), 184-194 (2013)
NCRNA00185		Hs.138453 Hs.729534 Hs.734681	NR_001543.3 NR_125733.1 NR_125734.1 NR_125735.1 NR_125736.1 NR_125737.1	2.28E-01	Prakash et al., PLoS ONE 5 (10), E13284 (2010)
SULT1E1		Hs.479898	NM_005420.2	2.33E-01	Xu et al., Mol. Cell. Endocrinol. 369 (1-2), 140-149 (2013)
EIF1AY		Hs.461178	NM_001278612.1 NM_004681.3	2.38E-01	Luna et al., Biochemistry 52 (52), 9510-9518 (2013)

Gene set analysis yielded a number of gene signatures predictive of subject relapse to CTL019 therapy in B-ALL. The following genes showed increased levels in relapsers and decreased levels in non relapsers: MIR199A1, MIR1203, uc021ovp, ITM2C, and HLA-DQB1.

- 5 The following genes showed decreased levels in relapsers and increased levels in non relapsers: PPIAL4D, TTTY10, TXLNG2P, MIR4650-1, KDM5D, USP9Y, PRKY, RPS4Y2, RPS4Y1, NCRNA00185, SULT1E1, and EIF1AY.

In particular, the present Example describes methods of Gene Set Analysis to discover novel gene signatures, for use in accordance with the present invention.

- 10 Among other things, the present Example describes novel gene signatures based on Gene Set Analysis, that are predictive of patient relapse to CD19 CAR-expressing cell (e.g., T cell, NK cell) therapy (e.g., CTL019) in B-ALL. Gene set analysis was performed on gene sets described in **Table 17**, and with gene sets described in Example 2, e.g., gene sets were sourced from (1) additional experiments were based on gene sets by Szabo *et al.*, (disclosed herein); (2) gene sets
15 published by Abbas *et al.* in Genome Research 2005; and (3) gene sets published by Gattinoni *et al.* in Nature Medicine 2011. Each of Szabo, Abbas and Gattinoni gene sets are described in detail in Example 2. The gene sets defined by Szabo and considered in this analysis are tabulated in **Table 2** of Example 2. The gene sets defined by Abbas and considered in this analysis are tabulated in **Table 3** of Example 2. The gene sets defined by Gattinoni and
20 considered in this analysis are tabulated in **Table 4** of Example 2.

Each gene set (e.g., B-ALL RNAseq gene sets, Szabo gene sets, Abbas gene sets, and Gattinoni gene sets) was evaluated to determine its association with subject response (i.e., relapser or non-relapser) in the following manner: a meta-gene was calculated for each subject, where the meta-gene score for subject j was defined as

$$m_j = \sum_{i=1}^G \frac{x_{ij} - \mu(x_{.j})}{\sigma(x_{.j})}$$

where x_{ij} is the expression value of gene i in subject j for a given gene set $n=1,...,G$; $\mu(x_{.j})$ is the mean of genes $1,...,G$ in subject j ; and $\sigma(x_{.j})$ is the standard deviation of genes $1,...,G$ in subject j .

A 2-group statistical model was applied to each gene set to determine whether the meta-gene was statistically different between the manufactured CTL019 product of relapsers and non-relapsers. A schematic illustrating this approach is given in **FIG. 2B**. Of the Szabo, Abbas, and Gattinoni gene sets, there was one gene set that was significantly differentially enriched between relapsers and non-relapsers. This gene set was from the Szabo collection and contains genes upregulated in T_{REG} versus T_{EFF} cells at resting, and correlated with patient relapse to CTL019 therapy. Specifically, this gene set was found to be enriched in relapsers, indicating that relapsers have higher levels of T_{REG}s compared to non-relapsers. For example, the meta-gene score for the gene set comprised of genes upregulated in T_{REG} in comparison to T_{EFF} cells is found to be correlated with patient relapse in product samples (see **FIG. 20**). **FIG. 20** depicts exemplary results ($p=0.000215$) illustrating that T_{REG} genes have high expression levels in relapsers (R) compared to non-relapser, complete responders (CR). The x-axis is samples by response group where CR=complete responder and R=relapser. The y-axis is normalized meta-gene expression scores.

In an embodiment, gene signatures described herein are used to enable manufactured product improvements, thereby reducing the likelihood of patient relapse. In an embodiment, gene signatures described herein are used to modify therapeutic application of manufactured product, thereby reducing the likelihood of patient relapse.

In an embodiment, gene signatures described herein are identified in a subject prior to CAR-expressing cell (e.g., T cell, NK cell) treatment (e.g., a CD19 CAR-expressing cell

treatment, e.g., CTL019 therapy) that predict relapse to CAR-expressing cell (e.g., T cell, NK cell) treatment. In an embodiment, gene signatures described herein are identified in an apheresis sample. In an embodiment, gene signatures described herein are identified in a bone marrow sample. In an embodiment, gene signatures described herein are identified in a manufactured CAR-expressing cell (e.g., T cell, NK cell) product (e.g., a CD19 CAR-expressing cell product, e.g., CTL019) prior to infusion.

Without wishing to be bound by a particular theory, these data indicate that decreasing the T_{REG} signature in the patient prior to apheresis or during manufacturing of the CAR-expressing cell (e.g., T cell, NK cell) product significantly reduces the risk of patient relapse.

Example 7: Quantity of CD27+PD1- CART cells infused into patient predicts response to therapy

The number of CD27+PD1- cells in the CTL019 infusion product was determined for 29 CLL patients (8 complete responders and 21 non-responders). The relationship between number of CD27+ PD1- CART cells infused and response to therapy is shown as a bar graph in **FIG. 22**. and as a scatter plot in **FIG. 23**. A threshold was set at 1×10^7 CART cells per patient. A statistically significant difference ($p < 0.0001$) was observed between the complete responders and non-responders. This experiment shows that complete remission of CLL patients to CART19 immunotherapy is associated with higher numbers of infused CD27+PD1- CART cells.

EQUIVALENTS

Other embodiments of the invention will be apparent to those skilled in the art from a consideration of the specification or practice of the invention disclosed herein. While this invention has been disclosed with reference to specific aspects, it is apparent that other aspects and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such aspects and equivalent variations.

CLAIMS

1. A method of evaluating or monitoring the effectiveness of a CD19 CAR-expressing cell therapy in a subject, having a hematological cancer, comprising
measuring a value for the level of CD27+ CD45RO- immune effector cells, in a sample,
wherein said level is predictive of the subject's response to the CD19 CAR-expressing cell therapy, thereby evaluating the subject.
2. The method of claim 1, wherein a greater level of CD27+ CD45RO- immune effector cells in the immune effector cell population, compared to a non-responder number of CD27+ CD45RO- immune effector cells indicates that the subject has an increased likelihood of being responsive to the CD19 CAR-expressing cell therapy.
3. The method of claim 2, wherein the greater level of CD27+ CD45RO- immune effector cells comprises a greater percentage (e.g., 7% or greater number).
4. The method of any one of claims 1-3, further comprising identifying the subject as having an increased likelihood of being responsive to the CD19 CAR-expressing cell therapy, e.g., identifying the subject as a responder, e.g., a complete responder, partial responder or non-relapser.
5. The method of any one of claims 1-4, wherein the sample comprises an apheresis sample.
6. The method of any one of claims 1-5, wherein the sample comprises a manufactured CD19 CAR-expressing cell product sample.
7. The method of any one of claims 1-6, further comprising acquiring a measure of one, two, three, four, five, six or more (e.g., all) of the following:
 - (i) the level or activity of one, two, three, or more (e.g., all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, in a sample;
 - (ii) the level or activity of one, two, three, or more (e.g., all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in a sample;
 - (iii) the level or activity of an immune cell exhaustion marker, e.g., one, two or more immune checkpoint inhibitors (e.g., PD-1, TIM-3 and/or LAG-3) in a sample;

(iv) the level or activity of one, two, three, four, five, ten, twenty or more of the biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature;

(v) a cytokine level or activity (e.g., quality of cytokine repertoire) in a CD19 CAR-expressing cell product sample wherein the cytokine is chosen from one, two, three, four, five or more (or all) of the cytokines listed in Table 16;

(vi) a transduction efficiency of a CD19 CAR-expressing cell in a manufactured CD19 CAR-expressing cell product sample; or

(vii) a quantity of CD27⁺ PD-1⁻ cells in a sample, e.g., a quantity greater than or equal to 1×10^7 cells.

8. The method of any one of claims 1-7, further comprising arranging for one, two, three, four, five, six, seven, or more (e.g., all) of the following to be carried out:

the administration of a CD19 CAR-expressing cell therapy;

the administration of an altered dosing of a CD19 CAR-expressing cell therapy;

the administration of a CD19 CAR-expressing cell therapy according to an altered schedule or time course;

the administration of, e.g., to a non-responder or a partial responder, an additional agent in combination with a CD19 CAR-expressing cell therapy, e.g., a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein;

the administration of to a non-responder or partial responder a therapy that increases the number of younger T cells in the subject prior to treatment with a CD19 CAR-expressing cell therapy;

the modification of a manufacturing process of a CD19 CAR-expressing cell therapy, e.g., enriching for younger T cells prior to introducing a nucleic acid encoding CD19 CAR, or increasing the transduction efficiency, e.g., for a subject identified as a non-responder or a partial responder;

the administration of an altered infusion dose of the CD19 CAR-expressing cell to achieve clinical efficacy;

the administration of an alternative therapy, e.g., for a non-responder or partial responder or relapser;

the administration of an alternative therapy, e.g., for a non-responder or partial responder, e.g., a standard of care for a particular cancer type; or

if the subject is, or is identified as, a non-responder or a relapser, the decrease of the T_{REG} cell population and/or T_{REG} gene signature, e.g., by CD25 depletion, administration of cyclophosphamide, anti-GITR antibody, mTOR inhibitor, or a combination thereof.

9. Use of a CD19 CAR-expressing cell therapy in the manufacture of a medicament for the treatment of a hematological cancer in a subject wherein the therapeutically effective dose of a CD19 CAR-expressing cell therapy in the form of the medicament is to be administered to the subject, if the subject is identified, or has been identified as being responsive to a therapy comprising a CD19 CAR-expressing cell population,

wherein said identifying comprises measuring, in a sample from the subject or population of subjects a value for the level of CD27+ CD45RO- immune effector cells,

wherein the subject identified as being responsive to the CD19 CAR-expressing cell therapy has an increased level of CD27+ CD45RO- immune effector cells compared to a non-responder number of CD27+ CD45RO- immune effector cells

thereby treating the subject.

10. The use of claim 9, wherein the increased level of CD27+ CD45RO- immune effector cells comprises a greater percentage (e.g., 7% or greater number) of CD27+ CD45RO- immune effector cells.

11. Use of a CD19 CAR-expressing cell therapy in the manufacture of a medicament for the treatment of a hematological cancer in a subject, comprising acquiring a value for the level of CD27+ CD45RO- immune effector cells,

wherein an increased level of CD27+ CD45RO- immune effector cells in the immune effector cell population, compared to a non-responder number of CD27+ CD45RO- immune effector cells indicates that the subject has an increased likelihood of being responsive to the CD19 CAR-expressing cell therapy,

responsive to said value, arranging for one, two, three, four, five, six, seven, or all of the following to be carried out:

the administration of a CD19 CAR-expressing cell therapy to a responder or a non-relapser;

the administration of an altered dosing of a CD19 CAR-expressing cell therapy;

the administration of a CD19 CAR-expressing cell therapy according to an altered schedule or time course;

the administration of an additional agent in combination with a CD19 CAR-expressing cell therapy to a non-responder or a partial responder;

the administration of to a non-responder or partial responder a therapy that increases the number of younger T cells or naïve T cells in the subject prior to treatment with a CD19 CAR-expressing cell therapy;

the modification of a manufacturing process of a CD19 CAR-expressing cell therapy, by enriching for younger T cells or naïve T cells prior to introducing a nucleic acid encoding a CD19 CAR, or increasing the transduction efficiency for a subject identified as a non-responder or a partial responder;

the administration of an alternative therapy such as a standard of care for a particular cancer type for a non-responder or partial responder or relapser; or

if the subject is, or is identified as, a non-responder or a relapser, decreasing the T_{REG} cell population and/or T_{REG} gene signature.

12. The use of claim 11, wherein the increased level of CD27⁺ CD45RO⁻ immune effector cells comprises a greater percentage (e.g., 7% or greater number) of CD27⁺ CD45RO⁻ immune effector cells.

13. The use of any one of claims 9-12, further comprising acquiring a measure of one, two, three, four, five, six or more (e.g., all) of the following:

(i) the level or activity of one, two, three, or more (e.g., all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, in a sample;

(ii) the level or activity of one, two, three, or more (e.g., all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in a sample;

(iii) the level or activity of an immune cell exhaustion marker, e.g., one, two or more immune checkpoint inhibitors (e.g., PD-1, TIM-3 and/or LAG-3) in a sample;

(iv) the level or activity of one, two, three, four, five, ten, twenty or more of the biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature;

(v) a cytokine level or activity (e.g., quality of cytokine repertoire) in a CD19 CAR-expressing cell product sample (e.g., CTL019), wherein the cytokine is chosen from one, two, three, four, five or more (or all) of the cytokines listed in Table 16;

(vi) a transduction efficiency of a CD19 CAR-expressing cell in a manufactured CD19 CAR-expressing cell product sample; or

(vii) a quantity of CD27⁺ PD-1⁻ cells in a sample, e.g., a quantity greater than or equal to 1 x 10⁷ cells.

14. The use of any of claims 9-13, wherein the sample comprises an apheresis sample.

15. The use of any of claims 9-13, wherein the sample comprises a CD19 CAR-expressing cell product sample.

16. The method of any one of claims 1-8, or the use of any one of claims 9-16, wherein the CD19 CAR-expressing cell therapy comprises a CD19 CAR having an antigen binding domain that binds to CD19.

17. The method or use of claim 16, wherein the CD19 CAR-expressing cell therapy is a CTL019 therapy.

18. The method of any one of claims 1-8 or 16-17, or the use of any of claims 9-17, wherein

(a) the CD19 CAR-expressing cell therapy comprises a plurality of CD19 CAR-expressing immune effector cells;

(b) the measure of the level of CD27 + CD45RO- immune effector cells, or one or more of (i)-(vii) is obtained from:

an apheresis sample acquired from the subject, wherein optionally the apheresis sample is evaluated prior to infusion or re-infusion; or

from a manufactured CD19 CAR- expressing cell product sample (e.g., CTL019), wherein optionally the manufactured CD19 CAR-expressing cell product is evaluated prior to infusion or re-infusion; and/or

(c) the subject is evaluated prior to, during, or after receiving the CD19 CAR-expressing cell therapy.

19. The method of any one of claims 1-8 or 16-18, or the use of any of claims 9-18, wherein the hematological cancer is an ALL or a CLL; and/or the subject is a human patient.

20. The method of any one of claims 1-8 or 16-19, or the use of any of claims 9-19, further comprises identifying the subject as:

(a) having an increased likelihood of being responsive to the CD19 CAR-expressing cell therapy, e.g., identifying the subject as a responder, e.g., a complete responder, partial responder or non-relapser; or

(b) a non-responder or relapser,

based on a measure of the level of CD27 + CD45RO- immune effector cells, or one or more of (i)-(vii).

21. The method of any one of claims 1-8 or 16-20, or the use of any of claims 9-20, wherein
- (a) the measure of the level of CD27 + CD45RO- immune effector cells, or one or more of (i)-(vii) evaluates a profile for one or more of gene expression, flow cytometry or protein expression;
 - (b) the level or activity of a CD8+ T cell is evaluated using a profile or signature indicative of the percentage of CD8+ T cell in the sample;
 - (c) the level or activity of CD27+ CD45RO- immune effector cells is evaluated using a profile or signature indicative of the percentage of CD27+ CD45RO- immune effector cells in the sample;
 - (d) the level or activity is evaluated using a profile or gene signature according to one, two, three, four, five, ten, twenty, fifty, sixty, seventy, one hundred or more of a biomarker or gene set listed in Tables 1A, 1B, 3, 4, 5, 6, 7A, 7B, or FIG. 2B; and/or
 - (e) the biomarker is a secreted or a cell surface biomarker listed in Table 8.
22. The method or the use of claim 21, wherein
- (a) a non-responder has, or is identified as having, a greater level or activity of one, two, three, four, five, six, seven, or more (e.g., all) of IL22, IL-2RA, IL-21, IRF8, IL8, CCL17, CCL22, effector T cells, or regulatory T cells, as compared to a responder;
 - (b) a responder (e.g., a complete responder) has, or is identified as having, a greater level or activity of one, two, or more (all) of GZMK, PPF1BP2, or naïve T cells as compared to a non-responder;
 - (c) a complete responder has, or is identified as having, a greater, e.g., a statistically significant greater, percentage of CD8+ T cells compared to a reference value, e.g., a non-responder percentage of CD8+ T cells;
 - (d) a complete responder or a partial responder has, or is identified as having, a greater, e.g., a statistically significant greater, percentage of CD4+ T cells compared to a reference value, e.g., a non-responder percentage of CD4+ T cells;
 - (e) a complete responder has, or is identified as having, a greater percentage of one, two, three, or more (e.g., all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells, or gamma/delta cells), or early memory T cells, or a combination thereof, compared to a reference value, e.g., a non-responder number of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells), early memory T cells;
 - (f) a non-responder has, or is identified as having, a greater percentage of one, two, three, or more (e.g., all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells, or a combination thereof, compared to a reference value, e.g., a responder number of activated T_{EFF} cells, activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells;
 - (g) a non-responder has, or is identified as having:

- a greater percentage of PD-1 or LAG-3 expressing immune effector cells (e.g., CD4+ T cells and/or CD8+ T cells) (e.g., CD19 CAR-expressing CD4+ cells and/or CD8+ T cells) compared to the percentage of PD-1 or LAG-3 expressing immune effector cells from a responder, or a greater percentage of PD-1+/LAG-3+ cells in the CD19 CAR-expressing cell population compared to a responder (e.g., a complete responder) to the CD19 CAR-expressing cell therapy;
- an exhausted phenotype of PD1+ CAR+ and co-expression of LAG3 in the CD19 CAR-expressing cell population; or
- a greater percentage of PD-1+/TIM-3+ cells in the CD19 CAR-expressing cell population compared to the responder (e.g., complete responder);
- (h) a partial responder has, or is identified as having:
 - a higher percentage of PD-1+/LAG-3+ cells than responders in the CD19 CAR-expressing cell population; or
 - a higher percentage of PD-1+/TIM-3+ cells than responders in the CD19 CAR-expressing cell population;
- (i) the presence of CD8+ CD27+ CD45RO- T cells in an apheresis sample is a positive predictor of the subject response to a CD19 CAR-expressing cell therapy (e.g., CTL019 therapy);
- (j) a high percentage of PD1+ CAR+ and LAG3+ or TIM3+ T cells in an apheresis sample is a poor prognostic predictor of the subject response to a CD19 CAR-expressing cell therapy (e.g., CTL019 therapy);
- (k) a responder (e.g., a complete responder) to a CD19 CAR-expressing cell therapy has, or is identified as having, the biomarker profile of Table 9;
- (l) a non-responder to a CD19 CAR therapy has, or is identified as having, the biomarker comprising one or more of PD-1+ immune effector cells, TIM-3+ immune effector cells, LAG-3+ immune effector cells, KLRG1+ immune effector cells, CD27-immune effector cells, activated T_{EFF} cells, activated T_{REG} cells, activated TH1, activated TH2 cells, stimulated memory cells, or late T memory cells, or a combination thereof;
- (m) a non-responder to a CD19 CAR-expressing cell therapy has, or is identified as having, the biomarker profile of Table 10;
- (n) gene expression of one, two, three, four or more (all) of KLRG1, CD57, CD27, CD122, or CD62L is predictive of patient response to a CD19 CAR-expressing cell therapy;
- (o) a relapser has, or is identified as having, elevated levels of one, two, three, four, five, six, seven, eight, nine, ten or more of C5orf32, CCL17, CSF1, CTSL1, EMP1, EPAS1, GCLM, GK, GPR56, HMOX1, IKBIP, IL10, IL13, IL1RN, IL4, IL5, IL9, MIR155, PANX2, PGAM4, PRKAR1B, TNFRSF11A, TNFRSF1B, TNFRSF8, VTRNA1-3, or ZNF282; and/or

(p) the responder (e.g., the complete or partial responder) has one, two, three or more (or all) of the following profile:

- (i) has a greater number of CD27+ immune effector cells compared to a reference value, e.g., a non-responder number of CD27+ immune effector cells;
- (ii) has a greater number of CD8+ T cells compared to a reference value, e.g., a non-responder number of CD8+ T cells;
- (iii) has a lower number of cells expressing one or more checkpoint inhibitors, e.g., a checkpoint inhibitor chosen from PD-1, LAG-3, TIM-3, or KLRG-1, or a combination, compared to a reference value, e.g., a non-responder number of cells expressing one or more checkpoint inhibitors; or
- (iv) has a greater number of one, two, three, or more (all) of resting T_{EFF} cells, resting T_{REG} cells, younger cells, or early memory T cells, or a combination thereof, compared to a reference value, e.g., a non-responder number of resting T_{EFF} cells, resting T_{REG} cells, naïve CD4 cells, unstimulated memory cells or early memory T cells.

23. The method of any one of claims 1-8 or 16-22, or the use of any of claims 9-22, wherein:

the cytokine level or activity of (v) is chosen from one, two, three, four, five, six, seven, eight, or more (or all) of cytokine CCL20/MIP3a, IL17A, IL6, GM-CSF, IFN γ , IL10, IL13, IL2, IL21, IL4, IL5, IL9 or TNF α , or a combination thereof; or

a transduction efficiency of 15% or higher in (vi) is indicative of increased responsiveness or decreased relapse.

24. The method of any one of claims 1-8 or 16-23, or the use of any of claims 9-23, wherein the method or use comprises a measure of the level or activity of one, two, three, four, five, ten, twenty or more (e.g., all) of the biomarkers having a FDR p-value of below 0.1 or 0.01 listed in Table 1A, 1B, 17, 18, or 20.

25. A method of evaluating the potency of a CD19 CAR-expressing cell product, said method comprising acquiring a value for the level of CD27+ CD45RO- immune effector cells, in the CD19 CAR-expressing cell product; wherein an increase in the level of CD27+ CD45RO-, is indicative of increased potency of the CD19 CAR-expressing cell product.

26. The method of claim 25, wherein the method comprises acquiring a value for one, two, three, four, five, six, seven, or more (e.g., all) of:

(i) the level or activity of one, two, three, or more (*e.g.*, all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (*e.g.*, younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, in the CD19 CAR-expressing cell product;

(ii) the level or activity of one, two, three, or more (*e.g.*, all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (*e.g.*, older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in the CD19 CAR-expressing cell product;

(iii) the level or activity of an immune cell exhaustion marker, *e.g.*, one, two or more immune checkpoint inhibitors (*e.g.*, PD-1, TIM-3 and/or LAG-3) in the CD19 CAR-expressing cell product;

(iv) the level or activity of one, two, three, four, five, ten, twenty or more of the biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (*e.g.*, CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature;

(v) a cytokine level or activity (*e.g.*, a cytokine repertoire) in the CAR-expressing cell product sample, wherein the cytokine is chosen from one, two, three, four, five or more (or all) of the cytokines listed in Table 16;

(vi) a transduction efficiency of CD19 CAR-expressing cells in the product;

(vii) a quantity of CD27⁺ PD-1⁻ cells in a sample, *e.g.*, a quantity greater than or equal to 1 x 10⁷ cells; or

(viii) the level or activity of a T_{REG} cell or cell population;

wherein an increase in (i), (v), (vi), (vii), or any combination thereof, is indicative of increased potency of the CAR-expressing cell product, and

wherein an increase in (ii), (iii), (viii), or any combination thereof, is indicative of decreased potency of the CAR-expressing cell product.

27. The method of claim 26, wherein:

the cytokine is chosen from one, two, three, four, five, six, seven, eight, or more (or all) of CCL20/MIP3a, IL17A, IL6, GM-CSF, IFN γ , IL10, IL13, IL21, IL4, IL5, IL9 or TNF α , or a combination thereof; or

a transduction efficiency of 15% or higher is indicative of increased potency.

28. A method for optimizing manufacturing of a CD19 CAR-expressing cell product, comprising:

(1) acquiring a sample comprising a population of CD19 CAR-expressing immune effector cells;

(2) activating the population of CD19 CAR-expressing cells *in vitro*; and

(3) evaluating the potency of the activated CD19 CAR-expressing cell population by determining the level of CD27⁺ CD45RO⁻ immune effector cells in the CD19 CAR-expressing cell

product, wherein an increase in the level of CD27⁺ CD45RO⁻ immune effector cells, is indicative of increased potency of the CD19 CAR-expressing cell product, thereby optimizing manufacturing of the product.

29. The method of claim 28, comprising determining one, two, three, four, five, six, seven, or more (e.g., all) of:

(i) the level or activity of one, two, three, or more (e.g., all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, in the CD19 CAR-expressing cell product;

(ii) the level or activity of one, two, three, or more (e.g., all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in the CD19 CAR-expressing cell product;

(iii) the level or activity of an immune cell exhaustion marker, e.g., one, two or more immune checkpoint inhibitors (e.g., PD-1, TIM-3 and/or LAG-3) in the CD19 CAR-expressing cell product;

(iv) the level or activity of one, two, three, four, five, ten, twenty or more of the biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature;

(v) a cytokine level or activity in a CD19 CAR-expressing cell product sample, wherein the cytokine is chosen from one, two, three, four, five or more (or all) of the cytokines listed in Table 16;

(vi) a transduction efficiency of CD19 CAR-expressing cells in the product;

(vii) a quantity of CD27⁺ PD-1⁻ cells in a sample, e.g., a quantity greater than or equal to 1 x 10⁷ cells; or

(viii) the level or activity of a T_{REG} cell or cell population,

wherein an increase in (i), (v), (vi), (vii), or any combination thereof, is indicative of increased potency of the CD19 CAR-expressing cell product, and

wherein an increase in (ii), (iii), (viii), or any combination thereof, is indicative of decreased potency of the CD19 CAR-expressing cell product.

30. The method of any one of claims 1-8 or 16-29, or the use of any one of claims 9-24, wherein the CD19 CAR-expressing immune effector cells comprise CD4⁺ T cells or CD8⁺ T cells.

31. The method of any one of claims 26-30, wherein the CD19 CAR-expressing cell product comprises a CAR having an antigen binding domain that binds to CD19, optionally wherein the CD19 CAR-expressing cell product is CTL019.

32. The method of any one of claims 26-31, further comprising a step of enriching for, e.g., isolating, cells having:

- an increase in the level of CD27⁺ CD45RO⁻ immune effector cells, or any of (i), (v), (vi), (vii), or any combination thereof, or
- a decrease in any of (ii), (iii), (viii), or any combination thereof; or
- wherein the cytokine level or activity is chosen from one or more of cytokine CCL20/MIP3a, IL17A, IL6, GM-CSF, IFN γ , IL10, IL13, IL2, IL21, IL4, IL5, IL9 or TNF α , or a combination thereof.

33. The method of any one of claims 26-32, wherein the level of CD27⁺ CD45RO⁻ immune effector cells, or (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), or any combination thereof (e.g., all) are evaluated following activation *in vitro*.

34. The method of any one of claims 1-8 or 16-32, or the use of any one of claims 9-24, wherein

(i) the subject has received or is to receive a treatment, e.g., a pre-treatment or concurrent treatment with an agent, e.g., an mTOR inhibitor, and/or a checkpoint inhibitor, e.g., a pre-treatment prior to the initiation of a CD19 CAR-expressing cell therapy or a treatment post- CD19 CAR-expressing cell therapy;

(ii) the hematological cancer is associated with CD19 expression;

(iii) the hematological cancer is selected from the group consisting of B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), B cell promyelocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, and Waldenstrom macroglobulinemia; or

(iv) the CD19 CAR-expressing cell gene signature comprises a value for expression of at least 5, 6, 7, 8, 9 or 10 genes comprising a CD19 CAR-expressing cell gene signature.

35. A system for evaluating a hematological cancer in a subject, comprising:

at least one processor operatively connected to a memory, the at least one processor when executing is configured to:

acquire a value for the level of CD27⁺ CD45RO⁻ immune effector cells, wherein an increased level of CD27⁺ CD45RO⁻ immune effector cells is indicative of the subject's increased likelihood of being responsive to a CAR-expressing cell therapy,

responsive to a determination of the level of CD27⁺ CD45RO⁻ immune effector cells, perform one, two, three, four, five, six, seven, or all of:

identify the subject as a complete responder, partial responder, non-responder, relapser or non-relapser;

recommend administering a CD19 CAR-expressing cell therapy;

recommend a selection or alteration of a dosing of a CD19 CAR-expressing cell therapy;

recommend a selection or alteration of a schedule or time course of a CD19 CAR-expressing cell therapy;

recommend administering to a non-responder or a partial responder an additional agent in combination with a CD19 CAR-expressing cell therapy;

recommend administering to a non-responder or partial responder a therapy that increases the number of naïve T cells in the subject prior to treatment with a CD19 CAR-expressing cell therapy;

recommend modifying a manufacturing process of a CD19 CAR-expressing cell therapy by enriching for naïve T cells prior to introducing a nucleic acid encoding a CD19 CAR for a subject identified as a non-responder or a partial responder;

recommend administering an adjusted CD19 CAR-expressing cell infusion dose to achieve clinical efficacy;

recommend administering an alternative therapy for a non-responder or partial responder or relapser;

recommend a selection of an alternative therapy such as a standard of care for a particular cancer type for a non-responder or partial responder; or

if the subject is, or is identified as, a non-responder or a relapser, recommend decreasing the T_{REG} cell population and/or T_{REG} gene signature.

36. The system of claim 35, further comprising acquiring a value for one, two, three, four, five, six, or more (all) of the following:

(i) the level or activity of one, two, three, or more (*e.g.*, all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (*e.g.*, younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, in a sample;

(ii) the level or activity of one, two, three, or more (*e.g.*, all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (*e.g.*, older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in a sample;

(iii) the level or activity of an immune cell exhaustion marker, *e.g.*, one, two or more immune checkpoint inhibitors (*e.g.*, PD-1, TIM-3 and/or LAG-3) in a sample;

(iv) the level or activity of one, two, three, four, five, ten, twenty or more of the biomarkers listed in Table 1A, Table 1B, Table 7A, Table 7B, Table 8, Table 9, Table 10, Table 14 (e.g., CCL20, IL-17a and/or IL-6), Table 16, Table 17, Table 18, Table 20, FIG. 2B, PD-1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1, or a CD19 CAR-expressing cell gene set signature;

(v) a cytokine level or activity (e.g., quality of cytokine repertoire) in a CD19 CAR-expressing cell product sample (e.g., CTL019), wherein the cytokine is chosen from one, two, three, four, five or more (or all) of the cytokines listed in Table 16;

(vi) a transduction efficiency of a CD19 CAR-expressing cell in a manufactured CD19 CAR-expressing cell product sample; or

(vii) a quantity of CD27⁺ PD-1⁻ cells in a sample, e.g., a quantity greater than or equal to 1×10^7 cells.

37. The system of claim 35 or 36, wherein the sample comprises an apheresis sample.

38. The system of claim 35 or 36, wherein the sample comprises a manufactured CD19 CAR-expressing cell product sample.

39. The system of claim 35 or 36, wherein the CD19 CAR-expressing cell therapy comprises a CD19 CAR having an antigen binding domain that binds to CD19, optionally wherein the CAR-expressing cell therapy is CTL019.